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FOREWORD
Foreword
This 2020 edition of Health at a Glance: Europe marks the start of a new State of Health in the EU
cycle – an initiative launched by the European Commission, in co-operation with the OECD and the
European Observatory on Health Systems and Policies to assist EU Member States in improving the
health of their citizens and the performance of their health systems.
This year, the COVID‑19 pandemic has made clear how vulnerabilities in health systems can have
profound implications for the health of our people, economic progress, trust in governments, and
social cohesion across Europe and around the globe. The new coronavirus has caused severe human
suffering and loss of life. As governments grappled with the spread of the virus – by closing down
entire  sectors  of  economic  and  social  activity  and  imposing  restrictions  on  mobility  that  are
unprecedented in our lifetimes, the public health crisis evolved into a major economic and social crisis,
with sharply rising unemployment rates and growing income inequalities.
There has been much talk of COVID‑19 as a ‘once in a century’ shock, but this might not be the case.
In the absence of important changes in our societies and health systems, the current coronavirus
pandemic does not reduce the probability of new pandemics caused by emerging or already known
pathogens. Nor does it diminish the likelihood that other low probability, high-impact risks might hit
health systems, economies and societies in the near future. In fact, other looming crises, such as
climate change and environmental degradation, are likely to increase the probability of repeated
public health shocks. Building the resilience of our health systems and promoting a green recovery
has never been so urgent.
Recognising the importance of national, European and broader international efforts to
suppress the spread of the pandemic
The COVID‑19 pandemic, as well as other global threats such as climate change and air pollution,
have brought to light the need for effective and inclusive multilateralism and co‑ordinated actions at
national, European and global levels to effectively and equitably deal with these issues. The European
Commission and the OECD have worked on many fronts, in co-operation with the WHO and other
international  organisations,  to  support  countries  in  their  efforts  to  contain  the  spread  of  the
coronavirus. We have also worked together to share and promote best practices from European as
well as non-European countries that have been leading the way in policy responses.
The race is on to find effective and safe treatments and vaccines for COVID‑19 to treat infected people
globally  and  contain  the  spread  of  the  virus.  The  European  Commission  is  participating  in
the  COVAX  Facility  to  promote  equitable  access  to  affordable  COVID‑19  vaccines  and  has
contributed EUR 400 million in guarantees to COVAX. European countries also have the collective
responsibility to ensure that all  new vaccines are developed in a way that ensures the highest
standards of quality and safety and, once available, are distributed with the objective of achieving fair
access across and within countries.
Digitalising public health management
The COVID‑19 pandemic has also highlighted the pressing need for improved data collection and
exchange to better monitor and manage public health issues and health systems. Data fragmentation
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and the limited degree of interoperability of health information systems are inadequate to provide the
right information to the right people at the right time. The 2017 OECD Council Recommendation on
Health Data Governance lays out the framework to encourage greater availability of timely health data
within countries and across borders, while ensuring that risks to privacy and security are minimised
and appropriately managed.
To step up co‑ordination between authorities across the EU, and as part of its effort to create a
European Health Data Space,  the European Commission is currently developing a governance
framework to promote a better use of health data, as well as a digital health infrastructure supporting
such access. Once operational, it will allow better use of data for health care, research, innovation and
more evidence-based health policy-making. Two decades into the 21st century, health systems need
to harness more fully the potential of new information and communication systems.
Giving priority to the prevention of non-communicable diseases is also crucial
The COVID‑19 pandemic should not make us lose sight of the major impact of environmental and
lifestyle risk factors in the current burden of chronic diseases, which also bear an increasing toll on
mortality. In fact, the pandemic has compounded the harm of chronic diseases, given that severe
cases of COVID‑19 disproportionally affect not only older people, but also those who are obese or
have preexisting conditions. Each year, hundreds of thousands of people across EU countries die
because of air pollution, tobacco and alcohol consumption, unhealthy diets and lack of physical
activity. Cross-sectoral policies need to be actively pursued to reduce population exposure to these
health risks.
The prevention and early diagnosis of cancers must play a central part in Europe’s Beating Cancer
Plan. In 2020, 2.7 million people are expected to be diagnosed with cancer across the 27 EU Member
States, and 1.3 million to die from it. Over 40% of cancer cases are preventable, and mortality can also
be reduced through earlier diagnosis and improved care for cancer patients.
The prevention and early diagnosis of mental health issues has also too often been neglected in the
past.  The COVID‑19 pandemic has increased the risk of development of various mental health
conditions, particularly among young people and people in lower-income groups. The previous edition
of Health at a Glance: Europe, published in 2018, made a strong case for preventing and addressing
the huge burden of mental health issues in Europe. This has become an even greater priority now.
The OECD Council Recommendation on Integrated Mental Health, Skills and Work Policy calls on
governments to promote the provision of early and fully integrated services in order to improve social
and labour market outcomes for people with mental health problems.
Promoting an economic recovery that improves people’s health and the environment
Urgent actions are also needed to counter the huge consequences of the COVID‑19 pandemic on the
economy, labour markets and people’s quality of life. GDP fell by more than 10% in the second quarter
of 2020 in many European countries, and the initial impact of the COVID‑19 crisis on labour markets
has been ten times larger than that observed in the first months following the 2008 Global Financial
Crisis. The EU recovery plan from the COVID‑19 crisis provides a tremendous opportunity to promote
a stronger, more sustainable, fairer and resilient economy.
We are encouraged to see many governments seizing this once-in-a-lifetime opportunity to ensure a
truly  sustainable  recovery,  respectful  of  the  environment  and people’s  health.  Climate  change,
pollution and biodiversity loss are the next crises around the corner, and actions must be taken now to
tackle them. Green recovery measures are a win-win option as they can boost economic activities
while improving environmental outcomes and enhancing people’s health and well-being. Decisions
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taken now must focus on achieving the national emissions reduction commitments by 2030, to reduce
the serious health and mortality consequences of air pollution.
Promoting more resilient health systems through multilateralism
The COVID‑19 pandemic has exposed the insufficient preparation of countries to cope with major
public health emergencies. The costs of having more resilient health systems pale in comparison with
the huge economic consequences of failing to do so. The new coronavirus is neither the first pandemic
nor the last one, and many other more or less predictable events may have a huge impact on public
health. It has thus become apparent that both the global and EU health security framework need
significant strengthening. Fragmentation makes us all vulnerable and it is only through multilateral
cooperation that we can face up to public health threats of the magnitude of COVID‑19.
The  initiatives  aimed  at  setting  out  a  more  comprehensive  approach  to  crisis  preparedness,
surveillance and response presented by the European Commission in November 2020 – including the
Pharmaceutical  Strategy  for  Europe  and  the  proposals  to  build  a  European  Health  Union  by
reinforcing the mandates of the European Centre for Disease Control and the European Medicines
Agency – are some of the first, important steps towards this goal. These initiatives provide examples
of greater public health cooperation across borders, in the context of reforming and strengthening the
WHO.
In addition, we must harness the lessons of this crisis and plan for a thorough assessment of health
system resilience, drawing on the best practices from countries within and outside Europe and the
support that the European Commission and the OECD can provide. This exercise should involve all
stakeholders and lead to better preparedness for pandemics and other public health emergencies in
the future.
The foremost lesson learnt from the COVID‑19 pandemic is that there is no trade-off between lives
and livelihoods. Public health and the global economy are inextricably linked. We cannot have one
without the other. Healthy global economic systems depend on healthy citizens. Strengthening the
preparedness and resilience of  health  systems will  require  additional  resources.  With  the right
investment – from better global public health governance, to stronger health information systems and
support for a digital transformation of health systems – the return on the well-being of people and the
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Executive summary
The COVID‑19 outbreak has spread in 2020 to become the most severe pandemic in the last one
hundred years. The public health crisis has led to a major economic crisis, which will have serious
consequences on individual  and societal  well-being both now and in the future. COVID‑19 has
exposed latent health system fragilities that existed before the outbreak. Despite much talk of health
spending being an investment rather than a cost, policy approaches had not changed significantly
before the crisis. Health spending overwhelmingly goes on curative care, not prevention.
The staggering impact of COVID‑19 on our society and economy has abruptly brought public health
back to the top of the policy agenda. COVID‑19 mortality has a clear social gradient, which is a bleak
reminder of the importance of the social determinants of health.
The COVID‑19 pandemic has highlighted the need to consider the resilience of health systems as an
equally important dimension of health system performance alongside accessibility, quality of care and
efficiency.
The resilience of health systems to COVID‑19
By the end of October 2020, over 7 million people were infected and 220 000 had died from COVID‑19
across EU countries, Iceland, Norway, Switzerland and the United Kingdom. During the first wave of
the pandemic,  the virus particularly  affected a number of  Western European countries,  notably
Belgium, France, Italy, the Netherlands, Spain and the United Kingdom, as well as Sweden. However,
since August 2020, the virus also started to spread more widely across Europe.
A few countries have managed to minimise the health and economic impacts
of COVID‑19
Providing an overall assessment of country responses to COVID‑19 is difficult at this time, given that
the pandemic is still very active across the world. European countries struggled to varying degrees to
respond to the first wave of the pandemic in Spring 2020 and to the second wave in Autumn 2020.
Many countries struggled during the initial months of the crisis to increase the availability of masks and
other personal protective equipment. Most countries also struggled to scale-up their testing capacity,
which limited the effectiveness of testing, tracking and tracing efforts. This left them with few options to
contain the spread of  the virus during the first  wave,  necessitating more stringent  confinement
measures.
Outside of Europe, Korea is a good example of a country that has managed to control the COVID‑19
outbreak  through  quick,  effective  and  targeted  measures,  thereby  avoiding  full  lockdowns.
New Zealand has been another successful example. In Europe, up until October 2020, a few countries
like Finland, Norway and Estonia were better able to contain the spread of the virus and mitigate the
economic consequences, in part because of geographic factors (lower population density) but also
because  of  timely  implementation  of  targeted  containment  measures,  and  strong  trust  and
compliance by populations.
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Older people have been disproportionately hit, with residents in long-term care
facilities particularly at risk
The virus has disproportionately hit older people and those with underlying health conditions. In nearly
all countries, at least 90% of COVID‑19 deaths were amongst people aged 60 and over. In many
countries, about half or more of COVID‑19 deaths were amongst residents in long-term care (LTC)
facilities.  The initial  response in  many countries focused on protecting patients and workers in
hospitals. It was only later that similar measures were taken to protect residents and workers in LTC
facilities. In several countries, there was at least a two‑month lag between the first reported COVID‑19
cases and the issuance of guidelines to prevent infections in LTC institutions. In a quarter of countries
for which information is available, it took two weeks longer to restrict visits in nursing homes than the
restrictions  imposed  in  public  spaces.  The  first  wave  of  the  pandemic  highlighted  the  crucial
importance of protecting older people and other vulnerable populations from COVID‑19 to reduce
hospitalisations and deaths.
There has been a clear social gradient in COVID-19 deaths
Poor people, people living in deprived areas and ethnic minorities have also been disproportionately
affected. This highlights the need for a strong focus on policies to tackle the social determinants of
health, including inclusive social and economic policies and interventions beyond the health system
that address the root causes of inequalities.
Addressing the health and welfare impact of air pollution
Between 168 000 and 346 000 premature deaths across EU countries can be
attributed to air pollution from fine particles alone
While most of the attention in 2020 was on COVID‑19, it is important not to neglect other important risk
factors to health, including environmental factors like air pollution. Although air quality has improved in
most  European countries  over  the  past  two  decades,  pollution  levels  remain  above  the  WHO
guidelines in most countries, particularly in large cities. This has serious consequences for people’s
health and mortality. Across EU countries, an estimated 168 000 to 346 000 premature deaths can be
attributed to exposure to air pollution from fine particles (PM2.5) alone in 2018. The mortality of air
pollution is particularly high in Central and Eastern Europe because of greater use of fossil fuels.
Within each country, disadvantaged groups are disproportionally affected due to greater exposure to
air pollution and greater susceptibility to serious health consequences.
Air pollution causes about EUR 600 billion in economic and welfare losses
annually across EU countries, equivalent to 4.9% of EU GDP in 2017
The economic and welfare losses from air pollution are substantial. New estimates of the impact of
PM2.5 and ozone show that losses amounted to about EUR 600 billion in 2017 or 4.9% of GDP across
the EU as a whole. This is due mainly to the impact these air pollutants have on mortality, but also to
the lower quality of life and labour productivity for people living with related diseases, and higher
health expenditure.
Efforts to reduce air pollution need to focus on the main sources of emissions. These include the use
of fossil fuels in energy production, transportation and the residential sector, as well as industrial and
agricultural activities. The EU recovery plan from the COVID‑19 crisis provides a unique opportunity to
promote a green economic recovery by integrating environmental considerations in decision-making
processes, thereby supporting the achievement of the 2030 EU national emission reduction targets.
The health sector itself can contribute to achieving this objective by minimising its own environmental
footprint.  Through  multi-sectoral  approaches,  public  health  authorities  can  also  contribute  to
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environmentally  friendly urban and transport  policies,  which may also promote greater  physical
activity.
Reducing other important risk factors to health
Beyond environmental issues, a number of modifiable risk factors also have important impacts on
people’s health and mortality, notably smoking, alcohol consumption, unhealthy nutrition, lack of
physical activity and obesity.
Smoking remains the most important cause of premature mortality across the
EU, accounting for about 700 000 deaths per year
Despite progress in reducing smoking rates over the last decades, tobacco consumption remains the
largest  behavioural  risk factor  to health,  accounting for  about  700 000 deaths per  year  across
EU countries.
Harmful consumption of alcohol is responsible for another 255 000 to 290 000 deaths per year across
EU countries. While alcohol control  policies have reduced overall  alcohol consumption in many
countries over the past decade, heavy alcohol consumption remains an issue. One-third of adults
report at least one “binge drinking” event in the past month, and more than one‑fifth of adolescents
aged 15 years old report having been drunk more than once in their life.
More than one in six adults are obese across EU countries, and there are wide
socio-economic disparities in overweight and obesity rates
Adult obesity rates continue to increase in most EU countries, with more than one in six adults being
obese in the EU. Obesity is also a recognised risk factor for complications from COVID‑19. There are
large socio-economic inequalities in overweight and obesity rates, often starting at a young age. For
example, overweight and obesity rates among children are about two times greater among those
living in the lowest income families compared to those living in the highest income families.
Ensuring universal and effective access to care for all the population
Most EU countries have achieved universal coverage for a core set of health services, which is crucial
to deal effectively with the COVID‑19 pandemic. However, the range of services covered and the
degree of cost-sharing vary substantially. Effective access to different types of care can also be
restricted because of shortages of health workers, long waiting times or long travel distances to the
closest health care facility.
Only a small share of the population reported unmet needs for health care in most EU countries in
2018. Still, this proportion was nearly five times higher among low-income households than high-
income households across the EU as a whole. Further, the affordability of health services can be
restricted when they involve high out-of-pocket payments. On average across EU countries, around
one‑fifth of all health spending is paid out-of-pocket by households, but this proportion exceeds more
than one‑third in Latvia, Bulgaria, Greece and Malta. In general, countries that have a high share of
out-of-pocket spending also have a higher proportion of the population facing catastrophic out-of-
pocket payments for health services, particularly among low-income groups.
The COVID-19 pandemic highlighted the shortages of health workers in many
countries, and the need for mechanisms to mobilise human resources quickly
in times of crisis
Although the number  of  doctors  and nurses has increased over  the past  decade in  nearly  all
EU countries, shortages persist in many countries. These shortages were thrown into sharp relief
during  the COVID‑19 pandemic,  when health  workers  were  put  under  intense pressure.  Many
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countries have sought to mobilise additional staff quickly, often by recalling inactive and retired health
professionals and mobilising students in medical, nursing and other health education programmes
nearing the end of their studies. Some countries were also able to redeploy some of the staff from less
affected regions to those that were more affected. This crisis also highlights the needs for creating
additional reserve capacity that can be quickly mobilised.
Waiting times for elective surgery are likely to increase further following the
COVID-19 pandemic
Long waiting times for health services like elective surgery have been a longstanding issue in many
EU countries. Even before the COVID‑19 pandemic, waiting times for elective surgery were on the rise
in many countries, as the demand for surgery increased more rapidly than supply. These waiting times
are likely to increase further in the short term in several countries as many elective surgeries were
postponed during the pandemic.  Countries like Denmark and Hungary that  have succeeded in
achieving lasting reductions in waiting times for many elective health services typically combine some
supply-side and demand-side interventions along with a regular monitoring of progress.
Monitoring and improving the State of Health in the EU
Health at a Glance: Europe 2020 is the result of ongoing close collaboration between the OECD and
the European Commission to improve country-specific and EU-wide knowledge on health issues as
part of the Commission’s State of Health in the EU cycle.
In 2016, the European Commission launched the State of Health in the EU cycle to assist EU Member States in
improving the health of their citizens and the performance of their health systems. Health at a Glance: Europe is the first
product of the two‑year cycle, presenting every even-numbered year extensive data and comparative analyses that can
be used to identify both the strengths and the opportunities for improvement in health and health systems.
The second step in the cycle is the Country Health Profiles for all EU countries. The next edition of these profiles will be
published in 2021 jointly with the European Observatory on Health Systems and Policies, and will highlight the particular
characteristics and challenges for each country. A Companion Report from the European Commission accompanies the
release of the profiles. The final step in the cycle is a series of Voluntary Exchanges with Member States. These are
opportunities to discuss in more detail some of the challenges and potential policy responses.
For more information, please consult: ec.europa.eu/health/state.
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Infographic 1. Key facts and figures from Health at a Glance: Europe
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Readers’ guide
Health at a Glance: Europe is the first step in the State of Health in the EU cycle of knowledge
brokering. While the structure of the 2020 edition is still based on the 2014 European Commission
Communication on effective, accessible and resilient health systems (https://ec.europa.eu/health/
sites/health/files/systems_performance_assessment/docs/com2014_215_final_en.pdf),  the chapter
on resilience has been brought forward this year given the challenge that European health systems
had to face in response to the COVID‑19 pandemic.
The publication is divided in two parts. Part I contains two thematic chapters. Chapter 1 provides an
initial assessment of how resilient European health systems have been to the COVID‑19 pandemic
and their ability to contain and respond to the worst pandemic over the past century. Chapter 2
reviews the health and welfare burden of air pollution across EU countries, and highlights the need for
sustained efforts to reduce air pollution to mitigate its impact on health and mortality.
Part II includes the five regular chapters of this publication, providing an overview of key indicators of
health and health systems across the 27 EU member states, 5 candidate countries, 3 European Free
Trade Association countries and the United Kingdom. The selection of indicators is based largely on
the European Core Health Indicators (ECHI) shortlist  (https://ec.europa.eu/health/indicators/echi/
list_en). New indicators have also been included to cover often neglected areas such as mental health
issues and dental care.
The data presented in this publication come mainly from official national statistics, and have been
collected in many cases through the administration of joint questionnaires by the OECD, Eurostat and
WHO. The data have been validated by the three organisations to ensure that they meet high
standards of  data quality and comparability.  Some data also come from European surveys co-
ordinated by Eurostat, notably the European Union Statistics on Income and Living Conditions Survey
(EU-SILC) and the second wave of the European Health Interview Survey (EHIS), as well as from the
European Centre for Disease Prevention and Control (ECDC), the European Commission’s Joint
Research Centre (JRC) and other sources.
Presentation of indicators and calculation of EU averages
With the exception of the first two thematic chapters, all indicators in the rest of the publication are
presented in the following way. The text provides a brief commentary highlighting the key findings
conveyed by the data, defines the indicator and signals any significant data comparability limitation.
This is accompanied by a set of figures that typically show current levels of the indicator and, where
possible, trends over time. For those countries that have a relatively small population (less than
1 million), three‑year averages are often calculated to minimise random errors due to small numbers.
The EU averages include only EU member states and are calculated either as population-weighted
averages (to be consistent with the averages that are calculated by Eurostat or JRC) or as unweighted
averages (when these averages are calculated by the OECD or other organisations). The calculation
method is generally mentioned in a footnote under each figure. By definition, a weighted average
gives  more  weight  to  the  most  populated  countries  and  can  be  interpreted  as  a  measure  of
comparison with the EU as a whole, whereas an unweighted average gives equal weight to all
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countries regardless of their population size and can be interpreted as a measure of comparison with
other countries.
Population data
The population data used to calculate rates per capita and population-weighted averages come from
the Eurostat  demographics database.  The data relate to mid-year estimates (calculated as the
average between the beginning and the end of the year). Population estimates are subject to revision,
so they may differ from the latest population figures released by Eurostat or national statistical offices.
Data limitations
Limitations in data comparability are indicated both in the text (in the box related to “Definition and
comparability”) as well as in footnotes underneath the figures.
Data sources
Readers interested in using the data presented in this publication for further analysis and research are
encouraged to consult  the full  documentation of  definitions,  sources and methods contained in
OECD  Health  Statistics  for  all  OECD member  countries,  including  22  EU member  states  and
five  additional  countries  (Iceland,  Norway,  Switzerland,  Turkey  and  the  United  Kingdom).  This
information is available in OECD.Stat (https://oe.cd/ds/health-statistics). For the nine other countries
(Albania, Bulgaria, Croatia, Cyprus, Malta, Montenegro, North Macedonia, Romania and Serbia),
readers are invited to consult the Eurostat database for more information on sources and methods
(http://ec.europa.eu/eurostat/data/database).
Readers interested in an interactive presentation of the European Core Health Indicators (ECHI) can
consult DG SANTE’s ECHI data tool at http://ec.europa.eu/health/indicators/indicators/index_en.htm.
Readers interested in indicators that quantify the burden of cancer in Europe can also visit the JRC’s
European Cancer Information System (ECIS): https://ecis.jrc.ec.europa.eu/.
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PART I
Chapter 1
How resilient have European health
systems been to the COVID‑19 crisis?
This chapter provides an initial assessment of the impact of COVID‑19 and the
resilience of European health systems to the pandemic, bearing in mind that the
pandemic is ongoing and so any definitive assessment would be premature. As of
31 October, over 7 million people were infected and 220 000 died from the virus
across EU countries, Iceland, Norway, Switzerland and the United Kingdom. During
the first wave, the virus had a much more adverse impact on a number of Western
European countries, notably Belgium, France, Italy, Netherlands, Spain and the
United Kingdom, as well as Sweden. Since August, COVID‑19 also started to spread
more widely across Europe. The virus has disproportionately hit older people, and
there has been a clear social gradient in COVID‑19 deaths.
Countries that were better prepared and acted quickly to reduce the spread of the
virus through rapid scaling-up of testing, tracking and tracing strategies, were more
able to avoid the most stringent and costly containment and mitigation measures. In
terms of treating COVID‑19 patients, policies to temporarily boost hospital beds and
equipment have helped deal with surges in demand. However, a lack of health
personnel has been more of a binding constraint,  putting health workers under
intense pressure. Further, many non-COVID‑19 patients were unable to access
needed  care  during  the  peak  of  the  pandemic  in  Spring  2020.  Health  system
resilience therefore also requires strengthening primary health care and mental
health services to minimise delays and forgone care for all health care needs.
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Introduction
Since late 2019, the COVID‑191 outbreak has spread to become the most serious pandemic in a
century. European countries have been severely affected, with over 7 million cases and 220 000
deaths reported across EU countries, Iceland, Norway, Switzerland and the United Kingdom as of
31 October 2020. As the pandemic continues through 2020 and beyond, the eventual death toll will
rise.
One has to look back to 1918 to see similar numbers for an emerging virus in Europe in such a
short space of time. Yet the health impact reaches well beyond these numbers. As well as some
COVID‑19 cases and deaths going undetected, COVID‑19 has had a major indirect impact on people
that did not contract the virus. For example, people with emergency health needs have sometimes
struggled to receive timely acute care, and those with chronic health conditions have faced disruptions
to routine care. In addition, the pandemic and the subsequent economic crisis have led to a growing
burden of mental ill-health, with emerging evidence of higher rates of stress, anxiety and depression;
compounded by disruptions to health care for those with pre-existing mental health conditions.
The socio-economic impacts have also been dramatic. In the second quarter of 2020, seasonally
adjusted GDP fell by 13.9% across the EU, compared with the same quarter in 2019. Thanks to the
widespread use of various short-term work schemes, employment was comparatively less affected,
though there was still a registered decrease of 2.9% over the same time period (Eurostat, 2020[1]).
The COVID‑19 pandemic has therefore put an immense strain on European countries, testing
the resilience of every country’s government and people. It has also tested the ability of EU Member
States and the European Commission to develop a co‑ordinated set of responses to a common threat
(European Commission, 2020[2]). This chapter focuses predominantly on health system responses,
and on a review of the resilience of European countries’ health systems to the COVID‑19 crisis.
Analysis covers the first ten months of the year, with a focus on the first wave of the pandemic. Based
on this review, the chapter draws out policy insights that are likely to contribute to better preparedness
and more effective responses to the evolving pandemic and future health threats. Assessments made
in this chapter and associated policy insights are based on information predominantly from the first
half of 2020 (Box 1.1). As the data and evidence are still developing, results from this chapter are
“initial findings”, not a definitive review.
Defining health systems resilience
The concept of resilience has been applied to shocks and disruptive events such as epidemics,
economic crises and environmental disasters. In the health sector, its usage has become more
frequent following the Ebola epidemic in West Africa in 2013‑16. Resilience was also a key concept in
the 2014 European Commission Communication on effective, accessible and resilient health systems
(European Commission, 2014[3]). In this chapter, conceptual work from both the OECD and the
European Commission underpin assessments of health system resilience to the COVID‑19 crisis. The
OECD’s New Approaches to Economic Challenges (NAEC) resilience framework analyses core
attributes of resilient systems, within the context of tensions between resilience and efficiency (OECD,
2020[4]). It recognises the importance of risk management, but also that absolute prevention or
avoidance of shocks such as COVID‑19 is impossible given the unpredictable nature of systemic
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threats. Resilience is therefore seen to be as much about recovery and adaption, as it is about
prevention and avoidance. That is:
“Resilience acknowledges that massive disruptions can and will happen – in future, climate
disruption will likely compound other shocks like pandemics – and it is essential that core systems
have the capacity for recovery and adaptation to ensure their survival, and even take advantage of
new or revealed opportunities following the crises to improve the system through broader systemic
changes… The new approach to resilience will focus on the ability of a system to anticipate,
absorb, recover from, and adapt to a wide array of systemic threats.” (OECD, 2020[4]).
The  EU  Expert  Group  on  Health  Systems  Performance  Assessment  (HSPA)  provides
complementary insights focused on health system resilience. It emphasises the importance of more
general health system strengthening alongside preparedness to specific threats, and provides a
working definition of resilience consistent with the work of the OECD. That is:
“Health system resilience describes the capacity of a health system to (a) proactively foresee,
(b) absorb, and (c) adapt to shocks and structural changes in a way that allows it to (i) sustain
required operations, (ii) resume optimal performance as quickly as possible, (iii) transform its
structure and functions to strengthen the system, and (possibly) (iv) reduce its vulnerability to
similar shocks and structural changes in the future” (EU Expert Group on HSPA, 2020[5]).
Building on these conceptual analyses, the focus of this chapter is predominantly on the capacity
of European countries’ health systems to absorb and adapt to the shock of COVID‑19.
The rest of this chapter is structured as follows. The next section provides an assessment of the
initial health impact of COVID‑19 in European countries. Analysis then turns to outbreak prevention
strategies, analysing the range of containment and mitigation approaches adopted by governments,
as well as how effective these have been in preventing and slowing down the spread of the virus. The
focus is then on assessing curative efforts, investigating the capacity of European countries’ health
systems to treat COVID‑19 patients and actions taken to respond to the massive surge in health care
demand.  Subsequently,  the report  analyses the impact  of  the virus on older  people and other
vulnerable  groups,  and  the  associated  policy  responses.  Policy  responses  and  approaches  to
maintaining high quality care for non-COVID‑19 patients are then discussed. The concluding section
presents some emerging insights on how health systems can become more resilient to the ongoing
pandemic as well as future health crises.
Box 1.1. Key sources of information on COVID-19 related policies and data
The chapter builds on several recent publications and databases, particularly those provided by the:
• OECD Digital Hub on Tackling the Coronavirus, including policy briefs and policy trackers (https://www.oecd.org/
coronavirus)
• COVID‑19 Health System Response Monitor  (HSRM) of  the WHO Regional  Office for  Europe, the European
Commission,  and  the  European  Observatory  on  Health  Systems  and  Policies  (https://
www.covid19healthsystem.org)
• European Centre for Disease Prevention and Control (ECDC) datasets monitoring the COVID‑19 pandemic (https://
www.ecdc.europa.eu/en/COVID-19-pandemic)
• Eurostat  COVID‑19  datasets  of  weekly  mortality  data  to  calculate  excess  mortality  (https://ec.europa.eu/
eurostat/web/COVID-19/data)
These sources complement data collected for Health at a Glance: Europe that come from official national statistics,
often collected through joint questionnaires of the OECD, Eurostat and WHO.
In this chapter, data and analysis cover 31 European countries, including all 27 EU countries plus Iceland, Norway,
Switzerland and the United Kingdom.
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The health impact of COVID‑19 in European countries
The first officially reported COVID‑19 death in Europe was on 15 February 2020, with the virus
circulating on the continent from January or earlier (Spiteri et al., 2020[6]). The virus spread rapidly
across Europe, with Spain, France and the United Kingdom each reporting over one million COVID‑19
confirmed cases as of 31 October. In the first ten months of 2020 reported infection rates were highest
in Belgium, the Czech Republic, Luxembourg, and Spain, all of which reported over 25 000 confirmed
cases per million people. It is important to note, though, that the number of confirmed COVID‑19 cases
are influenced by cross-country differences in testing strategies, intensity of testing and differences in
the actual transmission of the virus.
Most people who are infected with COVID‑19 survive – infection fatality rate estimates have
ranged between 0.17‑1.7% (Meyerowitz-Katz and Merone, 2020[7]). Yet the number of deaths are still
striking due to the sheer number of people infected: as of 31 October 2020, over 7 million Europeans
have been infected by the virus. In most Western and Northern European countries, the first wave of
the outbreak occurred in March 2020. Over the summer period, most of these countries reported few
cases before facing a surge in the number of infections from late August (Figure 1.1). Central and
Eastern European countries did not experience many cases during the first half of 2020, but the
numbers have increased exponentially since August (Figure 1.2).
In terms of reported COVID‑19 deaths, as of 31 October 2020, the United Kingdom reported the
highest absolute number (over 46 000), followed by Italy, France and Spain with each reporting more
than 35 000 deaths. Adjusting for population size, Belgium reported over 1 000 COVID‑19 deaths
per million people; followed by Spain, the United Kingdom, Italy, Sweden and France, all with over 500
COVID‑19 reported deaths per million people. During the first wave, daily COVID‑19 deaths peaked in
early April for these countries, before gradually declining from May through July, though from late
August deaths have started to increase again (Figure 1.3). Reported rates up until the end of October
Figure 1.1. Evolution in reported COVID-19 cases, EU average and most populated European
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Note: The EU average is weighted.
Source: European Centre for Disease Prevention and Control (ECDC).
StatLink 2 https://stat.link/rphivu
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2020 were lowest in some Nordic countries (Finland, Iceland, Norway), the Baltic countries (Estonia,
Latvia, Lithuania), the Slovak Republic, Greece, and Cyprus (Figure 1.4 and Table 1.1).
Whilst reported COVID‑19 deaths are a critical measure of the health impact of the pandemic on
countries, comparability of this indicator is limited by differences in recording, registration and coding
practices across countries. Moreover, other factors, such as the low availability of diagnostic tests at
Figure 1.2. Evolution in reported COVID-19 cases, selected Central and Eastern European countries,
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Figure 1.3. Evolution in reported COVID-19 mortality rates in some of the most adversely affected
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the start of the pandemic are likely to have impinged on the accuracy of attributing the causes of death.
Therefore the reported count of deaths due to COVID‑19 may well be underestimated to varying
degrees across countries.
An analysis of mortality from all causes – and particularly excess mortality, a measure of deaths
from all causes over and above what would have normally been expected at a given time of the year –
provides a broader measure of mortality due to COVID‑19 that is less affected by the limiting factors
mentioned above. Although data on excess mortality is not a direct measure of COVID‑19 deaths, this
measure has the advantage of encompassing all deaths directly attributable to COVID‑19 and those
indirectly linked to it. This indicator therefore captures the net effect of the various actions taken by
governments and individuals during the pandemic that impact all-cause mortality rates. For example,
the number of indirect deaths may increase due to disruptions to patients’ care for other conditions, or
may decrease as a result of fewer deaths from traffic and workplace accidents following the lockdown
measures. Nonetheless, caution is needed when comparing excess mortality across countries at a
given  point  in  time,  notably  because  of  cross-country  variations  in  population  age  structures,
underlying death rates and evolution of the virus. Box 1.2 outlines the main methodological issues for
both variables. In this chapter, excess mortality is measured by comparing total recorded deaths from
March-June 2020 with the average for the same time period over the past five years (2015‑19).
Box 1.2. Limitations of COVID-19 deaths and excess mortality indicators
Main methodological issues limiting the cross-country comparability of COVID‑19 deaths data
For reported COVID‑19 deaths, cross-country comparability is linked to different registrations depending on where the
death occurred and the availability of testing (particularly early on in the pandemic), and different coding practices. In
particular:
• Whether COVID‑19 deaths occurring outside of hospitals are fully recorded. Belgium, France and Italy, among
others, put in place improved and faster reporting procedures early on to count deaths occurring in other settings,
notably care homes.
• Coding differences, especially whether suspected cases are counted alongside those confirmed by tests. Belgium
and the Netherlands are examples of countries coding probable as well as confirmed cases in their data on COVID‑19
deaths.
• Differences in testing capacity across countries and over time, with many countries having faced severe constraints in
testing capacities early in the pandemic.
Main methodological issues limiting the cross-country comparability of excess mortality data
Excess mortality has less severe cross-country comparability limitations than reported COVID‑19 deaths. However, it
is not a direct measure of COVID‑19 deaths, as it captures all excess deaths irrespective of their cause. National
variations in underlying death rates related to various events and evolution of the virus mean that caution is needed when
comparing excess mortality at a given point in time. In particular:
• Cross-country differences in other significant events this year and in previous years, such as severe or mild flu
seasons, heatwaves and natural disasters, can lead to under- or over-estimates of the impact of COVID‑19 on excess
mortality. In this report a five‑year period (2015‑19) is chosen to help smooth out such variations.
• Differences in timing of the onset of COVID‑19 can affect comparability. But the March-June timeframe used is wide
enough to include the first wave of the pandemic experienced in European countries to date.
For COVID‑19 and excess deaths, different delays in reporting deaths can affect cross-country comparisons.
Source: Morgan et al. (2020[8]), “Excess mortality: Measuring the direct and indirect impact of COVID-19”, https://doi.org/10.1787/c5dc0c50-en.
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Figure 1.4. Reported COVID-19 deaths per million population, up to end of October 2020







Note: Data comparability is limited due to different reporting practices.
Source: European Centre for Disease Prevention and Control (ECDC).
StatLink 2 https://stat.link/nowzuk
Figure 1.5. Excess deaths per million population, March to June 2020







Note: Data on Ireland are missing because of late registrations of deaths.
Source: Eurostat, except for the United Kingdom where data come from the Office for National Statistics; National Records of Scotland; Northern Ireland
Statistics and Research Agency.
StatLink 2 https://stat.link/wfk9ep
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Analysis of excess mortality data shows broadly consistent results with reported COVID‑19
deaths in terms of which countries were most adversely affected by COVID‑19, with some exceptions.
Spain and the United Kingdom recorded the highest excess death rates between March and June
2020 (over 950 excess deaths per million people),  followed by Italy,  Belgium, the Netherlands,
Sweden and France (between 400 and 750 deaths per million people). Excess mortality rates were
under 100 deaths per million people in 12 countries (Figure 1.5 and Table 1.1), including negative
rates in Bulgaria, Croatia, Latvia, Hungary, Iceland, Norway, Romania and the Slovak Republic.
Table 1.1. Confirmed COVID-19 cases, reported COVID-19 deaths and excess mortality
Country
COVID‑19 confirmed cases
(up to end of October)
Reported COVID‑19 deaths













Excess deaths Excess deathsper 1m pop
Austria 106 584 12 031 1 097 124 1 460 165
Belgium 429 134 37 461 11 625 1 015 8 388 732
Bulgaria 52 844 7 549 1 279 183 ‑1 346 ‑192
Croatia 49 316 12 098 546 134 ‑415 ‑102
Cyprus 4 366 4 985 26 30 141 161
Czech Republic 335 102 31 466 3 251 305 477 45
Denmark 46 351 7 983 721 124 208 36
Estonia 4 905 3 702 73 55 143 108
Finland 16 113 2 920 358 65 970 176
France 1 364 625 20 364 36 788 549 29 993 448
Germany 532 930 6 419 10 481 126 9 707 117
Greece 39 251 3 660 626 58 880 82
Hungary 79 199 8 104 1 819 186 ‑387 ‑40
Iceland 4 865 13 628 12 34 ‑14 ‑40
Ireland 61 456 12 531 1 913 390 .. ..
Italy 679 430 11 256 38 618 640 44 654 740
Latvia 5 894 3 070 71 37 ‑362 ‑188
Lithuania 14 824 5 305 165 59 52.2 19
Luxembourg 17 134 27 910 152 248 135 220
Malta 6 042 12 242 62 126 93 188
Netherlands 350 764 20 296 7 385 427 9 710 562
Norway 19 563 3 672 282 53 ‑24 ‑5
Poland 362 731 9 552 5 631 148 4 060 107
Portugal 141 279 13 748 2 507 244 3 554 346
Romania 241 339 12 431 6 968 359 ‑1 007 ‑52
Slovak Republic 57 664 10 580 219 40 ‑59 ‑11
Slovenia 34 307 16 487 231 111 251 120
Spain 1 185 678 25 261 35 878 764 47 904 1 021
Sweden 124 355 12 156 5 938 580 5 407 528
Switzerland 153 728 17 991 2 035 238 1 715 201
United Kingdom 1 011 660 15 179 46 555 699 64 022 961
EU27/26 (total) 6 343 617 14 197 174 428 390 164 612 372
Note: EU averages are weighted. EU totals and averages include 27 countries for COVID‑19 cases and deaths, and 26 for excess 
mortality. Data refer to the number of cases and deaths reported as of 31 October 2020; data for the most recent weeks may be 
under-reported and subject to revision. The calculation of excess deaths is with reference to the average of 2015‑19 and with 2020 
figures for weeks 10 to 26. Data were extracted on 1 November 2020.
Source: European Centre for Disease Prevention and Control (ECDC) for COVID‑19 cases and deaths. Eurostat for excess
mortality in EU and EFTA countries. Office for National Statistics, National Records of Scotland, Northern Ireland Statistics and
Research Agency for excess mortality in the United Kingdom.
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Negative rates are indicative of fewer deaths overall between March and June 2020 as compared to
previous years. All these countries also had relatively few reported COVID‑19 deaths.
It is critical to stress, though, that higher COVID‑19 and/or excess death rates do not necessarily
equate to less effective government responses to the virus. Some countries may be more susceptible
to COVID‑19 due to inherent  factors that  go beyond policy makers’  responses to the virus.  In
particular, the share of older people, the prevalence of certain risk factors such as obesity and
diabetes in a population, the intensity of tourism and international travel in and out of the country, and
population density are all likely to have affected the number of COVID‑19 deaths. Further, countries
that were first hit by large outbreaks (e.g. Italy) had necessarily less time to develop and implement
comprehensive policy responses, thus contributing to higher cases and deaths (see next section on
containment and mitigation policies).
The health crisis has also led to a major economic crisis, with countries hardest hit by COVID‑19
typically experiencing the largest economic contractions. All 31 European countries in this report
experienced negative economic growth in the second quarter of 2020, with the United Kingdom and
Spain most adversely affected, and Finland, Norway, Estonia and Lithuania less affected (Figure 1.6).
To what extent have containment and mitigation strategies adopted in European countries
contributed to slowing the spread of COVID‑19 during the first wave?
From the onset of the pandemic until the end of October 2020, non-medical containment and
mitigation actions2 were the only policy options countries had to prevent the spread of COVID‑19. This
reflects a context of limited information on the natural history of the infection and absence of a vaccine
or effective prophylactic treatment. This section describes the different policy measures implemented
by countries in the first half of 2020 and discusses their effects on citizens’ mobility as well as on the
dynamics of the epidemic.


























Note: The EU average is weighted.
Source: Eurostat.
StatLink 2 https://stat.link/zdqk7n
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The majority of European countries implemented similar containment and mitigation
measures during the first wave of the pandemic
Containment and mitigation strategies aim to minimise the risk of transmission of infections and
slow the spread of the virus. Without any intervention, the spread of a viral infectious disease generally
follows an S-shaped curve. That is, infections grow slowly at the beginning of the outbreak, accelerate
exponentially in its central phase when a critical mass of people are infected and many others are still
susceptible, and slow in its final phase when enough people are immune (either through natural
infection or vaccination). The central phase of this cycle corresponds to the peak of the infection. The
different policy options described in this section aimed to prevent the COVID‑19 outbreak from
reaching its exponential acceleration phase, or to at least curb it to alleviate the burden on health care
systems (Figure 1.7) (OECD, 2020[9]).
Containment and mitigation strategies can be grouped into three broad policy categories:
• Social  distancing  measures,  notably:  closing  workplaces  and  non-essential  services;  school
closures; banning mass gatherings; travel restrictions; and full society lockdowns.
• Improved personal and environmental hygiene, including the use of personal protective equipment
such as face masks.
• Testing, tracking and tracing of infected individuals, with confinement of affected persons. This can
be targeted or more large-scale testing and quarantine policies.
Table 1.2 summarises the main containment and mitigation strategies adopted by European
countries in the first half of 2020 in order to tackle the first wave of the pandemic. The information
reported in this section is retrieved from the European Centre for Disease Prevention and Control
(ECDC), the OECD health system policy tracker, and the European Observatory Health System
Response Monitor (see Box 1.1).
Figure 1.7. Flattening the epidemic curve to allow the health system to cope with surges in demand
Health system capacity
Number of infected persons
Time
Without containment and mitigation measures With containment and mitigation measures
Surge capacity
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Table 1.2. Containment and mitigation strategies adopted by European countries to address the first






institutions (days) Closure of public
spaces of any
kind (days)1










Austria 45 63 48 28 Compulsory Full closure
Belgium 53 65 65 51 Compulsory Selective closure








65 Compulsory Selective closure
Croatia No formal stay-at-
home order
55 55 60 Compulsory Selective closure
Cyprus 40 72 61 51 Compulsory Selective closure
Czech Republic 39 88 88 59 Compulsory Selective closure
Denmark No formal stay-at-
home order
30 63 33 Recommended Full closure
Estonia No formal stay-at-
home order
62 62 65 Recommended Full closure





74 Recommended Selective closure
France 55 98 55 55 Recommended Selective closure
Germany No formal stay-at-
home order2
52 52 49 Compulsory Selective closure
Greece 42 82 60 50 Compulsory Selective closure














55 Compulsory Full closure








55 Recommended Full closure
Lithuania 76 62 62 76 Compulsory Full closure
Luxembourg 32 70 48 34 Compulsory Selective closure
Malta No formal stay-at-
home order
109 109 64 Compulsory Full closure
Netherlands No formal stay-at-
home order
55 77 47 Recommended Selective closure
Poland 26 73 73 50 Compulsory Selective closure





62 51 Compulsory Selective closure
Romania 52 77 77 56 Compulsory Full closure
Slovak Republic No formal stay-at-
home order
81 81 65 Compulsory Selective closure







50 Compulsory Full closure




89 No formal closure Not recommended Selective closure





49 48 Not recommended Selective closure
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Table 1.2. Containment and mitigation strategies adopted by European countries to address the first






institutions (days) Closure of public
spaces of any
kind (days)1










Norway No formal stay-at-
home order
46 64 64 Not recommended Full closure
Switzerland No formal stay-at-
home order
58 75 34 Recommended Selective closure
United Kingdom 46 69 83 54 Recommended Selective closure
1. Public spaces refer to all leisure places (parks, restaurants, bars, cinemas, etc.) and all non-essential shops and services. 2. In Germany, some federal 
states imposed general stay-at-home orders.
Source: ECDC, OECD health system policy tracker, European Observatory Health System Response Monitor.
Social distancing measures were implemented in almost all European countries, but with
different levels of stringency
Social (physical) distancing refers to policies that deliberately increase physical space between
people. These come in many forms, including banning large gatherings; school closures; encouraging
people to work from home; closing non-essential stores, restaurants and cafes, and formal stay-at-
home orders. They can be implemented across an entire community, or target specific at-risk groups
such as the elderly and those with pre-existing health conditions (Anderson et al., 2020[10]). Several
challenges are associated with the implementation of social distancing measures. These include:
reduced economic activity, loss of human capital due to the closure of schools, neglect of vulnerable
populations (such as the elderly), and psychological damage (Boddy, Young and O’Leary, 2020[11];
Brooks et al., 2020[12]).
Among the European countries analysed in this report, just over half (16 out of 31) adopted
formal  stay-at-home  orders  (with  different  degrees  of  stringency,  for  instance  in  terms  of
authorisations to circulate) during the first wave of the pandemic. Such orders lasted an average of
47.5 days, ranging from 26 days in Poland to 76 days in Lithuania. Some countries also adopted
specific measures targeting specific population groups. For instance, the United Kingdom subjected
highly vulnerable individuals with pre-existing health conditions to even more stringent isolation and
confinement measures relative to the general population. Closure of public spaces such as non-
essential stores, bars, or restaurants was enforced in all countries except Sweden, for an average
duration of 56 days. This measure was enforced for the shortest duration in Austria (28 days),
Denmark (33 days) and Switzerland (34 days), with the longest duration in Ireland (120 days).
All countries but Sweden and Iceland closed primary schools, for an average of 68 days. In
seven countries (Bulgaria, Ireland, Italy, Latvia, Poland, Portugal and Spain), primary school closures
were maintained until the respective start dates of their school summer holidays. Denmark reported
the shortest duration of primary school closure (30 days). For secondary schools, all  European
countries opted for closure, for an average of 69 days. Austria and Luxembourg reported the shortest
duration of secondary school closure (48 days), and in six countries (Bulgaria, Finland, Ireland, Italy,
Latvia and Spain) closures were maintained until the summer break. All countries closed higher
education institutions until the new academic year.
To prevent or delay the entry of a disease into a country, governments have also implemented
travel restrictions. Such measures included, among others, bans on non-essential travel, voluntary or
legally mandated isolation upon arrival into a new country, and border closures. On 17 March 2020,
EU Member States agreed on a co‑ordinated action at external borders, restricting non-essential
travel for a specific period (which was extended a number of times). This meant that travel to the EU
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and Schengen Area  countries  were  not  allowed for  third  country  citizens.  As  for  cross-border
movement within the EU and the Schengen Area, most countries (20 out of 31) only closed access to
their territory to citizens from selected countries. The remaining 11 countries closed their borders
entirely at some point during the outbreak.
In response to the second wave of COVID‑19, countries initially adopted more geographically
targeted social distancing measures. In France, for instance, containment and mitigation decisions
were taken region by region, and included a four level gradation (based on epidemiologic indicators),
with  progressive restrictions.  In  Spain,  the Inter-territorial  Council  agreed to  a set  of  restrictive
measures to be taken in municipalities with more than 100 000 inhabitants if certain epidemiologic
thresholds were reached. Such measures included restrictions on exit and entries from the affected
municipality, limits on maximum capacity of retail and services businesses open to the public, and
early closures of restaurants and bars.
Yet, such measures have not managed to slow the spread of the virus in Autumn, with many
European countries  implementing stronger  containment  measures from late  October  2020.  For
example, France re-installed a new nationwide lockdown from October 30, very similar to their first
lockdown other than initially keeping primary and secondary schools open. The United Kingdom took
similar measures as of November 5. In Germany, a partial nationwide lockdown was enforced from
November 2 (during the first wave, such decisions were made by regional authorities), with schools
kept open but non-essential businesses closed. Belgium and the Czech Republic are other recent
examples  of  countries  introducing  more  stringent  containment  and  mitigation  measures  in  the
Autumn.
Wearing face masks in indoor public spaces became compulsory in most European
countries
Personal hygiene measures include frequent hand washing, use of hand sanitisers, coughing
and sneezing etiquette, and the use of protective face masks (e.g. surgical-type). For the COVID‑19
outbreak, the most vigorous discussions focused on face masks as a means to prevent contamination
in public spaces. Official recommendations on mask wearing by the general population often evolved
substantially over the course of the outbreak, despite existing evidence available suggesting their
potential effectiveness to help contain the spread of the virus. For instance, studies of influenza,
influenza-like illness, and human coronaviruses (not including COVID‑19) showed that medical masks
can prevent the spread of infectious droplets from a symptomatic infected person (Canini et al.,
2010[13]; MacIntyre et al., 2016[14]; Asadi et al., 2020[15]). Similarly, a study of the SARS outbreak in
Hong Kong, China found that people who became infected were less likely to have frequently worn a
face mask in public or to have regularly washed their hands (Lau et al., 2004[16]). Overall, even if the
possibility  of  aerosol  transmission  (on  top  of  droplet  transmission)  has  not  been  formally
demonstrated, such means of contamination (particularly in specific indoor locations, e.g. crowded
and inadequately ventilated spaces, over a prolonged period of time) cannot be totally ruled out and
adds credit to the utilisation of face masks in situations where social distancing rules cannot be
properly enforced (WHO, 2020[17]).
Following the gradual easing of confinement measures, mask wearing was made compulsory in
closed  public  areas  such  as  shops  or  public  transport  in  the  majority  of  European  countries
(18 out of 31). For instance, France required the use of face masks on public transit and in public
whenever appropriate physical distancing could not be maintained. Violations could be met with a
EUR 135 fine. Some countries imposed even more stringent measures: in Italy, an August 2020
decree of the Ministry of Health made mask wearing mandatory at night (defined as 6pm to 6am) in “all
spaces open to the public”. In eight countries, government authorities recommended the use of face
masks, but without imposing fines for non-compliance. Only three countries (Iceland, Norway3 and
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Sweden) did not make any recommendation to the general population regarding the utilisation of face
masks.
Limited testing capacities in some countries hampered early large-scale population testing
Large-scale population testing and associated quarantines are an essential means to control the
outbreak. From the beginning of the outbreak, OECD and the WHO have recommended prioritising
active, exhaustive case finding and immediate testing and isolation, along with rigorous contact
tracing and quarantine of close contacts (OECD, 2020[18]; WHO, 2020[19]). Ensuring an adequate
availability of diagnostic laboratory equipment and a sustained supply of related products needed to
perform testing has been a major concern for health policy makers. Large-scale testing for COVID‑19
infections requires trained staff, supplies, testing kits and equipment, in addition to the entire workflow
from logistics of collecting samples from patients to the reporting of results to them and to public health
authorities. This has proven to be particularly challenging in larger or more populated countries.
One way to estimate the initial COVID‑19 testing capacity of countries is to look at the number of
daily tests performed at the beginning of the outbreak. Figure 1.8 reports the daily number of tests per
100 000 population by country, 30 days after each country reached a mortality rate of ten deaths
per million population.4 Germany reported the highest number of daily tests performed, with more than
434 tests per 100 000 people. This is roughly twice as much as the group of countries with the second-
highest daily testing rates: Denmark, Sweden, Netherlands, Lithuania, Spain and Malta (between
200‑250 tests). At the other end of the spectrum, some countries reported much lower numbers,
notably Bulgaria, Croatia, Hungary, Romania, Switzerland and France (all with under 50 tests per
100 000 people).
However, daily tests at the start of the outbreak in each country provide only a partial picture of
the situation. The number of cumulated COVID‑19 tests performed in each country in the early phase
of the outbreak provides further insights. All studied countries increased their initial testing capacity,
Figure 1.8. Daily number of tests per 100 000 population 30 days after the country recorded 10 deaths
per million population (averaged over a week)
434
250 243 234 229 225 208
162 159
126 124 120












Number of tests, per 100 000 population
Note: The EU average is unweighted. In order to mitigate daily fluctuations in reporting, values displayed correspond to an average of the daily number of
tests performed on the week of analysis. The analysis covers the period between February and June 2020.
Source: Roser et al. (2020[20]), “Our World in Data”, https://ourworldindata.org/coronavirus.
StatLink 2 https://stat.link/i5txc1
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sometimes substantially. Between the first and second months after reaching ten deaths per million
population, nine countries – Belgium, Denmark, Ireland, Italy, Portugal, Romania, Spain, Sweden and
the United Kingdom – managed to at least double the cumulated number of tests per population. Yet,
two months after each country reached ten deaths per million population, the cumulated number of
tests per 1 000 population still varied substantially across countries, ranging from less than 20 in
Croatia, France and the Netherlands, to more than 100 in Denmark, Luxembourg, Lithuania, Iceland
and Malta.
Variation in countries’ testing capacities can be explained by a mix of strategic, logistic, capacity,
and regulatory considerations. For instance, in Italy and France, at the beginning of the outbreak
authorities decided to limit testing to patients in serious conditions while in Iceland, a large-scale
testing regime was implemented early on in the outbreak. From mid-March, Iceland started mass
screening for COVID‑19 on the basis of voluntary self-referrals to identify the extent of the spread of
the virus in the general population; screening was performed on any volunteers, regardless of their
health status. Some countries also brought testing closer to where people lived. For instance, in
Lithuania municipalities were asked to set up mobile points for testing so as to facilitate access in
remote areas. Digital tools to track cases frequently complemented testing capacities in countries (see
below).
Finally, wastewater-based epidemiology (measuring chemical signatures in sewage, such as
fragment biomarkers from COVID‑19) has the potential to complement countries’ surveillance efforts
– by helping to detect early on possible infection outbreaks across an entire community (Daughton,
2020[21]). Some countries such as the Netherlands are currently studying whether this method could
become a valuable tool for rapid outbreak detection and intervention5.
Mobile technologies to help track, trace and isolate SARS-CoV‑2 infections have been
developed
Contact tracing is an investigative process through which the recent contacts of confirmed cases
are traced backwards, so that they can in turn be tested and isolated as a means to “break the chain”
of contagion. Especially when the prevalence of infection is still relatively low and geographically
limited, contact tracing can thus be an important component of an effective containment strategy.
However, it is a very labour-intensive activity, which requires trained investigators to manually track
down people who have been exposed to infected individuals. As the number of professional contact
tracers was insufficient in most countries, and the speed at which contacts are traced is a crucial
variable  for  the  success  of  this  strategy,  several  countries  have  looked  into  the  possibility  of
automating at least part of this process using digital instruments such as smartphone apps and related
technologies.
Across Europe, digital contact-tracing apps have either been developed or launched in at least
23 European countries.  Based on a self-report  system by users who have been diagnosed as
infected, these apps use data on proximity (Bluetooth) and location (cell towers and global positioning
system, i.e. GPS) to identify individuals who may have been exposed to confirmed cases. Alerts are
then sent to those individuals, recommending that they should be tested or even self-isolate. Some
apps send broad alerts that cases have been confirmed in a certain area, and other apps target alerts
at specific individuals who may have been in contact with a confirmed case. Some apps are used by
traditional face-to-face contact-tracers to assist them in interviewing potential contacts, while other
apps are fully automated. The data generated by these apps can be communicated to, and stored in, a
central server or it can be decentralised, saved only in the mobile devices of users (this is the case with
the Google/Apple protocol that some countries have adopted).
Some digital tools – like the Google COVID‑19 Mobility Report – use aggregate data from many
individuals to monitor changes in mobility in response to lockdowns, social distancing and quarantine
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policies. Other digital applications take advantage of data on specific individuals to enforce policies to
contain the spread of the virus. In Poland, the Home Quarantine app uses facial recognition and
location data to monitor and enforce quarantine, including by levying fines, and can be used by the
police. In France, cities are using artificial intelligence and CCTV to monitor the use of masks in public
spaces. Lichtenstein is the first European country to use electronic bracelets to collect biometric data
in real time, and the United Kingdom is using an app to collect self-reported symptoms from users.6
Over 50 million Europeans downloaded digital contact tracing apps in the first nine months of
2020.7 Close to 40% of the Icelandic population has downloaded its Rakning C‑19 app; and between
20‑30% of populations in Finland, Germany, Ireland, Norway, Switzerland and the United Kingdom
have downloaded national apps. Most apps target 50‑60% penetration to reduce the reproduction
number (i.e. the expected number of cases directly generated by one case in an infection-naïve
population).
While lower adoption rates may still have some benefits, low rates will inevitably fail in their
objective of facilitating traditional contact tracing efforts. There are also questions regarding the
reliability and accuracy of the underlying data, and the potential for false positives and false negatives.
Furthermore, in 2019, around 27% of individuals aged 16‑74 years old did not use mobile devices to
access the internet in the EU, going up to 51% among individuals aged 55‑74. For all this, a fully
automated digital contact-tracing strategy is unlikely to be successful, although it can complement
traditional contact-tracing efforts (ECDC, 2020[22]).There are also significant concerns regarding the
potential for misuse and privacy abuses. A recent assessment of 17 contact-tracing apps (including
apps from Europe) found them to be insecure and easy to hack (Guardsquare, 2020[23]). There is
also a fear of “mission creep”, and that once new powers of surveillance are introduced, they are
difficult to reverse, even when the crisis has passed (OECD, 2020[24]).
Routinely collected data from electronic health records are underutilised but could be
instrumental to containment and mitigation strategies
Beyond innovative uses of mobile technology, there are rich opportunities to take advantage of
the massive amount of data that are collected every day in health systems across Europe. Countries
with standardised national electronic health records (EHRs) can extract high quality routine data from
those systems for real-time surveillance, but only six European countries (Austria, Denmark, Estonia,
Finland, Slovak Republic and the United Kingdom), have high technical and operational readiness to
generate information from EHRs (Colombo, Oderkirk and Slawomirski, 2020[25]; Oderkirk, 2017[26]).
Finland and Iceland both have national EHR systems with patient portals and, as a result, were able to
quickly develop the capability to track COVID‑19 patients’ longitudinal progress, offer integrated tools
for people to report their symptoms, and triage people to appropriate services as their symptoms
progressed. In England, where an analytics platform for research with primary care EHRs was already
established, data from records covering over 17 million primary care patients were linked to deaths in-
hospital from February through to the end of April to identify risk factors for death from COVID‑19, with
results published online in early May (Williamson et al., 2020[27]).
OECD data from 2019/20 indicate that ten EU countries are prepared to undertake national
dataset linkages in support of COVID‑19 research because they routinely link at least hospital and
mortality data (Austria, Czech Republic, Denmark, Finland, France, Latvia, Netherlands, Norway,
Slovenia and Sweden). However, very few of these countries had data timely enough to be useful for
decision-making. Only 3 out of 16 surveyed European countries had hospital and emergency care
data that were updated either daily or weekly, and only two had mortality data in real time. Further,
only six countries (Austria, Denmark, Estonia, Finland, Slovak Republic and the United Kingdom)
made a range of health care data readily and securely available to the research community through
real-time remote access services or a research data centre. These services increase the probability of
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having a strong cadre of researchers familiar with the data who could respond quickly to generate new
information to address the crisis.
Time of implementation has been the main factor differentiating countries’ strategies
Overall, apart from Sweden, most European countries implemented similar containment and
mitigation measures during the first wave of the pandemic. Sweden encouraged social distancing but
largely limited mandatory restrictions to prohibiting gatherings above 50 people. In addition, even in
countries with no formal stay-at-home orders, the closure of both academic institutions and public
spaces has contributed to similar intended effects on people’s mobility (see Table 1.2).
However, one of the elements differentiating countries’ policy interventions is the timing of their
enforcement. Not all countries were able to implement measures at an early stage of the first wave of
the pandemic. Countries that were first hit by the outbreak implemented mitigation and containment
strategies at a moment when the disease was already spreading widely in the communities. For
instance, public spaces were closed less than ten days before the country reached the threshold of ten
deaths per million population in Italy (one day), Spain (four days), France (seven days), Belgium
(seven days), the United Kingdom (ten days). In contrast, Hungary, Lithuania, Poland, Latvia and the
Slovak  Republic  enforced  containment  and  mitigation  strategies  more  than  one  month  before
reaching the threshold of ten deaths per million population. Being able to learn from the experiences of
countries first hit by COVID‑19 appears to have helped these countries control the first outbreak of the
pandemic.
Containment and mitigation policies, particularly early targeted interventions, have
contributed to control the first wave of the pandemic
There  is  no  commonly  accepted  method  to  estimate  the  relative  efficacy  of  the  different
containment and mitigation strategies adopted by countries during the first wave of the pandemic. In
this section, analysis focuses first on the general effect of these policies on population mobility, relying
on Google Community Mobility data. Then, in order to compare the relative effects of these policies on
the control  of the outbreak, two indicators are used: the reproduction number and daily patient
admissions in intensive care units (ICUs).
Containment and mitigation strategies substantially reduced people’s mobility
Google Community Mobility  data show how visits  to (or  time spent  in)  categorised places
changed compared to a baseline reference. This reference was defined as the median value from the
period 3 January to 6 February 2020. In order to estimate the overall stringency of the containment
and mitigation measures taken by countries, an average reduction in mobility was calculated over
March to May 2020 (i.e. from when most European countries enforced general social distancing
measures), as compared with the reference period (Figure 1.9). Analysis focused on leisure activities
(notably restaurants, cafes, shopping centres, theme parks, museums, libraries, movie theatres) and
public transport (notably metros/subways, bus hubs and train stations).
As shown in Figure 1.9, containment and mitigation strategies have had a substantial impact on
people’s mobility. All countries reported a reduction in the mobility of their populations over the studied
period, ranging from ‑7.4% in Sweden to over ‑20% in Spain and Italy. In the first weeks following the
enforcement of these policy options, the mobility of the population in certain countries was almost
total, with reductions of ‑85% or more in Spain, Italy or France. Differences in the measures adopted
can explain some of the variation observed across countries. For example, places with formal stay-at-
home orders had an average reduction of ‑16.5% compared to ‑12.8% for those without. Overall, it
appears that general lockdowns and closures of public spaces reached their intended objective to limit
people’s mobility and as a result their potential interactions.
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It took on average 34 days to European countries to control the first wave of the outbreak
However, other indicators are needed to assess whether containment and mitigation strategies
were effective in actually controlling the epidemic. One measure of viral spread is the R0, the expected
number of secondary infectious cases produced by a primary infectious case. This calculation is used
to determine the potential for epidemic spread in a susceptible population. In order to estimate the
dynamic of an epidemic over time, the effective reproduction number (Rt), can be used. It describes
the potential for epidemic spread at a specific time t under the control measures in place (Pan et al.,
2020[29]; Xiao et al., 2020[30]; Inglesby, 2020[31]).
The objective of prevention interventions, including containment and mitigation strategies, is
therefore to bring the value of Rt to below one, that is, when the number of infected persons will
decrease over time. Figure 1.10 presents the number of days needed to bring the Rt from its highest
value in each country to below one for at least four consecutive days. On average, it took 34 days for
countries to bring this indicator to below one after the epidemic started spreading in the country. The
country with the shortest period was Malta (11 days), with Sweden reporting the longest period
(58 days).
Many of the countries that have been most severely hit by the COVID‑19 outbreak – such as
Belgium, France, Italy, the Netherlands, Sweden and the United Kingdom – required a greater number
of days to bring down their Rt to below one from their respective peak levels. Simple correlations of the
rates at  which Rt  declined with  the duration and intensity  of  lockdowns shed some interesting
preliminary insights – notwithstanding that correlations do not equal causation, with multivariate
analysis needed to better identify the relative effect of each factor. First, there was no clear association
between the implementation of lockdown measures (using the mobility data reported in Figure 1.9
above) and decreases in the Rt, nor between the duration of general lockdown orders and the rate at
which the Rt decreased below one. Conversely, a moderate correlation was identified between earlier
closure of public spaces and higher rates of Rt decrease. Countries that could enforce early closures
of general public spaces (i.e. more than two weeks before the country reached ten deaths per million
population) reported an average of 30 days to reduce the Rt, compared to 39 days for countries with
later dates of public spaces closure.
Figure 1.9. Reduction in populations’ mobility over the March-May 2020 period, compared to baseline
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Note: This figure represents an average of the reduction in mobility of populations over a three‑month period (March to May 2020). It combines reductions
in public transport and leisure activities. The baseline reference was defined as the median value from the 5‐week period 3 Jan to 6 Feb 2020.
Source: Google LLC (2020[28]), “Google COVID-19 Community Mobility Reports”, https://www.google.com/covid19/mobility.
StatLink 2 https://stat.link/6utni1
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Along with the Rt,  another indicator  that  reflects the impact  of  containment  and mitigation
strategies is the number of daily ICU admissions for patients suffering from critical forms of COVID‑19.
This indicator is useful to analyse the dynamic of the epidemic, since admission criteria to ICUs are
similar across European countries, and changes in the propagation of the virus may quickly be
reflected in the number of admissions in these wards.
Figure 1.11 reports the evolution in the weekly number of new ICU admissions after the peak in
the number of new admissions for selected countries. In France, Ireland and the Netherlands (which
have enforced similar containment and mitigation strategies),  the number of weekly admissions
decreased sharply  while  for  Sweden,  which  relied  on  a  different  strategy  for  containment  and
mitigation, this reduction was much less marked.
The effectiveness of containment and mitigation strategies depends on the rapidity of policy
action, with population density and the degree of trust in government also important
Overall, it appears that the containment and mitigation strategies enforced by countries during
the first wave of the pandemic achieved their intended effects of reducing people’s interactions
(measured using mobility data as a proxy), thereby contributing to limiting the spread of the virus. Yet it
remains challenging to determine the relative effect of each of the decisions taken in the evolution of
the situation at country level, and how they interact with other characteristics of each country and of
their populations. Preliminary findings suggest that early targeted interventions are more likely to pay
off, but this needs to be further studied via more complex statistical models8. It is also useful to
compare approaches taken by European countries with actions taken by some Asian Pacific countries
that  successfully  controlled  COVID‑19,  such  as  Korea  (see  Box  1.3)  and  New  Zealand.  In
New Zealand, an “elimination strategy” (as opposed to a “mitigation strategy”) was implemented very
early on, in an effort to prevent the introduction and local transmission of COVID‑19. This approach
had a strong focus on border control (easier to apply on an island state) and emphasised case
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Number of days from the peak value of Rt to lower than one for at least four consecutive days
Note: The EU average is unweighted. Values displayed are sensitive to a number of factors that may limit comparability. In particular, the serial interval of
the disease (i.e. time between onset of symptoms in a first case and subsequent cases) is set at seven days – for COVID‑19 this value has been estimated
to be somewhere between four‑eight days.
Source: Real-Time Estimates of the Effective Reproduction Rate of COVID‑19, http://trackingr-env.eba-9muars8y.us-east-2.elasticbeanstalk.com/,
accessed 23 July 2020; Arroyo Marioli et al. (2020[32]), “Tracking R of COVID-19: A New Real-Time Estimation Using the Kalman Filter”, https://doi.org/
10.1101/2020.04.19.20071886.
StatLink 2 https://stat.link/qrh5cb
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isolation  and quarantine  of  contacts  to  “stamp out”  chains  of  transmission (Baker,  Wilson and
Anglemyer, 2020[33]).
Low population  density  and relatively  high  level  of  trust  and compliance with  government
recommendations have also contributed to the effectiveness of containment and mitigation strategies
in New Zealand as well as in some European countries. Up until the end of October 2020, countries
like Estonia, Finland and Norway were better able to limit the health and economic impacts from the
pandemic. These countries had the advantage of having amongst the lowest population density in
Europe. In addition, relatively high level of trust in government may have contributed to increased
compliance with government containment and mitigation strategies (OECD, 2019[34]).
Box 1.3. Korea managed to control the COVID-19 outbreak without relying on severe
social distancing policies
Korea has been praised for its successful containment of COVID‑19. Following substantial transmission among the
members of a large religious group that fuelled early virus transmission, the country was quickly able to bring COVID‑19
under control. Korea’s response stands out because it flattened the epidemic curve swiftly without closing businesses,
issuing stay-at-home orders, or implementing many of the stricter measures adopted by European countries.
This success seems first to stem from the lessons learnt by the country following the 2015 outbreak of MERS. After
this outbreak, the country enforced a series of policy changes to improve pandemic preparedness and response. When
COVID‑19 struck, the authorities were ready to establish an aggressive response and the population was experienced in
the use of facemasks or contact-tracing activities.
As a result, when the first COVID‑19 cases were reported, Korea focused on setting-up large-scale population testing.
Many biotechnology companies were created in the aftermath of the MERS crisis and this facilitated the establishment of
public-private partnerships to develop and scale up testing for SARS-CoV‑2. Following instructions from the Korean
Centre for Disease Control, companies were quickly able to produce thousands of test kits daily. By the end of April
2020, 118 institutions were available to run diagnostic tests. Collectively, these institutions had the capacity to run an
average of 15 000 tests per day.
After expanding testing capacity, the government designed a large population screening policy. Authorities opened
600 screening centres using innovative approaches to increase capacity such as drive-through or phone‑booth style
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Note: Variation in the number of new admissions are compared to the value at the peak of admissions. Data refer to first wave of the pandemic.
Source: European Centre for Disease Prevention and Control (ECDC).
StatLink 2 https://stat.link/vlf7po
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Box 1.3. Korea managed to control the COVID-19 outbreak without relying on severe
social distancing policies (cont.)
testing centres. To prevent infected people from entering hospitals, screening clinics were set up outside entrances.
Some facilities were also transformed into temporary isolation wards so as to avoid transmission within households and
reduce hospital occupancy rates. Health care workers regularly monitored these patients who did not warrant inpatient
treatment.
Widespread contact-tracing was also key. Authorities scaled up their network of contact-tracers and gave them
access to different types of data, in addition to what they might be able to learn from the classic patient interview. Lastly,
massive public communication campaigns were set up to encourage citizens to assist the health system with contact
tracing.
The Korean experience may not necessarily be relevant to all countries. The country is urbanised and is isolated in
terms of borders. Yet the country’s investments in preparedness and an early decision to focus on a massive testing and
tracing strategy certainly are important lessons for European countries.
Source: Roser et al. (2020[20]), “Our World in Data”, https://ourworldindata.org/coronavirus; OECD (2020[18]) “Testing for COVID-19: A way to lift
confinement restrictions”, http://www.oecd.org/coronavirus/policy-responses/testing-for-covid-19-a-way-to-lift-confinement-restrictions-89756248/.
Have European countries’ health systems had sufficient capacity to treat patients infected
with COVID‑19 during the first wave of the pandemic?
Despite efforts to limit the spread of COVID‑19, the first wave of the pandemic subjected health
systems across Europe to an overwhelming and sudden surge in the number of patients in need of urgent
treatment. This section evaluates the ability of European countries’ health systems to respond to this
unprecedented increase in demand for care. It includes an analysis of government spending to bolster the
health system response; and the adequacy of pre-existing capacity, as well as policies adopted to provide
surge capacity. Analysis is concentrated on health system responses to immediate needs and do not
include collective efforts on the search for effective future treatment, tests and vaccines.
Governments freed up additional resources to strengthen health system responses
to COVID‑19
Governments put together substantial financial packages to respond to the COVID‑19 pandemic.
These resources were used to protect people’s jobs and businesses, as well as to strengthen health
system responses to COVID‑19. Across European countries, most fiscal responses – including direct
budgetary measures related to spending and revenue policies, alongside other interventions such as
loans, equity injections and government guarantees – amounted to between 5‑20% of GDP (OECD,
forthcoming[35]).
The health sector was naturally among the first recipients of additional financial resources.
Amongst European countries with comparable data, central government budgetary commitments to
health  system  responses  to  COVID‑19  ranged  from  almost  EUR  450  per  person  in  the
United Kingdom, and around EUR 300 per person in Germany and Ireland, to under EUR 50 per
person  in  Latvia,  Greece,  Iceland  and  the  Netherlands,  adjusted  for  purchasing  power  parity
(Figure 1.12).
Common  COVID‑19‑related  budget  measures  in  the  health  sector  include:  financing  the
procurement of specialised medical and personal protective equipment (PPE), expanding testing
capacities, hiring of additional workforce and bonus payments, support to hospitals and to subnational
governments, and contributions to vaccine development (Table 1.3). For example, the first response
package in Spain contained EUR 3.9 billion additional spending measures for the health sector, of
which EUR 1 billion went as direct budget support to the Ministry of Health, EUR 2.8 billion was given
as advance transfers to regions for regional health services, and EUR 0.1 billion went on research on
new drugs and vaccines.
HEALTH AT A GLANCE: EUROPE 2020 © OECD/European Union 2020 43
1. HOW RESILIENT HAVE EUROPEAN HEALTH SYSTEMS BEEN TO THE COVID‑19 CRISIS?
These figures constitute only central government spending commitments, with differences in per
capita spending levels attributable in part to the different roles of sub-national governments (SNGs) in
the COVID‑19 response. For example, in Belgium, the government of Wallonia set EUR 115 million
earmarked  to  help  the  health  and  social  sector  (Walloon  Government,  2020[36]).  Spain  and
Switzerland are further examples of countries where SNGs have dedicated significant budgetary
resources for the health sector.
In  addition,  compulsory  health  insurance  played  a  significant  role  in  financing  emergency
responses (in countries with such health financing arrangements). For instance, in Germany health
insurance funds have contributed EUR 5 billion together with the federal government for a Protective
Shield that provides funding to hospitals to mitigate against revenue shortfalls and higher costs.
Given the scale of government financial support to health systems, a number of countries have
implemented specific expenditure tracking and performance monitoring measures. In Austria, the Ministry
of Finance has set up separate accounts for COVID‑19 expenditure, which are then shared in a monthly
report to the Parliament. In the United Kingdom, the government asked the NHS to use unique COVID‑19
cost centres and budget codes to help account for the resources used to tackle COVID‑19. In France, an
amended state budget law has created a new budget mission and two new budgetary programmes on
COVID‑19, with associated objectives, spending measures and performance indicators.
Health professionals have been at the forefront of the response to the COVID‑19
outbreak
As doctors, nurses and other health professionals mobilised on the frontline to respond to the
pandemic, health systems sought ways to increase the number of staff available during the peak of the
pandemic and to make the most efficient use of their work.
The first wave of the COVID‑19 pandemic made pre-existing shortages of doctors and nurses
more  visible  and acute  in  many countries.  Some countries,  such  as  Norway,  Switzerland  and
Figure 1.12. Central government additional COVID-19 health spending commitments per capita, 2020















Note: The EU average is unweighted. These figures represent estimates from official announcements of spending measures against COVID‑19. They are
commitments rather than actual expenditures. Figures reflect central government spending commitments only, excluding commitments by subnational
governments, external donors or private donations.
1. Denotes countries with a significant budgetary response at the subnational level.
Source: OECD member country governments (typically from ministries of finance or parliamentary reports).
StatLink 2 https://stat.link/3ou270
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Germany, had a relatively high number of doctors and nurses per capita prior to the start of the
pandemic relative to other countries. This provided them with a greater potential to respond to the
steep rise in demand for care, assuming that the activities of some of these health professionals could
be reallocated to deal with the crisis (for instance via additional training). Countries in Central and
Eastern Europe, such as Poland, Latvia and Romania, had comparatively fewer doctors and nurses
per population, and therefore less capacity to respond to the epidemic (Figure 1.13). During the first












Main expenditure areas Date of latest availableofficial announcement
Austria 579 55 Purchase of PPE and medical equipment, research 6 May
Belgium1 1 000 75 Purchase of medical equipment and PPE 20 April
Czech Republic 40 300 214 Health insurance payments, salaries, PPE, medical devices, hospital
debt relief
7 May
Denmark1 3 100 50 Procurement of PPE 29 May
Estonia 213 120 Transfer to Estonian Health Insurance Fund 2 April
Finland 1 087 155 Additional health costs, testing, PPE and medical equipment,
research on diagnosis and vaccines
24 September
France 8 000 108 Extraordinary health care expenses including equipment and masks,
staff remuneration
10 June
Germany1 26 790 302 Central procurement of PPE, vaccine development and treatment
measures
18 September
Greece 273 30 Hiring additional health workforce, acquisition of medical supplies 29 April
Iceland 2 500 32 Hospital services, testing capacities, mental health services, health
workforce bonuses
21 April
Ireland 1 800 274 Expand hospital capacity, develop primary and community-based
responses, procurement of medical equipment
12 May
Italy1 6 312 101 Hiring of medical and nursing personnel, expanded private hospital
capacity, purchase of medical equipment
17 March
Latvia 59 21 Health personnel expenditures, procurement of PPE, testing
equipment, ventilators, surveillance, laboratory network
4 September
Lithuania 249 53 Purchasing PPE, equipment, bonuses and social guarantees for
health care workers
1 July
Luxembourg 194 217 Medical equipment and health infrastructure, testing capacities 4 April
Netherlands 800 39 Purchase, distribution and sale of medical devices, contribution to
vaccine research, training additional health care personnel
24 April
Norway 12 160 148 Expenses for medicines and medical equipment, laboratory
expenses, vaccination development
12 May
Poland 7 500 80 Creating and equipping infection hospitals, medical transport,
additional health care services, purchasing PPE
1 April
Portugal 504 57 Health personnel expenditures, acquisition of medical equipment 18 June
Slovenia 247 99 Purchase of medical, protective equipment 30 August
Spain1 10 030 220 Ministry of Health support, transfer to regions, research on drugs and
vaccine development
12 July
Sweden 12 366 89 Public Health Agency, National Board of Health and Welfare,
Swedish Medical Produce agency, transfers to municipalities and
regions for costs associated with testing and tracking
21 September
Switzerland1 2 910 180 Procurement of PPE, tests, medical supplies, medicines, funds for
Coalition for Emergency Preparedness and Innovations
12 August
United Kingdom1 32 000 446 PPE; Test, Trace, Contain and Enable programme, procurement of
additional ventilators
8 July
1. Denotes countries with a significant budgetary response at the subnational level.
Source: OECD member country governments (typically from ministries of finance or parliamentary reports).
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phase of the pandemic in the spring of 2020, the COVID‑19 outbreak did not reach the same peak in
cases and mortality as in many countries in Western and Northern Europe. Still, since August, the
situation  has  deteriorated  in  some  Central  and  Eastern  European  countries  such  as  the
Czech Republic and Romania, overstretching an already limited staffing capacity.
Regardless of countries’ health workforce size and composition before the onset of the first wave,
the COVID‑19 pandemic substantially increased the workload of most health workers – particularly
frontline workers in hospitals, in all countries. In the United Kingdom, 60% of hospital doctors in England
and Wales reported having worked additional hours between March and August 2020 as part of the
response to COVID‑19 (BMA, 2020[37]). The pay rate for the overtime work of frontline workers in
hospitals was increased in many countries as a recognition of the exceptional circumstances and
workload. In France, for example, the overtime premium for people working in public hospitals was
increased markedly in March and April 2020, and an exceptional lump-sum bonus was also granted to
those working in the most affected regions to recognise their effort and commitment (Service Public
France, 2020[38]). Similar measures were taken in Germany and Belgium.
Most countries that were hard-hit by COVID‑19 tried to mobilise additional staff to respond to the
surge in demand for care during the peak of the pandemic. France already had in place before the
crisis some “reserve list” (“Réserve Sanitaire”) established in response to previous epidemics, which
was mobilised and expanded during the COVID‑19 outbreak, while Belgium, Ireland and Iceland
(among others) quickly set up new “reserve lists” to deal with the outbreak and reallocate staff across
regions.
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hospital.
Source: OECD Health Statistics 2020; Eurostat Database.
StatLink 2 https://stat.link/8fp4ge
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At least half of the countries in Europe started by recalling inactive and retired health professionals,
offering them some short training to update and upgrade their skills. Several countries decided against
deploying older health professionals coming back to work, to avoid exposing them to the greater risk of
severe complications should they become infected. Most countries mobilised students nearing the end
of their studies in medical, nursing and other health education programmes to respond to concerns and
questions of the population through telephone hotlines and support service delivery to patients. Two-
thirds of countries also transferred some health workers to hospitals in regions that were more affected
by the pandemic (see Table 1.4 and Annex Table 1.A.1 in Annex 1.A).
The need to maximise the efficiency of available resources also led to several innovations in the
roles and responsibilities of different health professionals. The role of community pharmacists, for
instance, was broadened in many countries at least temporarily to address urgent needs and reduce
Table 1.4. Overview of policies to boost the supply of health workers in response to





























France     
Germany  
Greece   
Hungary   
Iceland 
Ireland    
Italy    
Latvia 
Lithuania  
Luxembourg     
Malta   
Netherlands  
Norway   
Poland   




Spain   
Sweden   
Switzerland  
United Kingdom    
Source: OECD health system policy tracker, European Observatory COVID‑19 Health System Response Monitor.
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the  need for  doctor  consultations  for  non-COVID‑19 patients.  In  France,  Ireland and Portugal,
community pharmacists were allowed to renew and dispense the prescription for patients with certain
chronic conditions (PGEU, 2020[39]). The later section on maintaining high quality care for non-
COVID‑19 patients provides further examples on task-shifting at the primary care level.
Since health professionals were at the forefront of the response to the outbreak, ensuring they
received adequate personal protective equipment to avoid the emergence of clusters at the point of
care was of paramount importance. During the initial phase of the pandemic, most countries faced an
acute shortage of medical masks and other personal protective equipment for health workers, which
left many of them vulnerable to infection. Such shortages were particularly marked in outpatient and
long-term care settings. Over 30 000 health workers were infected by the virus in France and Italy
during the first few months of the pandemic, and this number reached over 50 000 health workers in
Spain (Santé Publique France, 2020[40]; Istituto Superiore di Sanità, 2020[41]; Ministerio de Sanidad,
2020[42]).9 The number was lower in Germany where about 15 000 people working in hospital and
other health care facilities were infected, but this number does not include people working in long-term
care facilities.  About  three‑quarters of  all  workers in health care facilities who were infected in
Germany were women as they account for a larger share of health workers (Robert Koch Institute,
2020[43]).
The exceptional workload and psychological drain on health professionals led to a considerable
mental health burden, with possible long-term effects for their well-being. For example, in August
2020, 35% of hospital doctors from England and Wales reported increased rates of depression,
anxiety,  stress or  other  mental  health  conditions relative to before the pandemic began (BMA,
2020[37]). In Italy, a survey of health care workers in March 2020 found increased symptoms of stress,
anxiety, depression and insomnia, especially amongst frontline workers and young females (Rossi
et al., 2020[44]). In Spain, research found that in April 2020, 57% of health workers presented with
symptoms of post-traumatic stress disorder (Luceño-Moreno et al., 2020[45]). Support services for
mental health and well-being of doctors, nurses and other hospital workers were expanded by many
countries to help them deal with the high level of stress, fatigue and psychological distress during
these extremely challenging times, for example through peer support groups or dedicated phone
support lines.
Some health systems lacked sufficient hospital beds, equipment, supplies and
medicines to treat COVID‑19 patients, but policies to boost surge capacity have
helped
Hospitals have often been placed under immense strain, but governments found innovative
solutions to increase surge capacity, particularly for intensive care units
While the pandemic has put all health services under severe strain, its impact on hospitals has
been particularly drastic. In this context, having a high number of beds per population is a useful
general proxy of the capacity of hospitals to meet surges in demand (Figure 1.14). In terms of existing
capacities, Germany had the most hospital beds per capita in 2018, with eight beds per 1 000
population, followed by Bulgaria and Austria. Most European countries have between three and seven
hospital beds per 1 000 population, but numbers are lower in Sweden, Denmark, Iceland and the
United Kingdom.
Bed occupancy rates provide complementary information to analyse hospital capacity, with (in
the current context) high occupancy rates symptomatic of a health system with limited capacity to
handle unexpected surges in patients requiring hospitalisation. In 2018, bed occupancy rates for
curative (acute) care averaged 73% across EU Member States. However, they were 91% in Ireland,
and just over 80% in Portugal, Belgium and Malta. Curative (acute) care occupancy rates broadly
mirror overall bed numbers (e.g. in Ireland, Italy and Spain), with the exception of Greece, which has
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relatively few hospital beds and relatively low bed occupancy rates. National averages hide wide
variations in occupancy rates within countries, as well as cyclical differences throughout the year,
meaning that occupancy rates can reach or even surpass 100% in some hospitals during peak
periods.
Whilst general hospital bed capacity matters, intensive care unit (ICU) capacity is paramount.
This is because a certain share of patients infected by the COVID‑19 will develop a severe form of the
disease requiring ICU-level care. The number of ICU beds – which typically are equipped with core
devices such as ventilators and monitoring equipment – is therefore an important indicator of a health
system’s capacity to respond to a crisis such as this one.
Notwithstanding definitional differences, the most recent publicly available data suggest that,
before the COVID‑19 crisis, the variation in ICU capacity across 17 European countries ranged from
34 ICU beds per 100 000 people in Germany, to five ICU beds per 100 000 people in Ireland
(Figure 1.15).
These data on overall hospital bed capacity and ICU beds provide an indication of European
countries’ core hospital capacity prior to the crisis. Combining data on the maximum daily number of
COVID‑19 patients occupying ICU beds during the first half of 2020 with estimates of total ICU beds
available provides further insights on countries’ resilience to the outbreak (Figure 1.16). This shows,
for example, that at the height of the outbreak in Italy in the first half of 2020, an equivalent to
almost 80% of regular pre-crisis ICU beds would have been occupied by COVID‑19 patients. For
Belgium, Ireland and France, the equivalent figure was around 65% of regular ICU beds.
Even if some capacity remains at the national level, these numbers point to local ICU capacity in
the worst hit areas of these countries being severely overstretched during the height of the outbreak.
For example, in France ICU capacity was almost reached in the greater Paris area and Eastern region
but almost untouched in most other regions. In contrast, COVID‑19 patients occupied less than 15%
Figure 1.14. General hospital capacity – hospital beds and average share occupied before the
COVID-19 crisis, 2018 (or nearest year)
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Note: The EU average is unweighted. The EU27 average refers to unoccupied beds, and the EU21 to occupied beds. Hospital beds include all beds
regularly maintained and staffed within general hospitals, mental health and substance abuse hospitals, and other specialty hospitals. Beds in residential
long-term care facilities are excluded. Note that occupancy rates are calculated on the basis of curative (acute) care beds – within which, intensive care
beds are a small sub-category.
Source: OECD Health Statistics 2020; Eurostat Database.
StatLink 2 https://stat.link/sb6p4o
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of regular pre-crisis ICU beds in Austria and Hungary on the worst day of the outbreak in these
countries.
In  response to  this  pressure  on  hospitals,  and  particularly  on  ICU beds,  many  European
governments have implemented policies to boost surge capacity. For example, in Estonia, France,














Number of intensive care beds per 100 000 population
Note: The EU average is unweighted. There may be differences in the notion of intensive care affecting the comparability of the data. Data refer to adults
only in Belgium and Ireland; to all ages in Germany, England and Spain. Data in France exclude beds in constant monitoring units and paediatric ICUs.
Source: German Federal Statistical Office, Austrian Ministry of Health, Belgian Ministry of Health, French Ministry of Health, Hungarian National Health
Insurance Fund, NHS England, Polish Ministry of Health, Spanish Ministry of Health, Italy: (Remuzzi and Remuzzi, 2020[46]), Norwegian Health Ministry,
Danish Society of Anesthesiology and Intensive Medicine, Dutch Intensive Care Society, Irish Department of Health.
StatLink 2 https://stat.link/v1lk48
Figure 1.16. Estimated ICUs capacity to cope with the surge in COVID-19 patients during the first wave
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Share of ICU beds occupied by Covid-19 patients at height of outbreak, %
Note: Values are based on when the number of COVID‑19 patients in ICU beds was at its highest, and relate this to the total number of regular ICU beds, for
each country. Therefore this is an estimation only, as additional temporary ICU beds are not included in calculations.
Source: European Centre for Disease Prevention and Control (ECDC) for number of COVID‑19 patients occupying ICU beds, national sources detailed in
Figure 1.15 for number of ICU beds.
StatLink 2 https://stat.link/cdlez5
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Hungary, Italy, Romania, Slovenia and Spain the military helped create field hospitals. Most European
countries converted general purpose and other clinical wards into ICU wards. In addition, many
countries postponed elective surgery to free up a maximum amount of hospital beds to deal with the
pandemic.
Such policies have significantly  boosted surge capacity in several  countries.  For example,
Belgium created an additional 759 ICU beds (i.e. an extra 6.6 per 100 000 population) since the start of
the COVID‑19 crisis, Ireland a further 399 ICU beds (i.e. an extra 8.1 per 100 000 population). In the
Lombardy region of Italy, turning wards into ICUs increased ICU capacity by 376 beds. There have
also  been  encouraging  examples  of  inter-country  support.  For  example,  some  patients  in
overburdened  hospitals  in  the  East  of  France  were  transferred  by  train  to  Austria,  Germany,
Luxembourg and Switzerland (see Annex Table 1.A.2 in Annex 1.A for further information by country).
A persistent challenge, though, has been how to adequately staff additional ICUs, with the consequent
effect of underutilised ICU beds.
In general, the four broad policy interventions aimed to maximise ICU capacity during the crisis
have been:
• The systematic transformation of other clinical wards into ICUs (at least 24 of 31 countries);
• The creation of field hospitals (at least 14 of 31 countries);
• The transfer of patients to localities with spare capacity (at least 8 of 31 countries);
• Partnerships with private hospitals (at least 11 of 31 countries).
Table 1.5 summarises which countries have adopted each of these policy levers.
At the same time, primary health care services were rapidly adapted in some European countries
to improve the triage of patients with potential COVID‑19. One innovative solution was to establish
COVID‑19 community care facilities, as implemented in France, Iceland, Luxembourg, Slovenia and
the United Kingdom. The overarching objective was to improve co-ordination between hospitals and
multi-disciplinary primary care practices to maintain adequate health services. While primary health
care providers continued to be responsible for managing patients with chronic diseases, efforts also
consisted of screening suspected COVID‑19 cases, coordinating patient’s follow-up after hospital
discharges and managing frail patients in the community (Julia et al., 2020[47]).
In  France,  triage and prioritisation  criteria  for  patients  without  COVID‑19 were  specifically
developed to ensure usual care of chronically ill patients to avoid further delays in follow-up visits. In
the United Kingdom and Luxembourg, COVID‑19 community centres were established to manage
both patients experiencing COVID‑19 symptoms and patients having acute or chronic conditions
requiring primary care treatment.  Such community  care facilities were made available to reach
underserved people and make sure that everyone in the community had access to the right health and
social support during the crisis (see the later section on maintaining access to high quality care for
non-COVID‑19 patients).
Obtaining the necessary equipment, supplies and medicines has proven challenging,
particularly early in the crisis
Alongside beds (both general, acute and ICU beds), hospitals and other health facilities require
sufficient  medical  equipment,  supplies  and  medicines.  Personal  Protective  Equipment  (PPE),
ventilators, infusion pumps, monitoring and laboratory equipment, and certain medicines (notably
anaesthetics, antibiotics, muscle relaxants, resuscitation medicines and anti-diuretics; as well as
medical oxygen) are some critical items needed to treat COVID‑19 patients.
However, purchasing and distributing such items under conditions of extreme urgency and
uncertainty is challenging – with risks of shortfalls in supply or poor quality products due to disruptions
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in the global supply chain. Even before the onset of the pandemic, countries have reported increased
shortages of critical medical supplies and products. For example, across a sample of 14 OECD
countries, the number of notifications of expected or actual medicine shortages grew by more than
60% between 2017 and 2019 (OECD, forthcoming[48]).
Effective public procurement, supply chain management, strategic stockpiling and trade policies
are all important tools to enable health providers to receive essential items in a timely manner. In
terms of procurement, most European countries used emergency contracting rules so that public
buyers could act more quickly – for example, by not requiring a minimum number of contractors to be
consulted, lighter checks on firms’ track record and other simplifications to tender procedures (see
OECD (2020[49]) for an in-depth analysis during the COVID‑19 crisis). While emergency contracting
speeds up procurement, the challenge is to also keep purchasing transparent and accountable.
Central price and supplier tracking and digitalisation of procedures can help identify red flags. For
Table 1.5. ICU capacity – overview of policies to boost surge capacity response to
COVID-19, during the first wave of the pandemic
Country Transformation of wardsinto ICUs
Creation of field
hospitals
Transfer of patients to










Estonia   
Finland 
France    
Germany  
Greece   
Hungary  
Iceland 
Ireland   












Spain   
Sweden    
Switzerland   
United Kingdom   
Source: OECD health system policy tracker, European Observatory Health System Response Monitor.
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example, in Italy the central purchasing body Consip only uses verified suppliers. In Lithuania, the
Public Procurement Office has made data on COVID‑19 related contracts publicly available.10
Centralised purchasing can make procurement rapid, efficient and well-coordinated. Increased
centralisation has been adopted in the Czech Republic, Latvia, Germany, Estonia, Italy, Lithuania,
Poland, Spain, Switzerland and the Slovak Republic as a direct response to COVID‑19. In Germany,
Italy  and other  decentralised countries,  centralised purchasing has been implemented in  close
partnership  with  sub-national  governments.  There  have  also  been  joint  procurement  efforts  at
supranational level (see Box 1.4 for further details on this and other European level initiatives).
Managing risks in the supply chain, notably through supply network mapping, limits over-reliance
on single suppliers. A temporary clearing house set up by the European Commission has identified
available supplies and potential risks to the supply chain (see Box 1.4). Strategic stockpiling can also
help, although this requires careful monitoring to avoid excessive buffers in some countries and
shortages in others. While many countries had stockpiles prior to the crisis, Finland was one of the few
countries whose stockpile was sufficiently well maintained to meet needs for medical supplies (OECD,
2020[50]). At the EU level, RescEU was set up in March 2020 as a strategic reserve of essential
medical  equipment,  with the European Commission financing most of the stockpiling costs and
managing distribution.
Several governments have also enacted temporary trade measures in order to restrict exports
and/or liberalise imports of  certain medical  products (OECD, 2020[51];  OECD, 2020[52]).  On a
national level, as of 8 October 2020, export restrictions on medical goods such as PPE and medicines
were put in place across at least 19 European countries (Belgium, Bulgaria, Cyprus, Czech Republic,
Estonia,  France,  Germany,  Greece,  Hungary,  Iceland,  Latvia,  Netherlands,  Norway,  Poland,
Portugal, Romania, Slovak Republic, Switzerland, the United Kingdom). Most measures have been
described as temporary, and at least 11 countries have already waived some of these restrictions.
These  measures  imposed  by  countries  during  the  pandemic  include  export  bans  (i.e.  entirely
prohibiting exports) and new licencing requirements (i.e. regulating new requirements for obtaining
export licenses).
Such measures can actually increase scarcity in international markets, put existing contracts at
risk, and raise prices and lower availability in non-producing countries. No country is self-sufficient in
the production of all the necessary medicines, including those to combat the COVID‑19 pandemic,
and trade is an essential tool to increase availability internationally. In terms of liberalising imports, at
least three countries (Norway, Switzerland, the United Kingdom) enacted measures to reduce tariffs
on medical equipment and PPE.
At the European Union level, various co‑ordinated responses have been taken on trade. These
include  an  EU-wide  regulation  on  export  authorisations  on  PPE,  with  most  member  states
subsequently lifting their national export restrictions on these products; the temporary waiving of
custom duties and VAT; and guidance on exemptions to labelling and packaging requirements for
medical imports – see Box 1.4 for further details on these policies.
Many governments have also sought innovative production solutions through the private sector.
In the United Kingdom, for example, over 5 000 companies responded to the government-launched
“Ventilator  Challenge”,  producing  an  estimated  14  000  ventilators11.  In  Italy,  the  government
subsidised companies to produce PPE. In the Czech Republic, the Programme “Czech Rise Up”
provided government subsidies to expand production capacities of essential items including PPE,
respirators and ventilators. Bulgaria, Estonia, France, Greece, Italy, Norway, Poland and Spain have
also incentivised domestic manufacturers to increase the production of core items such as PPE and
ventilators.
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Box 1.4. EU-level actions to support the availability of critical medical equipment,
supplies and medicines
A  number  of  collaborative  EU-level  initiatives  have  helped  alleviate  supply  constraints  and  support  a  more
co‑ordinated response across countries. Notable actions include:
• Joint procurement. The European Commission has launched several voluntary Joint Procurement procedures
since February 2020. These are based on Article 5 of Decision 1082/2013 on cross-border health threats, as well as
on the Joint Procurement Agreement (JPA) with participation open to all EU and EEA Member States (plus the
United Kingdom, six Candidate and Potential Candidate countries)1. Seven international tenders were launched to
address or prevent shortages of medical countermeasures relevant for COVID‑19. The European Commission
helped countries identify and select suppliers, and negotiate contracts, enabling them to purchase essential products
under the same (and more favourable) conditions. Between April and May 2020, countries placed orders for millions
of masks, goggles and coveralls, +100 000 ventilators, and 30 lots of different laboratory equipment through these
contracts. Over EUR 3.2 billion worth of orders can be placed by the 20‑26 countries participating in these contracts.
• Clearing house. The European Commission set up a temporary clearing house to facilitate matching supply and
demand between manufacturers and member states. Risk factors that may impact supply chain lead times are also
analysed. It uses a centralised platform that pools data on trade flows, production capacity in third countries, and
logistical, technical and regulatory bottlenecks.
• Enhanced monitoring.  The European Medicines Agency,  together  with  the pharmaceutical  industry  and EU
Member States, launched a fast-track monitoring system to help anticipate drug shortages. This reinforced a single
contact point for national medicines agencies (SPOC) and the launch of an industry single point of contact (i-SPOC).
• Strategic stockpiling. RescEU, a common reserve of medical equipment managed autonomously by the European
Commission, was established in March 2020. The European Commission finances most of the stockpiling costs, and
manages the distribution of equipment to member countries. At the same time, the European Commission provided
guidelines and urged member states to lift export bans and restrictions on medicines and to avoid national stockpiling
of medicines.
• Manufacturing  capacity.  The  European  Commission’s  new  pharmaceutical  strategy  emphasises  policies  to
increase the manufacturing  capacity  for  certain  critical  medicines,  active  pharmaceutical  ingredients  and raw
materials within Europe.
• Trade policies: regulating exports. A temporary EU-wide export authorisation scheme for PPE set out conditions
for their export. This ran from 15 March to 26 May, to help safeguard supplies whilst also maintaining open trade
flows. Indeed, over 13 million protective masks and about 1 million protective garments were exported from the EU
since 26 April.
• Trade policies: liberalising imports. In April 2020, customs duties and VAT were temporarily waived on imported
medical devices and PPE from non-EU countries. Moreover, the European Medicines Agency published guidance on
regulatory expectations and flexibility during COVID‑19, where member states may “grant full or partial exemption to
certain labelling and packaging requirements” for crucial medicines used for COVID‑19 (Article 63(3) of Directive
2001/83/EC). This includes accepting that product information may not be translated into the official language in the
event of severe availability problems, and that national specific information may not appear or the presentation may
differ from those authorised in the member state.
• Anti-fraud measures. The European Anti-Fraud Office (OLAF) has launched investigations into imports of fake
health and hygienic products linked to COVID‑19, such as masks, testing kits and disinfectant.
• Simplifying standards. To speed up market entry for essential medical items, the European Commission adopted
revised harmonised standards for medical devices, with simpler processes for manufacturers of medical devices.
Guidance  documents  for  other  items,  such  as  PPE  and  testing  materials,  were  also  produced  to  assist
manufacturers.
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What has been done to protect older people and other vulnerable populations from
COVID‑19?
Almost all reported COVID‑19 deaths have been amongst those aged 60 and above,
with recipients of long-term care particularly at risk
While COVID‑19 has claimed the lives of many people across all  age groups, people with
comorbidities (e.g. obesity,  cardiovascular diseases) and in particular older populations face an
elevated risk of dying from COVID‑19. Among 22 European countries with data available by age
group, reported COVID‑19 deaths per million people aged 60/65 and over were on average 3.7 times
higher than amongst the population as a whole. In nearly all of these countries, 90% or more of
reported COVID‑19 deaths were amongst people aged 60/65 and over; with people aged 80 and over
accounting for around half of all COVID‑19 deaths.
The United Kingdom, Italy, Spain and France all reported more than 17 000 deaths amongst
those aged 60 and over (as of mid-September). Adjusting for population size, reported COVID‑19
mortality rates amongst people aged 60/65 and over were more than 3 000 deaths per million people
in this age group in the United Kingdom (England and Wales) and Belgium, and over 1 000 deaths
per million people in Ireland, Sweden, Italy, Spain, France and the Netherlands (Figure 1.17). Mortality
rates were even higher amongst those aged 80/85 and over, reaching over 10 000 reported deaths
per million people in this age group in the United Kingdom (England and Wales), Belgium and Ireland.
Recipients  of  care,  including  those  resident  in  long-term care  (LTC)  facilities,  often  have
compromised immune systems or chronic conditions that place them at high risk of infection –
especially, but not only, during the COVID‑19 crisis. Home care workers and carers in institutions are
also at high risk of being infected and of infecting an elderly person, given their direct contact with
them, typically heavy workload, and that they often work across several facilities. Discharged hospital
patients who are transferred back to nursing homes can also spread the virus.
Across 13 European countries with available data, there were over 75 000 deaths amongst
residents in LTC institutions (as of early October 2020). Absolute numbers of reported deaths were
particularly  high  in  the  United  Kingdom  (25  466  deaths),  Spain  (20  649  deaths)  and  France
(14 955 deaths), all countries that suffered heavily from COVID‑19. Adjusting for population size,
deaths among residents in LTC institutions were equivalent to over 5 000 deaths per million people
aged 80 and over in Belgium, the United Kingdom, Spain, Ireland and Sweden (Figure 1.18). Such
deaths among LTC residents reached over half of all reported COVID‑19 deaths in Spain, Belgium,
Ireland and Norway.
Box 1.4. EU-level actions to support the availability of critical medical equipment,
supplies and medicines (cont.)
• Vaccines. The EU Vaccine Strategy outlines how the European Commission intends to accelerate the development
and availability of a COVID‑19 vaccine. Its main objectives are to secure the production of vaccines within the EU; to
ensure their future availability for its member states through Advance Purchase Agreements with vaccine producers;
and to adapt EU rules to accelerate the development, authorisation and availability of vaccines while maintaining
safety standards. A significant part of the EUR 2.7 billion Euro Emergency Support Instrument will be dedicated to
fund implementation of this strategy.
1. https://ec.europa.eu/health/preparedness_response/joint_procurement_en.
Source: Information in this box is drawn largely from Box 6 of the EC’s report on Health Systems’ Resilience (2020[5]), “Assessing The Resilience of
Health Systems in Europe: An Overview of the Theory, Current Practice and Strategies for Improvement”, https://ec.europa.eu/health/sites/health/
files/systems_performance_assessment/docs/2020_resilience_en.pdf, OECD (2020[50]), “The face mask global value chain in the COVID-19
outbreak: Evidence and policy lessons”, http://www.oecd.org/coronavirus/policy-responses/the-face-mask-global-value-chain-in-the-covid-19-
outbreak-evidence-and-policy-lessons-a4df866 and OECD health system policy tracker.
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These data exclude deaths of LTC recipients receiving home-based care, thus underestimating
total deaths amongst people receiving long-term care, particularly for countries where home-based
Figure 1.17. Reported COVID-19 deaths per million people aged over 60/65, up to early October 2020 (or
latest data available)
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Deaths per million people aged over 60/65 
Note: Data on cumulative deaths up to mid-September/early October 2020, except for Portugal (August), Ireland and Luxembourg (July) and Spain (May).
Data are not fully comparable due to different testing, reporting and coding procedures. In Belgium and Ireland, data include confirmed and suspected
COVID‑19 deaths. Data refer to people aged 60 and over in Denmark, France, Germany, Italy, Hungary, Netherlands, Norway, Portugal, Spain and
Sweden. In France and Spain, as data disaggregated by age excluded deaths in long-term care (LTC) facilities, data on deaths in LTC facilities were added
to the count of deaths.
Source: Institut National d’Etudes Démographiques, https://dc-covid.site.ined.fr, Eurostat Database, national epidemiological summaries and European
Centre for Disease Prevention and Control (ECDC).
StatLink 2 https://stat.link/uh1g9o
Figure 1.18. Reported COVID-19 deaths among residents of long-term care institutions, per million














LTC deaths per million people aged 80 and over
Note: Data on cumulative deaths up to early October 2020, except for the United Kingdom (September), Hungary (August), Ireland (July), Italy and
Portugal (May). Data are not fully comparable due to different testing, reporting and coding procedures. Unless otherwise stated, deaths refer to confirmed
deaths of LTC residents, including deaths that occurred in LTC facilities and elsewhere (e.g. hospitals, homes).
1. Includes confirmed and suspected deaths. 2. Only includes deaths occurring in LTC facilities. 3. Data come from regional governments using different
methodologies, some including suspected deaths.
Source: Comas-Herrera, Ashcroft and Lorenz-Dant (2020[53]), “International examples of measures to prevent and manage COVID-19 outbreaks in
residential care and nursing home settings”, https://ltccovid.org.
StatLink 2 https://stat.link/szvxip
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care is more common. The under-reporting of COVID‑19 cases in the LTC sector (due to a lack of
testing, especially early on in the pandemic) also underestimate the true death toll, particularly in
those countries that only include confirmed cases.
Containment strategies limited the spread of the virus among long-term care
recipients, but had important repercussions for continuity of care
Countries have taken steps to mitigate the impact of COVID‑19, both on the recipients of LTC
and on LTC workers (OECD, 2020[54]). This includes measures to protect people from contracting the
virus, but also efforts to maintain continuity of care during the crisis.
Table 1.6 summarises the main measures taken across European countries. However, it should
be noted that policy responses in the LTC sector could have been quicker, with countries often
focusing first and foremost on hospitals. For example, in France, Italy, Spain and the United Kingdom
(England and Wales), there was an at least two‑month lag between the first reported COVID‑19 cases
and the issuance of guidelines on preventing infection in LTC institutions.
Some countries increased funding for LTC to cover increased costs caused by the pandemic
response. For example, in Austria a special endowment of EUR 100 million was transferred to the
Länder for additional expenditure in LTC facilities, including bonus payments for nursing staff. France
also announced support in the form of bonuses for workers and compensating institutions for some of
the increased costs caused by COVID‑19. In Germany, additional financial support for LTC included
funding an increase in minimum wages in the sector and bonuses for LTC workers. Austria, Hungary,
Ireland, Italy, Latvia, the Netherlands, Slovenia, Spain and the United Kingdom boosted staff numbers
for LTC through increased funding or redeployment of military staff. Psychological support to care
home staff has also been offered.
In terms of limiting the spread of infections, at least 17 of 31 European countries implemented
restrictions in the form of isolation measures and restricted visits to residents in LTC institutions. For
example, Austria, Hungary, Italy and Slovenia had a complete ban on all visits; Ireland and Portugal
suspended all  visits other than special permissions to visit  individuals in end-of-life care. Some
nursing  homes  also  limited  group  activities,  for  example  in  France  and  Spain,  although  such
restrictions were relaxed at a later stage. Day care activities and home-based care were also often
more restricted than prior to the pandemic. Efforts were widely made to isolate residents infected by
the virus, to the extent possible given the challenges of isolating residents living in collective dwellings
with limited spare capacity. In the Czech Republic, for example, LTC facilities were required to reserve
10% of their capacity to accommodate suspected or infected cases.
However, such restrictions were not always implemented in a timely manner. For example, as
compared to when countries implemented the closure of public spaces, there was over a four‑week
delay in introducing restrictions for LTC in the Slovak Republic and the United Kingdom (Table 1.7).
The LTC sector was not typically prioritised for testing across Europe in the early days of the
pandemic. As national testing capacity increased (see earlier section on containment and mitigation
policies), only 12 countries prioritised testing in care homes. Likewise, it took time for countries to
improve access to PPE in LTC facilities. As countries managed to alleviate the initial shortages, most
countries  did  secure  access to  PPE for  social  care  workers  through additional  funds or  direct
distribution to points of need. In France, for example, the government sent masks directly to LTC
workers. In Germany, many states facilitated the distribution of PPE for care providers.
Maintaining continuity of  care has also proven challenging. Closures of  day care, reduced
availability  of  home  care,  and  absence  of  some  LTC  staff  have  all  disrupted  care.  In  the
United Kingdom, for example, amongst older people needing support with two or more activities of
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daily living, one‑in-ten reported receiving less help than prior to the pandemic (Evandrou et al.,
2020[55]). Together, these factors placed an additional burden on informal carers.
Measures to contain the virus have also made LTC recipients even more socially isolated, with
potentially significant repercussions for their mental health. Still, there are some examples of countries
having used digital technologies to maintain essential clinical and social care, as well as to limit social
isolation by facilitating virtual contact with families. For instance, in England social care and health
care workers can connect using dedicated digital tools, and residents in LTC facilities have the option
of teleconsultations. Germany, Austria and Italy have also promoted the provision of care remotely
through digital means (Comas-Herrera, Ashcroft and Lorenz-Dant, 2020[53]). Although telehealth
Table 1.6. Overview of policies implemented to protect LTC recipients and workers


















Austria    




Czech Republic   
Denmark   
Estonia 
Finland  
France     
Germany    
Greece   
Hungary   
Iceland
Ireland    
Italy  
Latvia  
Lithuania   
Luxembourg     
Malta
Netherlands   
Norway    
Poland   
Portugal    
Romania
Slovak Republic   
Slovenia    
Spain   
Sweden    
Switzerland    
United Kingdom     
Note: For countries with all columns empty, this may reflect insufficient information from the sources used below.
Source: OECD health system policy tracker; European Observatory Health System Response Monitor; Comas-Herrera, Ashcroft
and Lorenz-Dant (2020[53]), “International examples of measures to prevent and manage COVID-19 outbreaks in residential care
and nursing home settings”, https://ltccovid.org.
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cannot replace all needed care, telemedicine and smartphone‑based assessments appear to have
helped with remote monitoring and care for people with dementia or other cognitive impairments
(Cuffaro et  al.,  2020[56]).  In  terms of  palliative care,  Austria,  France,  Italy  and Spain provided
guidelines on symptom management in a time of more limited capacity, and ways to help patients
maintain virtual contact with families.
COVID‑19 exacerbated existing social health inequalities
Poorer people, those living in deprived areas and ethnic minorities have all been more likely
to be affected by COVID‑19
COVID‑19  has  disproportionately  hit  the  poor,  those  living  in  deprived  areas  and  ethnic
minorities. This is because individuals from disadvantaged socio-economic backgrounds face an
accumulation of risk factors that place them at higher risk of complications and death from COVID‑19.
They more often are in poor health, have higher exposure to risk factors such as obesity, and may
have  more  limited  access  to  the  health  system  (OECD,  2019[57]).  Insufficient  information  on
COVID‑19 and related health services in minority languages may also make it harder for some ethnic
minorities to navigate the health system.
Discrimination and poverty increase the risk of ethnic minorities, other socially disadvantaged
groups and those who cannot telework, to have higher-risk jobs (such as retail grocery workers, public
transit employees, or health and social workers), and live in overcrowded or insecure housing – all of
which increase their exposure to the virus. They also face higher exposure to air pollution (European
Environment Agency, 2018[58]); see Chapter 2 for a further discussion on air pollution in European
countries).
Table 1.7. Timing of implementation of LTC restrictions (amongst countries introducing
restrictions)
Country Date restrictions introduced forlong-term care
Introduced before, after, or same
day as closure of public spaces? Difference (days)
Austria 21 March After 5
Belgium 11 March Before ‑2
Czech Republic 18 March After 2
Denmark 18 March Same day 0
France 11 March Before ‑5
Germany 2 April After 17
Hungary 6 April After 24
Ireland 6 March After 5
Italy 6 March Before ‑4
Luxembourg 15 March Before ‑1
Netherlands 19 March After 7
Norway 6 March Before ‑6
Portugal 13 March Same day 0
Slovak Republic 7 May After 52
Slovenia 9 April After 25
Spain 24 March After 10
Sweden 30 March (no closure of public spaces) NA
Switzerland 20 March After 4
United Kingdom 15 April After 30
Source: OECD health system policy tracker, European Observatory Health System Response Monitor, Comas-Herrera, Ashcroft
and Lorenz-Dant (2020[53]), “International examples of measures to prevent and manage COVID-19 outbreaks in residential care
and nursing home settings”, https://ltccovid.org.
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Emerging  evidence  clearly  shows  that  COVID‑19  has  exacerbated  existing  social  health
inequalities.  In  the United Kingdom (England),  the risk  of  dying among people diagnosed with
COVID‑19 was more than double for people living in the most deprived areas compared to those living
in the least deprived areas. Further, after accounting for age, sex, deprivation and region, ethnic
minorities had a higher risk of death compared to people of white ethnicity, among people diagnosed
with COVID‑19 (Public Health England, 2020[59]). The increased prevalence of pre-existing health
conditions such as obesity among minority ethnic groups, which increases the risk of severe infection
from COVID‑19, is likely to explain the higher risk of mortality.
In France, alongside disparities by income, immigrants were also disproportionately affected: all-
cause mortality rates for immigrants increased by 48% in March-April 2020 as compared with a year
earlier – much higher than the 22% increase observed for individuals born in France (Papon and
Robert-Bobée, 2020[60]). Similar findings were observed in Sweden, Spain and Norway. In Sweden,
men in the lowest income tercile had an 80% higher risk of dying from COVID‑19 than men in the
highest income tercile. Immigrants from low- and middle-income countries were more than twice as
likely  to  die  as  compared with  individuals  born  in  Sweden (Drefahl  et  al.,  2020[61]).  In  Spain
(Barcelona), people in poorer neighbourhoods were six to seven times more likely to contract the virus
than  those  in  wealthy  areas  (Mogi,  Kato  and  Annaka,  2020[62]).  In  Norway,  some  minority
communities had infection rates more than ten times above the national  average (Yaya et  al.,
2020[63]).
Targeted health and social interventions can help address the disproportionate impacts of
the COVID‑19 pandemic on ethnic minorities and poorer people
Universal health coverage is a key pre-requisite in improving access to care for vulnerable
groups. Whilst most European countries provide universal coverage, population coverage for core
services remains below 95% in seven EU/EFTA countries, and is below 90% in Cyprus, Romania and
Bulgaria (see Chapter 7). In Ireland, although health care coverage is universal, less than half of the
population is covered for the cost of GP visits. But in the case of COVID‑19 treatment, the Irish
Government did extend coverage for GP visits to the entire population. Similarly, in Poland, the costs
of health services related to COVID‑19 for both uninsured and insured persons are fully covered from
public funds. In Portugal, all foreigners were treated as permanent residents until at least 1 July, to
ensure migrants had access to health and other public services (OHCHR, 2020[64]). In Spain, the
government provided medicine and sanitary products to the Roma population to minimise the adverse
health consequences of COVID‑19.
Although  expanding  health  coverage  is  a  necessary  step  to  alleviate  the  socio-economic
gradient in mortality due to COVID‑19, it is not sufficient by itself. More targeted social policies are
required to address the core reasons why disadvantaged groups are at a higher risk of dying from
COVID‑19 in the first place. In this regard, providing better targeted health information and health
services for minorities is one core policy. Promising examples can be found in Austria, France,
Greece, Sweden and Norway. In Seine-Saint-Denis, France (the poorest region in mainland France),
20 ambulatory health care facilities were created to improve access in deprived areas. In addition,
377 information and testing missions were undertaken, targeting homeless and migrant populations
(Rousseau, Bevort and Ginot, 2020[65]; ARS, 2020[66]). In Rennes Nord/Ouest, multi-professional
primary care practices in deprived areas worked with community leaders to provide information about
COVID‑19 in several languages (Avenir Santé Villejean Beauregard, 2020[67]). Sweden and Norway
published COVID‑19 advice in multiple minority languages, and spread this information in partnership
with  relevant  community  leaders.  Austria  published  informational  material  in  multiple  minority
languages to address vulnerable settings and immigrants. Greece ensured the provision of adequate
information to the Roma communities to address the spread of COVID‑19 (OHCHR, 2020[64]).
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Other targeted policies go beyond the provision of COVID‑19 related services. Maintaining
continuity  of  care for  non-COVID‑19 health care needs (as discussed in the earlier  section on
maintaining access to high quality care for non-COVID‑19 patients) is particularly relevant for socially
disadvantaged groups, as they are more likely to suffer from chronic illnesses and be in worse health
(OECD, 2019[57]). Mobile health clinics are one important mechanism to provide targeted support for
COVID‑19 and non-COVID‑19 needs, such as preventive care, mental health or dental care (OECD,
2020[68]).
Policies beyond the health sector are also important. Some countries have introduced measures
to tackle the socio-economic impact of COVID‑19 on minorities (OHCHR, 2020[64]). In Spain, for
example,  financial  assistance  has  been  provided  to  settlements  with  high  numbers  of  Roma
population. In Switzerland, an aid project was introduced to provide advice, support, and financial
assistance for self-employed ethnic minorities to cover their daily living expenses.
How did countries try to maintain access to high quality care for non-COVID‑19 patients
during the first wave of the pandemic?
COVID‑19 has adversely affected patients with other health care needs
COVID‑19 has had a major indirect health impact on patients who did not contract the virus.
Acute  and chronic  care  patients  have faced disruptions  to  essential  care,  in  terms of  delayed
diagnoses, foregone care and impeded continuity of care. This contributes to worse health outcomes
for many people, now and in the future. A dual-track approach is therefore needed to maintain high
quality care for non-COVID‑19 acute and chronic care, alongside boosting surge capacity to combat
the virus.
COVID‑19 has led to postponed elective surgeries, fewer visits to emergency departments
and less use of outpatient services, affecting both acute and chronic care patients
In response to the COVID‑19 crisis, many countries postponed elective surgery to free up human
resources and hospital beds. This was the case, for example, in Germany and Portugal for all non-
urgent elective surgeries (OECD, 2020[69]). In France, the Académies de médecine et de chirurgie
estimated around 1.1 million non-urgent surgical acts were postponed during the pandemic (Santi and
Pineau, 2020[70]).
There have also been fewer visits  to emergency departments.  In the United Kingdom, for
example, emergency department visits in March 2020 were 29% lower than in March 2019 (Appleby,
2020[71]). In France, fewer emergency visits were observed early in the crisis for people requiring
urgent care for cardio- and neuro-vascular pathologies (Santé Publique France, 2020[72]). Moreover,
a study in Paris found that the incidence of out-of-hospital cardiac arrest doubled during 16 March to
26 April, as compared to the equivalent time period in previous years (Marijon et al., 2020[73]). In
Germany,  the  COVID‑19  pandemic  was  associated  with  a  significant  decrease  in  all-cause
admissions (30% lower than for the same period in 2019) and admissions due to cardiovascular
events in the emergency department (41% lower) (Schwarz et al., 2020[74]). In Italy, paediatric
emergency department visits were down by 73‑88% in March 2020 as compared with March 2019 and
2018 (Lazzerini et al., 2020[75]).
Beyond acute care, large reductions in the use of outpatient services have been reported in some
countries, including Belgium, France, Germany (Bavaria), Norway and the United Kingdom (England)
(Figure  1.19),  though the number  of  teleconsultations  has increased substantially.  France also
reported fewer specialist care appointments.
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Delays in cancer diagnoses and treatments are likely to increase cancer deaths
Disruptions to cancer care have also been evident. In the Netherlands, data from the Cancer
Registry  show a notable  decrease in  cancer  diagnoses as  compared to  before  the  COVID‑19
outbreak (Dinmohamed et al., 2020[77]). In the United Kingdom, urgent referrals from primary care for
people with suspected cancers decreased by 76% and chemotherapy appointments for  cancer
patients by 60%, in comparison to levels before the COVID‑19 crisis (Lai et al., 2020[78]). In France,
the number of cancer diagnoses decreased by 35‑50% in April 2020, as compared to April 2019 (Santi
and Pineau, 2020[70]).
In  Italy,  an  estimated  1.4  million  fewer  screening  exams  were  performed  during  the  first
five months of 2020 compared to the same period in 2019, leading to fewer cancer diagnoses (Italian
National  Oncology  Association,  2020[79]).  In  Spain  (Madrid),  outpatient  visits  in  oncology
departments decreased by 23% between 9 March and 13 April 2020, as compared with the same
period in 2019. New oncology referrals and the number of patients enrolled in clinical trials also fell,
suggesting treatment delays (Manso, De Velasco and Paz-Ares, 2020[80]).
Studies are starting to show how much delayed cancer diagnoses and treatments will impact
patient’s survival rates. In England, delays in diagnosis have been estimated to increase cancer
deaths by about 16% for colorectal cancer, 9% for breast cancer, 6% for oesophageal cancer, and 5%
for lung cancer over the next five years (Maringe, Spicer and Morris, 2020[81]). In France, delayed
diagnoses could lead to an excess mortality of 10‑15% per month of delay (Santi  and Pineau,
2020[70]).












Norway France England Bavaria, Germany¹ Belgium
Reduction, %
Note: Estimates are based on different tools and are not directly comparable. In Belgium and France, data on consultations compare April 2020 with April
2019; in Germany (Bavaria) March 2020 is compared to March 2019. In Norway and the United Kingdom (England), reductions uniquely during March
2020 are analysed. In Germany (Bavaria), data are calculated based on billing data. In France, Norway and the United Kingdom (England) estimates are
based on the number of consultations.
1. Germany data refer to Bavaria only.
Source: Norway (the Norwegian Control and Payment of Health Reimbursement), France (Santé Publique France), the United Kingdom (NHS Digital,
2020[76]) and Germany (Bavaria), information from https://www.aerzteblatt.de).
StatLink 2 https://stat.link/32k6l0
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Strengthened primary care systems are key to maintaining continuity of care for non-
COVID‑19 patients
The emerging evidence described above points to the risks of not giving sufficient weight to non-
COVID‑19 health  care  needs,  resulting  in  urgent  health  problems remaining  undiagnosed  and
exacerbated chronic illnesses. Maintaining primary health care practices, establishing community
care facilities, extending home-based programmes, expanding the role of primary health care workers
and increasing telemedicine consultations are  key to  minimise delays and forgone care for  all
patients.
Primary health care practices, community care facilities and home-based programmes help
maintain access to routine care
Primary  health  care  practices,  which  house multiple  professionals,  enable  better  care  co-
ordination and are proactively engaged in preventive care and management of chronic diseases.
Before the crisis,  primary health care practices based on teams or networks of  providers were
reported by 17 OECD countries (OECD, 2020[68]). However, during the COVID‑19 pandemic, very
few countries have relied on these multi-disciplinary team practices to maintain continuity of care for
non-COVID‑19 patients. Iceland and Slovenia are two exceptions. In Iceland, primary health care
practices have continued to work with patients to manage chronic diseases and maintain essential
services. At the same time, they were also responsible for identifying high-risk patients, testing
patients,  and  providing  patient  education  on  COVID‑19.  In  Slovenia,  health  promotion  centres
(established within primary health care practices), have maintained care continuity for chronically ill
people.
Primary health care services also rapidly adapted in some European countries. One innovative
response was the establishment of COVID‑19 community care facilities, as developed in France,
Iceland, Slovenia and the United Kingdom. These were designed to improve triage of patients with
potential COVID‑19, but also maintain essential services for non-COVID‑19 patients.
Expanded home-based programmes have also been used to maintain access to care for non-
COVID‑19 patients. Before the crisis, many European countries were already using home-based
programmes to provide post-discharge care or nursing care at home. During the COVID‑19 pandemic,
home-based programmes have helped keep people  out  of  hospitals  by maintaining access.  In
Heidelberg (Germany), mobile primary health care teams visited patients at home, equipped with
testing and monitoring material for patients with underlying conditions. In the United Kingdom, some
primary  health  care  services  pivoted  rapidly  to  providing  home-based  services  (Care  Quality
Commission, 2020[82]).
Mobilising community pharmacists helps ensure patients continue to get needed medicines
Before the crisis, many European countries focused on ensuring a right skills mix for the primary
health care workforce. The scope of practice of nurses in Estonia, Ireland, Latvia, Sweden and the
United Kingdom had already been expanded. Community pharmacists have also been taking a
greater role in health promotion and prevention, notably in remote and underserved areas, in Belgium,
the United Kingdom (England), Finland, Italy and Switzerland (OECD, 2020[68]).
During the pandemic, the implementation of such policies has accelerated. For instance, the
scope of practice of community pharmacists has rapidly been expanded to allow for greater continuity
of care for non-COVID‑19 patients (OECD, 2020[68]). In Austria, France, Ireland, Portugal and Spain,
pharmacists can now prescribe chronic medications and have been allowed to extend prescriptions
beyond what they were previously allowed to do (PGEU, 2020[39]). In the United Kingdom (Scotland),
extension of the Minor Ailment Service (MAS) has empowered community pharmacists to support
more patients by allowing them to give certain medicines without GP prescriptions.
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Some countries have also enhanced the role of  community health workers (Ballard et  al.,
2020[83]). For example, the United Kingdom proposed training community health workers to manage
long-term conditions and review medicines use for elderly people and those with underlying health
conditions (Haines et al., 2020[84]).
Telemedicine has helped preserve continuity of care while containing the spread
The adoption of telehealth and telemedicine12 was limited in Europe before the pandemic, with
providers and patients facing barriers to wider use (Oliveira Hashiguchi, 2020[85]). However, with
rising cases and lockdowns limiting face-to-face care, countries have moved at speed and at scale to
allow a range of services to be delivered remotely through digital means. Countries such as Austria,
Belgium, Estonia and the Czech Republic that did not have a national legislation, strategy or policy on
the use of telemedicine, and did not define jurisdiction, liability or reimbursement of services like
telehealth,  have since allowed provider payment for some telehealth consultations and clarified
regulations.
Countries  where  telemedicine  was  already  allowed  before  the  pandemic,  like  France,
Luxembourg and Poland, have made it easier for providers and patients to use remote consultations
by relaxing restrictions or by creating new platforms. In Poland, new COVID‑19 platforms combined
with existing digital services such as the Patient’s Online Account Platform made it possible to conduct
around 80% of consultations remotely during the first  wave of the pandemic. Since COVID‑19,
Belgium, Estonia, Greece and Ireland have allowed prescriptions and certificates of sick leave to be
issued and accessed electronically.
The use of telemedicine has increased substantially in some countries. In France, there were
close  to  500  000  teleconsultations  between  23‑29  March,  as  compared  to  around  10  000
teleconsultations per week before March. In Germany, an estimated 19 500 teleconsultations were
performed in March, compared to 1 700 teleconsultations per month in January and February. In
Norway, the share of e‑consultations with a GP rose from 5% between 2‑8 March to almost 60%
between 16‑22 March.
At least 11 European countries have helplines dedicated to COVID‑19, including needs triggered
by the lockdown, with an emphasis on mental health and emotional support (Mental Health Europe,
2020[86]). Denmark, Portugal, Spain, the United Kingdom and WHO/Europe among others have also
used AI-powered interactive chatbots to deal with the surge in service demand as well as to collect
information on symptoms, to triage patients, and to combat misinformation. Finally, even before the
crisis, many European countries were already using telemonitoring for chronic patients, and these
programmes have acquired a new impetus, with many patients unable to attend face-to-face routine
appointments.
As countries ease lockdown restrictions, and health care facilities open their doors again to
patients, the number of teleconsultations is likely to decrease, as is happening in the United States
(Commonwealth Fund, 2020[87]). While the pandemic has shown that countries can move very fast to
break down barriers to telehealth (and other digital tools), some barriers are structural and less
amenable  to  short  term  regulatory  changes.  Access  to  broadband,  medical  liability  across
jurisdictions, cybersecurity and data protection, are just a few examples.
While  it  is  unclear  how much medical  care  can be done remotely  through digital  means,
telehealth is unlikely to be a substitute for the majority of health care services. Still, it can play an
important and increasing role. For example, a recent US study estimated that 20% of all Medicare
spending could be virtualised (McKinsey, 2020[88]). What is clear is that the pandemic has led to an
unprecedented adoption and use of telehealth that would not have otherwise happened so quickly.
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Countries maintained access to mental health services under difficult
circumstances, and are starting to respond to emerging mental health needs
The COVID‑19 crisis has had a marked impact on the mental health of both people with pre-
existing mental health conditions and the general population. Countries have taken decisive action to
preserve some access to mental health support. Many countries have also been providing well-being
support to the general population, for example through online advice or phone hotlines. Nonetheless,
the combination of reduced capacity in mental health services and increased demand caused by the
worsening mental health status of the general population, risks putting additional strain on mental
health services which were already over-stretched in many countries.
People living with mental health conditions did not always get the care they need
The COVID‑19 outbreak had a significant disruptive impact on people living with mental health
conditions. The unfamiliar situation of social distancing and confinement measures, health fears, and
disruption to daily habits and routines may worsen existing conditions or provoke new episodes of
mental  disorders.  Losing  contact  with  mental  health  services  further  aggravates  symptoms
(Rajkumar, 2020[89]). Early indications suggest that people with existing mental health conditions,
including  schizophrenia,  eating  disorders,  and  attention  deficit  hyperactivity  disorder  (ADHD),
reported increased symptoms (Moreno et al., 2020[90]).
Many countries saw peaks in discharges from mental health care in March and April, linked to the
recommissioning of inpatient beds or staff for COVID‑19 wards, as well as to the risk of COVID‑19
transmission. In Madrid (Spain), in March 2020 the number of inpatient psychiatric beds was reduced
by 60%, outpatient units were closed, and the number of patients attending emergency psychiatric
services fell by 75% (Arango, 2020[91]). In the Italian region of Lombardy and the United Kingdom
(England), discharges from psychiatric inpatient care increased in March and April (NHSProviders,
2020[92]; WHO Europe, 2020[93]).
Multiple reports from OECD countries also suggest significant reductions in the number of
referrals to mental health services, mental health services contacts, and active community caseloads
during the peak of the spring COVID‑19 outbreak. In the Netherlands, for example, the impact has
already been significant: the number of referrals to mental health care fell  by 25‑80% after the
outbreak; demand for treatment dropped by 10‑40%; billable hours decreased by 5‑20%; and bed
occupancy dropped by 9% (House of Representatives, 2020[94]). In the United Kingdom psychiatrists
reported, as of May 2020, a fall in requests for routine appointments, at the same time as a marked
increase in urgent and emergency cases.
Some of these trends appear to be driven by reduced demand. For example, a common pathway
into mental health services is through a referral from a General Practitioner or through schools
(NHSProviders, 2020[92]).  With many populations being discouraged from “non-urgent”  medical
visits, and widespread school closures during the first half of 2020, these referral pathways were
disrupted. People may have also been less likely to seek help themselves, out of concern that they
could be infected, or because they did not wish to “burden” the health system (Rethink Mental Illness,
2020[95]).
Emerging needs – the COVID‑19 crisis has increased levels of mental distress
COVID‑19 has had a significant negative impact on the mental health of populations. As a novel
infectious  disease  outbreak,  it  is  an  understandable  source  of  anxiety  and  fear.  Furthermore,
populations have been asked to significantly change their habits in a way that may negatively affect
their mental health. Social distancing or living under confinement conditions include shifting away from
behaviours which can promote positive mental health, such as participation in the workplace, social
connection and physical exercise. Some people have faced the additional strain of illness or even loss
HEALTH AT A GLANCE: EUROPE 2020 © OECD/European Union 2020 65
1. HOW RESILIENT HAVE EUROPEAN HEALTH SYSTEMS BEEN TO THE COVID‑19 CRISIS?
of friends or family members (Gunnell et al., 2020[96]; Brooks et al., 2020[12]; WHO, 2020[97];
Holmes et al., 2020[98]).
Adverse impacts can already be seen for the general  population. For example, population
surveys from Belgium, the Czech Republic, Denmark, France and the United Kingdom all point to
increased levels of overall anxiety in the weeks since the start of the major outbreak and confinement
measures (Figure 1.20). Effects have been particularly pronounced among people with lower socio-
economic status, young people, frontline workers, especially health and care workers, and for people
with existing mental health conditions (Banks and Xu, 2020[99]; Sciensano, 2020[100]). Conversely,
people who were able to continue working during confinement or to telework were also less likely to
report depression and anxiety.
Innovative policies have helped protect population mental well-being
Some OECD countries are already taking steps to implement policies to protect mental well-
being and provide mental health support. Informational resources have been made available online by
WHO-Euro  and  national  governments  (WHO,  2020[106];  IASC,  2020[107];  NAMI,  2020[108]).
Materials include advice on steps to protect mental well-being. In addition, most EU countries have
introduced phone support lines for people experiencing mental distress during the COVID‑19 crisis. At
least 23 countries have helplines where people can seek psychological support, and in at least some
countries  –  including  Austria,  Belgium,  the  Czech  Republic,  Denmark,  France,  Germany,
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Note: The survey instruments used to measure anxiety differ between countries, and therefore may not be directly comparable. Differences in the
openness of populations to discussing their mental state also hampers cross-country comparability. In Belgium, the surveys record ‘Percentage of people
with an ‘anxiety disorder’. In the Czech Republic, the surveys record prevalence of anxiety disorders in the adult population using the Mini International
Neuropsychiatric Interview (MINI). In Denmark, the surveys record ‘Percentage of population with scores <50 on the WHO‑5 well-being scale’. In France,
the surveys record prevalence of anxiety in the population using the Hospital Anxiety and Depression scale (HADS). In the United Kingdom, the surveys
record ‘Percentage of the population experiencing ‘high anxiety’’. All 2020 surveys were undertaken at time points in the period March-April 2020.
Source: Sønderskov et al. (2020[101]), “The depressive state of Denmark during the COVID-19 pandemic”, http://dx.doi.org/10.1017/neu.2020.15;
Sciensano (2020[100]),  “Enquête de santé COVID-19: quelques résultats préliminaires”,  https://www.sciensano.be/en/biblio/troisieme-enquete-de-
sante-covid-19-resultats-preliminaires; ONS (2020[102]), “Coronavirus and anxiety, Great Britain: 3 April 2020 to 10 May 2020”, https://www.ons.gov.uk/
peoplepopulationandcommunity/wellbeing/articles/coronavirusandanxietygreatbritain/3april2020to10may2020; ONS (2020[103]), “Coronavirus and the
social  impacts  on  Great  Britain  -  Office  for  National  Statistics”,  https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/
healthandwellbeing/bulletins/coronavirusandthesocialimpactsongreatbritain/7may2020; Chan-Chee et al. (2020[104]), “The Mental Health of the French
facing  the  COVID-19  crisis:  prevalence,  evolution  and  determinants  of  anxiety  disorders  during  the  first  two  weeks  of  lockdown”,  https://
www.santepubliquefrance.fr/content/download/260547/2644064; Winkler et al. (2020[105]), “Sharp Increase in Prevalence of Current Mental Disorders in
the Context of COVID-19: Analysis of Repeated Nationwide Cross-Sectional Surveys”, http://dx.doi.org/10.2139/ssrn.3622402.
StatLink 2 https://stat.link/2is10b
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Luxembourg, Portugal, Spain and Sweden – dedicated COVID‑19 psychological support lines were
set up (Mental Health Europe, 2020[86]).
It is not yet clear what the impact of reduced confinement measures after the first outbreak on
mental well-being has been, nor whether the economic and employment fall out from the crisis will
lead  to  sustained  or  increased  levels  of  mental  distress.  Belgium,  Germany,  France,  and  the
United Kingdom have multi-wave surveys that have been tracking population mental well-being at
regular intervals since early March 2020, and should bring new insights into changing mental well-
being levels, post-confinement.
Going forward, some stakeholders have called for a need for a broader increase in the availability
of mental health support services in anticipation of a potential significant peak in demand (Douglas
et al., 2020[109]; Torjesen, 2020[110]; Roca, Vicens and Gili, 2020[111]). It will also be important to
include mental health support as part of rehabilitation efforts for people who have suffered from
COVID‑19, especially for persons who have spent extended periods in hospital, as these people may
be at greater risk of mental health problems including Post Traumatic Stress Disorder, anxiety, and
depression.
Countries have sought to protect access to care for people with mental health conditions,
including inpatient care where necessary
Across Europe, the capacity of mental health services to rapidly adapt to different ways of
delivering care during the COVID‑19 crisis has been impressive. Mental health services, including in
areas where the outbreak was most acute, were adapted to introduce new safety measures for staff
and patients, to maintain essential services for the most severe cases, and to move a significant
volume of services to phone or online services.
As the crisis has continued, Ministries of Health and professional associations have been issuing
guidance on managing COVID‑19 risk for mental health services, especially in inpatient settings. For
example, in the United Kingdom the Royal College of Nursing issued guidance on mental health care
delivery and the COVID‑19 risk. This guidance includes reviewing safety for inpatient activities based
on infection risk and therapeutic benefit, screening visitors, and preparing for an eventual COVID‑19
positive patient (Nursing, 2020[112]). Multiple countries and regions, including France, Italy and
Spain, set up dedicated wards for COVID‑19‑positive mental health patients.
Most countries sought to maintain access to a maximum of  acute mental  health services,
including in-person care where necessary. In Italy, where the Regional Health Authorities recognised
mental health as a priority service, inpatient and community mental health care was maintained, with
the introduction of new sanitary safeguards such as pre-scheduled appointment times for visits, limits
to interventions in service users’  homes,  and reduction in activities involving families or  carers
(Percudani et al., 2020[113]). At the same time, remote contacts were set up with an estimated 75% of
cases  (Carpiniello  et  al.,  2020[114]).  In  Spain,  the  Society  of  Psychiatry  made  a  series  of
recommendations promoting the use of mobile phones, digital resources such as apps, and other
forms of telemedicine (Vieta, Pérez and Arango, 2020[115]). Some of the broader steps taken to
maintain  access  to  health  care  should  also  benefit  mental  health  services,  such  as  allowing
pharmacists to renew repeat prescriptions as well as enhanced technical and legislative capacity
around telemedicine.
Countries have also been taking further steps to ensure or even increase access to mental health
support. Greece is providing psychiatric assistance in cooperation with NGOs and a large number of
volunteer psychologists, while Austria has facilitated teleconsultation in psychotherapy and covered
this  service  under  social  health  insurance  (OECD,  2020[116]).  In  Madrid  (Spain),  three  new
psychiatric liaison services were set up to take care of medical staff on COVID‑19 wards, to support
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families of COVID‑19 patients, and to support families of a relative at the point of death and following
the death of their loved one (Arango, 2020[91]).
Some of the experiences of mental health services during the first wave of the COVID‑19
pandemic may lead to positive changes going forward, notably increased use of telemedicine. In other
respects, as the COVID‑19 crisis continues all countries will need to take steps to ensure that good
access to mental health services continue, and that mental health services have the resources – such
as PPE and timely testing – that they need to maintain access.
How can policy makers improve the resilience of health systems to the ongoing pandemic
and future health crises? Emerging insights
COVID‑19 has had a huge and lasting impact in Europe and worldwide, testing the resilience of
health systems and placing immense pressure on health workers. The virus spread rapidly across
Europe, leading to many deaths and stringent containment policies by a large number of countries in
an attempt to contain the outbreak.
Providing an overall assessment of country responses is difficult, given that the pandemic is far
from over. Nevertheless, over the first ten months of 2020, data from reported COVID‑19 and excess
mortality rates suggest Belgium, Italy, Spain and the United Kingdom were the most severely affected,
followed by France, the Netherlands and Sweden. In contrast, most countries in Central and Eastern
and South-eastern Europe, as well as most Nordic countries, have been less adversely affected by
the first wave of the pandemic. Still, many Central and Eastern European countries have been more
adversely affected since August.
The health crisis has also led to a major economic crisis, with countries hardest hit by COVID‑19
typically experiencing the largest economic contractions. All 31 European countries in this report
experienced negative economic growth in the second quarter of 2020. Still, a few countries have
managed to limit both the adverse health and economic impacts over the first ten months of 2020 –
notably Estonia, Finland and Norway. These countries had the advantage of having amongst the
lowest population density in Europe. Relatively high levels of trust in government have also increased
compliance with government containment and mitigation strategies. However, no European country
has done as well in handling the pandemic as several countries in the Asia-Pacific region, such as
Korea and New Zealand.
It is important to note, though, that some countries have been more susceptible to COVID‑19 due
to inherent factors that go beyond policy makers’ responses to the virus – such as countries with older
populations, a higher prevalence of certain risk factors such as obesity, more inbound and outbound
tourism and international travel, and higher population density. Further, countries first hit by the
pandemic like Italy had necessarily less time to implement comprehensive policy responses.
As the situation evolves, further analysis will be needed to assess which policy interventions
have worked and which have not. Still, the country experiences analysed here, predominantly from
the first wave of the pandemic, offer emerging insights. These can help health systems become more
resilient to the ongoing pandemic and future crises. These are grouped into five priority policy areas,
focusing on lessons learned for future resilience.
If countries are prepared and are able to act quickly, they may be able to avoid costly
containment and mitigation measures
Most  European  countries  struggled  to  scale  up  their  testing  capacity.  This  limited  the
effectiveness of test, track and trace efforts, leaving countries with fewer measures at their disposal to
contain the spread of the virus, and necessitating full lockdowns. Many countries also lacked masks
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and other PPE early in the outbreak. Looking forward, countries can address these shortcomings at
relatively low cost – if they are well prepared and act quickly as new outbreaks emerge.
For testing, rapid scale-up of testing capacities, effective public health messages and population
screening policies are key. Outside Europe, these factors largely explain Korea’s excellent results in
the early stages of the outbreak with relatively few tests, based on a swift and targeted approach that
included innovative policies such as drive-through and phone booth testing centres, and strong public-
private partnerships. New Zealand has been another successful example. Within Europe, Germany
reported by far the highest number of daily tests in the early stages of the pandemic. Iceland was able
to rapidly scale-up testing, its success built on voluntary self-referrals and effective public information
to encourage people to come forward.
For subsequent tracking and tracing, mobile technologies (digital contact-tracing apps) may hold
some potential to improve early detection, but better use of routine health data is a more proven way to
obtain real-time surveillance, including environmental surveillance. Standardised electronic health
records (EHRs) can be used to quickly extract high quality routine data. Finland and Iceland both have
national EHR systems with patient portals and, as a result, could offer integrated tools for people to
report  symptoms and  triage  patients  to  appropriate  services.  Yet  OECD research  prior  to  the
COVID‑19 crisis found that most European countries did not have sufficient technical and operational
capabilities to generate information from EHRs.
Concerning the supply of PPE and other essential medical supplies, better procurement, supply
chain management, stockpiling and trade policies can improve the availability of these items. EU-level
actions have helped to strengthen health systems resilience by coordinating supplies and reducing
bottlenecks.
Adaptive surge capacity can help treat COVID‑19 patients in an effective manner, but
countries will also need to invest more in their health workforce
Looking beyond containment, health systems need to adapt and evolve so they can better
respond  to  surges  in  demand.  This  requires  reconsidering  health  workforce  and  hospital  bed
capacities. For hospital beds (of which ICU beds are particularly important for combatting COVID‑19),
permanent increases will be costly. Yet the success of many European countries in rapidly creating
surge capacity – such as by creating temporary field hospitals, converting regular beds to intensive
care beds or transferring patients to hospitals with spare capacity – shows that more flexible solutions
which adapt to needs can work.
Adaptive policies can also help mobilise additional staff to respond to surges in demand. France,
for example, already had a “reserve list” (“Réserve Sanitaire”), which was mobilised and expanded
during the COVID‑19 outbreak. Belgium, Iceland and Ireland quickly set up new “reserve lists” to deal
with the outbreak and reallocate staff across localities. Still, a lack of health personnel has been more
of a binding constraint than hospital beds, reflecting the fact that training skilled health workers is more
time-consuming than creating temporary facilities. Staff have also faced extreme pressures in many
countries. These factors suggest that countries will need to invest more in their health workforce.
Strong primary health care and mental health services are needed for COVID‑19
patients and to maintain high quality care for non-COVID‑19 patients
Whilst  the spotlight  has largely  fallen on hospitals,  primary health care and mental  health
services are critical in times of crisis and to foster longer-term resilience. Again, adaptability is key to
policy effectiveness. Much wider adoption of telehealth has helped preserve continuity of care for non-
COVID‑19 patients and contained the spread of the virus. Community care facilities and expanded
home-based programmes have improved access to care for non-COVID‑19 patients during the crisis,
as well as alleviated pressure on hospitals.
HEALTH AT A GLANCE: EUROPE 2020 © OECD/European Union 2020 69
1. HOW RESILIENT HAVE EUROPEAN HEALTH SYSTEMS BEEN TO THE COVID‑19 CRISIS?
Innovations in the roles and responsibilities of primary care health professionals also has lasting
potential. Alongside increasing the scope of practice for nurses, enhanced roles for pharmacists and
community health workers offer practical ways to maintain continuity of care when people are less
able to access doctors. For example, in Austria, France, Ireland, Portugal and Spain, pharmacists had
greater scope on extending prescriptions and prescribing chronic medications – thereby helping
ensure patients continue to get necessary medicines during the crisis.
Mental health policies are also critical, particularly given increased social isolation following
stringent containment policies. Better online advice and phone support lines for people experiencing
mental distress have helped. Going forward, a broader increase in the availability of mental health
support services should be planned for in anticipation of a potential significant increase in demand.
Vulnerable populations need much more support in the health system and beyond
COVID‑19 has disproportionately hit vulnerable populations. Older populations face an elevated
risk, and policy responses in the LTC sector could have been quicker, with countries often focusing
first on hospitals. Here, timely availability of PPE and testing in LTC facilities can better protect
workers and recipients of LTC.
The social gradient of deaths from COVID‑19 shows that the social determinants of health need
greater attention. Universal health coverage principles are a key pre-requisite in improving access to
care  for  vulnerable  groups.  Yet  policies  also  need  to  address  more  directly  the  reasons  why
disadvantaged groups are at higher risk of dying – because they more often have chronic illnesses
and are in worse health, have higher-risk jobs, and live in overcrowded or insecure housing. Tackling
this means more investment in prevention, but more importantly it calls for interventions beyond the
health system, addressing the root causes of inequalities through better social and economic policies.
Health resilience is a multi-system challenge that requires close international
cooperation
This report has focused on health system resilience, yet the COVID‑19 crisis has also highlighted
that broader health resilience is a multi-system challenge (OECD, 2020[4]). It relies upon interactions
across  different  sectors  of  interconnected  economies  and  between  governments.  International
collaboration is key to strengthening resilience. In Europe, joint procurement and other EU-level
actions  have  helped  reduce  strains  on  global  supply  chains.  The  transfer  of  patients  from
overburdened hospitals in the East of France to Austria, Germany, Luxembourg and Switzerland
showed the benefits of inter-country support. Yet lasting solutions, including R&D into vaccines and
effective treatments, will need close and continued international collaboration in the future.
Notes
1. The  official  name  for  the  virus  responsible  for  COVID‑19  is  “severe  acute  respiratory  syndrome
coronavirus 2 (SARS-CoV‑2)” and for the disease it causes is “coronavirus disease (COVID‑19)”. In this
chapter, “COVID‑19” refers to both the virus and the disease it causes.
2. Containment strategies aim to minimise the risk of transmission from infected to non-infected individuals in
order to stop the outbreak. Mitigation strategies aim to slow the disease, and, where the disease has
occurred, to lessen its impact or to reduce the peak in health care demand. In practice, containment and
mitigation  actions  largely  overlap  and  are  often  implemented  concurrently.  In  fact,  containment  and
mitigation policies may even be considered as a continuum with gradual increments of the same strategy.
3. In August 2020 Norway temporarily recommended wearing masks regionally in public transport during rush
hours.
4. This threshold was used to reflect  the moment when countries are likely  to face an active chain of
transmission on their territory (as opposed to sporadic or imported cases).
5. https://www.rivm.nl/en/COVID-19/sewage.
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8. Some research papers have started to estimate the effects of social distancing and other interventions on
the pandemic, using econometric models. For example, Flaxman et al. (2020[117]) found, using data from
serological  studies  to  estimate  the  true  number  of  infections,  that  non-pharmaceutical  interventions
including national ‘lockdowns’ could have averted about 3.1 million COVID‑19 deaths across 11 European
countries.
9. The data for France cover the period from 1 March to end of June 2020, while the data for Italy and Spain go
up until the end of August 2020.
10. https://vpt.lrv.lt/sudarytos-sutartys-kovai-su-COVID-19.
11. https://www.gov.uk/government/news/ventilator-challenge-hailed-a-success-as-uk-production-finishes.
12. Telehealth is the use of information and communication technologies to promote health at a distance,
including non-clinical services and education, while telemedicine is restricted to clinical services.
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Annex Table 1.A.1. Health workforce – policies to boost surge capacity response to COVID-19 during
the first wave of the pandemic in 2020
Country Selected policy examples (e.g. mobilising health care students, retired and non-practicing health care workers, foreign health careworkers, existence of official reserve list, transfer of staff to localities with greater needs)
Austria Young civil servants mobilised to support long-term care workers as paramedics – the government estimates about 14 600 additional
workers can be mobilised this way. Other policies included allowing foreign health care workers from Central and Eastern European
countries to enter Austria and the involvement of medical students.
Belgium Medical students, nursing students and physicians in training mobilised to mitigate possible shortage of health care professionals. At
the level of federated entities, lists of reserves were also organised to provide assistance in health services.
Bulgaria A call was launched to mobilise medical students and retired health professionals to combat COVID‑19.
Croatia Information not available.
Cyprus Workforce from private sector mobilised to support public hospitals. Final-year medical and nursing students employed on a
voluntary basis.
Czech Republic Non-EU medical staff without fully validated degrees allowed to work in hospitals (but was also the case before the pandemic). About
3 800 students engaged, mostly as nurses, auxiliaries or at Public Health Authorities call centres (with almost 5 500 students
registered to combat COVID‑19 by mid-April). Graduate nurses not working in health care applied to help and worked in health
facilities during the pandemic.
Denmark Students in medical, nursing and other health education programmes and retired health workers invited to join the workforce through
the establishment of a ‘job bank’. Fast track re-training of health professionals has also been set-up to facilitate work in ICU facilities.
Nurses from surgical departments have been redeployed depending on needs.
Estonia The Army sent a medical team of 18 members and a support team of 20 members to help set up a field hospital. As of 5 April, 11
voluntary doctors and nurses from Estonian hospitals, ambulances and the private sector were also mobilised to staff the field
hospital. In addition, medical and nursing students mobilised to work in primary care practices, while hospital staff were reassigned
when needed.
Finland Some health workers retrained and/or reassigned to different positions. Medical students have been recruited to do contact tracing as
testing capacity increases. From 26 March to 13 April, people working in both public and private health care facilities were required to
work during the crisis if needed.
France About 3 000 health professionals were registered in the sanitary reserve before the crisis. An additional 40 000 expressed their
interest to be registered by April 2020 (although not all of them were registered and the number who were deployed is unknown).
Germany Over 20 000 medical students registered to combat COVID‑19 (as of 26 March). Potential pool of about 14 000 foreign-trained
physicians waiting for recognition of their diplomas.
Greece New legislation allowed for the employment of private physicians in public hospitals. Since 4 March, 4 200 job placements have been
approved (medical, nursing and support staff) and 2 000 have been completed. Since 23 March, over 8 000 volunteers (doctors,
nurses, paramedics, psychologists, medical students, and retirees) have applied through the digital platform to combat COVID‑19.
Hungary Over 900 volunteers registered at the NHS website to combat COVID‑19 (students, health professionals from the private sector,
retired health workers).
Iceland The Ministry of Health established a health care service reserve which includes doctors, nurses, auxiliaries, retired health workers
and medical and nursing students. 1 000 health professionals registered to this reserve.
Ireland A total of 4 858 workers recruited in the public health care sector. Of which, mobilisation of 1 399 nursing, midwifery and science
students, 992 medical interns and 156 retired health care workers. Nationwide recruitment campaign ‘Be on Call for Ireland’ launched
in mid-March (197 applicants employed) and creation of a reserve list. In addition, 2 114 health care workers recruited through usual
channels. Redeployment of 558 health care workers to areas where they were most needed.
Italy The NHS hired 29 433 additional health professionals since March 2020 to combat COVID‑19 (across all contract types and
facilities), including 6 330 doctors (of which 22% in the Lombardy Region and 11% in Emilia-Romagna) and 13 607 nurses (of which
14% in the Lombardy Region and 17% in Emilia-Romagna).
Latvia Many volunteer students from several Latvian universities responded to the call to combat COVID‑19. In addition, the quota of
overtime hours increased for medical practitioners and epidemiologists.
Lithuania Health workers were reassigned depending on needs. Health professionals, medical students, residents and retired doctors can be
pooled if needed. On 19 March, the National Centre for Public Health issued a call for volunteers.
Luxembourg On 23 March, a national platform was launched to recruit volunteers. It targeted health workers, students, retired health workers and
people on leave without pay. In addition, GPs, nurses and medical students have been trained to support hospital staff during the
COVID‑19 crisis.
Malta Some health professionals and medical students retrained to be able to work in A&E or ICU units, while other volunteers have been
trained to support helplines. A public call was also issued for doctors, dentists, nurses and allied health professionals to combat
COVID‑19.
Netherlands Additional workforce mobilised in hospitals by reactivating former health professionals (retired workers or other people no longer
working in hospitals). Other measures included removing obligations for re-registration, allowing workers whose official registration
had expired to work and mobilising additional workforce from the military service.
Norway Hospitals staff have been reassigned, after receiving necessary training. The Directorate of Health advised the municipalities to hire
medical and nursing students and retired health workers. An official call was made on 24 March for all health professionals to register.
As of 18 May, 6 492 health personnel had registered in the national preparedness registry, including 1 453 nurses and 754
physicians.
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Annex Table 1.A.1. Health workforce – policies to boost surge capacity response to COVID-19 during
the first wave of the pandemic in 2020 (cont.)
Country Selected policy examples (e.g. mobilising health care students, retired and non-practicing health care workers, foreign health careworkers, existence of official reserve list, transfer of staff to localities with greater needs)
Poland Some medical doctors have been reassigned to other facilities depending on needs. Final-year students in medicine, pharmacy,
medical analytics, nursing and emergency allowed to perform support roles in hospitals and nursing homes. Legislation has been
passed to facilitate the hiring of retired health workers and non-practicing nurses in hospital.
Portugal The Ministry of Health implemented a series of measures, including: redeploying health workers; suspending overtime quota; training
for GPs; and simplified contractual arrangements for hiring students, retired health care workers or nurses. As of 15 May, 2 628 health
workers had been hired by the NHS under these new rules (including 118 doctors and 855 nurses).
Romania About 2 000 temporary jobs created (1 000 jobs at district public health authorities and 1 000 jobs for district emergency ambulance
services). A legislative basis was also introduced to allow the compulsory redeployment of doctors, nurses, and students.
Slovak Republic Information not available.
Slovenia Medical students and interns mobilised to increase the availability of health workers. A call targeting nursing professionals who had
previously worked in ICUs was made to help bridge the workforce gaps in ICU units.
Spain The Ministry of Health implemented a series of measures, including: hiring of retired health workers, resident doctors, nursing or other
health workers; and relocating health workers to facilities and regions with greater needs.
Sweden A call was launched to mobilise students, retired health workers and staff from other sectors with a health education to combat
COVID‑19. The Region of Stockholm requested SALAR to activate an emergency agreement to temporarily increase working hours
and transfer staff between various wards, departments within regions, and between two regions.
Switzerland The cantons and hospitals put out calls for health care volunteers (including medical students). As of June 2020, the army had
mobilised 8 000 persons to support various civilian services.
United Kingdom The UK Regulatory Bodies for all health care professions facilitated rapid re-registration of retired clinicians and over 50 000 of these
made an initial offer to return to support the NHS. Along with medical, nursing and AHP students, over 60 000 extra personnel
became available to work and many thousands were employed in front line and remote services. In addition, a call for volunteers to
support NHS services resulted in more than 750 000 applications.
Source: OECD health system policy tracker, European Observatory Health System Response Monitor and reports from national governments.
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Annex Table 1.A.2. Policies to boost surge capacity response to COVID-19, during the first wave of the
pandemic in 2020
Country Selected policy examples (e.g. turning wards into ICUs, creating field hospitals, transfer of patients to localities with spare capacity,partnerships with private hospitals)
Austria About 7 500 additional beds from facilities other than hospitals (such as rehabilitation facilities) and another 1 735 regular beds have
been made available for COVID‑19 treatment (as of 8 April).
Belgium An additional 759 intensive care beds created since the start of the COVID‑19 crisis (as of 22 March). Redistribution of patients from
the provinces of Limburg and Hainaut toward Anvers.
Bulgaria Private hospitals provided equipment and capacity. Armed forces prepared camp beds and mobile facilities for COVID‑19 treatment.
Croatia Hospitals converted to COVID‑19 respiratory centres with support from mobile medical facilities. Some non-medical facilities
(e.g. student campuses, sports halls) repurposed with hospital beds to treat patients with non-severe COVID‑19 symptoms. Other
non-medical facilities converted to quarantine facilities.
Cyprus Creation of a new ICU at the General Hospital of Nicosia with a capacity of 28 beds.
Czech Republic Transformation of standard beds into ICU beds. As of 16 April 2020, 4 197 ICU beds (beds in anaesthesiology and resuscitation
departments and ICUs for adults) were made available during the COVID‑19 pandemic.
Denmark Pre-existing intensive care capacity increased by 75%. Flexible adjustments in local capacity allowed for rapid re-location of
equipment. Private hospitals were required to make their facilities available to treat COVID‑19 patients.
Estonia Creation of Defence Forces field hospital to support the Kuressaare hospital, with 20 additional intensive care beds and 40 general
ward beds (on 2 April). Possible transfer of patients to non-medical facilities such as spas and hotels to boost hospital capacity.
Restructuring of post-surgery wakeup rooms and day surgery rooms into ICUs equipped with ventilators.
Finland Conversion of operation wards and recovery areas into ICUs. Helsinki University Central Hospital dedicated one of its buildings to
COVID‑19 patients.
France The resuscitation bed capacity increased from 5 000 to 8 000 beds (as of 24 March). Hospitals and private clinics increased their
intensive care capacity across the country. A Military Field Hospital also created to boost capacity. 644 patients from overburdened
hospitals transferred by train to less affected regions and other EU countries (Austria, Germany, Luxembourg and Switzerland).
Germany In many hospitals, capacities shifted from planned and elective procedures to increase general and ICU bed capacity. Non-medical
facilities (e.g. rehabilitation facilities, hotels, public halls) transformed into ICUs. Overall, the number of ICU beds increased by about
12 000.
Greece The total number of ICU beds increased by 305 (as of 31 March). This included 85 new ICU beds in public hospitals, the provision of
30 ICU beds by military hospitals, and the provision of 137 ICU beds by private clinics. Public hospital of Athens transformed into a
COVID‑19 hospital, along with a private hospital in the Attiki region. In selected general hospitals, ICU units also dedicated to
COVID‑19 patients.
Hungary Construction of emergency hospital and 4 major hospitals outside of Budapest dedicated to COVID‑19 patients. A 330‑bed capacity
temporary facility created in Budapest in the exhibition buildings of Hungexpo (by 16 March). A military camp hospital was also built
(by 24 March).
Iceland Landspitali University Hospital and Akureyri hospital dedicated to COVID‑19, including a specialised COVID‑19 ambulatory care unit
at Lanspitali. Transformation of wards into intensive care units. Reserve beds prepared in other health care institutions in the Capital
Region to admit patients from Landspitali hospital in case of need.
Ireland Opening additional beds in existing critical care units, transforming wards and other spaces such as theatre into ICUs and
transferring patients to units with spare capacity or with additional expertise (10‑15% of COVID patients transferred). Private
hospitals operated as public hospitals under Section 38 of the Health Act for the duration of the Emergency (31 March‑30 June).
Overall, increased capacity of ICU beds reached 8.1 beds per 100 000 population (399 additional intensive care beds), as of 1 May
2020.
Italy In Lombardy the ICU capacity increased by 376 beds by turning wards into ICUs (by 16 March). The city of Milan converted existing
industrial spaces into hospitals. In some regions, the Department of Civil Protection set-up military camp hospitals with additional ICU
beds and lower intensity care beds. Patients in need of intensive care in affected regions transferred to other regions by air.
Latvia Measures to boost capacity included re-orienting hospital ward into ICUs to manage COVID‑19 patients and using medical
equipment from the private sector. As of 28 March, approximately 1 000 hospital beds were available in Latvia for the placement of
COVID‑19 patients.
Lithuania Reallocating some non-COVID‑19 patients into other facilities to create more inpatient beds for COVID‑19 patients. Secondary care
was reorganised into a network of hospitals to manage the treatment of COVID‑19 patients on a regional basis.
Luxembourg Inter-country support (some patients in overburdened hospitals in the east of France transferred to Luxembourg), creation of military
field hospital, increased bed capacity in ICU and non-ICU hospital facilities, increased number of ventilation equipment and CT
scans.
Malta An additional 600 beds were made available for COVID‑19 patients from acute hospitals, private medical facilities and other state-
owned health facilities. In addition, the number of Intensive Therapy Unit (ITU) beds increased five‑fold (from 20 to over 100).
Netherlands Redistribution of patients in need of ICU care to hospitals with spare capacity. For instance, in the Groningen hospitals (north of the
country) 32 of the 34 COVID‑19 patients came from the provinces of Noord-Brabant and Limburg (the south of the country).
Norway Plan to increase ICU capacity to 1 200 beds by 15 April.
Poland 22 hospitals transformed into single-infection hospitals. Non-COVID‑19 patients moved to alternative facilities nearby. The Ministry
of Health estimates approximately 10 000 beds were available in these designated single-infection hospitals.
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Annex Table 1.A.2. Policies to boost surge capacity response to COVID-19, during the first wave of the
pandemic in 2020 (cont.)
Country Selected policy examples (e.g. turning wards into ICUs, creating field hospitals, transfer of patients to localities with spare capacity,partnerships with private hospitals)
Portugal Measures to increase hospital capacity included reorganisation of the hospital network with one hospital fully dedicated to the
treatment of COVID‑19 patients, turning hospital wards into ICUs (the NHS had further increased general level 3 ICU beds for adults
by 25%), increasing patient discharges, contracting out with the private sector, and creation of field hospitals.
Romania Re-deployment of hospital beds into ICU beds. The army also deployed a mobile hospital near Bucharest, and a second one bought
from the Netherlands was located near Constanta. Many other modular hospitals built and 5 intensive care mobile units bought with
the support of local authorities, NGOs and other donors.
Slovak Republic Information not available.
Slovenia The first mobile hospital created by the military base Edvard Peperk in Ljubljana to host up to 120 patients in ICUs.
Spain 16 additional temporary hospitals created with the help of the Armed Forces. All ICU beds from private hospitals made available to
treat COVID‑19 patients. Three speed trains converted to transfer 24 critical patients to ICUs.
Sweden Additional 524 ICU beds gradually created during the crisis, which doubled the capacity of ICU beds (normal capacity is around 500
beds).
Switzerland Transfer of patients from the Canton of Ticino to the German-speaking part of Switzerland. Some hospitals were converted to treat
exclusively COVID‑19 patients, others transforming general hospital wards into ICUs. Private hospitals and clinics also mobilised to
treat COVID‑19.
United Kingdom New temporary hospitals built in seven locations to provide additional intensive care unit capacity (for example 500 beds in the
London Nightingale hospital). New hospital discharge criteria introduced that freed up around 33 000 beds (England).
Source: OECD health system policy tracker, European Observatory Health System Response Monitor and reports from national governments.
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PART I
Chapter 2
Air pollution and its impact on health in
Europe: Why it matters and how the
health sector can reduce its burden
This chapter reviews the health and welfare impacts of air pollution in Europe. Although
air pollution has decreased in most European countries over the past two decades, it
remains above WHO guidelines in most countries, particularly in some large Central and
Eastern  European  cities.  This  has  serious  consequences  on  people’s  health  and
mortality: in the EU, estimates attribute between 168 000 and 346 000 deaths to air
pollution from fine particles (PM2.5) alone in 2018. The welfare losses from air pollution
are substantial. A conservative estimate of the welfare impact of PM2.5 and ozone shows
that this amounts to an annual loss of 4.9% of GDP in the EU. This welfare loss is mainly
attributable to the impact of these pollutants on mortality, along with lower quality of life,
lower labour productivity and higher spending on health.
Efforts to reduce air pollution need to focus on the main sources of emissions. These
include the use of fossil fuels in energy production, transportation and the residential
sector, as well as industrial and agricultural activities. The EU recovery plan from the
COVID‑19 crisis provides a unique opportunity to promote a green economic recovery by
integrating  environmental  considerations  in  decision-making  processes,  thereby
supporting the achievement of the 2030 EU national emission reduction targets. The
health sector itself can contribute to achieving this objective by implementing various
measures  to  minimise  its  own  environmental  footprint.  Through  multi-sectoral
approaches, public health authorities can also contribute to environmentally friendly
urban and transport policies, which may also promote greater physical activity.
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2. AIR POLLUTION AND ITS IMPACT ON HEALTH IN EUROPE: WHY IT MATTERS AND HOW THE HEALTH SECTOR CAN REDUCE ITS BURDEN
Introduction
Air pollution is the main environmental risk factor for health in Europe and around the world. It has
substantial health, economic and welfare consequences, including ill-health and greater premature
mortality, increased health care costs, as well as reduced labour productivity and economic output in
some sectors (e.g. agriculture and forestry sectors). The main sources of air pollution arise from the
burning of fossil fuels in energy production, transport and households, and from some industrial and
agricultural activities.
Depending on the methods of estimation, between 168 000 and 346 000 premature deaths
across all EU member states in 2018 can be attributed to exposure to outdoor air pollution in the form
of  fine  particles  (PM2.5)  alone  (Institute  for  Health  Metrics  and  Evaluation,  2020[1];  European
Environment Agency, 2020[2]). This represented 4% to 7% of all deaths in 2018. In addition, hundreds
of thousands of people develop various illnesses associated with air pollution, leading to a loss of
about 3.9 million disability-adjusted life years (DALYs) annually in the European Union (Institute for
Health Metrics and Evaluation, 2020[1]).
While  most  European  countries  have  substantially  reduced  their  emissions  of  various  air
pollutants since 2005, most EU member states are still at risk of failing to fulfill their 2030 national
emission reduction commitments unless additional measures are taken (European Commission,
2020[3]). A key element of the European Green Deal, announced in December 2019, is the zero-
pollution ambition for a toxic-free environment. A proposed zero-pollution action plan for air, water and
soil will be announced for 2021 (European Commission, 2019[4]). The EU recovery plan from the
COVID‑19 crisis, approved by the European Council in July 2020, aims to promote a green recovery
by integrating environmental considerations into the recovery process (European Council, 2020[5]).
This plan should also promote the achievement of national emission reduction commitments.
This chapter first reviews the evidence of the health effects of air pollution in Europe and offers
estimates of the welfare losses associated with its considerable impact on morbidity and mortality. It
then reviews some of the main EU policy goals and actions to achieve good air quality and to promote
steady reductions in air pollution, including progress in the implementation of the 2016 National
Emission reduction Commitments (NEC) Directive (European Commission, 2016[6]). This chapter
ends with a discussion of the potential contribution of the health sector to efforts to reducing air
pollution,  including  through  decreasing  its  ecological  footprint  and  encouraging  lifestyle  and
environmental changes that both promote better health and benefit the environment.
The health and economic burden of air pollution in Europe
Air  pollution  causes  different  health  problems,  particularly  respiratory  and  cardiovascular
diseases. Different air pollutants can affect different parts of the body (Box 2.1). The greatest health
damage from air pollution is caused by chronic exposure to particulate matter, in particular to fine
particulate matter (PM2.5) which increases the risk of heart diseases, stroke, lung cancer and many
respiratory diseases including asthma, bronchitis, chronic obstructive pulmonary disease (COPD) and
respiratory infections. This explains why this chapter focuses primarily on the health and welfare
consequences of exposure to PM2.5.
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Box 2.1. Main air pollutants with adverse effects on health
Particulate matter (including PM10 and PM2.5) are particles that are suspended in the air. Primary PM emissions
result from the combustion of fuels, such as for power generation, domestic heating and in vehicle engines. Chronic
exposure to particles contributes to the risk of developing cardiovascular and respiratory diseases, irritates eyes, nose
and throat, causes disorders in the reproductive and central nervous systems, as well as increases the risk of lung
cancer. Small particulates of less than 10 microns in diameter (PM10) are capable of penetrating deep into the respiratory
tract and causing significant health damage. Fine particulates smaller than 2.5 microns in diameter (PM2.5) cause even
more severe health effects because they penetrate deeper into the respiratory tract and are potentially more toxic.
Nitrogen dioxide (NO2) is formed primarily from vehicle exhausts, especially from diesel vehicles, power plants and
combustion in industry. In addition to being a primary pollutant, it contributes to the formation of particulate matter and
ozone. NO2 can cause bronchitis and asthma, lead to irritations of eyes, nose and throat, cause respiratory infections
and reduced lung function, and impact on liver, spleen and blood.
Ozone (O3) at ground level, is formed by chemical reactions (triggered by sunlight) involving pollutants emitted into the
air, including those by transport, natural gas extraction, landfills and household chemicals. Excessive ozone in the air
can cause cardiovascular diseases as well as lead to breathing problems, irritations of eyes, nose and throat, trigger
asthma and reduce lung function.
Sulphur dioxide (SO2) is emitted mainly from the burning of fossil fuels such as coal and oil, and the smelting of
mineral ores that contain sulphur. Sulphur dioxide can affect the respiratory system, central nervous system and lung
function, and can cause headaches, anxiety and eye irritation. It can also aggravate bronchitis and asthma, and be a
cause of cardiovascular diseases.
Benzo(a)pyrene (BaP)  originates from incomplete combustion of fuels. Main sources include wood and waste
burning, coke and steel production and vehicle engines. BaP can affect the respiratory system, and irritates eyes, nose
and throat.
Infographic 2.1. Potential health impacts of major sources of air pollution
Source:  European  Environment  Agency,  https://www.eea.europa.eu/signals/signals-2013/infographics/health-impacts-of-air-
pollution/view.
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Exposure to air pollutants can take place both in outdoor (ambient) and indoor (household)
environments. In Europe, the impact on population health from exposure to outdoor air pollutants is
much greater compared to that from indoor air pollutants (see Figure 2.7 below).
Due to its impact on respiratory and cardiovascular diseases, emerging evidence suggests that
increased long-term exposure to air pollution (notably PM2.5) increases the risk of severe COVID‑19
complications (Box 2.2). In general, having pre-existing conditions linked to exposure to air pollutants
appears to make people more vulnerable to the effects of COVID‑19 (OECD, 2020[9]).
Air quality is improving in Europe, but exposure to various air pollutants remains
very high
Since 2005, most European countries have made progress in reducing air pollution and notably
PM2.5  emissions (Figure 2.1),  following the provisions included in the 2008 Ambient Air  Quality
Directive  and  the  more  recent  adoption  of  the  EU  Directive  on  National  Emission  reduction
Commitments (NEC) of certain air pollutants in 2016. On average across EU countries, emissions of
PM2.5  have  reduced  by  over  25%  between  2005  and  2017.  These  reductions  reflect  mainly
improvements in combustion processes in both industry and residential heating, a decrease in the use
of coal in the energy mix, and lower emissions from transport and to a lesser degree from agriculture.
However, this progress is not reflected in public opinion polls that show that most people believe that
air quality has deteriorated (see Box 2.3).
Reductions in emissions have led to reductions in (population-weighted) concentrations and,
therefore, reductions in population exposure to PM2.5 in most EU countries. Nonetheless, in 21 out of
31 European countries,  the annual  concentrations of  PM2.5  exceeded the 10 microgrammes/m3
values recommended by the WHO Air Quality Guidelines in 2018. This is particularly the case in many
Central and Eastern European countries, mainly because of greater reliance on fossil fuels and other
dirty energy sources for heating and other purposes. Northern European countries have the lowest
levels of population exposure, generally well below the WHO guideline value for PM2.5 (Figure 2.3).
Box 2.2. Air pollution and COVID-19
As widely illustrated in this chapter, exposure to air pollution is a risk factor for many chronic diseases, including
chronic respiratory and cardiovascular diseases. There is wide recognition that people with such conditions are at
increased vulnerability from COVID‑19, and may thus be prone to a more severe course of the disease (Clark et al.,
2020[10]). The World Health Organization and a number of national public health authorities have also issued warnings
for citizens with these pre-existing conditions of greater risks of complications from COVID‑19 (WHO, 2020[11]). It has
been estimated that long-term exposure to air pollution from PM2.5 contributed to about 19% of COVID-19 mortality in
Europe through its effect in increasing respiratory and cardiovascular diseases, but the confidence intervals around this
estimate are wide (8-41%), reflecting high levels of uncertainties (Pozzer et al., 2020[12]).
In addition, some studies suggest that air pollution (PM2.5 in particular) may increase the risk of infection by acting as a
vehicle spreading the virus (Copat et al., 2020[13]). While there are some concerns that air pollution could carry the virus
over longer distances, at this stage it is not known whether the virus remains viable on pollution particles (European
Environment Agency, 2020[7]). Further research is needed to verify this hypothesis.
On the other hand, the confinement measures that have been put in place to reduce the spread of the coronavirus
have led to at least a temporary reduction in air pollution. Reductions in economic and social activities led to significant
decreases in certain types of pollution, notably in nitrogen dioxide (NO2), largely due to reduced traffic and other
activities, especially in major cities. The extent of reductions varied considerably, with the largest reductions of up to 70%
observed in urban centres in those countries like Spain, Italy and France that were most affected by COVID‑19 in the
spring of 2020. Concentrations of particulate matter (PM10) also fell across Europe, although to a lesser extent than NO2.
However, these reductions were short lived, with levels of air pollution rebounding as lockdowns were eased and
vehicular transport resumed across Europe (European Environment Agency, 2020[7]).
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Box 2.3. Why do most Europeans think that air quality has deteriorated when the
evidence shows the contrary?
Despite evidence that significant progress has been achieved over the past decade in improving air quality in most
European countries, there is a widespread perception among Europeans that air quality has generally deteriorated.
According to a 2019 Eurobarometer survey conducted across all EU member states, 58% of respondents reported they
thought that air quality had deteriorated over the past decade, another 28% thought that it had stayed the same, while
only 10% believed that it had improved (Figure 2.2). The proportion of respondents who thought that air quality had
deteriorated increased by more than 10 percentage points compared with the previous survey in 2017.
Figure 2.2. People’s perception of changes in air quality over the last 10 years in their
own country
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Source: European Commission, (2019[15]), “Attitudes of Europeans towards Air Quality. Special Eurobarometer 497”.
StatLink 2 https://stat.link/xms9ul
Figure 2.1. Emissions of fine particulate matters (PM2.5) per capita have fallen in the vast majority of











Note: The EU average is unweighted.
Source: OECD Environment Database - Emissions of air pollutants, 2020. For non-OECD countries, the source is the Convention on Long-Range
Transboundary Air Pollution, UNECE-EMEP emissions database.
StatLink 2 https://stat.link/vs789l
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Box 2.3. Why do most Europeans think that air quality has deteriorated when the
evidence shows the contrary? (cont.)
In a minority of countries such as Bulgaria, Hungary and Romania, the public perception is in line with the objectively
measured situation, as levels of air pollution measured in terms of PM2.5 emissions have in fact increased. However, this
is not the case in the vast majority of European countries.
One possible explanation for the apparent inconsistency between objective indicators and subjective perceptions of
air quality trends is that, given the close relationship between air pollution and climate change, a growing awareness
among the public of the contribution of pollution to climate change may have led citizens to assess that air quality must
have also worsened.
Increasing media attention on the subject of air pollution itself, as well as the growing public awareness of the health
impact of exposure to air pollutants may have also played a role in shaping the perception that air quality is deteriorating.
At the same time, most respondents in the 2019 Eurobarometer survey did not feel well-informed about air quality in their
country. Interestingly, those respondents who reported that they were well-informed were less likely to believe that air
quality had deteriorated. For example in Finland, where more than 80% of the population believed that they were well-
informed about air quality, only a third of respondents thought that the quality of air had deteriorated.
Various initiatives have been taken to better inform people about air quality, for example through the EU Ambient Air
Quality directives. At the local level, a growing number of municipalities are issuing alerts when air pollution levels
exceed some thresholds, possibly contributing to the perception that air pollution levels are getting worse. Both at
national and European levels, key measurements on air pollution are regularly collected and reported at various levels of
aggregation, allowing people to monitor the situation on a day-to-day basis and progress over time. The EEA Air Quality
Index is a good example of the effort to widely disseminate information about air quality in real time at the EU level
(European Environment Agency, 2020[2]).
Some countries have a relatively high level of PM2.5 emissions per capita (Figure 2.1) but a
relatively low level of population-weighted concentration of such air pollutants (Figure 2.3). This is the
case, for example, in Finland and Estonia. This may be partly explained by the fact that emissions of
PM2.5 largely occur in areas outside national capitals and other large cities where most people live.
Figure 2.3. In 2018, annual country-level mean concentrations of PM2.5 in the atmosphere exceeded the









Note: Country values are population-weighted concentrations. The EU average is unweighted.
Source: European Environment Agency (2020[2]), Air quality in Europe – 2020 Report.
StatLink 2 https://stat.link/slio1t
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While some progress has been achieved in reducing exposure to PM2.5 in many European
capital cities between 2013 and 2018, the annual mean concentrations of PM2.5 still exceed the WHO
guideline by a wide margin in almost all European capitals (Figure 2.4). This is especially the case in
Warsaw, Bucharest, Zagreb, Prague, Ljubljana and Sofia, where the average PM2.5 levels in 2018
were about twice as high as the WHO guideline. On the other hand, PM2.5 concentrations were below
the WHO guideline in several Northern European capitals – Stockholm, Tallinn, Helsinki and Oslo –
and in Dublin.
Beyond differences in PM2.5 concentrations between capital cities and the rest of the country,
there can also be significant variations across different regions in each country. For example, PM2.5
pollution levels are much greater in the north of Italy than in the south. In Poland, PM2.5 levels are
particularly high in the central and southern parts of the country (European Environment Agency,
2020[2]).
Some population groups are particularly vulnerable to the effects of air pollution. Older people,
children, those with chronic diseases and those experiencing material deprivation are typically more
vulnerable to the effects of air pollution than the general population. Lower-income households are
more vulnerable to the health effects of air pollution, either because of greater exposure or greater
susceptibility to serious health consequences when they are exposed (Box 2.4). Improvements to air
quality  may  therefore  particularly  benefit  lower-income households  and  ultimately  contribute  to
reducing health inequalities.
Figure 2.4. The annual mean concentration of PM2.5 in the atmosphere has declined in most European











Note: For Valletta, only data from the neighbouring city of Msida was available. For Lisbon, initial data are from 2014 (not 2013). For Bratislava and
Bucharest, initial data are from 2016.
Source:  European  Environment  Agency  Air  Quality  Statistics  database,  2020  https://www.eea.europa.eu/data-and-maps/dashboards/air-quality-
statistics-expert-viewer. City-level data were estimated by averaging the station-level data in 2013 and 2018. As much as possible, the data from the same
stations were used in both years for each city.
StatLink 2 https://stat.link/fn4dy1
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Between 168 000 and 346 000 deaths each year in EU countries can be attributed to
outdoor air pollution
Between 168 000 and 346 000 people across all EU countries died prematurely in 2018 from
diseases attributable to outdoor air pollution (PM2.5), according to the most recent estimates from the
Global  Burden of  Disease study  (Institute  for  Health  Metrics  and Evaluation,  2020[1])  and the
European Environment Agency (European Environment Agency, 2020[2]), respectively.1 Box 2.5
provides information about differences in sources and methods that result in different estimates of the
mortality attributed to air pollution.
Box 2.5. Estimating the mortality burden of air pollution
All estimates of the impact of air pollution on mortality are based on some models and assumptions about the links
between exposure to different types of air pollution and mortality from various diseases, which are subject to a certain
degree of uncertainty. The models also often use different data inputs. Hence, it is not surprising to see that the use of
different data sources based on different estimation methods provide different results.
The European Environment Agency provides higher estimates of the number of premature deaths attributable to the
effect of outdoor air pollution from PM2.5 (346 000 in 2018 across the current 27 EU member states) compared with IHME
estimates (168 000 in 2018) and WHO estimates (204 000 in 2016). At least three methodological reasons can explain
these different results.
First,  the EEA, following the WHO’s recommendations (WHO Europe, 2013[19]),  takes a broader approach in
estimating the excess mortality due to PM2.5 emissions that takes into account all possible related causes of premature
death. By comparison, the IHME estimates take into account mortality from five main causes (cardiovascular diseases,
diabetes, chronic respiratory diseases, respiratory infections and tuberculosis, and some cancers), while the WHO
estimates focus on mortality from three main causes (ischemic heart disease, stroke and respiratory diseases). A
second reason for the differences is that the EEA estimates are based on more granular, location-based air pollution
exposure data, while both the IHME and WHO estimates are based on average country-level exposure to PM2.5. Thirdly,
the EEA assumes that the counterfactual minimum exposure level for PM2.5 equals zero, which is lower than in the other
two cases. Although WHO and IHME estimates rely on a similar “population attributable fraction”-based methodology
that estimates the fraction of deaths potentially linked to air pollution levels, some differences in their final estimates arise
due, for example, to differences in the assumed minimum exposure levels or in the underlying data sources.
All the available model-based estimates are subject to considerable uncertainty. In the case of EEA, the uncertainty
(or confidence) intervals of the number of estimated premature deaths from PM2.5 across all EU member states range
approximately between 218 000 and 462 000 (European Environment Agency, 2020[2]). When it comes to the 2016
WHO estimates, the uncertainty (or confidence) intervals range from 155 000 to 264 000 (WHO, 2018[20]), while the
range for the 2018 IHME estimates is between 128 000 and 211 000 (Institute for Health Metrics and Evaluation,
2020[1]).
Box 2.4. Unequal exposure and unequal impacts of air pollution
People’s ability to avoid or cope with the health impacts of air pollution is influenced by their socio-economic status
(i.e. income level and employment status). Lower-income households are generally more vulnerable to the health effects
of air pollution, both because of potentially greater exposure, and because of increased susceptibility to its negative
health consequences. This might be because they are in poorer health to start with, have limited access to high quality
health care, are more exposed to other risk factors (like smoking) and have limited ability to invest in protective measures
such as air filtration systems and better housing quality (Mackie and Haščič, 2019[16]).
Socioeconomically disadvantaged groups may be more exposed to indoor air pollution because they lack access to
cleaner energy sources for heating. In addition, people in lower socio-professional categories may be exposed to higher
levels of pollution in workplaces. Having said that, socio-economic disadvantage does not always correlates with air
pollution exposure in the expected direction, as in some cases wealthier households may prefer to live in more central
and more polluted parts of cities (Cournane et al., 2017[17]; European Environment Agency, 2018[18]).
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Premature death rates attributable to air pollution (PM2.5) were the highest in 2018 in Central and
Eastern European countries, reaching up to between 120‑180 deaths per 100 000 population in
Bulgaria, Hungary, Poland, Romania and Croatia. Deaths were the lowest in Nordic countries, with
rates about six times lower at 20‑30 deaths per 100 000 population (Figure 2.5).
Based on IHME estimates, the two main causes of premature deaths attributable to air pollution
(PM2.5)  are  cardiovascular  and  chronic  respiratory  diseases.  The  proportion  of  mortality  from
cardiovascular diseases attributed to PM2.5 exposure accounted for the largest share of premature
deaths associated with air pollution in all countries in 2017 (Figure 2.6).
While outdoor air pollution accounts for a much larger proportion of deaths than indoor air
pollution in all European countries, exposure to indoor PM2.5 also contributes to a sizeable number of
deaths, particularly in some Central and Eastern European countries like Estonia, Romania, Hungary
and Bulgaria (Figure 2.7). This is mainly due to the still prevalent use of solid fuels for cooking and
heating inside houses. Several countries have taken measures to improve indoor air quality, including
for example financial  support  for the phasing out of  high emission boilers and stoves in Latvia
(Asikainen et al., 2016[21]).
Figure 2.5. Premature death rates attributable to outdoor air pollution (PM2.5) are generally the highest











Crude death rate per 100 000 population, 2018
Note: The EU average is weighted.
Source: Based on European Environment Agency (2020[2]), Air quality in Europe – 2020 report.
StatLink 2 https://stat.link/yqfurb
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Air pollution causes about EUR 600 billion in welfare losses each year across EU
countries
The serious health consequences of air pollution result in large welfare losses because of greater
mortality and morbidity (lower quality of life due to ill-health), greater health spending care costs to
treat related conditions, and reduced labour productivity arising from greater absences from work due
to illness. Box 2.6 describes the methodology that is used to estimate the different welfare losses
related to air pollution, which is based on previous OECD work (OECD, 2016[22]). The estimates have
been updated to 2017 based on the assumption that the share of each cost category has remained
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Note: This figure shows estimates of the proportion of these causes of death that are attributed to air pollution.
Source: IHME (2018), “GBD Results Tool”, http://ghdx.healthdata.org/gbd-results-tool.
StatLink 2 https://stat.link/ju14a7
Figure 2.7. A relatively high proportion of premature deaths from PM2.5 exposure in Central and Eastern












Outdoor air pollution Indoor air pollution
% of deaths, 2017
Note: The data on indoor air pollution refers to the indoor use of solid fuels for cooking.
Source: IHME (2018), “GBD Results Tool”, http://ghdx.healthdata.org/gbd-results-tool.
StatLink 2 https://stat.link/vbrmas
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constant in recent years. The estimates relate to the impact of PM2.5 (both outdoor and indoor) and
ground-level ozone.
Table 2.2 shows that premature mortality due to air pollution from PM2.5 and ozone resulted in the
loss of an estimated EUR 527 billion across EU countries in 2017. Such costs account for about 88%
of total welfare losses from air pollution (OECD, 2016[22]).
Welfare losses related to the lower quality of life of people living with illnesses that can be
attributed to air pollution accounted for about 8% of total welfare losses, which is equivalent to about
Box 2.6. Methodology used to estimate the welfare losses from air pollution
The methodology used in this chapter to estimate the welfare losses from air pollution is based on previous work by the
OECD as described in the publication The Economic Consequences of Outdoor Air Pollution  (OECD, 2016[22]).
Table 2.1 below summarises the different categories of welfare losses considered in this analysis.
The first and main welfare loss from air pollution is related to its impact on premature death. These welfare losses are
calculated based on the value of a statistical life (VSL) approach, a standard economic method to measure the cost of
premature mortality. The VSL method is based on assumptions about how much people would be willing to pay to reduce
their risk of death, or how much additional money they would require to accept an additional risk, based on information
from stated preference surveys. For example, on average, people may be willing to pay USD 30 (EUR 24) to reduce their
risk of dying from diseases associated with air pollution by 1 per 100 000 people each year. If 100 000 people are willing
to pay on average USD 30, the value of statistical life is then equal to USD 3 million (EUR 2.4 million) per life saved.
Using information from such surveys, previous OECD work has estimated that one statistical  year of  life was
approximately equivalent to USD 3 million (EUR 2.4 million) on average across OECD countries (OECD, 2012[23]).
Country-specific estimations are adjusted to take into account differences in national income and standards of living.
These estimations, adjusted for purchasing power parity (PPP), range from USD 2.5 million in Greece (EUR 2 million) to
USD 7.3 million (EUR 5.8 million) in Luxembourg in 2017. This monetary value is then multiplied by the number of
premature deaths to calculate the total statistical value of life lost due to air pollution. The number of premature deaths is
based on IHME estimates, which are at the lower end of the range considered in this chapter, so estimates of these
welfare losses can be considered to be conservative.
The second category of welfare losses relates to the lower quality of life for people who are falling ill because of air
pollution. These values are estimated based on stated preference surveys and willingness to pay values from earlier
work (Holland, 2014[24]). For each of the morbidity impacts, the results are multiplied by an estimated value to calculate
the welfare costs related to the quality of life losses (or disutility) from different illnesses (e.g. respiratory diseases). The
third and fourth categories relate to market costs that are more directly measurable. These include the additional health
care costs for people requiring care for respiratory, cardiovascular and other diseases that are attributed to air pollution,
as well as lower labour productivity as measured by lost working days due to these illnesses among the working-age
population (OECD, 2016[22]).
Table 2.1. Non-market and market consequences considered in assessing the welfare losses of
air pollution
Health impacts Non-market consequences Market consequences
Mortality from cardiovascular and respiratory diseases,
lung cancer and other diseases due to high
concentrations of PM2.5 and ozone
Premature deaths [see note below]
Morbidity from cardiovascular and respiratory
diseases, lung cancer and other diseases due to high
concentrations of PM2.5 and ozone
Quality of life losses due to ill-health
(e.g. pain and suffering)
Higher health expenditure
Lower labour productivity (due to absence
from work)
Note: Premature deaths also have market consequences as it involves a loss of potential workers for premature mortality related to the working-
age population and a loss of potential consumers for mortality at all ages, but these losses are not taken into account in this analysis.
Source: OECD (2016[22]), The Economic Consequences of Outdoor Air Pollution, http://dx.doi.org/ 10.1787/9789264257474-en.
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EUR 48 billion across all EU countries. Greater health care costs related to air pollution represented
about 2.5% of total welfare losses, equivalent to about EUR 15 billion across EU countries. Finally, the
labour productivity losses from lost working days due to illnesses related to air pollution accounted for
the remaining 2% of welfare losses, equivalent to about EUR 11 billion across EU countries.2
Taken  together,  the  overall  welfare  losses  of  these  air  pollutants  amounted  to  about
EUR 600 billion in 2017, equivalent to 4.9% of the EU GDP. As a share of GDP, the estimated welfare
losses related to air pollution were highest in Central and Eastern European countries (reaching
over 9% of GDP in Bulgaria, Croatia, Hungary, Latvia and Romania), and lowest in Nordic countries
(except Denmark), Ireland and Luxembourg (less than 3% of GDP) (Figure 2.8). These variations
mainly reflect differences in the burden of premature mortality due to air pollution, the main driver of
welfare loss estimates.
The main challenges to reducing the heavy impact of air pollution on people’s health and welfare
consist of further reducing the emissions of air pollutants at all  levels (local, regional, national),
Table 2.2. Estimated welfare losses from air pollution (PM2.5 and ground-level ozone), 2017
Total cost Premature mortality Quality of life losses Health care cost Productivity losses
bn EUR % GDP bn EUR % GDP bn EUR % GDP bn EUR % GDP bn EUR % GDP
EU27 total 601.45 4.92 527.2 4.32 48.26 0.40 14.85 0.12 11.14 0.09
Austria 14.98 4.35 13.1 3.81 1.20 0.35 0.37 0.11 0.28 0.08
Belgium 20.15 4.84 17.7 4.24 1.62 0.39 0.50 0.12 0.37 0.09
Bulgaria 6.01 13.16 5.3 11.54 0.48 1.06 0.15 0.32 0.11 0.24
Croatia 4.21 9.44 3.7 8.27 0.34 0.76 0.10 0.23 0.08 0.17
Cyprus 0.94 5.28 0.8 4.63 0.08 0.42 0.02 0.13 0.02 0.10
Czech Republic 11.87 7.05 10.4 6.18 0.95 0.57 0.29 0.17 0.22 0.13
Denmark 12.45 4.56 10.9 4.00 1.00 0.37 0.31 0.11 0.23 0.08
Estonia 0.86 4.16 0.8 3.65 0.07 0.33 0.02 0.10 0.02 0.08
Finland 4.79 2.26 4.2 1.99 0.38 0.18 0.12 0.06 0.09 0.04
France 71.86 3.27 63.0 2.87 5.77 0.26 1.77 0.08 1.33 0.06
Germany 168.15 5.55 147.4 4.86 13.49 0.45 4.15 0.14 3.11 0.10
Greece 13.68 7.72 12.0 6.76 1.10 0.62 0.34 0.19 0.25 0.14
Hungary 11.08 9.88 9.7 8.66 0.89 0.79 0.27 0.24 0.21 0.18
Ireland 6.11 2.33 5.4 2.04 0.49 0.19 0.15 0.06 0.11 0.04
Italy 95.14 5.75 83.4 5.04 7.63 0.46 2.35 0.14 1.76 0.11
Latvia 2.24 9.18 2.0 8.04 0.18 0.74 0.06 0.23 0.04 0.17
Lithuania 3.17 8.49 2.8 7.44 0.25 0.68 0.08 0.21 0.06 0.16
Luxembourg 1.44 2.76 1.3 2.42 0.12 0.22 0.04 0.07 0.03 0.05
Malta 0.54 5.61 0.5 4.92 0.04 0.45 0.01 0.14 0.01 0.10
Netherlands 29.18 4.23 25.6 3.71 2.34 0.34 0.72 0.10 0.54 0.08
Poland 33.61 7.81 29.5 6.85 2.70 0.63 0.83 0.19 0.62 0.14
Portugal 9.04 5.03 7.9 4.41 0.73 0.40 0.22 0.12 0.17 0.09
Romania 14.89 9.29 13.0 8.14 1.19 0.75 0.37 0.23 0.28 0.17
Slovak Republic 5.42 6.79 4.7 5.96 0.43 0.55 0.13 0.17 0.10 0.13
Slovenia 1.98 5.09 1.7 4.46 0.16 0.41 0.05 0.13 0.04 0.09
Spain 46.46 4.31 40.7 3.78 3.73 0.35 1.15 0.11 0.86 0.08
Sweden 11.20 2.46 9.8 2.16 0.90 0.20 0.28 0.06 0.21 0.05
Iceland 0.29 1.85 0.25 1.62 0.02 0.15 0.01 0.05 0.01 0.03
Norway 7.82 2.25 6.9 1.97 0.63 0.18 0.19 0.06 0.14 0.04
Switzerland 17.77 2.90 15.6 2.54 1.43 0.23 0.44 0.07 0.33 0.05
United Kingdom 109.61 4.15 96.1 3.64 8.80 0.33 2.71 0.10 2.03 0.08
Source: OECD calculations, based on methodology described in Box 2.6 and OECD (2016[22]), The Economic Consequences of Outdoor Air Pollution,
http://dx.doi.org/ 10.1787/9789264257474-en, using data from 2017.
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achieving a strong decoupling of emissions from economic growth, and limiting people’s degree of
exposure  to  air  pollutants.  This  implies  implementing  effective  pollution  prevention  and  control
policies, sustainable transport and mobility policies, stimulating investment in cleaner technologies,
promoting more sustainable agricultural  methods, energy efficiency and the substitution of  dirty
energy sources with cleaner ones (OECD, 2020[8]).
EU countries have set ambitious goals to reduce air pollution by 2030
Since  the  1970s,  the  EU  has  been  working  with  its  member  states  and  international
organisations to improve air quality by controlling the emissions of air pollutants and integrating
environmental protection requirements into the energy, transport, industrial and agricultural sectors.
In the international context, EU member states have worked since 1979 with other countries in and
outside Europe to control international air pollution under the UNECE Convention on Long-Range
Transboundary Air Pollution (the Air Convention), recognising that air pollution does not respect
national borders. Reducing the negative impacts of air pollution is also part of the 2030 Global Agenda
for Sustainable Development Goals (SDG), notably under Goal 3 (Good health and well-being) that
calls for substantial reductions in the number of deaths from air pollution, under Goal 11 (Sustainable
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Source: OECD calculations, based on methodology described in Box 2.6 and OECD (2016[22]), The Economic Consequences of Outdoor Air Pollution,
http://dx.doi.org/ 10.1787/9789264257474-en.
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cities and communities) that aims to reduce the negative environmental impact of cities, and under
Goal 13 (Combat climate change) that calls for urgent actions to combat climate change.
At  the  EU  level,  most  of  the  provisions  under  the  current  Ambient  Air  Quality  Directive
(2008/50/EC) and the Directive on heavy metals and polycyclic aromatic hydrocarbons in ambient air
(2004/107/EC) were originally established in the Air Quality Framework Directive in 1996 or in one of
the four Daughter Directives adopted between 1999 and 2004. The two current directives are driving
improvements in ambient air quality in Europe. They have set the basic principles for assessing and
managing air quality and pollutant concentration thresholds that should not be exceeded (Box 2.7).
The 2013 Clean Air Programme for Europe reconfirmed the objective to achieve full compliance
with existing air quality standards across the EU as soon as possible and set objectives for 2020 and
2030. A new EU Directive (2016/2284) on national emission reduction commitments (NEC) of certain
air pollutants came into force at the end of 2016 (repealing the previous Directive 2001/81/EC), and is
the main legislative instrument to achieve the 2030 objectives of the Clean Air Programme. This
Directive sets national emission reduction commitments for each EU member state for the period
2020 to 2029 and more ambitious ones from 2030 onwards. It targets five pollutants responsible for
serious  health  and  environmental  damages:  sulphur  dioxide,  nitrogen  oxide,  volatile  organic
compounds, ammonia and fine particulate matter (PM2.5). The aim of the Clean Air Programme is to
reduce the health impact of air pollution by half by 2030 compared with 2005.
Emissions standards have also been set for key sources of pollution. These standards are set out
at EU level in legislation targeting industrial emissions, emissions from power plants, vehicles and
transport fuels, as well as the energy performance of products (European Commission, 2018[25]).
The effective implementation of this clean air legislation forms an essential contribution to the
zero-pollution ambition for a toxic-free environment announced by the European Commission in
Box 2.7. EU air quality standards and WHO guidelines
The EU’s air quality directives (2008/50/EC Directive on Ambient Air Quality and Cleaner Air for Europe and 2004/107/
EC Directive on heavy metals and polycyclic  aromatic hydrocarbons in ambient  air)  set  pollutant  concentrations
thresholds that shall not be exceeded in a given period of time. If the limit or target values are exceeded, competent
authorities are required to implement measures to improve air quality.
Selected EU air quality standards and WHO guidelines are summarised in Table 2.3 below. The WHO guidelines are
set for health protection and are generally stricter than the current EU standards. Some European countries have chosen
to apply these more stringent WHO guidelines. Under the European Green Deal, the European Commission is expected
to  propose  to  revise  the  air  quality  standards  to  align  them more  closely  with  the  WHO guidelines  (European
Commission, 2019[15]).
Table 2.3. Current EU Air Quality Directive and WHO guidelines for selected air pollutants
Pollutant Time period EU Air Quality Directive WHO guidelines
PM2,5 Calendar year Limit value, 25 microgrammes/m3 10 microgrammes/m3
PM10 Calendar year Limit value, 40 microgrammes/m3 20 microgrammes/m3
03 Maximum daily 8‑hour mean Target value, 120 microgrammes/m3 (1) 100 microgrammes/m3
NO2 Calendar year Limit value, 40 microgrammes/m3 40 microgrammes/m3
1. Not to be exceeded on more than 25 days per year, averaged over three years.
Source:  European Environment  Agency,  “Air  quality  standards”,  https://www.eea.europa.eu/themes/air/air-quality-concentrations/air-quality-
standards.
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December 2019 under the European Green Deal. The European Green Deal proposes to adopt a
“Zero-Pollution Action Plan” by 2021 (European Commission, 2019[15]).
According to the first European Commission report assessing the implementation of the 2016
NEC Directive released at the end of June 2020, 10 member states projected that they will be able to
fulfill all of their 2020 emission reduction commitments under current measures, while the number falls
to four only when it comes to the 2030 commitments. Regarding primary PM2.5 emissions specifically,
23 EU countries projected that they will be able to meet their 2020 emission reduction commitments,
but the number falls to 13 when it comes to the 2030 commitments (Table 2.4). Other member states
will need to put in place additional measures to fulfil their emission reduction commitments (European
Commission, 2020[3]).3 Compliance with the 2020 emission reduction commitments can only be
checked in 2022, when emission data for 2020 will become available.
Table 2.4. Projected compliance as reported by EU member states in 2019 under
existing policies and measures against 2020-29 and 2030-onwards national emission
reduction commitments
Member State NOx NMVOCs SO2 NH3 PM2.5
2020 2030 2020 2030 2020 2030 2020 2030 2020 2030
Austria          
Belgium          
Bulgaria          
Croatia          
Cyprus          
Czech Republic          
Denmark          
Estonia          
Finland          
France          
Germany          
Greece          
Hungary          
Ireland          
Italy          
Latvia          
Lithuania          
Luxembourg          
Malta          
Netherlands          
Poland          
Portugal          
Romania          
Slovak Republic          
Slovenia          
Spain          
Sweden          
United Kingdom          
 22 10 21 14 27 18 16 9 23 13
 6 18 7 14 1 10 12 19 5 15
Note: NOx are nitrogen oxides; NMVOCs are non-methane volatiles organic compounds; SO2 are sulphur oxides; NH3 is ammonia; 
PM2.5 are fine particles.
Source:  First  EC  report  on  implementation  of  NEC  Directive,  2020,  https://eur-lex.europa.eu/legal-content/EN/TXT/?
qid=1593765728744&uri=CELEX:52020DC0266.
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Beyond  enforcing  the  relevant  EU  legislation,  a  number  of  EU  actions  also  support  the
implementation of the National Emission reduction Commitments (NEC) Directive and the Ambient Air
Quality Directives. These actions focus on promoting the sharing of best practices and providing EU
funding to support measures to improve air quality (European Commission, 2018[25]).
The European Commission has organised two European Clean Air Fora so far to facilitate the
coordinated implementation of air quality legislation and policies across the EU. The first forum took
place in Paris in November 2017, and the second in Bratislava in November 2019. Both events were
met with strong interest from stakeholders. The Clean Air Forum 2017 focused on the themes of air
quality in cities, air pollution from the agricultural sector, as well as clean air business opportunities.
The Clean Air Forum 2019 followed up on the discussion on agricultural impacts of air pollution and
put an emphasis on clean air and health, domestic heating, as well as funding opportunities for clean
air measures (European Commission, 2020[3]).
EU funding has also been made available in recent years under various programmes and used
by member states to improve air quality. This funding either directly supports clean air projects or
effectively includes clean air objectives in other investments (e.g. infrastructure, rural and regional
development). During the period 2014‑20, an estimated EUR 46.4 billion of EU funds have been
allocated to contribute to clean air objectives through these various programmes (Table 2.5).
How can the health sector contribute to reducing the burden of air pollution?
Most policies that aim at reducing air pollution target those human activities that are its major
sources  –  notably  energy  production  and  consumption,  transportation,  and  the  industrial  and
agricultural sectors. The role and involvement of the health sector in achieving air pollution reductions
has to date been more limited.
The health sector can also contribute directly or more indirectly to overall efforts to reduce air
pollution in at least two ways:
1. the health sector can reduce its own “ecological footprint” by improving its energy efficiency and
reducing its use of various products that contribute to air pollutant emissions;
2. public health authorities and health professionals can also encourage a transition to less polluting
and more active modes of transportation through behavioural changes and promoting urban and
transport policies that are more supportive of health and environmental protection.
Table 2.5. Estimates of EU funds dedicated to clean air objectives from various
programmes
Programme Estimated Clean Air Contribution 2014‑20 (in million EUR)
Horizon 2020 4 219
EFSI (European Fund for Strategic Investments) 819
CEF (Connecting European Facility) 8 830
ERDF (European Regional and Development Fund) 20 458
CF (Cohesion Fund) 10 874
EAFRD (European Agriculture Fund for Regional Development) 1 138
LIFE (Financial Instrument for Environment) 105
Total 46 443
Source: First EC report on implementation of NEC Directive, 2020 (Annex 4), https://www.eea.europa.eu/themes/air/air-pollution-
sources‑1/national-emission-ceilings/nec-directive-reporting-status‑2019.
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The health sector can reduce its ecological footprint
The health sector accounts for more than 8% of GDP on average across EU countries, and its
wide  range  of  activities  contribute  to  air  pollution  and  climate  change  in  various  ways.  The
approximately 13 000 hospitals across the EU have a high demand for heating and also use a large
amount of energy for their day-to-day operations and activities. Health systems also consume a lot of
medical goods and equipment that can contribute to air pollution during the production and disposal
process (Health Care Without Harm Europe, 2016[26]). It has been estimated that the health sector is
responsible for 3% to 8% of the total greenhouse gas emissions in EU countries through energy
consumption and the industrial  production of  pharmaceuticals  and other  medical  goods (WHO,
2015[27]).
Under the project “Health Care Without Harm”, more than 43 000 hospitals and health centres in
72 countries around the world (including in all EU countries) have already committed to reduce their
environmental footprint and promote both human and environmental health through improving their
supply chain through the Global Green and Healthy Hospitals initiative. Many hospitals started a long
time ago to leverage their significant purchasing power to become more environmental-friendly. For
example, in Vienna, public hospitals and all other public institutions are expected to consider the
environmental impact of their purchasing decisions. This has led to phasing-out the use of toxic and
potentially  carcinogenic  chemicals  in  disinfectants,  surfaces  and  instruments,  from four  tonnes
annually in 1997 to almost zero in 2014 (Health Care Without Harm Europe, 2016[26]).
There is also great potential for hospitals and other health care facilities to achieve energy
efficiency gains and reduce their reliance on fossil fuels and other dirty energy sources. In Germany,
energy savings in hospitals are stimulated by the award of an “Energy Saving Hospital” quality label
(Bund Für Umwelt  Und Naturschutz Deutschland).  In Sweden, the region of Skåne has set an
ambitious goal to eliminate the use of fossil fuels in all public buildings managed by the region,
including hospitals. The region was already 86% fossil fuel-free in 2016 (Health Care Without Harm
Europe, 2016[26]).
The health sector can also reduce its environmental footprint by reducing its use and waste of
polluting materials and products. In many cases, the disposal of such waste involves incineration, with
the potential to generate harmful emissions, ashes, nitrogen oxides, particulate matter and various
volatile substances. Some hospitals in France and other countries have started to implement a
comprehensive waste management policy to minimise the quantities of materials going to landfill or
incineration (Health Care Without Harm Europe, 2016[26]).
Large amounts of food are wasted in hospitals and other health care facilities, contributing to food
overproduction, additional strains on available natural resources and air pollution (OECD, 2017[28]).
Estimates of food wasted in European hospitals range from 6% to 65% of all the food served (Williams
and Walton, 2011[29]). France has set a national objective to reduce food waste in hospitals and other
collective establishments by 50% by 2025 compared with 2015, in order to reduce greenhouse gas
and other emissions and avoid the unnecessary use of  natural  resources while reducing costs
(Ministère de la transition écologique, 2020[30])
More  broadly,  public  health  authorities  can  work  with  other  government,  environmental,
agricultural and industrial stakeholders to identify more effective ways to encourage both a healthy
diet  and  more  sustainable  food  production  for  the  population  as  a  whole.  Results  from  such
collaborations can be used to update nutritional guidelines to help the population make healthy
choices. At the European level, the new “Farm to Fork” strategy provides a good example of a strategy
designed to make food production and consumption more healthy and environment-friendly, with the
aim of reducing the emission of greenhouse gases and air pollutants (Box 2.8).
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Public health authorities can promote a transition to greener urban policies and
more active transportation
A substantial part of PM emissions and other air pollutants are due to the use of cars and other
motor vehicles, which also contributes to physical inactivity, another important cause of morbidity and
mortality. Public health authorities can work with other partners to encourage a transition to cleaner
and more active modes of transportation, such as cycling, walking or using public transport, with
benefits including less air pollution, fewer car accidents and greater physical activity (Infographic 2.2).
Health care systems can directly contribute to achieving these health and environment benefits
by making adjustments to their transportation services for patients, staff and supplies. For example,
over the past five years the network of public hospitals in Paris (APHP) has put in place a number of
green  mobility  options  for  its  staff  (Health  Care  Without  Harm  Europe,  2016[26];  European
Commission, 2020[33]).
Doctors and other health workers can also play an important role in promoting changes in
people’s behaviours, by discussing with their patients the benefits of greater physical activity for
transportation and other purposes. Evidence shows that GP prescriptions of physical activity for
people at risk of developing chronic diseases may increase their physical activity by about one hour of
moderate-level exercise per week – more than one third of the 150 minutes per week of moderate
exercise recommended by the WHO (Goryakin, Suhlrie and Cecchini, 2018[34]). To the extent that
such increases in physical activity reduce the use of motor vehicles, this may have the added benefit
of reducing air pollution.
Public  health  authorities  can  also  contribute  to  the  roll-out  of  mass  media  campaigns  to
encourage greater levels of physical activity among the population in general, thereby also possibly
contributing to the use of less polluting modes of transportation. Such campaigns can be implemented
through both traditional media (television, radio, newspaper) and new media (online marketing, social
networks), and be implemented at the national or local levels. Evidence shows that well-designed
mass media campaigns can increase the proportion of people who are at least moderately active by
more than one‑third (OECD, 2019[35]).
Since 2002, the European Mobility Week campaign has sought to improve public health and
quality of life by promoting clean and sustainable urban transport. Actions during this week typically
include a Car-free Day, where participating towns and cities set aside one or several areas solely for
Box 2.8. The EU Farm to Fork Strategy
Linked to the European Green Deal, the new EU Farm to Fork Strategy, announced in May 2020, is designed to make
food systems more sustainable, fair, healthy and environmentally friendly. The Strategy sets out various initiatives, both
regulatory and non-regulatory, to achieve several key changes to the food systems in Europe. The main goals of the
Strategy are to:
• Ensure that food systems will have at least a neutral or preferably positive environmental impact;
• Help everyone achieve access to safe, nutritious and sustainable food;
• Address  simultaneous  challenges  of  ensuring  food  affordability,  generating  fair  economic  returns,  fostering
competitiveness of the EU supply sector and promoting fair trade;
• Help to mitigate climate change and adapt to its impacts;
• Reverse the loss of biodiversity;
• Make sure that trade policies and international cooperation instruments support global transition to sustainable agri-
food systems.
Source: European Commission, (2020[31]), “Farm to Fork Strategy: For a fair, healthy and environmentally friendly food system”, https://
ec.europa.eu/food/farm2fork_en.
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pedestrians, cyclists and public transport. Over 2 700 towns and cities across Europe participated in
the European Mobility week in September 2020 under the theme of promoting zero-emission for all.
Population behaviour and the quality of air in cities are also influenced by urban design and
infrastructures. Most obviously, urban sprawl encourages the use of motor vehicles and discourages
more active modes of travelling (Stone et al., 2007[36]). While urban and transport policies are beyond
the usual responsibilities of public health authorities, a greater public health perspective can be
brought in these policies to improve both air quality and population health. Such policies can promote
a greater availability of public transportations, facilitate the use of more active modes of transportation
and increase the number of green spaces.
For example, Luxembourg has implemented a nation-wide free-of-charge public transportation
policy since the end of February 2020 (Luxembourg.public.lu, 2020[37]). The development of public
transportation systems generally increases the amount of walking, on average by about 30 minutes
per person per week (Xiao, Goryakin and Cecchini, 2019[38]), which is a fifth of the time that people
should spend on physical activity as recommended by WHO. The importance of public transportation
for air quality was highlighted, for example, during public transit strikes in five large German cities
between 2000 and 2011. During these strikes, PM10 levels in these cities increased by 14%, while
hospital  admissions  for  respiratory  diseases  among  young  children  increased  by  11%
Infographic 2.2. Encouraging less polluting and more active modes of transportation can lead to
multiple health and environmental benefits
Source: Adapted from © ONYXprj/Shutterstock and Figure 1 in Rojas-Rueda et al. (2016[32]), “Health Impacts of Active Transportation in Europe”, http://
dx.doi.org/10.1371/journal.pone.0149990.
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(Bauernschuster, Hener and Rainer, 2017[39]). In Barcelona, nitrogen oxide emissions increased by
8% during public transit strikes between 2005 and 2016 (Basagaña et al., 2018[40]).
The introduction or expansion of bicycle lanes and bike-sharing schemes increases the use of
bicycles and can help improve air quality. For example, in Barcelona, bike-sharing was estimated to
reduce yearly CO2 emissions by about 9 000 tonnes per year (Rojas-Rueda et al., 2011[41]). In
Warsaw, a study estimated that CO2 emissions could be reduced by up to 26 000 tonnes per year if
cycling accounted for 35% of all trips (Rojas-Rueda et al., 2016[32]). Another study, simulating the
impact of investment in cycling infrastructure in London and Antwerp, estimated that if the cycling
share of all trips increased by 23%, there would be a reduction of annual emissions of NOx by up to
27% in London and of PM10 by up to 19% in Antwerp (Hitchcock and Vedrenne, 2014[42]). While it is
possible that for individual bike users, exposure to air pollution can sometimes increase because they
may spend more time on the roads, the evidence indicates that benefits from physical activity at the
individual level far outweigh this risk (Rojas-Rueda et al., 2016[32]).
Several European countries have also introduced various financial incentives to encourage a
switch from cars to more active modes of transportation. These include greater parking fees in urban
centres, and subsidies for bike purchases in countries like Belgium, France, Luxembourg and Italy
(European Commission, 2020[33]).
Other urban and transport policies are also beneficial both to air quality and population health,
including the introduction of low emission zones, speed limits and congestion charges (Box 2.9). Low-
emission zones are areas within a city where vehicles with certain emission ratings cannot enter or are
charged a fee for entering. These zones have been implemented in over 200 cities in 10 European
countries with the aim to meet EU Air Quality Standards (Holman, Harrison and Querol, 2015[43]). In
Germany and the Netherlands, these low emission zones have contributed to a reduction in various
air  pollutants  (Boogaard  et  al.,  2012[44];  Holman,  Harrison  and  Querol,  2015[43]).  The
implementation of low-emission zones may also provide an opportunity to take stock of available
transportation choices in a city and to develop more environmental-friendly options such as public
transportation, bicycle and pedestrian-friendly infrastructure.
Public health authorities and other public health stakeholders can also advocate for a greater
number of green spaces and parks that can help reduce particulate matter levels, while also helping to
promote greater physical activity, more active lifestyles and lead to other benefits such as noise
Box 2.9. Examples of good practices in transportation policies with the potential to
reduce air pollution and improve population health
• In Stockholm, it was estimated that the Congestion Charges, introduced on a pilot basis in 2006 and on a more
permanent basis in 2007, resulted in a 15% drop in vehicle miles travelled, leading to emissions reductions of 8.5% for
nitrogen oxides, and 13% for PM10 (Johansson, Burman and Forsberg, 2009[45]).
• In Berlin, a speed limit of 30 km/h was imposed in several areas with particularly high air pollution levels in 2018, with
the aim of decreasing both the number of road accidents and air pollution. According to one evaluation, a speed limit
of 30 km/h in Berlin has resulted in the reduction of NO2 pollution levels by 10 to 15% (Berlin.de, 2018[46]).
• In Paris, the municipal authorities have announced the intention to phase out the use of diesel cars by 2024 and petrol
cars by 2030, with only electric cars being allowed. In 2019, all diesel vehicles aged 13 years or over were banned
from streets in the city centre. Likewise, the region of Brussels has decided to ban diesel cars from 2030, and all petrol
cars (although not trucks nor vans) from 2035.
• Low emission zones are implemented in a number of European cities. For example, in Belgium, to enter parts of
Antwerp, Brussels or Ghent, drivers have to check in advance whether their vehicles meet the emission level
thresholds, and in certain cases register their vehicles on relevant websites.
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reduction. This can be achieved by rehabilitating sites previously used for industrial or other purposes
to create new parks, playgrounds and recreational areas. Some of these interventions explicitly aim to
improve air quality, such as through the installation of green vegetated screens along main and heavy
traffic roads. Other projects may have other primary goals in mind, but nevertheless may lead to better
air quality as a by-product. For example, a project to facilitate everyday walks in Stavanger, Norway,
provides access to green trail system to 98% of its population within 500 metres of their home. In
Stuttgart, a former stone quarry was transformed into a green nature reserve, while also promoting
more active lifestyles. Another interesting example is the conversion of an old train track into a bike
and pedestrian path in central Copenhagen (WHO Europe, 2013[19]).
A study covering 245 cities worldwide found that investing USD 4 per resident to increase the
number of trees in a city can reduce particulate matter-related mortality by 2.7% to 8.7% (McDonald,
2016[47]).  In general,  such returns on investment were found to be higher in cities with higher
population density like Paris or Madrid.  In Paris,  it  was estimated that 2.3 million people could
potentially benefit from a reduction in PM2.5 by at least 1 µg/m³, at a cost of about USD 10 million per
year.
The availability of green spaces varies significantly between European cities (Figure 2.9). This
suggests significant potential for improvement especially in cities where this proportion is low.
At a global level, the C40 network of cities around the world, encompassing more than 650 million
people, represents a good example of how changes in the urban environment may promote a more
active lifestyle and a reduction of air pollution (Box 2.10).
At the EU level, a new Green City Accord has been launched in October 2020 to make cities
greener, cleaner and healthier, and accelerate the implementation of relevant EU environmental
directives and laws. By signing the Accord, cities will commit to tackling the most urgent environmental
challenges they are facing. With respect to air pollution, mayors who will join the Accord will agree to
step up their efforts to significantly improve air quality by moving closer to respecting the WHO
Figure 2.9. Percentage of population living in areas with green spaces (forests, gardens and parks) in










Source: Joint Research Centre, “Urban Centres database”, https://ghsl.jrc.ec.europa.eu/ucdb2018visual.php#.
StatLink 2 https://stat.link/0fs8ep
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guidelines and ending exceedances of EU air quality standards as soon as possible (European
Commission, 2020[51]).
Conclusion
Although air pollution has decreased in most European countries over the past two decades, it
still exceeds the WHO guideline in most countries, particularly in large cities. In almost all European
capital cities, population exposure to air pollutants like PM2.5 exceeds the WHO guideline, and by up to
twice in several Central and Eastern European capitals.
The impact of air pollution on health and mortality is considerable. Across all EU member states,
estimates of the number of premature deaths attributable to outdoor air pollution from PM2.5 alone
range from 168 000 to 346 000 deaths in 2018. The mortality attributed to air pollution is particularly
high in Central and Eastern European countries mainly because of greater use of fossil fuels and other
dirty energy sources for heating and other purposes. Premature death rates from air pollution reach
between 120‑180 per 100 000 population in Bulgaria, Hungary, Romania, Poland and Croatia. This is
six times higher than in most Nordic countries.
The welfare losses associated with air pollution are enormous. Taking into account the impact on
mortality, lower quality of life for people falling sick because of air pollution, lower labour productivity
and higher health spending, the total welfare losses from air pollution from PM2.5 and ozone across all
EU countries was estimated to reach EUR 600 billion in 2017, which is equivalent to 4.9% of the total
EU GDP.
Three EU Directives are driving improvements in air quality across Europe: the 2008 Ambient Air
Quality  Directive,  the 2004 Directive on heavy metals  and polycyclic  aromatic  hydrocarbons in
ambient air, and the 2016 Directive on National Emission reduction Commitments (NEC) of certain air
pollutants. This latter Directive has set emission reduction commitments for each member state for the
period 2020‑29 and more ambitious ones from 2030 onwards, targeting five pollutants that have
serious  negative  health  and  environmental  consequences.  The  first  EC  report  assessing  the
implementation of the 2016 NEC Directive released at the end of June 2020 concluded that most EU
member states were not on track to meet all of their 2030 emission reduction commitments under
current  measures,  hence  additional  measures  will  be  required  in  these  countries  (European
Commission, 2020[3]). Work is also done for cooperation on these issues beyond the EU within the
framework of the UNECE Air Convention.
Box 2.10. The world’s largest cities collaborate to take action on climate change and air
pollution while supporting active lifestyles
The C40 Cities Climate Leadership Group was established in 2005 to promote sustainable urban development
through knowledge and best practice sharing. Originally, the network was composed of 40 large cities of at least 3 million
people on all continents, but gradually opened up to smaller cities committed to sustainable development.
The network shares good practices to help tackle climate change and reduce urban air pollution. Many of these
practices promote active travelling and active lifestyle, as well as the use of less polluting modes of transportation. For
example, the Transport Authority of Milan plans to convert the local public transport network to electric power by 2030,
which is expected to lead to CO2 emission reductions by almost 75 000 tons/year and the reduction of emissions of PM
and several other air pollutants (C40, 2019[48]). In Warsaw, there are plans to make 25% of the bus fleet electric by 2030
(C40, 2017[49]). 
In 2018, the city of Venice signed an agreement to test the supply of fuel with 15% reusable content (with one source
being oil wastes supplied by local residents) for its public boat fleet, at the same cost as the more polluting diesel fuel.
The initial agreement was for seven months, but the programme is still in operation. It is expected to help reduce
pollutants like nitrogen oxides and primary and secondary particulate matters (C40, 2020[50]).
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Efforts to reduce air pollution have usually focused, first and foremost, on those sectors and
human  activities  that  are  the  main  sources  of  air  pollutants  (including  energy  production  and
consumption, transport, industry and agriculture). Even though the direct role the health sector can
play in reducing air pollution is limited, it can nonetheless contribute to the overall effort. The health
sector can reduce its own environmental footprint by decreasing its reliance on fossil fuels in electricity
generation and achieving greater energy efficiency, as well as reduce its use and waste of toxic and
polluting  products.  Public  health  authorities  can  also  work  with  other  relevant  agencies  and
stakeholders to promote more healthy and clean urban planning and a transition from the use of cars
and  other  motor  vehicles  to  less  polluting  and  more  active  modes  of  transportation.  During
consultations,  doctors  and  other  health  professionals  can  encourage  people  to  change  their
behaviours and become more physically active, contributing to a reduction in air pollution to the extent
that this decreases the use of motor vehicles. Such behavioural changes will be easier to achieve if
accompanied by changes in the urban environment and infrastructures that are more conducive to
promoting more active modes of transportation, like cycling, walking or taking public transportations.
As European countries start implementing recovery plans from the COVID‑19 crisis, there is a
great opportunity for governments, businesses and citizens to promote a green recovery to avoid the
looming health, economic and welfare consequences of environmental degradation, including climate
change, biodiversity collapse and air pollution. While the economic crisis following the COVID‑19
pandemic has led to at least a temporary reduction in various air pollutants in many countries, whether
these reductions will become more permanent depends on the policy actions that will be put in place to
support  the  economic  recovery.  A  green  recovery  will  require  a  systematic  integration  of
environmental considerations. The EU recovery plan that was adopted by the European Council in
July  2020  is  designed  to  support  the  economic  recovery  from  the  COVID‑19  pandemic  and
investments in the green and digital transitions of EU economies (European Council, 2020[5]).
Strengthening efforts in the short and longer-term to protect the environment and improve air
quality are key to reducing the huge health and mortality burden of air pollution in Europe and around
the world.
Notes
1. In addition to deaths related to PM2.5, the EEA estimates that about 48 000 people died in 2018 from
exposure to nitrogen dioxide (NO2) and about 18 000 from exposure to ozone (O3) across all EU countries
(European Environment Agency, 2020[2]). These numbers cannot be added with premature mortality from
PM2.5 due to potential double counting.
2. These estimates of labour productivity losses can also be considered to be conservative. Another recent
OECD study of the economic cost of air pollution in Europe, using other data sources and methods, found
that a 1 microgramme/m3 increase in PM2.5 concentration (or a 10% increase at the sample mean) led to a
0.8% reduction in GDP, with most of the impact due to reductions in labour productivity from greater absence
from work. These results suggest that policies to reduce air pollution may contribute to economic growth
(Dechezleprêtre, Rivers and Stadler, 2019[52]).
3. Alongside this first implementation report, at the end of June 2020 the European Commission also released
an analysis of the risk of non-compliance with national emission reduction commitments based on the
National Air Pollution Control Programme and the quality of projections. Over half of the countries assessed
(12 out of 20) were identified as facing medium to high risks of not meeting their 2020 national emission
reduction commitments of PM2.5  and three‑quarters (15 out of 20) of not meeting their 2030 national
emission reductions (European Commission, 2020[3]).
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This chapter  describes the health status of  EU citizens,  including trends in life
expectancy,  the  main  causes  of  death,  health  inequalities,  the  occurrence  of
communicable and chronic diseases, and mental health issues. Life expectancy now
reaches 81 years in the EU as a whole, but the gains have slowed markedly in
several Western European countries in recent years due to severe flu seasons and a
slowdown in reductions in cardiovascular mortality. The COVID‑19 pandemic will
result in a further stagnation or even reduction in life expectancy in 2020 in those
countries  that  have  been  most  impacted.  The  main  causes  of  deaths  across
EU countries remain cardiovascular diseases (over 1 700 000 deaths in 2017) and
cancers (1 200 000 deaths), which together account for over 60% of all deaths. Large
inequalities in life expectancy persist by gender and socio-economic status. On
average across EU countries, 30‑year‑old men with a low education level can expect
to live about seven years less than those with a university degree or the equivalent.
This education gap among women is smaller, at about three years. At age 65, men
and women across EU countries could expect to live over 75% of their remaining
years of life free of disability in 2018. Nearly 40% of people aged 65 and over report
having at least two chronic conditions, although this does not necessarily impede
them from leading a normal life. About 30% of people aged 65 and over report at
least one limitation in (instrumental) activities of daily living that may require some
long-term care assistance.
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3. TRENDS IN LIFE EXPECTANCY
Life expectancy has increased in EU countries over the past
decades,  but  progress has slowed down in recent years in
many countries. The COVID‑19 pandemic will result in a further
stagnation or possible decline in life expectancy in 2020 in
those countries that have been most impacted.
In the EU as a whole, life expectancy at birth reached 81 years
in 2018. Spain and Italy had the highest life expectancy among
EU countries, with life expectancy reaching over 83 years in
2018.  Life  expectancy at  birth  exceeds 80 years  in  almost
two‑thirds of  EU countries,  but  still  remains at  only  around
75 years in Bulgaria, Latvia and Romania (Figure 3.1).
Women continue to live longer than men in all EU countries – on
average  almost  6  years  longer  –  although  this  gap  has
narrowed  by  about  one  year  since  2000  as  men’s  life
expectancy  increased  more  rapidly  than  women’s  in  most
countries. The gender gap in life expectancy is particularly large
in Latvia and Lithuania, where women live almost 10 years
longer than men, and is also quite large in Estonia (nearly
9 years). These gender differences in life expectancy are partly
due to greater exposure to risk factors among men, particularly
greater tobacco consumption, excessive alcohol consumption
and less healthy diet, resulting in higher death rates from heart
diseases, various types of cancer and other diseases. Men are
also more likely to die from violent deaths, such as suicide and
accidents.
Until  recently,  life  expectancy  was  rising  fairly  rapidly  and
steadily across EU countries, increasing by about 2.5 years per
decade on  average.  While  some countries  have  registered
fairly  large  gains  in  life  expectancy  during  the  last  decade
(notably Baltic countries like Estonia), gains in life expectancy
have  slowed  down  markedly  in  some  Western  European
countries like Spain,  France and Germany even before the
COVID‑19 pandemic. The gains in life expectancy at birth in
these countries have been limited to only about half a year
between 2011 and 2018. The slowdown has been particularly
marked among older people (Figure 3.2).
The severe flu seasons of 2014/15, 2016/17 and 2017/18 have
contributed  to  substantial  excess  mortality  in  those  years,
especially among older people. A slowdown in the reduction in
death rates from circulatory diseases, which was previously the
main factor driving life expectancy gains, also contributed to the
recent  slowdown  in  many  EU countries  (OECD/The  King’s
Fund, 2020).
The  COVID‑19  pandemic  will  further  contribute  to  the
stagnation  in  life  expectancy  in  2020  –  and  even  possible
reduction – in those European countries severely hit, such as
Belgium,  France,  Italy,  Spain,  Sweden  and  the
United Kingdom. The impact of COVID‑19 on mortality and life
expectancy will depend on both infection rates and fatality rates
of  people  infected  during  the  year.  According  to  some
estimations at the beginning of the pandemic, COVID‑19 might
lead to a reduction in life expectancy in all the countries where
life expectancy was already high and where the infection rate
will  exceed  1% or  2% of  the  population  (IIASA,  2020).  In
France,  preliminary  estimates  based  on  the  number  of
COVID‑19 deaths until the end of June 2020 indicate that life
expectancy may fall by 0.2 year for men and 0.1 year for women
in 2020, if the number of deaths were to stabilise at that level
(The Conversation, 2020). In addition to direct deaths related to
COVID‑19, the number of indirect deaths may increase due to
disruptions  to  patients’  care  for  other  conditions,  or  may
decrease due to lower mortality from other causes such as road
accidents.
Definition and comparability
Life expectancy at birth measures the average number of
years that  a person can expect  to live based on current
mortality  rates  (age-specific  death  rates).  However,  the
actual age-specific death rates of any particular birth cohort
cannot be known in advance. If age-specific death rates are
falling, actual life spans will be, on average, higher than life
expectancy calculated with current death rates.
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3. INEQUALITIES IN LIFE EXPECTANCY
Large inequalities in life expectancy exist not only by gender,
but also by socio-economic status, no matter how they are
measured – by education level, income or occupational group.
This section focuses on inequalities by education level since
this  is  the  socio-economic  indicator  with  the  most  widely
available data, although the data coverage still remains limited
to only about half of EU countries.
Inequalities in life expectancy by education level are generally
larger among men than among women, and are particularly
large in Central and Eastern Europe. On average across 14
EU countries for which data are available, 30‑year‑old men with
less than an upper secondary education can expect  to live
about seven years less than those with a tertiary education (a
university degree or the equivalent) in 2017 (Figure 3.3). In the
Slovak Republic, Poland and Hungary, 30‑year‑old men with a
low level of education can expect to live more than 10 years less
than those with a high level of education.
The  education  gap  among  women  is  smaller,  at  about
three years on average across the 14 EU countries. In the
Slovak Republic and Estonia, 30‑year‑old women with a low
level of education can expect to live over five years less than
those with a high level of education.
This education gap in life expectancy is due to higher mortality
rates among the least educated at different ages. The gap in
mortality rate between low-educated and high-educated prime-
age men (the 25‑64 year‑olds) is particularly large. This gap is
due to much higher mortality rates from all the main causes of
death among low-educated prime-age men. Half of the gap in
mortality rate among men in this age group is due to higher
death rates from circulatory diseases and cancer, and another
20% is due to external causes of death (e.g. accidents and
suicide). An important gap in mortality rates by education level
also exists among older men and women, also driven mainly by
higher death rates from circulatory diseases and cancer (Murtin
et al., 2017).
Many factors contribute to the education gap in mortality and life
expectancy. These include lower income and standard of living
for people with lower educational attainment, higher smoking
rates and obesity rates, and less healthy nutritional habits (see
indicators in Chapter 4 for more information on disparities in risk
factors by socio-economic group). If the prevalence of smoking
among the least educated was identical to that of the most
educated,  life  expectancy  between  ages  35  to  80  could
increase  by  one  year  among  men  and  six  months  among
women  on  average  across  12  EU  countries  (Figure  3.4).
Similarly, reducing the prevalence of high bodyweight among
the least educated could contribute to a four‑month increase of
life expectancy between ages 35 to 80 among men and women.
Wider  determinants  of  health  matter  too,  notably  income.
Reducing the share of the least educated people living on low
incomes could also further increase life expectancy, especially
among  men  in  Central  and  Eastern  European  countries
(Mackenbach et al., 2019).
Reducing  socio-economic  inequalities  in  life  expectancy
requires  inter-sectoral  actions  involving  not  only  health
ministries but also other ministries responsible for education,
employment,  social  protection,  housing  and  environment
(James et al., 2017).
Definition and comparability
Life  expectancy  measures  the  average  number  of
remaining years of life for people at a specific age based on
current mortality conditions. Education level is based on the
ISCED 2011 classification. The lowest education level refers
to people who have not completed their secondary education
(ISCED 2011 0‑2).  The highest  education level  refers  to
people who have completed a tertiary  education (ISCED
2011 5‑8). Data on life expectancy by education level have
been  extracted  from  the  Eurostat  database  for  most
countries, with the exception of the Netherlands where the
data come from Statistics Netherlands.
References
INSEE (2018), “L’espérance de vie par niveau de vie” [Life expectancy
by living standards], Insee Première, No. 1687, February 2018.
James, C. et al. (2017), “Inclusive growth and health”, OECD Health
Working  Papers,  No.  103,  OECD  Publishing,  Paris,  http://
dx.doi.org/10.1787/93d52bcd-en.
Mackenbach,  J.  et  al.  (2019),  “Determinants  of  inequalities  in  life
expectancy:  an  international  comparative  study  of  eight  risk
factors”,  The  Lancet  Public  Health,  Vol.  4/10,  pp.  e529‑e537,
https://doi.org/10.1016/S2468-2667(19)30147-1.
Murtin, F. et al. (2017). “Inequalities in longevity by education in OECD
countries: Insights from new OECD estimates”, OECD Statistics
Working  Papers,  2017/02,  OECD  Publishing,  Paris,  http://
dx.doi.org/10.1787/6b64d9cf-en.
114 HEALTH AT A GLANCE: EUROPE 2020 © OECD/European Union 2020
3. INEQUALITIES IN LIFE EXPECTANCY











Difference in life expectancy in years between the most and the least educated
Note: The EU average is unweighted.
Source: Eurostat Database, complemented with data from Statistics Netherlands for the Netherlands.
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Estimated gain in life expectancy if the prevalence of each risk factor among the least educated was the same as that among the most educated (in years)
Smoking Low income High bodyweight Low fruit and vegetable consumption
Others (high alcohol intake, low physical activity, few social contacts, father with a manual occupation)
Note: The United Kingdom refers to England and Wales. The EU average is unweighted. Life expectancy is for people aged 35 to 80.
Source: Mackenbach et al., 2019.
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3. HEALTHY LIFE EXPECTANCY AT BIRTH AND AT AGE 65
Healthy life expectancy is an important indicator of population
health, as it indicates whether any gains in life expectancy are
lived in good health or with some health issues and disabilities.
A  greater  number  of  healthy  life  years  generally  means  a
healthier  workforce,  fewer  early  retirements  due  to  health
problems, and reduced or postponed long-term care needs.
The main indicator of healthy life years used in the EU is the
number of years lived free of activity limitations due to health
problems (in other words, disability-free life expectancy). On
average across EU countries, men could expect to live 81% of
their lives free of disability in 2018, while this proportion was
only  77% among  women (Figure  3.5).  The  lower  share  of
healthy life years among women is due to the fact that they
generally report more activity limitations due to health problems
at any given age and also because they live longer. Whereas
the gender gap in life expectancy at birth is almost six years on
average across EU countries, it is only half a year in healthy life
expectancy (64.2 years for women compared with 63.7 years
for  men).  In  the Netherlands,  Denmark,  Portugal,  Slovenia,
Sweden and Finland, the number of healthy life years is lower
for women than men because they report more disabilities.
In 2018, Malta and Sweden were the two countries with the
highest healthy life expectancy among both women and men. In
these two countries, women can expect to live about 85% of
their life expectancy free of disability, while this share reaches
around 90% for men. Latvia and Estonia had the lowest healthy
life expectancy among both women and men, reflecting both a
relatively  low  life  expectancy  and  a  substantial  share  of
people’s life lived with some disabilities.
As people get older, the share of the remaining years of life that
they can expect to live free of disability falls. This is particularly
the case among women. While women across EU countries can
expect to live almost another 22 years when they reach the
age of 65, only ten of these years can be expected to be free of
activity limitations. For men, the remaining life expectancy at
age  65  is  almost  four  years  shorter  across  EU  countries
(18 years), but they can also expect to live only about ten years
free of disability (Figure 3.6).
Inequalities in healthy life years by socio-economic status are
even  greater  than  inequalities  in  life  expectancy,  because
women and men with lower education or income are also more
likely to report some activity limitations throughout their lives
than those with higher level  of  education or income. In the
Netherlands, the gap in life expectancy at age 25 between the
most and the least educated people was around six years in
2011, but this gap was over seven years when it comes to
healthy life expectancy (Gheorghe et al., 2016).
A range of policies can contribute to increasing healthy life
expectancy while reducing health inequalities, including greater
efforts  to  prevent  health  problems  starting  early  in  life,
promoting equal access to care for the whole population, and
better managing chronic health problems when they occur to
reduce their disabling effects (OECD, 2017).
Definition and comparability
Healthy life years (HLY) are defined as the number of
years  spent  free  of  long-term  activity  limitation  (this  is
equivalent  to  disability-free  life  expectancy).  Healthy  life
years are calculated annually by Eurostat based on life table
data and age-specific prevalence data on long-term activity
limitations.  The  disability  measure  is  the  Global  Activity
Limitation  Indicator  (GALI),  which  measures  limitation  in
usual activities, based on the EU-SILC survey.
The comparability of data on healthy life years is limited by
the fact that the indicator is derived from self-reported data
which can be affected by people’s subjective assessment of
their activity limitation (disability) and by social and cultural
factors. There are also differences across countries in the
formulation of the question on disability in national languages
in EU-SILC, limiting data comparability.
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3. MAIN CAUSES OF MORTALITY
Over  4.6  million  people  died  in  EU  countries  in  2017
(Figure 3.7). The main causes of death in EU countries are
circulatory diseases and various types of cancer, followed by
respiratory diseases and external causes of death.
Circulatory diseases continue to be the leading cause of death
across the EU, accounting for about 1.7 million deaths in 2017
or 37% of all deaths. Ischaemic heart diseases (including heart
attack and other diseases) and stroke are the most common
causes of cardiovascular mortality (see indicator “Mortality from
circulatory diseases”). Mortality rates from circulatory diseases
are much higher among men than women (about 40% higher).
Some 1.2 million people in EU countries died of cancer in 2017,
accounting for 26% of all deaths (25% among women and 28%
among men). Breast cancer and lung cancer are the leading
causes of cancer death among women, whereas lung cancer
and colorectal cancer are the two main causes of cancer death
for men (see indicator “Cancer incidence and mortality”).
After circulatory diseases and cancer, respiratory diseases are
the third leading cause of death in EU countries, causing some
366 000 deaths in 2017 or 8% of all deaths. The vast majority of
these deaths occur among people aged over 65. Respiratory
diseases accounted for 7% of all deaths among women and 9%
among men. Chronic obstructive pulmonary disease (COPD) is
the  most  common  cause  of  mortality  among  respiratory
diseases, followed by pneumonia.
External  causes  of  death,  including  accidents,  suicides,
homicides and other violent causes of death, were responsible
for 4% of all deaths among women and 5% of deaths among
men across EU countries in 2017. The most important causes
of violent deaths are suicides (48 000 deaths in 2017) and
transport accidents (about 27 000 deaths). Transport accidents
are a particularly important cause of death among young people
(aged 18‑25), whereas suicide rates generally increase with
age (see indicator “Adult mental health”).
Looking  at  other  specific  causes,  Alzheimer’s  and  other
dementias accounted for 5% of all deaths in 2017, and were a
cause  of  death  more  important  among  women.  Diabetes
represented 2% of all deaths across EU countries.
The  main  causes  of  death  differ  between  socio-economic
groups, explaining the gap in life expectancy. Social disparities
are generally larger for the most avoidable causes of death
(Mackenbach et al., 2015).
Overall mortality rates (age-standardised) ranged in 2017 from
less than 900 deaths per 100 000 population in France, Spain
and Italy (which is about 15% lower than the EU average) to
over 1 400 deaths per 100 000 population in Bulgaria, Romania,
Latvia, Hungary and Lithuania (over 40% higher than the EU
average) (Figure 3.8). The main reason for the much higher
mortality rates in this latter group of countries is higher mortality
rates from circulatory diseases, the leading cause of death. In
Hungary, higher mortality rates from cancer also explain a large
part of the difference with the EU average (Eurostat, 2020).
Definition and comparability
Deaths from all causes are classified to ICD‑10, Codes
A00‑Y89,  excluding  S00‑T98.  The  grouping  Alzheimer’s
disease and other dementias include G30 (Alzheimer) and
F01‑F03 (other dementias). Mortality rates are based on the
number of deaths registered in a country in a year divided by
the population. The rates have been age-standardised to the
revised European standard population adopted by Eurostat
in 2012 to remove variations arising from differences in age
structures across countries and over time.
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Age-standardised rates per 100 000 population
Note: External causes of death include accidents, suicides, homicides and other causes. The EU average is weighted (using imputed estimates for France for 2017). Data
for France refer to 2016. 1. Three-year average.
Source: Eurostat Database.
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3. MORTALITY FROM CIRCULATORY DISEASES
Circulatory (or cardiovascular) diseases remain the main cause
of mortality in nearly all EU member states, accounting for some
1.7 million deaths and 37% of all deaths across EU countries in
2017.  The  morbidity  and  mortality  related  to  circulatory
diseases has major economic costs as well as human costs for
Europe. The cost of circulatory diseases to the EU economy
was estimated at EUR 210 billion in 2015, of which slightly more
than half  was due to direct  health  care costs,  a  quarter  to
productivity losses and a fifth to the informal care of people with
cardiovascular diseases (Wilkins et al., 2017). This estimate
does not take into account the welfare losses associated with
premature mortality related to these diseases.
The two main causes of death from circulatory diseases are
ischaemic  heart  diseases  (notably  heart  attacks)  and
cerebrovascular diseases (strokes). These two causes of death
alone  account  for  over  half  of  all  deaths  from  circulatory
diseases, and more than one‑fifth of all deaths in EU member
states in 2017.
Ischaemic  heart  diseases  (IHD)  are  caused  by  the
accumulation of fatty deposits lining the inner wall of a coronary
artery, restricting blood flow to the heart. Some 550 000 deaths
were attributed to IHD across EU countries in 2017, accounting
for 12% of all deaths. Death rates for IHD are over 80% higher
for men than for women across EU countries, because of a
greater  prevalence  of  risk  factors  among  men,  such  as
smoking, hypertension and high cholesterol.
Mortality rates from IHD are highest in Lithuania, Hungary, the
Slovak Republic and Latvia, with age-standardised rates three
to four times greater than the EU average. The countries with
the lowest IHD mortality rates are France, the Netherlands,
Portugal and Spain, with death rates about half the EU average
(Figure 3.9).
Cerebrovascular  diseases (or  strokes)  were responsible  for
some 375 000 deaths across the EU in 2017, accounting for
about 8% of all deaths. Strokes are caused by the disruption of
the blood supply to the brain. In addition to being an important
cause  of  mortality,  the  disability  burden  from  stroke  is
substantial.  The gender  gap in  (age-standardised)  mortality
rates from stroke is not as large as for IHD (less than 20%).
As with IHD, there are wide variations in stroke mortality rates
across countries.  The rates  are  around three to  four  times
higher than the EU average in Bulgaria, Romania and Latvia.
They are the lowest in France, Luxembourg and Spain, with
death rates about half the EU average (Figure 3.10).
Steady and substantial reductions in mortality rates from IHD,
strokes and other circulatory diseases were the main driver of
increases in life expectancy in previous decades, but these
reductions have slowed down over the past five to ten years in
several Western European countries (e.g. France, Germany
and the United Kingdom). This has contributed to the slowdown
in  life  expectancy  improvements  (OECD/The  King’s  Fund,
2020).
There are wide socio-economic inequalities in mortality from
circulatory  diseases  in  most  European  countries,  reflecting
socio-economic differences in major risk factors. Many of these
deaths can be prevented, but trends in several risk factors are
going in the wrong direction. While smoking rates overall have
fallen, cholesterol, blood pressure, low physical activity, obesity
and diabetes are on the rise in many EU countries (OECD/The
King’s Fund, 2020).
A number of public health measures can be implemented to
counter  the  slowdown  in  reducing  mortality  rates  from
circulatory  diseases.  Fiscal  and  regulatory  measures  can
promote  healthy  lifestyles  and  help  reduce  the  burden  of
cardiovascular diseases, as well as also ease pressures on
health care systems.
Definition and comparability
Mortality  rates  are  based  on  the  number  of  deaths
registered in a country in a year divided by the population.
The  rates  have  been  age-standardised  to  the  revised
European standard population adopted by Eurostat in 2012
to  remove  variations  arising  from  differences  in  age
structures across countries and over time.
Deaths from ischaemic heart diseases relate to ICD‑10
codes I20‑I25, and cerebrovascular diseases (or stroke) to
I60‑I69.
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Note: The EU average is weighted (using imputed estimates for France for 2017). Three-year average (2015‑17) for Cyprus, Iceland, Luxembourg, and Malta. Data refer
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3. CANCER INCIDENCE AND MORTALITY
In 2020, about 2.7 million people in the 27 EU countries are
expected to be diagnosed with cancer, and nearly 1.3 million to
die from it (Joint Research Centre, 2020). Over 40% of cancer
cases  are  preventable,  and  mortality  can  also  be  reduced
through earlier diagnosis and the provision of more timely and
effective treatments. The Europe’s Beating Cancer Plan aims to
reduce the cancer burden for patients, their families and health
systems, and address cancer-related inequalities between and
within  countries,  with  actions  to  support,  coordinate  and
complement the efforts of Member States (EC, 2020).
More men than women are expected to be diagnosed with
cancer  in  2020  across  EU  countries  (54%  men  and  46%
women).  Among  men,  the  main  cancer  sites  are  prostate
cancer, which is expected to account for 23% of all new cancers
diagnosed  in  2020,  followed  by  lung  cancer  (14%)  and
colorectal cancer (13%). Among women, breast cancer is the
main cancer site, expected to account for 29% of all new cancer
cases, followed by colorectal cancer (12%) and lung cancer
(9%) (Figure 3.11).
Ireland, Denmark, the Netherlands and Belgium are expected
to have the highest incidence rate of all cancers combined in
2020, with age-standardised rates more than 10% higher than
the EU average (Figure 3.12). These variations reflect not only
variations in the real number of new cancers occurring each
year, but also differences in national policies regarding cancer
screening  to  detect  different  types  of  cancer  as  well  as
differences in the quality of cancer surveillance and reporting.
Cancer is the second leading cause of mortality in the EU after
cardiovascular diseases. Reflecting mainly higher incidence,
mortality  from  cancer  is  greater  among  men  than  women.
Overall  across  EU  countries,  about  706  000  men  and
555 000 women are expected to die from cancer in 2020 (JRC,
2020).
Mortality rates from cancer are lowest in Finland, Malta, Spain,
Luxembourg, and Sweden, with rates at least 15% lower than
the  EU average.  They  are  highest  in  the  Slovak  Republic,
Poland, Cyprus, and Hungary, with rates more than 20% higher
than the EU average (Figure 3.12).
Lung cancer remains by far the most common cause of death
from cancer among men and the second most common among
women  (after  breast  cancer).  Over  257  000  people  are
expected to die from lung cancer across EU countries in 2020
(JRC, 2020). The main risk factors for lung cancer are tobacco
smoking and environmental factors such as air pollution (see
Chapter 2 on the impact of air pollution on health and mortality).
While the survival rate after a diagnosis for lung cancer has
increased over the past decade, it still remains fairly low (see
indicator “Incidence, survival and mortality from lung cancer” in
Chapter 6).
Colorectal cancer is the second most common cause of cancer
death,  with  about  156  000  people  expected  to  die  from
colorectal cancer in EU countries in 2020. The mortality rate
from colorectal cancer is about 75% higher among men than
among women across EU countries.  There are several  risk
factors for colorectal cancer besides age, including a diet high
in  fat  and  low  in  fibre,  alcohol  consumption,  smoking  and
obesity.  Earlier  detection  and  better  treatment  have  led  to
higher survival rates after diagnosis (see indicator “Screening,
survival and mortality from colorectal cancer” in Chapter 6).
Breast cancer is the leading cause of cancer death among
women, expected to cause about 95 000 deaths in 2020 and
accounting  for  17%  of  all  female  cancer  deaths.  While
incidence rates of breast cancer have increased over the past
decade,  death  rates  have  declined  or  stabilised,  reflecting
increases in survival rates due also to earlier diagnosis and
better  treatment  (see  indicator  “Screening,  survival  and
mortality for breast cancer” in Chapter 6).
The estimates of cancer incidence and mortality reported here
do not reflect any effect that the COVID‑19 pandemic might
have on the burden of cancer as they are based on trends from
previous years. At the time of writing this report, it is not clear
yet what effect the COVID‑19 outbreak might have on cancer
incidence, mortality or survival in each country and in the EU as
a  whole.  However,  many  EU  countries  faced  significant
challenges  during  the  peak  of  the  epidemic  in  maintaining
cancer screening and treatment, impacting the quality of care
for cancer patients and possibly also survival rates.
Definition and comparability
The 2020 cancer incidence and mortality estimates have
been  computed  using  the  European  Cancer  Information
System (ECIS) which is used for reporting the cancer burden
in  Europe.  These  estimates  are  the  outcome  of  a
collaborative  project  between  the  Joint  Research  Centre
(JRC)  and  the  European  Network  of  Cancer  Registries
(ENCR), together with the International Agency for Research
on Cancer (IARC). The estimates are based on the cancer
registries historical data on incidence and mortality. Rates
have been age-standardised based on the new European
Standard  Population  to  remove  variations  arising  from
differences in age structures across countries. The estimates
for 2020 may differ from national estimates due to differences
in methods.
The  incidence  and  mortality  from all  cancers  relate  to
ICD‑10  codes  C00‑C97  (excluding  non-melanoma  skin
cancer C44).
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3. INFANT HEALTH
Poor living conditions and other socio-economic factors affect
the health of mothers and newborns, but the quality of health
care can greatly reduce the number of infant deaths, particularly
by addressing life-threatening issues during the neonatal period
(i.e. the first month of life). The main causes of death during the
first  month are congenital  anomalies,  prematurity  and other
conditions arising during pregnancy. For deaths beyond the first
month (post neonatal mortality), there tends to be a greater
range  of  causes,  with  the  most  common  being  sudden
unexpected death in infancy (Euro-Peristat, 2018).
Infant mortality rates are low in most EU countries, with an
average of less than 3.5 deaths per 1 000 live births across
EU countries in 2018 (Figure 3.13). However, a small group of
countries – Malta, Romania, Bulgaria and the Slovak Republic –
still have infant mortality rates of 5 deaths per 1 000 live births or
more.  In  Malta,  infant  mortality  rates  are  higher  because
induced  abortions  following  the  detection  of  congenital
anomalies are illegal, whereas this is possible in other countries
in cases of severe and/or lethal anomalies.
All  European  countries  have  achieved  notable  progress  in
reducing infant mortality rates over the past few decades. The
EU average went down from over 10 deaths per 1 000 live births
in 1990 to 3.4 deaths in 2018. Reductions in infant mortality
rates have been particularly rapid in Bulgaria and Romania,
converging towards the EU average (Figure 3.14).
Across EU countries, 1 in 15 babies (6.6%) weighed less than
2 500 grammes at birth in 2018 (Figure 3.15). Low birthweight
can occur as a result of restricted foetal growth or from pre-term
birth. Low birthweight infants have a greater risk of poor health
or death, require a longer period of hospitalisation after birth,
and are more likely to have health problems and disabilities
later in life. Some of the main risk factors for low birthweight
include  maternal  smoking,  alcohol  consumption  and  poor
nutrition during pregnancy, low body mass index, lower socio-
economic status, having had in-vitro fertilisation treatment and
multiple births, and higher maternal age.
The  percentage  of  low  birthweight  is  more  than  two‑times
greater in some EU countries than in others. There is a marked
geographical  variation  that  may  reflect  physiological
differences  in  mothers  and  babies.  The  Baltic  countries
(Estonia, Latvia and Lithuania) and Nordic countries (Finland,
Sweden  and  Denmark)  have  the  lowest  proportion  of  low
birthweight babies, whereas some countries in Southern and
Eastern Europe (Cyprus, Greece, Bulgaria and Portugal) have
the highest proportion.
Between 2010 and 2018, some countries like Austria and the
Czech  Republic  registered  substantial  reductions  in  the
percentage  of  low  birthweight  babies,  whereas  this  share
remained fairly stable in most other countries.
Definition and comparability
Infant mortality rate is the number of deaths of children
under one year of age per 1 000 live births. Some of the
international variation in infant and neonatal mortality rates
may be due to  variations  among countries  in  registering
practices of premature infants. While some countries have no
gestational  age  or  weight  limits  for  mortality  registration,
several  countries  apply  a  minimum  gestational  age  of
22 weeks (or a birth weight threshold of 500 grammes) for
babies to be registered as live births (Euro-Peristat, 2018).
Low  birth  weight  is  defined  by  the  World  Health
Organization as the weight of an infant at birth of less than
2 500 grammes (5.5 pounds) irrespective of the gestational
age of the infant. This threshold is based on epidemiological
observations regarding the increased risk of death of the
infant. Despite the widespread use of this 2 500 grammes
limit, physiological variations in size occur across different
countries and population groups, and these need to be taken
into  account  when interpreting  differences  (Euro-Peristat,
2018). The number of low weight births is expressed as a
percentage of total live births.
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Figure 3.13. Infant mortality, 2018
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Figure 3.15. Low birthweight, 2018 (or nearest year)
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3. NOTIFIED CASES OF VACCINE-PREVENTABLE DISEASES
Communicable diseases,  such as measles,  hepatitis  B and
many others, pose major threats to the health of European
citizens,  although  vaccination  can  efficiently  prevent  these
diseases (EC, 2018).
Measles is a highly infectious disease of the respiratory system,
caused by a virus, which can lead to severe complications,
including pneumonia, encephalitis, diarrhoea and blindness. All
EU Member States and other countries around the world have
adopted the goal to eliminate measles. In the 12‑month period
preceding the COVID‑19 outbreak (between March 2019 and
February 2020), 11 576 cases of measles were reported to the
European Surveillance System by the 27 EU countries, Iceland,
Norway, Switzerland and the United Kingdom. Following the
COVID‑19 pandemic and the confinement measures, there has
been a sharp decrease in the reporting of measles cases with
the number falling to 692 in the six‑month period from March to
August 2020 in the same group of countries (ECDC, 2020).
The average rate across EU countries in 2019 was 3.9 cases
per 100 000 population, but with wide variations (Figure 3.16).
Lithuania  reported  the  highest  number  of  new  cases  and
highest rate (29.8 cases per 100 000 population), followed by
Bulgaria with a rate of 17.6 per 100 000 population. An outbreak
of measles started in 2019 in Lithuania, most notably in the
cities of Kaunas and Vilnius. The authorities responded with a
large vaccination campaign to contain the outbreak and prevent
any  future  epidemic.  Vaccination  against  measles  is  very
effective, and the vast majority of newly diagnosed people in
Europe were not vaccinated. While most measles cases are
among infants under one year old as they are often still too
young to have received the first dose of vaccine, about 45% of
cases occur among adults.
Hepatitis B is a liver infection caused by a virus transmitted by
contact with blood or body fluids of an infected person. People
who are infected can go on to develop a chronic infection,
especially those who are infected at younger ages. People with
chronic hepatitis B are more likely to suffer from liver cirrhosis
and liver cancer. About 24 500 hepatitis B cases were reported
in  EU  countries,  Iceland,  Norway,  Switzerland  and  the
United Kingdom in 2018, nearly 10% down from 26 900 cases
in 2017 (ECDC, 2020b).  Latvia  had the highest  notification
rates, with 1.5 cases per 100 000 population (Figure 3.17). The
rates were also high in the Slovak Republic, Malta, Germany,
and Spain, the United Kingdom and Turkey.
Reported cases of hepatitis B are higher in men than in women.
About one‑third of all reported hepatitis B cases occurs among
people  aged  25‑34.  For  acute  infections,  heterosexual
transmission  is  the  most  common  route  of  transmission,
followed by nosocomial transmission, transmission among men
who have sex with men, injuries and drug injection. Mother-to-
child transmission is the most common route for chronic cases.
The most effective prevention is vaccination (see indicators on
childhood vaccination in Chapter 6).
Definition and comparability
Mandatory  notification  systems  for  communicable
diseases, including measles and hepatitis B, exist in most
European countries,  although case definitions,  laboratory
confirmation requirements and reporting systems may differ.
Measles and hepatitis B notification is mandatory in all EU
member states. Caution is required in interpreting the data
because  of  the  diversity  in  surveillance  systems,  case
definitions and reporting practices. For hepatitis B, the data
for five countries (France, Greece, Hungary, Lithuania and
Spain) only include acute cases, not chronic cases, resulting
in a large under-estimation. Variation between countries also
likely reflects differences in testing as well as differences in
immunisation and screening programmes.
References
EC (2018), Proposal for a council recommendation on strengthened
cooperation  against  vaccine  preventable  diseases,  European
Commission, Brussels.
ECDC (2020a), Communicable Disease Threats Report on Measles,
Stockholm.
ECDC (2020b), Hepatitis B – Annual epidemiological report for 2018,
Stockholm.
126 HEALTH AT A GLANCE: EUROPE 2020 © OECD/European Union 2020
3. NOTIFIED CASES OF VACCINE-PREVENTABLE DISEASES

































Notification rate per 100 000 population, measles
EU 3.9
Source: ECDC Surveillance Atlas of Infectious Diseases.
StatLink 2 https://stat.link/e3f0ah



































Note: Data for France, Greece, Hungary, Lithuania and Spain only include acute cases, not chronic cases, resulting in a large under-estimation.
Source: ECDC Surveillance Atlas of Infectious Diseases.
StatLink 2 https://stat.link/xd1o8y
HEALTH AT A GLANCE: EUROPE 2020 © OECD/European Union 2020 127
3. CHILD AND ADOLESCENT HEALTH
Childhood and adolescence are fundamental phases in human
development,  when  young  people  develop  knowledge  and
skills to deal with critical aspects of their health, and are also the
period during which many mental health problems first emerge.
The COVID‑19 crisis has significantly disrupted children and
adolescents’ daily lives, and makes attention to young peoples’
health all the more critical (see Chapter 1 on resilience to the
COVID‑19 pandemic).
Across EU countries in 2018, about one in three 11‑year‑old
girls and less than one in three 11‑year‑old boys experienced
multiple health complaints, such as feeling “low” or irritable, or
experiencing  headaches,  stomach  aches  or  backaches,  or
having  difficulties  falling  asleep (Figure  3.18).  Some of  the
physical health complaints that adolescents experience, such
as  stomach  ache  or  headache,  can  also  be  signs  of
psychological distress. In contrast, over one in two 15‑year‑old
girls  reported  multiple  health  complaints,  a  difference  of
over 20 percentage points compared to 11‑year‑old girls. The
rates of 11‑year‑olds and 15‑year‑olds reporting multiple health
complaints are highest among boys and girls in Italy, Bulgaria
and Malta.
Mental  health  problems  can  be  associated  with  major  risk
factors, such as heavy episodic drinking, tobacco or illicit drug
use,  unhealthy  nutrition  and  lack  of  physical  activity  (see
Chapter 4). Behavioural risk factors such as excessive drinking
or drug use can both worsen adolescents’ mental health, and
be  used  as  a  coping  mechanism  in  the  absence  of  more
effective mental health support, as well as contributing to lasting
effects on physical health across the life course (e.g. circulatory
diseases and some cancers).
Mental  health  problems and psychological  distress are one
important  driver  of  suicide among adolescents.  Over 1 000
15‑19 year‑olds died of suicide across EU countries in 2017,
and  most  of  these  deaths  were  among  boys.  Despite  the
relatively low absolute number of suicides among adolescents,
suicide is one of the leading causes of death in this age group.
Young people are more likely to attempt suicide if they have a
family history of alcohol and drug abuse disorders, have access
to firearms, and experience difficult life events at school or at
home (McLoughlin, Gould and Malone, 2015). The number of
death  by  suicide  among teenagers  has  decreased by  over
one‑third on average across EU countries between 2000 and
2017.
In recent years (2015‑17), the suicide rate among teenagers
was highest in Lithuania and Estonia, with rates of over 11
deaths per 100 000 15‑19 year‑olds, a rate more than 2.5 times
higher than the EU average. The lowest rates are reported in
Southern European countries (Greece, Portugal, Cyprus, Italy
and Spain). Suicide rates among boys was 2.5 times higher
than among girls on average across EU countries (Figure 3.19).
Countries have taken steps to support vulnerable adolescents
with  mental  health  problems  (McDaid  et  al.,  2017;  OECD,
2015).  Inter-sectoral  strategies  encompassing  health,
education and welfare policies can promote and protect the
health  and  wellbeing  of  adolescents.  School-based  mental
health programmes have been introduced in many countries
and  can  improve  social  and  educational  outcomes.  For
example, the Youth Aware of Mental Health (YAM) programme
is in place in ten European countries and is associated with a
55% reduction in suicide attempts and 50% fewer cases of
suicidal ideation after 12 months (Wasserman et al., 2015).
Definition and comparability
The indicator on multiple health complaints is based on the
following  symptoms  experienced  in  the  last  six  months:
headache;  stomach  ache;  backache;  feeling  low;  feeling
irritable  or  bad  tempered;  feeling  nervous;  difficulties  in
getting  to  sleep;  and  feeling  dizzy.  Differences  across
countries  may  reflect  a  different  understanding  and
interpretation of the questions.
Data on multiple health complaints come from the Health
Behaviour  in  School-aged  Children  (HBSC)  study.  The
HBSC surveys have been undertaken every four years since
1993‑94 and now include all EU countries except Cyprus.
Data are drawn from school-based samples of 1 500 children
in  three  age groups  (11‑,  13‑  and  15‑year‑olds)  in  most
countries, ensuring that the sample is representative of each
age group.
Data on suicide rates come from the Eurostat Database.
The registration of suicide is a complex procedure, affected
by factors such as how intent is ascertained, responsibility for
completing  the  death  certificate,  and  cultural  dimensions
including  stigma.  Caution  is  therefore  needed  when
comparing suicide rates.
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3. ADULT MENTAL HEALTH
Good mental health is vital for people to be able to lead healthy
and productive lives. Living with a mental health problem can
have a significant impact on daily life, contributing to worse
educational  outcomes,  higher  rates  of  unemployment,  and
poorer physical health. As of 2020, the COVID‑19 crisis is also
having  a  negative  impact  on  mental  wellbeing,  especially
amongst young people and people with lower socio-economic
status (see Chapter 1).
In  2018,  one  in  nine  adults  (11%)  on  average  across
EU  countries  had  symptoms  of  psychological  distress
(Figure 3.20). Prevalence ranged from about 5% in Ireland,
Poland, Estonia, the Slovak Republic and Finland, to about
20% or over in Croatia and Portugal. While these rates suggest
that psychological distress is common in all EU countries, they
do not reflect a clinical diagnosis. Self-reported data can be
influenced by cultural differences, and different levels of stigma
and literacy around mental health.
Without  effective  treatment  and  support,  mental  health
problems can have a devastating effect on people’s lives, and
significantly increase the risk of dying from suicide (OECD/EU,
2018).  In 2017,  over 48 000 people died of  suicide across
EU countries.  The  most  frequent  number  of  suicides  were
amongst  men  aged  45  and  over  (Figure  3.21).  Gender
differences in suicidal behaviour are significant; men represent
over  three‑quarters of  suicides in  EU countries,  though the
gender gap is narrower amongst older age groups. In Lithuania,
the suicide rate among men was more than five times higher
than that for women.
On average, there were 11 deaths by suicide per 100 000
population across EU countries in 2017 (Figure 3.22). Suicide
rates were lowest in Cyprus, Greece, Italy and Malta, where
there were fewer than six suicides per 100 000 population in
2017. Lithuania and Slovenia had the highest suicide rate, with
26 and 20 deaths per 100 000 population, respectively.
Suicide rates have decreased in almost all EU countries, falling
by  50%  between  2000  and  2017.  In  some  countries,  the
declines  have  been  significant,  including  in  Hungary,  the
Slovak Republic and Bulgaria, where deaths by suicide have
fallen by more than 50%.
Effective approaches to reducing death by suicide include good
access to support and mental health care; suicide prevention
training for gatekeepers such as health workers and community
leaders; reducing access to lethal means such as firearms and
pharmaceuticals; responsible media reporting around suicide;
and  awareness  and  anti-stigma  campaigns.  Some
EU countries include suicide prevention as part of their broader
mental  health  policies,  while  others  such  as  Ireland,
Luxembourg, the Netherlands and Switzerland have specific
suicide reduction plans.
In the Netherlands, the National Agenda for Suicide Prevention
2018‑21  takes  a  multi-pronged  approach,  including  suicide
prevention  training  for  General  Practitioners  and  hospital
nurses, improving aftercare following a suicide attempt, and
training for persons in contact with identified high-risk groups
such  as  agencies  working  with  debt  relief,  unemployment
support workers, and the police. In France, suicide prevention
includes training for peer workers and General Practitioners, as
well as a specific suicide reattempt prevention programme.
In  Ireland,  too,  the  National  Strategy  to  Reduce  Suicide
2015‑20  focuses  attention  on  groups  at  particular  risk  of
suicide, and persons who have already presented with suicide
attempts.  Ireland  focuses  on  strengthening  pathways  to
services  for  people  vulnerable  to  suicidal  behaviour,  and
improving the capacity of community-based organisations to
provide appropriate information around suicide and recognising
risks.
In Switzerland, the suicide rate has decreased by 64% since
2000. While rates of ‘assisted suicide’ are rising, mainly in older
people, since 2009 assisted suicides have been excluded from
overall suicide data, explaining the sharp decline the year the
reporting  changed.  Switzerland  has  taken  steps  to  reduce
deaths by suicide, including a suicide prevention action plan in
2016 that focused on providing fast access to mental health
support,  reducing  stigma  around  suicide,  and  raising
awareness of suicide risks.
Definition and comparability
The  prevalence  of  psychological  distress  symptoms  is
based on EU survey on Statistics  on Income and Living
Conditions (EU-SILC). Questions are based on the module
on mental health of the SF‑36 questionnaire. The prevalence
is calculated from responses to five items such as “Have you
been very nervous over the past four weeks?” on a 5‑point
scale (0‑4) ranging from ‘at no time’ to ‘all of the time’. The
scores can amount to a maximum score of 20, which is then
multiplied  by  5  to  get  a  maximum  of  100.  Someone  is
considered  with  psychological  distress  symptoms  if  they
scored  above  50.  Items  refer  to  feeling  nervous,  feeling
down, feeling calm, feeling down-hearted or depressed, and
feeling happy. Prevalence is weighted by population size.
Suicide  data  come  from  the  Eurostat  Database.  The
registration of suicide is a complex procedure, affected by
factors such as how intent is ascertained, who is responsible
for completing the death certificate, and cultural dimensions
including  stigma.  Caution  is  therefore  needed  when
comparing rates between countries.
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3. CHRONIC DISEASES AND DISABILITIES AMONG OLDER PEOPLE
Life expectancy has increased greatly in EU countries over the
past few decades, but many years of life in old age are lived with
some  chronic  diseases  and  disabilities  (see  the  indicator
Healthy life expectancy). The EU approach to addressing the
challenge of chronic diseases involves an integrated response
focusing on prevention across sectors, combined with efforts to
strengthen  health  systems  to  improve  the  management  of
chronic conditions (EC, 2020).
Based on the latest wave of the Survey on Health, Ageing and
Retirement in Europe (SHARE), about 37% of people aged 65
and over  reported having at  least  two chronic  diseases on
average across EU countries in 2017 (Figure 3.23). Women
report multiple chronic diseases more often than men (41%
versus  32%  on  average).  As  expected,  the  prevalence  of
chronic diseases increases with age. Among people aged 80
and over,  56% of  women and 47% of  men report  multiple
chronic diseases on average across EU countries.
There are substantial disparities in the prevalence of chronic
diseases by income group. On average across EU countries,
27% of people aged 65 and over in the highest income quintile
reported at least two chronic diseases, compared with 46% for
those in the lowest income quintile.  This reflects to a large
extent the cumulative effect of more difficult living and working
conditions  and  greater  exposure  to  various  risk  factors  for
chronic conditions earlier in life (OECD, 2017).
Living with chronic diseases does not necessarily hinder older
people  from carrying  on  their  usual  activities.  Nonetheless,
about  30%  of  people  aged  over  65  on  average  across
EU countries reported having at least one limitation in activities
of daily living (ADL, including basic activities such as eating or
dressing)  or  instrumental  activities  of  daily  living  (IADL,
including  activities  such  as  cooking  or  doing  the  laundry)
(Figure 3.24). Such limitations in ADLs and IADLs may require
long-term care assistance.
Women report more often having at least one ADL or IADL
limitation than men in all EU countries (34% of women and 24%
of men on average across EU countries). This reflects mainly
the fact that women report more chronic diseases with disabling
effects, such as arthritis.
The prevalence of activity limitations increases greatly with age:
about 45% of people aged 75 years and over report to be limited
in their daily activities across EU countries. There are also large
disparities in disability by income quintile: on average across
EU countries, about 18% of people aged over 65 in the highest
income quintile report such activity limitations compared with
43% among those in the lowest income quintile.
The provision of long-term care for people with limitations in
ADL or IADL can be very costly. All EU countries have some
type of social protection for people requiring long-term care, as
most people would not be able to afford the full cost. In many
EU countries, the access and level of support to long-term care
benefits depend on people’s income and asset, and in some
countries, on the availability of informal carers. Older people
with  the  most  severe  needs  and  limited  assistance  from
informal carers are the most likely to be pushed into poverty or
to  have to  move to  LTC facilities  (Oliveira  Hashiguchi  and
Llena-Nozal, 2020).
Definition and comparability
The question used in SHARE to measure the prevalence
of any chronic disease is “Has a doctor ever told you that you
had any of the conditions on this card?” Data reported here
include  people  who  report  Alzheimer’s  disease,  cancer,
chronic kidney diseases, chronic lung diseases, diabetes,
heart  attack,  hip  fracture,  Parkinson’s  disease,  stroke,
rheumatoid arthritis and osteoarthritis.
As for limitations in daily activities, the questions is: “Do
you have any difficulty with these activities because of a
physical, mental, emotional or memory problem?”. Activities
of daily living (ADL) or instrumental activities of daily living
(IADL) included here relate to limitations in: dressing, walking
across the room, bathing/showering, eating, getting in/out of
bed,  using  the  toilet,  preparing  a  hot  meal,  doing  the
groceries, making telephone calls, taking medications, doing
work around the house/garden, managing money, leaving
the house independently and doing the laundry. Difficulties
expected to last less than three months are excluded.
The prevalence of limitations in daily activities is adjusted
by the OECD to correct for the underrepresentation of the
population living in LTC facilities (except in Greece and in the
Netherlands,  resulting  in  an  under-estimation),  while  the
prevalence  of  chronic  diseases  excludes  those  who  live
permanently in LTC facilities and is not adjusted.
Data are weighted by population size in  each country,
except in the Netherlands.
References
EC (2020), “EU integrated approach to non-communicable diseases”,
https://ec.europa.eu/health/non_communicable_diseases/
overview_en.
OECD  (2017),  Preventing  Ageing  Unequally,  OECD  Publishing,
Paris, https://doi.org/10.1787/9789264279087-en.
Oliveira Hashiguchi, T. and Llena-Nozal, A. (2020), “The effectiveness
of social protection for long-term care in old age: Is social protection
reducing the risk of poverty associated with care needs?”, OECD
Health Working Papers, No. 117, OECD Publishing, Paris, https://
doi.org/10.1787/2592f06e-en.
132 HEALTH AT A GLANCE: EUROPE 2020 © OECD/European Union 2020
3. CHRONIC DISEASES AND DISABILITIES AMONG OLDER PEOPLE
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3. DIABETES PREVALENCE
Diabetes is a chronic condition that occurs when the body is
unable to regulate excessive glucose levels. If left undiagnosed
or  poorly  controlled,  it  can  result  in  serious  complications,
including blindness, kidney failure and lower limb amputation.
Diabetes also increases the risks of cardiovascular diseases,
and people with diabetes also have a greater risk of becoming
severely ill if infected by the COVID‑19 virus. Many diabetic
patients also did not get proper management and control of
their  condition  during  the  initial  phase  of  the  COVID‑19
pandemic, possibly resulting in avoidable complications.
About 32.3 million adults were diagnosed with diabetes in the
European Union in 2019, up from an estimated 16.8 million
adults in 2000. An additional 24.2 million people in Europe were
estimated to have diabetes but be undiagnosed in 2019 (IDF,
2019).  The  number  of  men  with  diagnosed  diabetes  has
increased particularly rapidly since 2000, more than doubling
from around 7.3 million in 2000 to 16.7 million in 2019. The
number of women with diabetes has also gone up substantially,
rising  from 9.5  million  in  2000  to  15.6  million  in  2019,  an
increase of over 50% (Figure 3.25). Men are more prone to
develop diabetes because of biological factors and have to gain
less weight than women to develop the condition.
Diabetes is more common among older people: 19.3 million
people  aged  60‑79  have  diabetes  across  EU  countries,
compared  with  11.3  million  people  aged  40‑59  and  only
1.7 million aged 20‑39 (Figure 3.26). While more men than
women have diabetes in middle-age (between 40 and 59 years
old), a greater number of women have diabetes after age 70
mainly because they live longer.
Diabetes  prevalence  among  adults  (diagnosed  and  age-
standardised) was 6.2% on average in EU countries in 2019.
The rates varied from 9% or more in Cyprus, Portugal, and
Germany to less than 4% in Ireland and Lithuania (Figure 3.27).
The prevalence of diabetes appears to have stabilised in many
European  countries  in  recent  years,  especially  in  Nordic
countries, although they have continued to go up slightly in
Southern  European  countries  and  Central  and  Eastern
European countries. These upward trends are partly due to the
rise in obesity and physical inactivity, and their interactions with
population ageing (NCD Risk Factor Collaboration, 2016).
Based on results from the 2014 European Health Interview
Survey, adults with the lowest level of education are more than
twice as likely to report having diabetes than those with the
highest level of education on average across EU countries. This
may partly be due to a higher proportion of low-educated people
in  older  population  groups.  However,  the  prevalence  of
important  risk factors for  diabetes such as obesity  is  much
higher  among the  least-educated  people  (see  the  indicator
“Obesity among adults” in Chapter 4).
The economic burden of diabetes is substantial. The health
expenditure  allocated  to  treat  diabetes  and  prevent
complications are estimated at about EUR 150 billion in 2019 in
the  EU,  with  the  average  expenditure  per  diabetic  adult
estimated at about EUR 3 000 per year (IDF, 2019).
Type 2 diabetes is largely preventable. A number of risk factors,
such  as  overweight  and  obesity,  nutrition  and  physical
inactivity, are modifiable through effective preventive strategies
and lifestyle changes. Effective management of the growing
number  of  people  with  diabetes  is  also  a  priority  in  many
countries, usually involving a considerable amount of self-care.
Therefore,  proper  advice  and  education  are  central  to  the
primary care of people with diabetes (OECD, 2020).
Definition and comparability
The  sources  and  methods  used  by  the  International
Diabetes Federation are outlined in the Diabetes Atlas, 9th
edition (IDF, 2019). The IDF produced estimations based on
a variety of sources of which the majority was peer-reviewed
articles  and  national  health  surveys.  Sources  were  only
included  if  they  met  several  criteria  for  reliability.  Age-
standardised  rates  were  calculated  using  the  world
population based on the distribution provided by WHO. The
data  include  adults  with  Type  1  or  Type  2  diagnosed
diabetes.
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Note: Data include people aged 20‑79 with Type 1 or Type 2 diabetes. The number of people with diabetes in 2000 has been estimated for some countries due to data
gaps.
Source: IDF Atlas, 9th Edition, 2019 and OECD estimates.
StatLink 2 https://stat.link/u4i1ze
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Note: Population with Type 1 or Type 2 diabetes. Data are only available up to 79 years old.
Source: IDF Atlas, 9th Edition, 2019.
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Note: Age-standardised prevalence of population aged 20‑79 with Type 1 or Type 2 diabetes. The EU average is unweighted.
Source: IDF Atlas, 9th Edition, 2019.
StatLink 2 https://stat.link/lqs2vc
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This chapter focuses on modifiable risk factors to health, including smoking, alcohol
consumption, illicit drug use, unhealthy nutrition, lack of physical activity and obesity.
Despite progress in reducing smoking rates over the last decades, about one‑fifth of
adults  still  smoke  every  day  and  tobacco  consumption  remains  the  largest
behavioural risk factor to health, accounting for about 700 000 deaths per year
across EU countries. Alcohol consumption is responsible for another 255 000 to
290 000 deaths per year across EU countries. While alcohol control policies have
achieved  progress  in  reducing  overall  alcohol  consumption,  heavy  alcohol
consumption remains an issue among a sizeable share of adolescents and adults:
more than one in five adolescents aged 15 report having been drunk more than once
in their life and one‑third of adults report regular heavy drinking. The use of illicit
drugs is another important public health issue in Europe: about 15% of young people
aged 15 to 34 report having used cannabis in the last year. Weight problems are
widespread in most EU countries, with nearly one in five adolescents overweight or
obese on average across EU countries in 2018 and more than one in six adults
obese. Overweight and obesity is driven by unhealthy nutrition habits and lack of
physical activity. Only one in seven 15‑year-olds on average across EU countries
report doing at least moderate physical activity at least one hour daily, and less than
half report eating at least one fruit or vegetable per day. Large socio-economic
inequalities exist for most risk factors to health. For example, overweight and obesity
rates among children and adolescents are 50% greater among those living in the
least affluent families than those living in the most affluent.
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4. TOBACCO AND CANNABIS SMOKING AMONG CHILDREN AND ADOLESCENTS
Childhood and adolescence is  a  period of  experimentation,
sometimes linked to engagement in behaviours that are harmful
for health, including tobacco consumption and the use of illicit
drugs. Children and adolescents who smoke tobacco are more
likely  to  become  regular  tobacco  smokers  in  adulthood.
Tobacco  smoking  in  childhood  and  adolescence  has  both
immediate and long-term health consequences, increasing the
risks of respiratory diseases like asthma in the short term and
the risks of cardiovascular diseases, respiratory illnesses and
cancer in the long term.
While in recent years tobacco smoking among adolescents has
continued  to  decline  in  most  EU  countries,  too  many
adolescents still smoke. On average across EU countries, more
than one in six (18%) 15‑year‑olds reported having smoked
cigarettes at least once in the past month in 2018 (Figure 4.1).
This proportion reached a high of more than one in four in
Bulgaria, Lithuania and Italy. Less than one in eight reported to
have smoked cigarettes in the past month in Ireland, Portugal,
Malta,  Sweden  and  Belgium.  Smoking  rates  among
15‑year‑olds  have  decreased  since  2014  in  almost  all
EU countries,  except  in Spain,  Bulgaria and Lithuania.  The
largest reductions occurred in Croatia and France, although
another  survey  shows  a  smaller  reduction  in  these  two
countries between 2007 and 2015 (ESPAD Group, 2016).
The gap in tobacco smoking between 15‑year‑old boys and
girls is fairly small in most countries. On average, a slightly
greater proportion of 15‑year‑old girls reported smoking in 2018
(19% compared with 17% for boys).
Over the last few decades, a mix of policies including increased
taxes  on  tobacco  products,  smoking  bans  in  indoor  public
places, restrictions on youth purchase of tobacco, advertising
restrictions, plain packaging of tobacco products, and greater
investment  in  education  about  the  health  consequences  of
tobacco use have contributed to reducing smoking rates among
children and adolescents.
The EU Tobacco Products Directive (2014/40/EU) banned the
sale of cigarettes with characterising flavours, such as menthol,
starting  in  May  2020.  Legislation  stemming  from  this  EU
Directive may contribute to further reducing tobacco smoking
among adolescents and young adults, since they tend to be the
main target market for these products. Across EU countries,
about one in ten 15‑24 year‑olds who smoked on a regular
basis were opting for menthol cigarettes in 2017, a proportion
much greater than among older population groups (European
Commission, 2017).
This  EU  Directive  also  contains  provisions  concerning  the
production  and  sales  of  e-cigarettes,  including  maximum
nicotine  concentration  and  compulsory  health  warnings
advising consumers that e-cigarettes also contain nicotine. In
2017,  a  quarter  of  15‑24  year‑olds  across  EU  countries
reported  having  tried  e-cigarettes  at  least  once,  although
regular  use  tends  to  be  fairly  low  (European  Commission,
2017).
Smoked cannabis is by far one of the most used drugs among
adolescents.  Frequent  and  heavy  cannabis  use  during
adolescence  is  linked  to  long-term  increased  risk  of
dependence  and  cognitive  functioning  problems,  including
memory losses and attention deficits.
On average in EU countries, 1 in 14 (7%) 15‑year‑olds reported
smoking cannabis at  least  once in the past  month in 2018
(Figure 4.2). This proportion ranged from over 10% in Bulgaria,
Slovenia  and  Italy  to  less  than  5%  in  Finland,  Denmark,
Romania, Portugal and Sweden. Cannabis use has decreased
since 2014 in about half of EU countries, whereas it increased
in  the  other  half.  The  largest  decreases  have  occurred  in
France, Poland and Denmark, with drops of over 4 percentage
points.
A  greater  proportion  of  15‑year‑old  boys  report  smoking
cannabis than girls in all EU countries (9% of boys and 6% of
girls on average in 2018).
EU countries use a mix of  approaches to reduce cannabis
consumption among adolescents, combining legal controls of
drug  dealers  and  users,  education  and  public  awareness
programmes of the health risks of drug use, and treatments for
young people who have developed addictions.
Definition and comparability
The data come from the Health Behaviour in School-aged
Children  (HBSC)  study.  The  HBSC  surveys  have  been
undertaken every four years since 1993‑94 and now include
all EU countries except Cyprus. Data are drawn from school-
based samples of 1 500 children in three age groups (11‑, 13‑
and  15‑year‑olds)  in  most  countries,  ensuring  that  the
sample is representative of each age group. The data relate
to the proportion of adolescents reporting to have smoked a
cigarette or cannabis at least once in the past month.
The data source on cannabis use in this edition of Health at
a  Glance:  Europe  is  different  from the  one  used  in  the
previous edition in 2018, which was based on the European
School Survey Project on Alcohol and Other Drugs (ESPAD).
This explains the difference in results.
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Figure 4.1. Tobacco smoking rates among 15-year-olds, 2014 and 2018
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% of 15-year-olds who reported smoking a cigarette at least once in the last 30 days
Note: The EU average is unweighted. 1. The value for Belgium is the unweighted average of the Flemish and French Communities.
Source: HBSC data from Inchley et al. (2020).
StatLink 2 https://stat.link/r2elhu


































% of 15-year-olds who reported using cannabis on at least one day in the last 30 days
Note: The EU average is unweighted. 1. The value for Belgium is the unweighted average of the Flemish and French Communities.
Source: HBSC data from Inchley et al. (2020).
StatLink 2 https://stat.link/8gb1jq
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4. SMOKING AMONG ADULTS
Tobacco consumption is the largest avoidable behavioural risk
factor to health in the European Union and the most significant
cause of premature death across EU countries, accounting for
about 700 000 deaths per year. Around half of smokers die
prematurely,  dying  14  years  earlier  on  average  (European
Commission, 2020). It is a major risk factor for at least two of the
leading causes of mortality – circulatory diseases and cancer –
and an important risk factor for many severe chronic respiratory
diseases.
Despite some progress in reducing smoking rates over the last
decade, more than one in five adults still smoked daily in 2018
on average across EU countries. The proportion of adults who
smoke daily varies more than three‑fold across countries. It is
lowest in Nordic countries (Sweden, Finland, as well as Iceland
and Norway) and highest in Greece, Bulgaria and Hungary
(Figure 4.3).  Nordic countries,  the Netherlands,  Ireland and
Estonia  have  achieved  the  largest  reductions  in  smoking
among adults over the past decade.
Tobacco consumption remains more common among men than
women in all EU countries, but there is virtually no gender gap in
the United Kingdom, Norway and Iceland (Figure 4.4). About
one in four men and one in six women smoke daily on average
in  EU  countries.  This  gender  gap  is  particularly  large  in
Lithuania, Cyprus and Romania.
The  Eurobarometer  survey  reports  higher  smoking  rates
among  both  men  and  women  because  it  includes  people
smoking  daily  or  occasionally.  The  results  from  the  latest
Eurobarometer survey in 2017 indicate that 30% of men and
22% of women are daily or occasional smokers on average
across EU countries (European Commission, 2017).
The  EU Tobacco  Products  Directive  (2014/40/EU)  requires
health warnings to appear on packages of tobacco and related
products,  bans all  promotional  and misleading elements on
tobacco products, and sets out safety and quality requirements
for electronic cigarettes (European Commission, 2014). Many
European countries (e.g. Belgium, France, Hungary, Ireland,
Slovenia, the United Kingdom and Norway) have also adopted
a plain packaging policy to reduce smoking attractiveness in
recent years.
According to the tobacco control scale from the Association of
European  Cancer  Leagues,  the  United  Kingdom,  France,
Ireland,  Iceland  and  Norway  were  the  top  five  European
countries with the most comprehensive tobacco control policies
in 2019. Slovenia, Greece and Austria achieved the greatest
progress in recent years in adopting tobacco control measures
(Joossens et al.,  2020). Slovenia notably introduced a plain
packaging policy, advertising and display ban at sales points,
permits for sale, and smoking ban in private cars when minors
are present. In Austria, a smoke free legislation in public places
was adopted and started to be implemented in 2019, following a
decade-long debate, bringing the country’s law in line with most
other EU countries. In Greece, a new smoke-free legislation
was also adopted in 2019 to update and expand the previous
legislation from 2010, including greater fines for people and
establishments violating the law.
Increasing taxes on tobacco is one of the most effective ways to
reduce tobacco use and to encourage users to quit smoking
(WHO, 2017). A number of EU countries recently increased
taxes on tobacco products.  For  example,  France increased
taxes on a pack of 20 cigarettes by nearly EUR 1 on average in
2018, contributing to a reduction in cigarettes sales of 9% in that
year. In 2019, taxes on tobacco increased further, resulting in
an  average  retail  price  increase  of  50‑60  cents  for  a
20‑cigarette pack. In early 2020, taxes on cigarettes in Europe
were  highest  in  Ireland,  the  United  Kingdom,  France  and
Finland and lowest in Bulgaria, Poland, the Slovak Republic
and Romania (Tax Foundation, 2020).
Definition and comparability
The  proportion  of  daily  smokers  is  defined  as  the
percentage of people aged 15 years and over who report
tobacco  smoking  every  day.  Other  forms  of  smokeless
tobacco products, such as snuff in Sweden, are not taken into
account. The comparability of data is limited to some extent
due to the lack of standardisation in the measurement of
smoking  habits  in  health  interview  surveys  across
EU Member States.  Variations remain in the age groups
surveyed, wording of questions, response categories and
survey methodologies.
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Figure 4.3. Changes in daily smoking rates among adults, 2008 and 2018 (or nearest year)
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Note: The EU average is unweighted.
Source: OECD Health Statistics 2020 (based on national health interview surveys), complemented with Eurostat (EHIS 2014) for Bulgaria, Croatia, Cyprus, Malta, and
Romania.
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Romania.
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Alcohol use in adolescence continues to be very common in
Europe with two in three adolescents aged 15 years old having
tried alcohol at least once in their life in 2018, although the
proportion of adolescents reporting to have been drunk more
than  once  in  their  life  has  decreased  in  recent  years
(Figure 4.6).
Drinking initiation and heavy drinking in adolescence are of
particular  concern,  since  these  can  have  severe  health,
education and social consequences. Despite the fact that the
legal  drinking age in  most  EU countries  is  18,  on average
two‑thirds of European adolescents report having drunk alcohol
at least once in their life by age 15, and over 20% report having
been drunk more than once in their life (Inchley et al, 2020).
Adolescents who report early exposure to alcohol and having
been  drunk  multiple  times  are  more  likely  to  develop
problematic alcohol use and dependence later in life (Spear,
2015).
More than 30% of 15‑year-olds in Hungary, Austria, Lithuania
and Denmark reported having been drunk more than once in
their life in 2018, compared with 10% or less in Romania and
Luxembourg (Figure 4.5). Boys are more likely than girls to
report repeated drunkenness in most EU countries (24% versus
20%  on  average  across  EU  countries),  with  the  biggest
differences  in  Croatia,  Malta  and  Denmark.  By  contrast,  in
Ireland, Poland, Spain and Sweden, a greater proportion of girls
report having been drunk more than once.
On a positive note,  the proportion of  15‑year‑olds reporting
repeated drunkenness has declined in most EU countries over
the past two decades, decreasing on average from 41% to 24%
among boys, and from 29% to 20% among girls between 1998
and 2018 (Figure 4.6). Focusing on the most recent trends,
between 2014 and 2018, the proportion of adolescents who
reported having been drunk more than once has decreased
significantly  in  most  countries,  although it  has increased in
Austria, Germany and Denmark.
A number of policies have proven to be effective to reduce
alcohol use among adolescents, such as limiting accessibility to
alcohol (e.g. through restrictions on location and hours of sales,
and raising the minimum legal  age for  drinking),  increasing
prices (through taxation or minimum pricing of alcohol units),
regulating advertisement in traditional and social media, and
restricting  industry  sponsorship  of  sport  and  youth  events.
Taxes  on  alcoholic  beverages  exist  in  all  EU  countries.
However, despite the existence of a common EU-wide legal
framework,  tax  levels  vary  widely  across  countries  and  by
beverage type. When it comes to advertising on social media
and the internet, the most common type of regulation across
EU countries relates to restrictions on the content and/or the
placement of advertising, although some countries have gone
further  and  adopted  advertising  bans  on  social  media
(e.g.  Norway).  Regarding industry sponsorship of  sport  and
youth  events,  about  one‑third  of  European countries  report
having voluntary agreements in place, while one‑quarter have
no restrictions (WHO, 2019).
Definition and comparability
The data source is the Health Behaviour in School-aged
Children  (HBSC)  survey.  The  HBSC  survey  has  been
collecting comparable data on alcohol use among 11‑, 13‑
and 15‑year‑old students every four years since 1993‑94 in
nearly  all  EU  countries  with  the  exception  of  Cyprus.
Repeated drunkenness is  defined as having experienced
drunkenness at least twice in life.
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Note: The EU average is unweighted. The value for Belgium is the unweighted average of the Flemish and French Communities.
Source: HBSC data from Inchley et al. (2020).
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Figure 4.6. Trends in repeated drunkenness among the 15-year-olds, EU average, 1993 to 2018
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Alcohol-related  harm  is  a  major  public  health  issue  in  the
European Union. Alcohol use is responsible for some 255 000
to 290 000 deaths each year across EU countries (WHO, 2019;
IHME,  2019).  High  alcohol  consumption  is  associated  with
increased risk  of  heart  diseases and stroke,  liver  cirrhosis,
certain cancers and foetal alcohol disorders, but even moderate
alcohol consumption increases the long-term risk of developing
such  diseases.  Alcohol  also  contributes  to  morbidity  and
mortality through accidents and injuries, violence, homicide and
suicide.
Measured  through  sales  data,  overall  alcohol  consumption
stood at 10 litres of pure alcohol per adult on average across
EU countries in 2018, down from 11 litres in 2008 (Figure 4.7).
Latvia  and  Austria  have  the  highest  level  of  alcohol
consumption,  with  over  12  litres  per  adult,  followed by  the
Czech Republic, France, Bulgaria, Lithuania and Luxembourg,
with over 11 litres per adult. Greece, Sweden, Italy and Malta
have relatively low levels of consumption, below 8 litres of pure
alcohol per adult.
Over the past decade, alcohol consumption has decreased in
most  EU  countries,  with  the  largest  reductions  in  Estonia,
Greece and Lithuania (reductions of about 3 litres per adult). It
has slightly increased in Bulgaria, Latvia and Malta, although it
remains well below the EU average in Malta.
Although overall  alcohol consumption per capita is a useful
measure to assess long-term trends,  it  is  also important  to
consider drinking patterns across population groups to identify
those who drink the most and are most at risk of alcohol-related
disorders. Men consume about four times more alcohol than
women on average across EU countries (WHO, 2019). Beyond
quantity, drinking frequency and intensity are also crucial to
measure the extent of harmful consumption. In 2016, one‑third
(33%)  of  adults  on  average  across  EU  countries  reported
having had six drinks or more on a single occasion during the
last month (Figure 4.8). This proportion was three times higher
among men than women (51% compared with 17%). Men and
women in Lithuania, Luxembourg, Latvia, the Czech Republic
and Estonia were more likely to report episodic heavy drinking,
with the proportion reaching over 40%. Heavy drinking is on the
rise  in  many  countries  among  young  adults  and  women
especially. Men in lower socio-economic groups are also more
likely  to  drink  heavily  than  those  in  higher  socio-economic
groups, while it is the opposite for women (OECD, 2015).
Many  European  countries  have  implemented  a  range  of
policies  to  limit  alcohol  consumption,  including  taxation,
restrictions  on  the  availability  of  alcohol,  bans  on  alcohol
advertising,  and  public  health  campaigns  (OECD,  2015).
Recent  innovative  measures  include  minimum  unit  pricing,
regulation of digital alcohol marketing, and alcohol labelling.
Minimum pricing of  alcohol  units,  introduced in  Scotland in
2018,  has  been  associated  with  a  reduction  in  alcohol
purchases, especially among households that bought the most
alcohol (O’Donnell et al, 2019).
The confinement measures following the COVID‑19 pandemic
in the first half of 2020 had at least a temporary impact on
people’s  lifestyle  and  drinking  habits.  Different  population
groups reported either an increase or a decrease in alcohol use.
In France and Belgium, the closure of bars and restaurants
during the lockdown was associated with an overall reduction in
alcohol consumption, especially among young adults. At the
same  time,  other  population  groups  (such  as  people
aged 35‑50 and parents of young children) reported having
drunk  more  than  usual  during  the  confinement  period
(Sciensano, 2020; Santé Publique France, 2020).
Definition and comparability
Overall alcohol consumption is defined as annual sales of
pure alcohol in litres per person aged 15 years and over. The
methodology to convert alcohol drinks to pure alcohol may
differ  across  countries.  Official  statistics  do  not  include
unrecorded alcohol consumption, such as illegal production.
In some countries (e.g. Luxembourg), national sales do not
accurately  reflect  actual  consumption  by  residents,  since
purchases by non-residents may create a significant  gap
between  national  sales  and  consumption.  Alcohol
consumption  in  Luxembourg  is  thus  estimated  as  the
average alcohol consumption in France and Germany.
The proportion of heavy episodic drinkers is defined as the
share of adults aged 15 years and over who reported having
had at least 60 grammes or more of pure alcohol (6 drinks or
more) on at least one occasion in the past 30 days.
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4. ILLICIT DRUG CONSUMPTION AMONG ADULTS
The use of illicit drugs remains an important public health issue
in  Europe.  Almost  a  third  of  adults  in  the European Union
aged 15‑64, or around 97 million people, have used illicit drugs
at some point in their lives, with the experience of drug use
being more frequently reported by men than women. Cannabis
is the most frequently used drug, but some have also used
cocaine,  ecstasy  (MDMA),  amphetamines,  and  other  drugs
(EMCDDA, 2020). The use of illicit drugs, particularly among
people who use them regularly and heavily, is associated with
higher  risks  of  cardiovascular  diseases,  mental  health
problems, accidents, as well as infectious diseases such as HIV
when the drug is injected. Illicit drug use is a major cause of
preventable  mortality  among young people  in  Europe,  both
directly through overdose and indirectly through drug-related
diseases, accidents, violence and suicide.
Cannabis is the illicit drug most used among young adults in
Europe. Around 15% of people aged 15 to 34 in EU countries
report  having  used  cannabis  in  the  last  year  (Figure  4.9).
Cannabis use is highest in France and Italy, with 20% or more
people aged 15 to 34 reporting to have consumed cannabis in
the last year. It is estimated that around 1% of European adults
are daily or almost daily cannabis users – that is, they have
used the drug on 20 days or more in the last month. Around
58% of these are older drug users, aged 35 to 64, and around
three‑quarters are men. Cannabis use among young adults has
remained stable over the past decade in several countries, but it
has  increased  in  some  Nordic  countries  (Denmark  and
Finland). It has also increased in recent years in France and
Germany.
Cocaine is the most commonly used illicit stimulant in Europe:
around 2.4% of young adults reported having used cocaine in
the last year (Figure 4.10). The percentage of young adults
using cocaine is highest in Denmark, France, the Netherlands
and the United Kingdom with 3% or more having used cocaine
at least once in the last year. After years of reported decreases
in cocaine use, there are now signs of increases in use in many
countries (EMCDDA, 2020).
The use of ecstasy (MDMA) is slightly lower than the use of
cocaine,  with  about  1.9% of  young  adults  in  EU countries
reporting to have used ecstasy in the last year. The use of
ecstasy  is  highest  in  the  Netherlands,  Ireland,  the
United Kingdom, Bulgaria and Germany. In many countries, the
use of ecstasy declined after a peak in early and mid‑2000s.
Recent  surveys,  however,  point  to  an  increase  in  use
(EMCDDA, 2020).
The consumption of opioids (i.e.  heroin and other drugs) is
responsible for the majority of drug overdose deaths (reported
in about 80% of  fatal  overdoses).  The main opioid used in
Europe  is  still  heroin,  but  there  are  concerns  in  several
countries about the increasing use of other synthetic opioids
(such as buprenorphine, methadone, fentanyl and tramadol).
The  prevalence  of  high-risk  opioid  use  among  adults
(15‑64 years old) is estimated at 0.4% of the EU population, the
equivalent of 1.3 million high-risk opioid users in 2018. Several
countries have implemented different interventions to reduce
opioid-related deaths, such as overdose reversal medications,
needle  and  syringe  programmes  and  medically  supervised
consumption centres. Research initiatives to boost innovation
in pain relief and opioid use disorders treatments have also
been launched (OECD, 2019).
Definition and comparability
Data  on  drug  use  prevalence  come  from  national
population surveys, as gathered by the European Monitoring
Centre for Drugs and Drug Addiction (EMCDDA). The data
presented in this section focus on the percentage of young
adults  aged  15  to  34  years  old  reporting  to  have  used
different types of illicit drugs in the last year. Such estimates
of  recent  drug  use  produce  lower  figures  than  “lifetime
experience”,  but  reflect  better  the  current  situation.  The
information is based on the last survey available for each
country. The study year ranges from 2014 to 2018. To obtain
estimates of the overall number of users in Europe, the EU
average is applied to countries without prevalence data.
Data  from  web  surveys  can  provide  complementary
information to general population surveys and further insight
into the use of drugs in Europe. While not representative of
the general population, these surveys are able to reach large
samples  of  people  who  use  drugs.  The  European  Web
Survey on Drugs collected information about patterns of use
and purchases of the most commonly used illicit drugs from
40 000 people who use drugs, recruited primarily through
social media.
For  more  information,  please  see:  http://
www.emcdda.europa.eu/data/.
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4. NUTRITION AMONG CHILDREN AND ADOLESCENTS
Nutrition is fundamental for child and adolescent development
and long-term health. Taking good nutrition habits at a young
age, including eating fruit and vegetables regularly, can protect
against  many serious health problems such as obesity and
diabetes.
On average across  EU countries,  more than half  (56%) of
15‑year‑olds reported not eating any fruit or vegetable each day
in  2018  (Figure  4.11).  In  Belgium,  Denmark,  Ireland,  the
Netherlands and Bulgaria, a larger share of the 15‑year‑olds
reported eating fruit or vegetable each day, although this does
not  necessarily  mean  that  they  consume  a  greater  overall
quantity of fruit and vegetables each day. According to another
comprehensive  food  consumption  survey,  adolescents  in
Belgium and the Netherlands were usually consuming a lower
quantity of fruit and vegetables per day (measured in grammes)
than the EU average (Sciensano, 2019). In all EU countries
except Malta, boys are more likely than girls to report eating no
fruit or vegetable each day.
A number of policies can promote greater fruit and vegetable
consumption among young people, including health education
and promotion in schools, increasing the fruit and vegetables
content  in  food  served in  schools,  mass  media  campaigns
targeting both young people and parents, and regulations on
advertising of unhealthy food targeting children (OECD, 2019).
Most  EU  countries  have  launched  national  campaigns  to
promote greater consumption of fruit and vegetables, notably
through  “five  a  day”  campaigns  (e.g.  in  Germany,  Spain,
France).  However,  only  one in  nine  (11%) 15‑19 year‑olds
reported eating five portions or more of fruit and vegetables in
2014 on average across EU countries.
At the European level, the School Fruit Scheme adopted in
2008 promotes fruit and vegetable consumption among school-
aged children. This programme was later combined with the
school scheme on milk and other dairy products. In 2017/2018,
over 20 million children in 159 000 schools across EU countries
benefited  from  this  joint  scheme  (European  Commission,
2019). Some programme evaluation indicates that the scheme
led to a short-term increase in the frequency and volume of fruit
and  vegetable  consumption  among  school  children
(Methner et al., 2016). More recently, the 2020 EU Farm to Fork
strategy has set ambitious goals to improve food quality and
promote more informed consumer choices about food products,
including among children and adolescents.
Across EU countries,  the share of  15‑year‑olds who report
eating at least one fruit every day increased slightly from 35% to
37% between 2014 and 2018,  and the proportion of  those
reporting to eat at least one vegetable also increased slightly
from 32% to 34%.
Promoting better nutrition at a young age also entails reducing
the consumption of products high in sugars, fat and salt. On
average  across  EU  countries,  about  one  in  six  (16%)
15‑year‑olds  drank  sugared  soft  drinks  each  day  in  2018
(Figure 4.12). This proportion was highest in Belgium, France,
Luxembourg, Malta and Bulgaria, where more than one in four
15‑year‑olds reported to consume soft drinks every day. Across
all countries, boys were more likely to report drinking sugared
soft drinks each day than girls (19% compared with 13% on
average in EU countries).
The share of 15‑year‑olds consuming sugared soft drinks every
day  has  decreased  since  2014  in  most  EU  countries  (by
5 percentage points on average), but it has increased at least
slightly in Finland, Lithuania, Slovenia, Latvia and Denmark.
A number of policy actions have been taken in many countries
to reduce the consumption of sugared soft drinks, such as the
reformulation  of  products  to  reduce  sugar  levels,  smaller
portion  sizes,  front-of-pack  labels  promoting  low-sugared
drinks,  taxes  based  on  the  sugar  level  in  products,  and
marketing/advertising restrictions on products highly sugared
(OECD, 2019).
Definition and comparability
Dietary  habits  are  measured  in  terms  of  the  share  of
15‑year‑olds who report not eating any fruit or vegetables
every day and drinking a sugared soft drink each day. Since
the survey questions on fruit and vegetable consumption do
not explicitly ask respondents to exclude juices, soups or
potatoes, these may be included in responses.
Data  come from the  Health  Behaviour  in  School-aged
Children  (HBSC)  study.  The  HBSC  surveys  have  been
undertaken every four years since 1993‑94 and now include
all EU countries except Cyprus. Data are drawn from school-
based samples of 1 500 children in three age groups (11‑, 13‑
and  15‑year‑olds)  in  most  countries,  ensuring  that  the
sample is representative of each age group.
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% of 15-year-olds who report drinking sugared soft drinks at least once every day
Note: The EU average is unweighted. 1. The value for Belgium is the unweighted average of the Flemish and French Communities.
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4. PHYSICAL ACTIVITY AMONG CHILDREN AND ADOLESCENTS
Physical  activity  is  beneficial  for  child  and  adolescent
development and can set good habits for adulthood, thereby
influencing health outcomes later in life. WHO recommends
that children do at least 60 minutes of moderate-to-vigorous
physical activity daily, yet these recommendations are not met
by most children and adolescents in all countries.
On  average  across  EU countries,  only  around  one  in  four
11‑year‑olds and only about one in seven 15‑year‑olds reported
that  they  undertook  moderate-to-vigorous  exercise  at  least
one hour daily in 2018 (Figure 4.13). In all countries, girls are
less physically active than boys at both ages. Physical activity
also falls sharply between ages 11 to 15 in most EU countries
for  both  genders.  The  proportion  of  girls  and  boys  doing
sufficient physical activity each day is lowest in Italy, France,
Portugal  and  Denmark.  In  Italy,  France  and  Denmark,  the
shares were already low in 2014, while they decreased from
16%  in  2014  to  11%  in  2018  among  the  11‑,  13‑  and
15‑year‑olds in Portugal.
On average across EU countries, the proportion of children and
adolescents doing moderate-to-vigorous physical activity each
day has decreased slightly between 2006 and 2018 for both
boys and girls, and in all age groups (Figure 4.14). For boys
aged 11 years old and 13 years old, the rate decreased by
4 percentage points, narrowing the gap with the physical activity
level of girls at the same age.
Some of the factors influencing the levels of physical activity
undertaken by children include the availability of safe space and
equipment,  their  school  curricula  and  other  competing
pastimes, in particular screen activities. Heavy use of mobile
devices  and internet  takes  time away from other  activities,
including physical activity (OECD, 2019).
Physical  activity  can  be  encouraged  by  the  promotion  of
physical education, such as active play or recreation as well as
safe independent mobility (WHO, 2018). EU countries have
taken a number of initiatives to change behaviours in children
and adolescents, and more generally, in the whole population.
For example, in Slovenia, the National Nutrition and Physical
Activity  Strategy  2015‑25  aims  to  improve  physical  activity
habits across all age groups to tackle growing obesity, including
through  school-based  programmes  such  as  the  “SLOfit
surveillance system” (OECD/European Observatory on Health
Systems and Policies, 2019). In Finland, The National Obesity
Programme  2012‑18  aimed  at  reducing  obesity  rates  by
encouraging  healthy  nutrition  and  physical  activity.  This
programme  included  objectives  for  the  whole  population,
specific  age  groups  (such  as  school-age  children),
municipalities and schools. It also offered check-lists to support
implementation  for  schools,  health  professionals  and
municipalities. In addition, other initiatives intend to address the
gender  gap  in  physical  activity,  such  as  “This  Girl  Can”
campaign in the United Kingdom (Owen et al. 2017; Guthold
et al., 2020).
Definition and comparability
Moderate-to-vigorous physical activity refers to exercise
undertaken for at least an hour each day that increases the
heartbeat, and sometimes leaves the child out of breath.
Data  come from the  Health  Behaviour  in  School-aged
Children  (HBSC)  study.  The  HBSC  surveys  have  been
undertaken every four years since 1993‑94 and now include
all EU countries except Cyprus. Data are drawn from school-
based samples of 1 500 children in three age groups (11‑, 13‑
and  15‑year‑olds)  in  most  countries,  ensuring  that  the
sample is representative of each age group.
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4. OVERWEIGHT AND OBESITY AMONG CHILDREN AND ADOLESCENTS
Overweight and obesity among children and adolescents is a
major public health issue. Children and adolescents who are
overweight or obese are at a greater risk of poor health, and this
effect  persists  into  adulthood.  Moreover,  obesity  among
children  and  adolescents  is  often  related  to  psychosocial
problems  such  as  poor  self-esteem,  bullying  and
underachievement at school, which can further worsen health
and economic outcomes in adulthood (OECD, 2019).
In  2018,  almost  one  in  five  (19%)  15‑year‑olds  was  either
overweight or obese on average across EU countries, up from
one in six (16%) in 2010 (Figure 4.15). There is a three‑fold
variation in overweight and obesity rates among adolescents
across EU countries, ranging from 12% in the Netherlands to
36% in Malta.
In all EU countries except Portugal, overweight and obesity is
more  prevalent  in  boys  than  girls.  On  average  across
EU countries, the prevalence in 2018 was 23% in 15‑year‑old
boys compared to 15% in girls. This gender difference is driven
by  a  combination  of  biological,  social  and  environmental
factors. In Poland, Italy and Greece, overweight and obesity
among boys are more than twice as prevalent as among girls.
In all countries except Albania, children and adolescents from
more affluent families are less likely to be overweight or obese
than those from less affluent families (Figure 4.16). On average
across EU countries,  overweight  and obesity  among young
people  from less  affluent  families  is  over  50% higher  than
among those from more affluent families.
Many countries have implemented policies to reduce obesity
specifically  targeting  children.  These  include  restrictions  on
advertising  of  food  and  drinks  to  children,  school-based
wellness and educational programmes, reducing the availability
of unhealthy food options in schools, encouraging or enabling
active  transport  to  school,  and  family  physical  activity
programmes (OECD, 2019). Other policies, such as warning
labels, marketing restrictions of unhealthy foods to children,
pricing policies  and mass media  campaigns,  can also help
tackle childhood obesity.
The EU Action Plan on Childhood Obesity 2014‑20 aims to halt
the rise in obesity in children and young people in the EU by
2020.  It  identifies  several  key  areas  for  action,  such  as
supporting a healthy start in life, making healthier choices the
easy option (e.g. food reformulation),  reducing marketing to
children, encouraging physical activity, and promoting healthier
environments  in  schools  (European Commission,  2014 and
2019). A mid-term evaluation from 2018 found that although
many  European  countries  were  active  in  creating  healthier
school environments and improving the quality of food products
through reformulation, making the healthier option the ‘easy
option’  for  children  and  restricting  marketing/advertising  of
unhealthy foods still required further actions (Boer, 2018).
The EU Joint Action on Nutrition and Physical Activity (JANPA),
which ran from 2015 to 2017, produced a web-based toolbox to
help  decision-makers  and  programme planners  design  and
implement effective interventions on childhood obesity. Starting
in  2018,  the Science and Technology in  childhood Obesity
Policy (STOP) project, funded by Horizon 2020, brings together
academic  and  other  stakeholders  from  across  Europe  to
generate evidence on the factors that contribute to childhood
obesity, and the effectiveness of different actions to address
this  problem.  In  2020,  a  new  Joint  Action  was  launched
focusing on the promotion of food reformulation, the reduction
of aggressive marketing to children of foods high in fat, salt and
sugar, and the improvement of public procurement of food.
Definition and comparability
Childhood and adolescent data on overweight and obesity
come from the Health Behaviour in School-aged Children
(HBSC) study. This survey asked young people aged 11‑,
13‑ and 15 years old to report their height and weight. Body
mass index (BMI) was calculated from this information and
cut-offs for overweight and obesity allocated based on the
WHO growth reference for age.
The indicator of socio-economic status is based on the
Family  Affluence  Scale,  which  asks  young  people  about
material assets in the household.
References
Boer, J. (2018), Supporting the mid-term Evaluation EU Action Plan on
Childhood Obesity: Results of the Childhood Obesity Study, https://
ec.europa.eu/health/sites/health/files/nutrition_physical_activity/
docs/ev_20180601_co03_en.pdf.
European Commission (2014), EU Action Plan on Childhood Obesity
2014‑20,  Brussels,  https://ec.europa.eu/health/sites/health/files/
nutrition_physical_activity/docs/
childhoodobesity_actionplan_2014_2020_en.pdf.
European Commission  (2019),  Initiatives  on Nutrition  and Physical
Activity,  https://ec.europa.eu/health/sites/health/files/nutrition_
physical_activity/docs/2019_initiatives_npa_en.pdf.
Inchley, J. et al. (2020), Spotlight on adolescent health and well-being:
Findings from the 2017/2018 Health  Behaviour  in  School-aged
Children  (HBSC)  survey  in  Europe  and  Canada,  International
report,  Vol.  2,  Key  data,  WHO  Regional  Office  for  Europe,
Copenhagen.
OECD  (2019),  The  Heavy  Burden  of  Obesity:  The  Economics  of
Prevention, OECD Health Policy Studies, OECD Publishing, Paris,
https://doi.org/10.1787/67450d67-en.
152 HEALTH AT A GLANCE: EUROPE 2020 © OECD/European Union 2020
4. OVERWEIGHT AND OBESITY AMONG CHILDREN AND ADOLESCENTS





















Note: The EU average is unweighted. 1. The value for Belgium is the unweighted average of the Flemish and French Communities.
Source: HBSC data from Inchley et al. (2020).
StatLink 2 https://stat.link/5m3ak7












Least affluent families Most affluent families
Note: The least and most affluent are defined as those living in the lowest and highest quintiles (20%) in each country. 1.The value for Belgium is the unweighted average
of the Flemish and French Communities.
Source: HBSC data from Inchley et al. (2020).
StatLink 2 https://stat.link/80koap
HEALTH AT A GLANCE: EUROPE 2020 © OECD/European Union 2020 153
4. OBESITY AMONG ADULTS
Obesity is a known risk factor for numerous non-communicable
diseases,  including  hypertension,  diabetes,  cardiovascular
diseases, and some forms of cancer. On average in the EU,
overweight  and  obesity  reduce  life  expectancy  by  nearly
three years (OECD, 2019). Evidence from some countries also
suggests that obesity increases the risk of developing severe
COVID‑19  symptoms  and  requiring  intensive  care  (Caussy
et al., 2020).
On average across EU countries, more than one in six adults
(17%) were obese in  2018,  according to  self-reported data
(Figure  4.17).  Obesity  rates  among  adults  vary  more  than
two‑fold across EU countries, from 10% in Romania to 26% in
Malta. While in most countries obesity is more prevalent in men,
in  the  Netherlands,  Lithuania,  Latvia,  Turkey  and  Iceland
considerably more women than men are obese.
Obesity rates based on the actual measurement of height and
weight are higher than those based on self-reported data, as
many people either overestimate their height or underestimate
their  weight.  However,  these  more  reliable  data  are  only
available in a limited number of countries. When looking at
measured  data  for  nine  EU countries,  the  average  obesity
prevalence is 24% (Figure 4.18). The highest rate is in Hungary
(30%) and the lowest in France (17%).
Over  the  last  two  decades,  the  prevalence  of  obesity  has
increased in the EU. Among the 18 EU countries with self-
reported data available since around 2000, the average obesity
rate increased from 11% in 2000 to 17% in 2018 (Figure 4.19).
Finland  and  Latvia  saw  particularly  large  increases.  The
COVID‑19 pandemic may contribute to further increases.  A
Belgian  survey  conducted  in  April  2020 found that  25% of
respondents gained weight during the confinement (Sciensano,
2020), although this may only be a temporary effect.
The  rising  prevalence  of  obesity  is  driven  by  a  number  of
behavioural and environmental factors, including urbanisation,
increased sedentary behaviour, and the widespread availability
and marketing of energy-dense foods. Socially disadvantaged
groups  are  particularly  at  risk  of  becoming  obese,  either
because of  less  healthy  nutrition  habits  or  lack  of  physical
activity. For example, the prevalence of low fruit and vegetable
consumption is 59% higher among low-educated women in
England  compared  to  high-educated  women.  In  Spain,  the
prevalence of low physical activity is approximately 50% higher
in low-educated people (Graf and Cecchini, 2017).
A growing number of countries have taken actions to tackle the
rise  in  obesity  rates.  A  wide  range  of  policy  options  exist,
including  food  and  menu  labelling,  public  awareness
campaigns,  mobile  apps,  restrictions  on  food  advertising
targeting  children,  school  and  workplace  programmes,  and
price policies. In general, policies to provide information and to
increase the number of  healthy options are common, while
measures to modify the cost of health-related choices and to
regulate promotion of unhealthy choices are less widely used
(OECD, 2019).  Among initiatives to enable people to make
healthy  choices,  the  Nutri-Score  front-of-pack  logo  which
informs about the nutritional quality of the food product in a
simplified design, developed by the French institute of public
health,  is  been increasingly  used by  the  food industry  and
retailers in France and under development in other European
countries (Santé Publique France, 2020).
At the EU level, a number of initiatives have been implemented
to improve diets and increase physical activity. To reduce the
amount of sugar in food, in 2015, the EU brokered agreements
with business operators – food manufacturers, supermarkets
and caterers – to reduce the amount of added sugars in their
products by a minimum of 10% by 2020.
Definition and comparability
Obesity is defined as excessive weight presenting health
risks because of the high proportion of body fat. The measure
is based on the body mass index (BMI), which is a single
number that evaluates an individual’s weight in relation to
height (weight/height², with weight in kilograms and height
in metres). Based on the WHO classification, adults with a
BMI greater than or equal to 30 are defined as obese.
Obesity  rates  can  be  assessed  through  self-reported
estimates of height and weight from population-based health
interview  surveys,  or  measured  estimates  from  health
examinations.  Estimates  from  health  examinations  are
generally  higher  and  more  reliable  than  from  health
interviews.
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PART II
Chapter 5
Health expenditure and financing
This chapter looks at recent trends in health spending, both at an overall level but also
disaggregated by type of health service and by health care provider. A particular focus is
on analysing spending on primary health care and pharmaceuticals. The chapter also
analyses how health care is financed in Europe, both in terms of the type of financing
arrangements in place and the revenues that ultimately fund health spending.
In 2019, health spending across EU countries stood on average at 8.3% of GDP,
ranging from over 11% in Germany and France to less than 6% in Luxembourg and
Romania. This share remained largely unchanged from previous years as health
spending grew in line with the economy but it can be expected that the COVID‑19
pandemic will lead to an increase of the health spending share of GDP in many
countries in 2020. On a per capita basis, there is a three‑fold difference between the
EU countries  in  Western  and Northern  Europe that  spend the  most  on  health
(Germany, Austria, Sweden and the Netherlands) and those in Central and Eastern
Europe that spend the least (Romania, Bulgaria, Latvia and Croatia).
In most countries, payments for curative and rehabilitative care services make up the bulk
of health spending, while spending on pharmaceuticals also account for a large share of
health  expenditure  particularly  in  some  Central  and  Eastern  European  countries.
Regarding  the  financing  of  health  care,  compulsory  schemes,  either  government
financed or through compulsory public or private health insurance, account for nearly
three‑quarters of overall health spending on average across EU countries. However, out-
of-pocket expenditure also plays an important role in health financing in several Southern
as well as Central and Eastern European countries.
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5. HEALTH EXPENDITURE PER CAPITA
The level of health spending in a country and how this changes
over time is dependent on a wide range of demographic, social
and economic factors, as well as the financing arrangements
and organisational structure of the health system itself.
Given these factors, there are large variations in the level and
growth of health spending across Europe. There is a strong
correlation between income and spending on health, such that
high-income European countries are typically those that spent
the most on health. With spending at EUR 5 241 per person –
adjusted  for  differences  in  countries’  purchasing  powers  –
Switzerland was the biggest spender in Europe followed by
Norway (EUR 4 505). Among EU member states, spending
levels in Germany, Austria, Sweden and the Netherlands were
all at least 50% above the EU average (EUR 2 572). At the other
end of the scale, Romania, Latvia, Bulgaria and Croatia were
the lowest spending countries in the EU, only at around half the
EU average (Figure 5.1). This means that on a per capita basis
(and after adjusting for differences in price levels), there is a
three‑fold difference in health spending between high-income
countries  in  Western  and  Northern  Europe  and  some  low
spending countries in Central and Eastern Europe.
After  a  period  of  slow  or  even  negative  growth  in  health
spending across Europe in the wake of the economic crisis in
2008, growth rates picked up again in nearly all countries. On
average  across  EU  countries,  health  spending  per  capita
increased by around 3.0% each year in real terms (adjusted for
inflation) between 2013 and 2019, compared with an annual
growth  rate  of  only  0.7%  between  2008  and  2013.  All
EU countries saw positive growth in health spending between
2013 and 2019, although it remained slow in some countries
(Figure 5.2).
Some  Central  and  Eastern  European  member  states  with
relatively low spending levels like Bulgaria, Romania, Latvia,
Lithuania and Estonia, had some of the highest growth rates in
health spending since 2013, with annual increases of around
6% or more. In Belgium, Finland, France and the Netherlands,
annual  per  capita  health  spending  growth  over  the  same
six‑year period remained positive but at around 1% or below
and the growth rates were lower than those seen during the
years  following  the  2008  financial  crisis.  Both  Norway  and
Switzerland  maintained  a  relatively  stable  rate  of  health
spending growth over the last ten years or so at around 2‑2.5%
per annum.
Health spending in 2020 across Europe will  be significantly
affected by the COVID‑19 pandemic. The development of the
crisis has seen the need for the rapid deployment of resources
across the health sector – building up testing and diagnostic
capabilities, and providing increased capacity for treatment of
patients  in  the  hospital  sector.  In  some  countries,  health
providers  received  substantial  subsidies  in  exchange  for
reserving treatment capacity for COVID‑19 patients. On the
other  hand,  many countries  have seen sharp reductions in
many non-COVID related services, such as primary health care
consultations and elective surgeries, potentially reducing health
care costs for these services. Which of these two opposing
trends will dominate in a country is unclear at the time of writing
and will depend on many different factors. Chapter 1 provides
further  information  on  the  budgetary  measures  that
governments  have  taken  to  strengthen  the  health  system
responses to the coronavirus crisis.
Definition and comparability
Expenditure on health, as defined in the System of Health
Accounts (OECD, Eurostat and WHO, 2017), measures the
final consumption of health goods and services. This refers to
current  spending  on  medical  services  and  goods,  public
health  and  prevention  programmes,  and  overall
administration  of  health  care  provision  and  financing
irrespective of the type of financing arrangement. Subsidies
paid to health care providers should also be included in the
figures.
Under Commission Regulation 2015/359, all EU countries
are obliged to produce health expenditure data according to
the definitions of the System of Health Accounts. Data on
health  expenditure  for  2019  are  considered  preliminary,
either estimated by national authorities or projected by the
OECD Secretariat, and are therefore subject to revision.
Countries’  health  expenditures  are  converted  into  a
common currency (Euro) and are adjusted to take account of
the different purchasing power of the national currencies, in
order  to  compare  spending  levels.  Economy-wide  Actual
Individual Consumption (AIC) PPPs are used to compare
relative expenditure on health in relation to the rest of the
economy.
For the calculation of growth rates in real terms, economy-
wide  AIC  deflators  are  used.  Although  some  countries
(e.g. France and Norway) produce their own health-specific
deflators, based on national methodologies, these are not
currently  used  due  to  the  limited  availability  and
comparability for all countries.
For countries where breaks in the time series exist, growth
rates are estimated by the OECD Secretariat.
References
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5. HEALTH EXPENDITURE PER CAPITA
Figure 5.1. Health expenditure per capita, 2019 (or nearest year)
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Note: The EU average is unweighted.
Sources: OECD Health Statistics 2020; Eurostat Database; WHO Global Health Expenditure Database.
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Note: The EU average is unweighted. Growth rates and time periods may have been adjusted by the OECD Secretariat to take account of breaks in series.
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5. HEALTH EXPENDITURE IN RELATION TO GDP
How much a country spends on health care in relation to all
other  goods  and  services  in  the  economy,  and  how  that
changes over time, depends not only on the level of health
spending but also on the size of the economy as a whole.
In 2019, it is estimated that EU countries devoted on average
8.3% of their GDP to health care (Figure 5.3). This figure has
stayed  largely  unchanged  since  2014  as  growth  in  health
spending  remained  broadly  in  line  with  overall  economic
growth. In 2019, a quarter of all EU member states spent at
least 10% of their GDP on health, with Germany (11.7%) and
France (11.2%) having the highest shares. The lowest shares
of GDP allocated to health care were in Luxembourg (5.4%),
Romania (5.7%), Poland (6.2%) and Latvia (6.3%). Across the
whole  of  Europe,  Switzerland  allocated  the  largest  share
(12.1%) of its GDP to health.
When analysing countries’ health expenditure dynamics, it is
important to consider the health spending to GDP ratio of a
country in tandem with levels of health spending per capita.
Higher  income countries  generally  tend  to  devote  a  higher
proportion of their resources to health care but some countries
with  high  levels  of  health  expenditure  per  capita  can have
relatively low health spending to GDP ratios, and vice versa.
For example,  while the Czech Republic and Bulgaria spent
roughly the same share of their GDP on health in 2019, per
capita health spending (adjusted to EUR PPP) was 72% higher
in the Czech Republic because of its higher GDP. Luxembourg
provides a striking example of a country that has a high level of
per capita health spending, but because of the peculiarities of
its economy and working population, has the lowest share of
health spending relative to GDP. Since a large proportion of its
wealth  is  produced  by  non-residents  and  not  available  for
domestic final consumption, relating health spending to Gross
National Income may be more meaningful than looking at the
health spending to GDP indicator for that country.
Over time, trends in health spending often react to changes in
the broader economy, although there is typically a lag before
changes in economic conditions are reflected in adjustments to
health  spending.  When  overall  economic  conditions  rapidly
deteriorated in many European countries because of the 2008
financial crisis, overall health spending was initially maintained
or even continued to grow (Figure 5.4). As a result, the average
health  spending  to  GDP ratio  across  EU countries  jumped
sharply to reach 8.5% in 2009 – up from 7.8% in 2008. As
countries introduced a range of measures in attempts to rein in
government health spending and reduce burgeoning budgetary
deficits  (Morgan  and  Astolfi,  2014),  subsequent  health
expenditure  growth per  capita  was more closely  aligned to
economic growth in many European countries. Consequently,
the ratio of health spending to GDP has been relatively stable
since 2014.
As a result of this step increase in the health spending to GDP
ratio ten years ago and the closer alignment with economic
growth in recent years, overall growth in health expenditure per
capita (in real terms) in the European Union between 2005 and
2019 has been greater than that of GDP per capita.
Looking at the trends in some individual EU countries, both
France and Germany saw their health spending to GDP ratio
jump sharply in 2009 but the trajectory of the indicator has
diverged in recent years (Figure 5.5). While Germany continued
to show a steady increase in the share of GDP allocated to
health between 2015 and 2019, France has seen its ratio drop
as health spending growth has remained low, both in overall
terms and compared with overall economic growth. Italy and
Spain also experienced a similar jump in 2009, although since
then growth in health spending was more closely aligned with
economic growth, resulting in the health to GDP ratio remaining
stable over the last ten years.
The COVID-19 pandemic has important consequences for both
GDP and health spending growth in 2020. While there remains
much uncertainty at the time of writing, it is clear that GDP will
substantially contract in all EU member states, even under the
most  optimistic  scenarios.  For  health  spending,  further
increases can be expected – at least in some countries. As a
result, another hike in the health spending to GDP ratio is likely
in 2020.
Definition and comparability
See  indicator  “Health  expenditure  per  capita”  for  a
definition of current expenditure on health.
Gross  domestic  product  (GDP)  is  the  sum  of  final
consumption, gross capital formation and net exports. Final
consumption includes all the goods and services used by
households  or  the  community  to  satisfy  their  needs.  It
includes  final  consumption  expenditure  of  households,
general  government  and  non-profit  institutions  serving
households.
Data  on  health  expenditure  for  2019  are  considered
preliminary,  either  estimated  by  national  authorities  or
projected by the OECD Secretariat, and are therefore subject
to revision.
The GDP figures used to calculate the indicator health
expenditure to GDP are based on official GDP data available
as of mid-June 2020. Any subsequent revisions to GDP data
are not reflected in the indicator.
In countries such as Ireland and Luxembourg, where a
significant proportion of GDP refers to profits exported and
not  available  for  national  consumption,  gross  national
income (GNI) may be a more meaningful measure than GDP,
but for international comparability, GDP is used throughout.
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Figure 5.3. Health expenditure as a share of GDP, 2019 (or nearest year)
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Note: The EU average is unweighted.
Source: OECD Health Statistics 2020; Eurostat Database; WHO Global Health Expenditure Database.
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5. FINANCING OF HEALTH EXPENDITURE
Health  care  is  purchased  through  a  variety  of  financing
arrangements.  In countries where individuals are entitled to
health care services based, for example, on their residency,
government  schemes are  the  predominant  arrangement.  In
others, some form of compulsory health insurance (either social
health insurance or one organised through private insurers)
usually covers the bulk of health expenditure. In addition, out-
of-pocket payments by households as well as various forms of
voluntary health insurance intended to replace, complement or
supplement automatic or compulsory coverage make up the
rest of health spending.
In 2018, around 73% of health spending was financed through
governments and compulsory  insurance on average across
EU countries (Figure 5.6). In Sweden and Denmark, central,
regional or local governments covered around 85% of all health
spending.  In  Luxembourg,  Croatia,  Germany,  France,
Slovak  Republic  and  the  Netherlands,  compulsory  health
insurance  financed  more  than  three‑quarters  of  all  health
expenditure. Cyprus was the only EU country where less than
half of all health spending was financed through government or
compulsory  insurance  schemes.  The  introduction  of  the
National Health Insurance System starting in 2019 is expected
to increase this share substantially.
In five EU countries – Cyprus, Latvia, Bulgaria, Greece and
Malta  –  households’  out-of-pocket  payments  accounted  for
more than one‑third of health spending in 2018 (compared with
an EU average of 22%), while only in Slovenia, Ireland and
Cyprus did voluntary health insurance finance more than 10%
of health spending (EU average: 5%).
To  purchase  health  care  goods  and  services,  financing
schemes rely on different types of revenues. In 2018, public
sources  (which  includes  government  transfers  and  social
insurance contributions) funded 73% of all health spending on
average across EU countries (Figure 5.7). While this share is
identical to the one seen in Figure 5.6, there are differences for
some  countries.  For  example,  compulsory  private  health
insurance is generally financed from private revenues, which
explains why the share of publicly sourced health spending in
Germany, France and Switzerland is substantially lower than
their  respective  share  of  health  spending  financed  from
government and compulsory schemes.
Generally,  the types of  revenues are closely  related to  the
system of health care financing. In Sweden and Denmark, for
example,  where  health  care  is  predominantly  purchased
through  local  government  schemes,  this  is  almost  entirely
funded via government transfers. Other types of financing may
rely on a mix of different revenue sources. For example, in
countries  where  social  health  insurance  schemes  exist,
insurance  contributions  will  typically  be  a  major  revenue
source,  but  this  may  be  complemented  with  governmental
transfers to cover non-working population groups. Analysing
the structure of financing schemes together with the types of
revenues  that  these  schemes  receive  shows  that  the
government’s role in funding health care is typically more than
being just a simple purchaser of health services.
Public  budgets  (including  social  security  schemes)  finance
many different services. Hence, health is competing for public
funds with many other sectors such as education, defence and
housing. In 2018, around 14% of total government expenditure
was  allocated  to  health  on  average  across  EU  countries
(Figure  5.8).  In  Ireland  and  Germany,  the  share  of  public
spending dedicated to health care was around 20%, while in
Hungary, Greece, Latvia and Cyprus it was below 10%. Since
2013, with the exception of Finland, the Slovak Republic and
Cyprus, these shares increased (slightly) in all EU countries,
most notably in Ireland (by 2.1 percentage points) and Greece
(by 1.4 percentage points) reflecting that a greater share of
government  spending  is  allocated  to  health.  In  Greece,
however, the share in 2018 is still below the level of 2010.
Definition and comparability
The financing of health care can be analysed from the point
of  view  of  financing  schemes  (financing  arrangements
through which health services are paid for and obtained by
people, e.g. social health insurance) and types of revenues
of financing schemes (e.g. social insurance contributions)
(OECD, Eurostat and WHO, 2017).
Financing  schemes  include  government  schemes,
compulsory  health  insurance  as  well  as  voluntary  health
insurance and private  funds  such as  households’  out-of-
pocket payments, NGOs and private corporations. Out-of-
pocket payments are expenditures borne directly by patients,
which can take the form of cost-sharing of services included
in  the  publicly  defined  benefit  package  and  also  direct
purchases of goods and services.
These financing schemes have to raise revenues in order
to pay for health care goods and services for the population
they are covering. Public revenue sources refer to transfers
from the  government  and  social  insurance  contributions,
whereas  private  revenue  sources  comprise  insurance
premiums (for private voluntary or compulsory insurance) as
well as other any other fund from households or corporations.
Total government expenditure is used as defined in the
System  of  National  Accounts  and  includes  as  major
components:  intermediate  consumption,  compensation  of
employees, interest, social benefits, social transfers in kind,
subsidies, other current expenditure and capital expenditure
payable by central, regional and local governments as well
as social security funds.
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5. HEALTH EXPENDITURE BY TYPE OF GOOD AND SERVICE
A variety of factors, from disease burden and system priorities
to  organisational  aspects  and  costs,  help  determine  the
allocation of resources across the various types of health care
goods and services.  In  2018,  EU member  states  spent  on
average around 60% of their health budgets on curative and
rehabilitative  care,  just  over  20%  on  retail  medical  goods
(mainly pharmaceuticals), and 12% on health-related long-term
care. The remaining 5% was spent on collective services, such
as  prevention  and  public  health  (3%)  as  well  as  the
administration of health care systems (Figure 5.9).
In  2018,  the  share  of  current  health  expenditure  going  to
curative and rehabilitative care ranged from just over half of all
health spending in Germany and the Netherlands to nearly
three‑quarters in Cyprus and Portugal. Breaking it down further,
Romania had the highest proportion of spending on inpatient
care (including day care in hospitals), accounting for 45% of
health  spending.  For  most  EU countries  (17),  spending  on
outpatient  care  (including  home-based  curative  and
rehabilitative  care and ancillary  services)  exceeded that  on
inpatient care, notably in Portugal, where outpatient care (in
both  ambulatory  settings  and  hospitals)  accounted  for  just
under half of all health spending (47%).
The other major category of health spending is retail medical
goods (which mainly refers to pharmaceuticals) consumed in
outpatient settings. A range of factors can influence spending
on  pharmaceuticals  including  differences  in  distribution
channels, the prevalence of generic drugs, as well as relative
prices  in  different  countries.  The  share  of  medical  goods
spending tends to be highest in Central and Eastern European
countries – in the Slovak Republic, it represented the largest
component of health spending (33%). In contrast, the relative
weight  of  medical  goods  on  some  Western  European  and
Nordic countries’ health budgets tends to be smaller (<15%).
The  variation  between  countries  in  price  levels  of  medical
goods is generally smaller than that for health services. Hence,
because of the influence of international pricing, spending on
medical goods will tend to make up a larger share of health
spending in lower-income countries.
Countries’  spending  on  health-related  long-term  care  also
varies  considerably  across  the  EU.  Countries  such  as  the
Netherlands, Sweden and Denmark, with established formal
arrangements for the elderly and the dependent population,
allocated more than a quarter of their health spending to long-
term care in 2018. In many Southern as well as Central and
Eastern European countries, with more informal arrangements,
expenditure on formal long-term care services accounts for a
much smaller share of total spending.
Figure 5.10 presents the spending growth rates for key health
goods and services for two time periods: at the start and in the
aftermath of the financial crisis (2008‑13) and in the most recent
five‑year period for which comprehensive data are available
(2013‑18).  In the years following the financial  crisis,  annual
spending  growth  rates  for  most  parts  of  the  health  sector
witnessed either a slowdown or even a reversal. Since 2013,
average annual health spending growth rates have bounced
back for most key health system functions, however still falling
short of pre-crisis levels.
Between 2008 and 2013,  retail  pharmaceutical  expenditure
across the EU fell by an annual average rate of 1.2% following
the  implementation  of  various  cost-containment  policies  in
many EU countries.  Between 2013 and 2018,  spending on
pharmaceuticals  recovered,  having  risen  by  an  average  of
1.4% per year. Spending on inpatient care and administrative
activities followed a similar pattern over these two time periods.
Spending for preventive services stagnated between 2008 and
2013 before returning to moderate growth in the second period.
For outpatient care, while the average annual spending growth
rate declined over the five years from the start of the financial
crisis compared to the previous five‑year period, it nevertheless
remained positive at 0.7%, suggesting that these services were
better  protected  from  cuts  relative  to  other  health  care
functions. The same is true for long-term care (health), the only
major health care function that reported strong spending growth
throughout the 2008‑13 period (4.3%). Since then, long-term
care spending continued to grow strongly.
Definition and comparability
The System of  Health  Accounts  (OECD,  Eurostat  and
WHO,  2017)  defines  the  boundaries  of  the  health  care
system.  Current  health  expenditure  comprises  personal
health care (curative and rehabilitative care, long-term care,
ancillary services and medical goods) and collective services
(prevention  and  public  health  services  as  well  as  health
administration). Curative, rehabilitative and long-term care
can also be classified by mode of provision (inpatient, day
care, outpatient and home care). Concerning long-term care,
only care that relates to the management of the deterioration
in  a  person’s  health  is  reported  as  health  expenditure,
although it is difficult in certain countries to clearly separate
out the health and social aspects of long-term care.
Some countries can have difficulties separating spending
on pharmaceuticals used as an integral part of hospital care
from  those  intended  for  use  outside  of  the  hospital,
potentially leading to an underestimate of pharmaceutical
spending and an overestimate of inpatient and/or outpatient
care.
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5. EXPENDITURE ON PRIMARY HEALTH CARE
Effective primary health care is the cornerstone for efficient,
people-centred, and equitable health systems. Strengthening
primary care has been identified as an effective policy tool to
improve care coordination and health outcomes and reduce
wasteful spending, by limiting unnecessary hospitalisations and
associated costs  in  hospitals  and other  parts  of  the  health
system. However, in many EU and OECD countries, primary
care has not yet fully realised this potential (OECD, 2020).
Primary health care is a complex concept that stretches across
different  types  of  services  and  providers.  No  definitive
consensus exists on which services or providers should be
included. Data presented here defines spending on primary
health  care  as  general  outpatient,  dental  and  home-based
curative  care,  as  well  as  preventive  services  (collectively
termed as “basic care services”) when provided by ambulatory
care providers – meaning that care in hospitals or outpatient
specialist care are not included. Using this as a proxy, primary
health care accounts for around 13% of health spending on
average across EU countries, ranging from less than 10% in the
Slovak Republic and Romania to more than 17% in Lithuania
and Estonia (Figure 5.11). Primary health care spending as a
share of total health spending remained relatively constant over
the last five years in most EU countries, suggesting expenditure
growth in line with overall health spending. Exceptions to this
are Latvia and Romania – where primary health care spending
grew on average by about 10% per year over the last five years
– or Finland and the Slovak Republic, where primary health
care spending retracted in real terms since 2013.
On average across EU countries, half of primary care spending
is on general outpatient care services. A further 39% is related
to dental care. Prevention services (9%) as well as home visits
by GPs or nurses (2%) make up a much smaller proportion of
spending  on  primary  care.  Looking  at  specific  country
examples, the share of general outpatient care provided by
ambulatory providers is particularly high in Poland and reaches
12% of all health spending. In Germany, Austria and Romania,
spending on general outpatient care is much lower in relative
terms, accounting for less than 4.5% of total health spending
(Figure 5.11).
In Lithuania and Estonia, the relatively large weight of primary
care in total health spending is explained by the importance of
dental care, which accounts for 50% of primary health care
spending. In both countries, dental care constitutes 9% of their
total health budget – nearly twice the EU average (5% of all
health  spending).  Conversely,  dental  care  spending  is
comparatively small in Poland, Belgium, Spain, the Netherlands
and Romania,  where it  represents  only  around 3% of  total
health spending.
The “basic care services” described above can be delivered in
various  settings,  including  hospitals.  The  proportion  of
spending on all basic care services that are delivered by the
ambulatory care sector may be interpreted as an approximate
measure of allocative efficiency, as it could indicate what is
delivered in the most appropriate setting.  Nevertheless,  the
cross-country comparability  of  this  measure remains limited
due to the diversity of organisational models for primary health
care across EU countries. For example, some EU countries
have established dedicated primary health care units within
hospitals. Across EU member states, 85% of all  basic care
spending is for services delivered by ambulatory care providers
(Figure 5.12). This share stood at 90% or more in Belgium,
Denmark, Latvia, Spain, Lithuania and Romania but was less
than 75% in Estonia, Luxembourg and Switzerland.
Definition and comparability
International  comparisons  of  what  is  spent  on  primary
health care have to date been largely absent due to both the
lack of a commonly accepted definition, and an appropriate
data collection framework.  Working with data and clinical
experts and international partners, OECD has developed a
methodological framework to estimate primary health care
spending.  The results  presented  here  are  based on  this
methodology (Mueller and Morgan, 2018).
Estimates are based on data submitted using the System
of Health Accounts 2011 framework. The following functions
are first identified as basic care services:
• General outpatient curative care (e.g. routine visits to a
GP or nurse for acute or chronic treatment)
• Dental outpatient curative care (e.g. regular control visits
as well as more complex oral treatment)
• Home-based curative care mainly refer to home visits by
GPs or nurses
• Preventive  care  services  (e.g.  immunisation  or  health
check-ups)
Where basic care services are provided by ambulatory
health care providers such as medical practitioners, dentists,
ambulatory health care centres and home health care service
providers,  this can be considered as a proxy for  primary
health care. It should be stressed that this proxy measure is a
simplified  approach  to  operationalise  a  complex  multi-
dimensional concept.
Comparability for this indicator is still limited and depends
on  countries’  capacity  and  methods  used  to  distinguish
between general outpatient and specialist services.
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Figure 5.11. Spending on primary health care services as share of total health spending, 2018
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Figure 5.12. Basic care spending delivered by ambulatory care providers as share of total basic care spending, 2018
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5. HEALTH EXPENDITURE BY PROVIDER
How and where health care is delivered can have a significant
impact on spending for different goods and services. Health
care can be provided in many different organisational settings,
ranging from hospitals and medical practices to pharmacies
and  even  private  households  caring  for  family  members.
Analysing  health  spending  by  provider  can  be  particularly
useful when considered alongside the functional breakdown of
health expenditure, giving a fuller picture of the organisation of
health systems (see indicator “Health expenditure by type of
good and service”).
Activities  delivered  in  hospitals  account  for  the  largest
proportion of health care expenditure in almost all EU countries.
In 2018, hospitals received 39% of health system funding on
average across EU countries. In Croatia, Romania and Cyprus,
hospitals received more than 45% of their entire health care
budget (Figure 5.13). On the other end of the scale, hospitals
account for less than 30% of Germany’s total health spending.
This comparatively low share is partially due to country-specific
organisational features stipulating a relatively strict separation
between inpatient and outpatient service provision, which, in
turn,  results  in  comparatively  limited  outpatient  activity  in
German hospitals.
After hospitals, the second-largest category of care providers
are ambulatory providers. This category covers a wide range of
facilities and, depending on the country-specific organisation of
health service delivery, most spending relates either to medical
practices including offices of GPs and specialists (e.g. Austria,
France  and  Germany)  or  ambulatory  health  care  centres
(e.g. Finland, Ireland and Sweden). Across EU countries, care
delivered  by  ambulatory  providers  accounts  for  around  a
quarter of health spending on average across EU countries.
This share stands at 30% or above in Belgium, Germany and
Luxembourg, but is less than 20% in Greece, Croatia, Malta,
the Netherlands, Romania and Bulgaria. On average across the
EU, around two‑thirds of all spending on ambulatory providers
relate to GP and specialist practices together with ambulatory
health care centres, and one‑fifth to dental practices.
Other  main  provider  categories  include  retailers  (mainly
pharmacies  selling  prescription  and  over-the-counter
medicines) – accounting for 20% of health spending on average
across EU countries – and residential long-term care facilities
(mainly  providing  inpatient  care  to  long-term  dependent
people), making up 8% of health spending on average.
There is a large variation in the range of activities that may be
performed by the same category of provider across countries,
depending on the structure and organisation of each health
system.  This  variation  is  most  pronounced  in  hospitals
(Figure 5.14). Although the majority of hospital expenditure in
almost  all  EU  countries  is  allocated  to  inpatient  (curative-
rehabilitative)  care,  in  some  countries  hospitals  constitute
important providers of outpatient care services – for example,
through  accident  and  emergency  departments,  specialist
outpatient units, or laboratory and imaging services provided to
outpatients. In Germany, Greece and Bulgaria, hospitals are
generally  mono-functional,  with  the vast  majority  (>90%) of
spending directed to inpatient care, and very little spending on
outpatient and day care. On the other hand, outpatient care
accounts  for  over  40% of  hospital  expenditure  in  Portugal,
Finland, Denmark, Sweden and Estonia. In these countries,
specialists typically receive outpatients in hospital outpatient
departments.
To increase efficiency and reduce waiting times for selected
procedures,  many EU countries have shifted some medical
services from inpatient to day care settings in recent years
(OECD, 2017). As a result, in 2018 day care accounted for
more  than  10%  of  all  hospital  expenditure  in  seven
EU countries.
Finally, the provision of inpatient long-term care in hospitals for
people  with  long-term care needs (which does not  refer  to
regular inpatient curative and rehabilitative care) makes up a
sizeable share of hospital expenditure in some countries such
as the Czech Republic, Romania and Iceland. This may be due
to a lack of available beds in appropriate long-term care nursing
facilities when patients requiring care cannot be discharged to
their homes.
Definition and comparability
The  different  categories  of  health  care  providers  are
defined in the System of Health Accounts (OECD, Eurostat
and WHO, 2017).
The main categories of providers are hospitals (acute and
psychiatric), residential long-term care facilities, ambulatory
providers (practices of GPs and specialists, dental practices,
ambulatory health care centres, providers of home health
care  services),  providers  of  ancillary  services
(e.g.  ambulance  services,  laboratories),  retailers
(e.g.  pharmacies),  and  providers  of  preventive  care
(e.g. public health institutes).
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Figure 5.13. Health expenditure by provider, 2018
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Figure 5.14. Hospital expenditure by type of service, 2018
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5. PHARMACEUTICAL EXPENDITURE
Pharmaceutical care is constantly evolving, with an increasing
number of novel medicines entering the market every year.
These may offer  alternatives  to  existing  treatments,  and in
some  cases,  the  prospect  of  treating  conditions  previously
considered  incurable.  However,  the  costs  of  new
pharmaceutical  drugs  can  be  very  high,  with  significant
implications  for  health  care  budgets.  In  2018,  retail
pharmaceuticals  (excluding  those  used  during  a  hospital
treatment) alone accounted for around one‑sixth of all health
care expenditure, and represented the third largest spending
component in EU countries after inpatient and outpatient care.
In  total,  the  EU  retail  pharmaceutical  bill  was  around
EUR  190  billion  in  2018.  However,  without  accounting  for
spending on medicines used in hospital  (generally  included
under inpatient care), this does not provide a complete picture
of overall pharmaceutical expenditure.
Spending for retail  pharmaceuticals averaged EUR 381 per
person  across  EU  member  states  in  2018,  adjusted  for
differences in purchasing power. The variations in per capita
retail  pharmaceutical  spending  across  countries  can  reflect
differences  in  the  basket  of  available  medicines,
pharmaceutical  prices,  consumption and the relative role of
hospitals in dispensing pharmaceuticals, as well as the market
penetration of generics (Figure 5.15). With EUR 615 per capita,
Germany spent by far the most on pharmaceuticals among EU
member states – 60% above the EU average. Belgium, France
and Austria spent between 20‑40% more on medicines per
capita than the EU average. At the other end of the scale,
Denmark and Croatia had relatively low spending levels.
Around  four  out  of  every  five  euros  spent  on  retail
pharmaceuticals goes on prescription medicines, with most of
the rest on over-the-counter medicines (OTC). OTC medicines
are  pharmaceuticals  that  are  generally  bought  without
prescription. In most cases, their cost is fully borne by patients.
The share of  OTC medicines is particularly high in Poland,
accounting for more than half of retail pharmaceutical spending,
and stands at 30% or more in Romania, Latvia and Cyprus.
In  most  countries,  the  costs  of  pharmaceuticals  are
predominantly  covered  by  government  or  compulsory
insurance  schemes  (Figure  5.16).  On  average  across
EU countries, these schemes cover around 56% of all retail
pharmaceutical spending, with out-of-pocket payments (41%)
and voluntary private insurance (2%) financing the remaining
part.  Public  coverage  is  most  generous  in  Germany  and
France,  where  government  and  compulsory  insurance
schemes pay for more than 80% of all pharmaceutical costs. By
contrast,  in  eight  EU  member  states,  public  or  mandatory
schemes cover less than half the amount spent on medicines
and coverage is particularly low in Bulgaria (27%) and Cyprus
(17%).
In recent years, spending growth on retail pharmaceuticals in
the  EU  was  low  compared  to  other  health  services  (see
indicator “Health expenditure by type of good and service”) and
was even negative in many countries during the years following
the 2008 financial crisis. This was due in part to a combination
of cost-containment policies and market dynamics, including
generic and biosimilar competition (Belloni, Morgan and Paris,
2016).
However, new high cost treatments such as for Hepatitis C and
some cancer drugs help explain a return to positive growth
rates in more recent years. For example, the number of new
cancer medicines and indications has been increasing rapidly,
along  with  the  prices.  The  value  and  sales  of  oncology
medicines  have  more  than  doubled  in  Europe  in  the  past
decade.
Yet the retail pharmaceutical sector only tells part of the story,
since spending on pharmaceuticals used during hospital care
can typically add another 20% to a country’s pharmaceutical
bill. Available data in a number of European countries suggest
that pharmaceutical spending growth in the hospital setting has
frequently outpaced that of retail pharmaceuticals, such as in
the  Czech  Republic,  Denmark,  Finland,  Germany  or  Spain
(Figure 5.17). In some countries, this may reflect deliberate
policy  decisions  to  transfer  high  cost  medicines  to  hospital
dispensing.
Definition and comparability
Pharmaceutical  expenditure  covers  spending  on
prescription medicines and over-the-counter products. Other
medical  non-durable  goods  (such  as  first  aid  kits  and
hypodermic syringes) are also included.
Retail pharmaceuticals are provided outside hospital care,
such as those dispensed through a pharmacy or bought from
a  supermarket.  Hospital  pharmaceuticals  include  drugs
administered or  dispensed during  an episode of  hospital
care.  Expenditure  on  retail  pharmaceuticals  includes
wholesale and retail margins and value-added tax.
Total pharmaceutical spending refers in most countries to
“net” spending – i.e. adjusted for possible rebates payable by
manufacturers, wholesalers or pharmacies. Pharmaceuticals
consumed in hospitals and other health care settings as part
of an inpatient or day-case treatment are excluded from retail
pharmaceutical spending (available data suggests that their
inclusion  would  add  another  20%).  Comparability  issues
exist  regarding  the  administration  and  dispensing  of
pharmaceuticals  for  outpatients  in  hospitals.  In  some
countries,  the  costs  are  included under  curative  care;  in
others, under pharmaceuticals.
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Figure 5.16. Expenditure on retail pharmaceuticals by type of financing, 2018
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5. CAPITAL EXPENDITURE IN THE HEALTH SECTOR
While the health sector remains highly labour-intensive, capital
investment in infrastructure and medical equipment has been
an increasingly important factor of production of health services
in recent decades, as reflected, for example, by the growing
importance  of  diagnostic  and  therapeutic  devices,  or  the
expansion of information and communications technology (ICT)
in health care. However, the level of investment in buildings,
machinery and technology tends to fluctuate more than current
spending on health services over time, often responding to the
economic  climate  whereby  investment  decisions  may  be
postponed or brought forward.
In 2018, it is estimated that, on average, EU member states
allocated around 0.4% of their GDP on capital investment in the
health sector (Figure 5.18). This compares to an average of
8.3% of GDP allocated across EU health systems to health
services and medical goods. Levels of capital investment on
health vary significantly across EU countries and over time,
even more so than overall health spending.
In  relative  terms,  Belgium  and  Austria  were  the  largest
spenders on capital investment in the health sector in 2018,
having allocated around 0.7% of their respective GDP. At the
lower end, Cyprus and Hungary invested less than 0.2% of their
GDP in 2018 on capital infrastructure and equipment in the
health sector.
By its nature, capital  spending fluctuates more than current
spending from year to year,  in  line with capital  projects on
construction and investment programmes on new equipment.
Capital  investment  decisions also tend to be more strongly
determined  by  economic  cycles,  with  spending  on  health
system infrastructure and equipment often being a prime target
for  reduction  or  postponement  during  periods  of  economic
uncertainty. While capital spending on health grew by more
than  20% in  real  terms  on  average  across  the  EU  in  the
three years prior to the 2008 financial crisis, over the following
two years  it  fell  by  almost  10%.  Between 2010 and 2014,
average levels of capital investment in health across the EU
slightly  increased before a jump in 2015.  In 2016,  average
capital investment dropped again and remained flat in 2017. As
a result, the investment level in 2017 is only around the 2008
level (Figure 5.19).
Despite the 2008‑09 economic crisis, between 2005 and 2018
capital spending in health continued to increase fairly steadily in
real terms in some European countries. Sweden and Austria,
for  example,  managed  to  maintain  generally  stable  annual
growth rates of capital investment in health over this extended
period. Conversely, capital spending in health was very volatile
in Ireland over this period. After having decreased significantly
from 2007 to 2012 as a result of measures to balance public
budgets,  investment  spending  in  health  infrastructure  and
equipment  in  Ireland  rebounded  strongly  in  2013  and  has
followed a generally upward trend ever since. On the other
hand,  Italy  and  the  United  Kingdom  witnessed  a  severe
reduction in their capital spending in health. In Italy, levels have
been on a negative trajectory between 2010 and 2016 with only
a small uptick in 2017. In the United Kingdom, capital spending
in health dropped by almost 50% between 2009 and 2011 but
has steadily increased since 2013. Nevertheless, in 2018, the
investment level in health was still around 20% lower compared
to its 2009 level.
The European Union has been supporting capital investment in
national  health  systems  across  the  EU  via  the  European
Structural and Investment Funds (ESIF) since 2014. The key
objectives of these various funds in the area of health are to
reduce health inequalities between regions and social groups,
and to increase the effectiveness and accessibility of national
health care systems (European Commission, 2020). Between
2014  and  2020,  the  European  regional  development  fund
(ERDF) and the European social fund (ESF) – two out of five
funds  subsumed  under  the  ESIF  –  provided  more  than
EUR 9 billion to member states for health-related investments.
In  the  aftermath  of  the  COVID‑19  pandemic,  investment
support  by the EU funds in the area of health systems will
significantly increase in the coming years as part of the “Next
Generation EU” recovery package.
Definition and comparability
Gross  fixed  capital  formation  in  the  health  sector  is
measured by the total value of the fixed assets that health
providers have acquired during the accounting period (less
the value of the disposals of assets) and that are used for
more than one year in the production of health services. The
breakdown by assets includes infrastructure (e.g. hospitals,
clinics, etc.), machinery and equipment (including diagnostic
and surgical machinery, ambulances, and ICT equipment),
as well as software and databases.
Gross fixed capital formation in health is reported by many
countries under the System of Health Accounts. It is also
included in National Accounts data where it is broken down
by industrial sector according to the International Standard
Industrial  Classification  (ISIC)  Rev.  4.  To  estimate
investment in health, section Q: Human health and social
work activities or Division 86: Human health activities can be
used. The former is normally broader than the SHA boundary
while the latter is narrower.
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PART II
Chapter 6
Effectiveness: Quality of care and patient
experience
This chapter starts with a broad indicator of avoidable mortality, providing a general
assessment of the effectiveness of public health and health care systems in reducing
premature  deaths.  In  2017,  more  than  1  million  people  in  EU  countries  died
prematurely from diseases and injuries that could potentially have been avoided
through more effective public health policies or health care. The main causes of
avoidable mortality include ischaemic heart diseases, lung cancer and accidents.
Vaccination rates among children and older  people  have decreased in  several
countries in recent years following anti-vaccination campaigns and a belief  that
vaccination might not be needed. It is important to tackle vaccine hesitancy and
improve vaccination coverage to reduce the spread of communicable diseases that
can be effectively prevented through vaccines and the burden on health systems.
Progress  has  been  made  in  tackling  cancer  in  many  countries  through  the
implementation of population-based screening programmes to detect cancer earlier
and the provision of effective and timely cancer care. These efforts have led to
increased survival following diagnosis and reduced mortality from cancer in most
countries, yet wide disparities in cancer care persist across countries. Promoting
more patient-centred care has become a growing priority across EU countries in
recent  years  to  improve  the  quality  of  care  and  responsiveness  to  patients’
expectations.  Based on  surveys  seeking  patient-reported  experience  measures
(PREMs), citizens in most countries rate the quality of primary care high. These
survey results signal clearly the importance of good provider/patient communication
and patient involvement in care and treatment decisions.
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6. AVOIDABLE MORTALITY (PREVENTABLE AND TREATABLE)
Indicators of avoidable mortality can provide a general “starting
point” to assess the effectiveness of public health and health
care systems in reducing deaths before 75 years of age from
various  diseases  and  injuries.  However,  further  analysis  is
required to assess more precisely different causes of potentially
avoidable deaths and interventions to reduce them.
In 2017, over 1 million premature deaths across EU countries
could have been avoided through better prevention and health
care interventions. This amounts to about two‑thirds of deaths
under age 75. Of these deaths, most (644 000 or about 64% of
the  total)  were  considered  preventable  through  effective
primary prevention and other public health measures, while
slightly  more  than  one‑third  (372  000  or  about  36%)  were
considered treatable through more effective and timely health
care interventions.
Lung cancer  (23% of  all  deaths  from preventable  causes),
ischaemic heart diseases (12%), alcohol-related deaths (11%),
and transport and other accidents (8%) accounted for more
than half  of  preventable mortality  (Figure 6.1).  Other  major
causes  included  stroke  (6%),  suicide  (6%)  and  chronic
obstructive  pulmonary  disease  (COPD)  often  related  to
smoking (6%).
The main treatable causes of mortality include ischaemic heart
disease (20% of all deaths from treatable causes), colorectal
cancer (16%), breast cancer (12%) and stroke (11%), which
together account for about 60% of all  deaths that could be
avoided through the provision of timely and effective treatment.
Pneumonia (6%),  diabetes (4%) and hypertensive diseases
(4%) are  other  major  causes of  premature deaths that  are
amenable to treatment.
Preventable mortality  rates in 2017 were about  three times
lower in Cyprus and Italy compared with the rates in some
Central  and Eastern  European countries  such as  Hungary,
Latvia, Romania and Lithuania (Figure 6.2).  Higher rates of
premature death in these countries were mainly due to much
higher mortality from ischaemic heart disease, accidents and
alcohol-related deaths, as well as lung cancer in Hungary.
Mortality  rates  from  treatable  causes  were  also  about
three times lower in some Western and Northern European
countries like France, the Netherlands, Spain, Sweden and Italy
than  in  Central  and  Eastern  European  countries  such  as
Romania, Latvia, Bulgaria and Lithuania. The higher rates in the
latter group of countries were mainly driven by higher mortality
rates from ischaemic heart disease, stroke and some treatable
cancers.
Across  the  EU,  preventable  mortality  rates  were  almost
three times higher among men than among women (235 per
100 000 population for men, compared with 89 for women)
because of higher death rates from all the leading causes of
preventable death. Mortality rates from treatable causes were
also nearly 40% higher among men than women, mainly due to
higher death rates from ischaemic heart disease and stroke.
Definition and comparability
In  2019,  the  OECD  and  Eurostat  adopted  new  joint
definitions  of  avoidable  mortality,  including  a  list  of
preventable and treatable causes of mortality. Preventable
mortality is defined as causes of death that can be mainly
avoided  through  effective  public  health  and  primary
prevention interventions (i.e. before the onset of diseases/
injuries, to reduce incidence). Treatable causes of mortality is
defined  as  causes  of  death  that  can  be  mainly  avoided
through  timely  and  effective  health  care  interventions,
including secondary prevention and treatment (i.e. after the
onset of diseases, to reduce case-fatality).
The attribution of each cause of death to the preventable or
treatable mortality list was based on the criterion of whether it
is predominantly prevention or health care interventions that
can reduce death. Causes of death that can be both largely
prevented and also treated once they have occurred were
attributed to the preventable category on the rationale that if
these diseases are prevented, there would be no need for
treatment. In cases when there was no strong evidence of
predominance of preventability or treatability (e.g. ischaemic
heart disease, stroke, diabetes, hypertension), the causes
were allocated on a 50%‑50% basis to the two categories to
avoid double-counting the same cause of death in both lists.
The age threshold of premature mortality is set at 74 years
(inclusive) for all causes (OECD/Eurostat, 2019).
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6. CHILDHOOD VACCINATIONS
All  EU  countries  have  established  childhood  vaccination
programmes to reduce the spread of many infectious diseases
and  related  deaths,  although  the  number  and  type  of
compulsory or  recommended vaccines vary to some extent
across countries.
In  recent  years,  some  parts  of  Europe  witnessed  a  steep
resurgence of vaccine-preventable diseases due to declining
vaccine  coverage  driven  at  least  partly  by  anti-vaccine
campaigns. To counter these alarming trends, over the past
years  the  European  Commission  has  repeatedly  called  for
stronger efforts and cooperation to tackle vaccine hesitancy
and improve vaccination coverage to  reduce the spread of
vaccine-preventable diseases (European Commission, 2018).
This has become even more important following the COVID‑19
pandemic to avoid any additional burden on health systems.
The confinement measures following the COVID‑19 outbreak
have  resulted  in  a  sharp  reduction  in  the  spread  of
communicable  diseases  like  measles  between  March  and
August 2020, but these reductions may only be temporary if
vaccination  coverage  does  not  go  up.  One  of  the  indirect
consequences of the COVID‑19 pandemic is that it disrupted
the implementation of routine vaccination programmes in some
countries, as some people feared exposure to the new virus,
and restrictions on the movement of people impacted children’s
accessibility to immunisation services (WHO, 2020).
Vaccination  against  measles  is  included  in  all  national
childhood  vaccination  programmes  in  Europe,  whereas
vaccination against hepatitis B has been included in a growing
number of countries, but not yet in most Nordic countries and
Hungary (ECDC, 2020a). WHO has recommended a coverage
of at least 95% of children with two doses of measles-containing
vaccine and three doses of the hepatitis B vaccine by 2020
(WHO, 2012; WHO, 2017).
In 2018, on average across EU countries, 94% of one‑year-old
children received at least one dose of measles vaccination. Half
of EU countries had not reached yet the target of at least 95%
coverage (Figure 6.3).  Measles outbreaks have occurred in
recent  years  in  several  countries,  even  in  those  that  had
previously eliminated or interrupted endemic transmission. In
2019,  WHO  announced  that  Albania,  the  Czech  Republic,
Greece  and  the  United  Kingdom  had  lost  their  measles
elimination status due to continuous transmission in 2017 and
2018. During the 12‑month period from March 2019 to February
2020, the highest number of measles cases were reported in
France (2 466), Romania (1 542), Italy (1 353), Bulgaria (1 347)
and Poland (1 032). Most measles cases were reported among
people  who  were  not  vaccinated,  including  children  below
age one who were too young to have received the first dose of
the vaccine but also adolescents and adults (ECDC, 2020b).
On average, 93% of one‑year-old children received hepatitis B
vaccination  in  2018  across  those  EU  countries  where  this
vaccination was part of the national immunisation programme.
The vaccination  rate  was above the  95% target  in  several
countries  such  as  Malta,  Portugal,  Belgium,  Cyprus,  the
Slovak  Republic,  Greece,  Latvia,  Luxemburg  and  Italy.
However, less than 90% of one‑year-old children were covered
in Austria,  Bulgaria,  Germany, Montenegro and Switzerland
(Figure 6.4). Data on childhood vaccination rate for hepatitis B
are not  available  in  most  Nordic  countries  except  Sweden,
because  this  vaccine  is  not  yet  part  of  the  general  infant
vaccination  programme,  although it  is  provided  to  high-risk
groups.
Definition and comparability
Vaccination rates reflect the percentage of one‑year-old
children who have received the respective vaccination (at
least  one  dose  of  measles-containing  vaccine  and  three
doses  of  hepatitis  B  vaccine).  The  age  of  complete
immunisation  differs  across  countries  due  to  different
immunisation schedules. For those countries recommending
the first dose of measles vaccine after age one, the indicator
is calculated as the proportion of children less than two years
of age who have received that vaccine. Thus, these data
reflect the actual policy in a given country and the age group
is not always strictly comparable across countries.
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6. VACCINATION AGAINST INFLUENZA AMONG PEOPLE AGED 65 AND OVER
Depending on the year, seasonal influenza affects between 4
and 50 million people across EU countries, Iceland, Norway,
Switzerland and the United Kingdom, and 15 000 to 70 000
people  die  every  year  of  causes  associated  with  influenza
(ECDC,  2020).  Older  people  are  at  higher  risk  of  serious
complications  and  death  from  influenza.  With  the  new
coronavirus, older people will face an increased risk of viral
infection during the 2020/21 winter season. Although influenza
vaccination is never fully effective in preventing all influenza
viruses that may spread in a given year, it does offer protection
and can effectively reduce the burden of seasonal influenza.
WHO recommends that 75% of elderly people be vaccinated
against  seasonal  influenza,  and  a  2009  EU  Council
Recommendation also set a goal of 75% vaccination coverage
among older people (European Union, 2009). In addition to
older people, the European Council also recommends influenza
vaccination  for  persons  with  chronic  conditions  and  health
workers,  and  WHO  recommends  influenza  vaccination  for
pregnant women and children as well.
All EU countries have national recommendations to promote
influenza vaccination among older people, although the specific
age threshold varies across countries. Despite this, in 2018 the
flu  vaccination coverage among the target  group of  people
aged  65  and  over  was  less  than  50%  in  the  majority  of
EU countries. On average, only 39% of people aged 65 and
over  were  vaccinated  against  influenza,  and  no  country
reached the recommended target of 75% vaccination coverage
(Figure 6.5). Vaccination rate against influenza among older
people was particularly low in Central and Eastern European
countries, with rates below 25% in all countries reporting these
data.
Vaccination rates against influenza have gone in the wrong
direction  over  the  past  decade  in  most  EU  countries.  In
countries like the Slovak Republic and Slovenia, vaccination
coverage has halved between 2008 and 2018.
A 2019 Eurobarometer survey asked people who had not been
vaccinated against influenza or other infectious diseases what
were the reasons for this (European Union, 2019). On average
across EU countries, over two in five people aged 65 and over
reported that they did not get vaccinated in the past five years
because they did not see the need for them. About one in five
people in this age group who were not vaccinated for the past
five years thought that they were still protected by vaccines they
had received earlier. About one in ten people aged 65 and over
who were not vaccinated thought that vaccines were not safe
and  could  have  side-effects  or  that  vaccines  were  only
necessary for children. One in five people aged over 65 also
reported that they did not have vaccinations recently because
this had not been offered to them by their general practitioner or
another doctor. Some older people also reported that it was not
easy to get access to vaccination and others also said that the
vaccine was too expensive (Figure 6.6).
Strategies to increase vaccination coverage against influenza
among older people need to address all these different beliefs
and  barriers.  Targeted  approaches  through  personalised
invitations or phone calls to the target population, awareness
building among health care providers, financial incentives to
encourage health professionals to provide vaccinations and the
provision  of  influenza  vaccinations  in  pharmacies  can  help
increase influenza vaccination  coverage (WHO, 2018).  The
COVID‑19 pandemic provides an opportunity to raise again
public awareness of the benefits of vaccination in general and
against seasonal influenza in particular, at a time when both the
influenza viruses and the new coronavirus will spread in the
2020/21 winter season.
Definition and comparability
Influenza vaccination rate refers to the number of people
aged 65 and older who have received an annual influenza
vaccination,  divided  by  the  total  number  of  people
over 65 years of age. In some countries, the data are for
people over 60 years of age.
The main limitation in terms of data comparability arises
from the use of different data sources, whether survey or
programme, which are susceptible to different types of errors
and biases. For example, data from population surveys may
reflect some variation due to recall errors and irregularity of
administration.
The  Special  Eurobarometer  survey  on  Europeans’
attitudes  towards  vaccination  conducted  in  2019  asked
respondents who did not have any vaccination in the past
five years to report all the reasons for not being vaccinated.
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6. PEOPLE-REPORTED EXPERIENCE AND QUALITY OF HEALTH CARE
Promoting more people-centred care has become a growing
priority  across EU countries in recent  years to improve the
quality  of  care  and  the  responsiveness  to  patients’
expectations.  This  has  been  accompanied  by  national  and
European efforts to develop and implement patient-reported
experience measures (PREMs) and patient-reported outcomes
measures (PROMs) to monitor progress for individual providers
and at the national level. For example, Norway collects patient-
reported measures through regular surveys and reports them at
a provider level to inform the public on patient-reported provider
performance  and  to  increase  accountability.  The
United Kingdom has been reporting PREMs at a provider level
since  2002  for  hospitals  and  since  2004  for  GP  practices
(Fujisawa and KIazinga, 2017; OECD, 2020).
At the European level, the European Quality of Life Survey has
collected  information  from people  about  their  views  on  the
quality of different services in their country, including different
aspects of the health system. The results from the last wave of
this survey from 2016 show that in most countries, citizens
rated the quality  of  primary care (care provided by general
practitioners/family doctors or at health centres) higher than the
quality of hospital care and specialist care, with the exception of
Finland and Sweden where the quality of hospital care and
specialist  care  was  rated  higher  (Figure  6.7).  In  general,
citizens who rate the quality of primary care in their country
higher than the EU average also generally rate the quality of
hospital and specialist care above average, and vice versa. The
perceived quality of both primary care and hospital care was
generally lower in Greece, Poland and Latvia in 2016.
The perceived quality of both primary care and hospital and
specialist  care is  generally  higher among people who have
used these services than among those who have not used
them.  In  primary  care,  different  aspects  of  the  interactions
between GPs or  other  primary  care  providers  such  as  the
personal attention given by professionals, the time devoted to
consultations, and the extent of consultations about the care
plan are also associated positively with the overall assessment
of quality (Eurofound, 2016).
The importance of good provider/patient communication and
patient involvement in care and treatment decisions also comes
up clearly from the results of more specific surveys on patient
experience. In those countries where these more specific data
are  available,  most  patients  generally  report  positive
experiences  in  their  interactions  with  their  primary  care
providers  on  these  aspects  of  quality  (OECD,  2019).  For
example, over 80% of patients in many countries reported in
2016 that a general practitioners/family doctors involved them
in care and treatment decisions (Figure 6.8). The proportion
was  lower  in  Poland,  but  substantial  progress  has  been
achieved in monitoring and improving this aspect of quality and
patient experience.
Definition and comparability
In  the  European  Quality  of  Life  Survey,  the  perceived
quality of primary care and hospital and specialist care is
based on a response scale to the following question, “In
general,  how do you rate the quality of the following two
health care services?” A rating of 1 means very poor quality
and 10 means very high quality.
An increasing number of countries have been collecting
information  on  patient-reported  experience  measures
(PREMs)  in  primary  care  based  on  a  common  module
through  nationally  representative  population  surveys.
Portugal  collects  this  information  through  a  nationally
representative service user survey. For Germany, Norway,
Sweden,  Switzerland  and  the  United  Kingdom,  the
Commonwealth Fund’s International Health Policy Surveys
of 2010 and 2016 are used as a data source. There are
limitations in data reliability and comparability related to the
sample size and response rates. Data from this source refer
to patient experience with a GP specifically (not any doctor).
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6. AVOIDABLE HOSPITAL ADMISSIONS
Asthma,  chronic  obstructive  pulmonary  disease  (COPD),
congestive heart failure (CHF) and diabetes are four widely
prevalent long-term conditions. About 30 million children and
adults  under 45 years of  age in Europe have asthma, and
5‑10%  of  adults  over  age  40  have  COPD  (European
Respiratory  Society,  2020),  It  is  estimated  that  more  than
15  million  people  are  affected  by  CHF  (European  Heart
Network,  2019).  And  about  32  million  adults  have  been
diagnosed with diabetes in the EU (IDF, 2019). Common to all
these four conditions is the fact  that  the evidence base for
effective treatment is well established, and much of it can be
delivered in primary care. Primary care is expected to serve as
the first point of contact for people in health systems and to
provide continuous and coordinated care over time, notably for
people having chronic diseases. A well-performing primary care
system should therefore reduce acute deterioration in people
living  with  chronic  conditions  like  asthma,  COPD,  CHF  or
diabetes,  thereby  preventing  costly  avoidable  hospital
admissions (OECD, 2020).
Figure 6.9 shows hospital admission rates for the two chronic
respiratory  diseases,  asthma and COPD together.  In  2017,
admission rates for both conditions varied more than five‑fold
across  EU  countries,  with  Italy  and  Portugal  reporting  the
lowest rates, and Denmark and Ireland reporting the highest
rates. On average across EU countries, the admission rates for
asthma and COPD have decreased slightly in recent years, with
Italy, Ireland and the Slovak Republic achieving the biggest
reductions (of more than 20% between 2012 and 2017).
Hospital admission rates for CHF also varied almost five‑fold
across EU countries in 2017. Portugal and Ireland have the
lowest rates for this condition, whereas Lithuania, Poland and
the Slovak Republic report rates almost twice the EU average.
Admission rates for CHF have fallen slightly on average across
EU countries between 2012 and 2017. Lithuania, Portugal and
Romania have achieved the biggest reductions (Figure 6.10).
While avoidable hospital  admissions for  diabetes have also
fallen in many countries over the past few years, there is still an
almost five‑fold variation in admission rates across countries.
Italy, Spain and Portugal report the lowest rates, whereas the
Slovak Republic, Lithuania and Malta report the highest rates
(more than 50% higher than the EU average (Figure 6.11)).
Between 2012 and 2017, avoidable hospital  admissions for
diabetes have decreased by more than 40% in Ireland and
Portugal.
These  declines  reflect  concerted  efforts  made  to  improve
service provision in primary and community care settings. In
Portugal, the National Strategy for Quality in Health 2015‑20
improved the quality of organisational and clinical practice for
people with chronic diseases, and increased the adoption of
clinical guidelines. Progress in implementing these measures is
supported  by  continuous  quality  monitoring.  This  shows
improvement  in  the  quality  of  primary  care  in  recent  years
(OECD/European  Observatory  on  Health  Systems  and
Policies, 2019a). In addition, the creation of family health units
staffed by multi-professional teams has allowed for greater care
co-ordination  and care  continuity  for  people  having  chronic
conditions.
In Lithuania, the role and responsibilities of some primary care
providers  have  been  expanded  to  allow  for  better  chronic
disease  management.  General  practice  nurses  and  nurse
assistants are allowed to coordinate the care, to prescribe some
medicines, and to monitor the progression of chronic diseases
(OECD/European  Observatory  on  Health  Systems  and
Policies, 2019b).
Definition and comparability
The  indicator  is  defined  as  the  number  of  hospital
admissions with a primary diagnosis of asthma, COPD, CHF
or  diabetes  among  people  aged  15  years  and  over  per
100  000  population.  Avoidable  admissions  for  diabetes
include  admissions  for  short-term  and  long-term
complications  and  for  uncontrolled  diabetes  without
complications. Rates are age-sex standardised to the 2010
OECD population aged 15 and over.
Admissions resulting from a transfer from another hospital
and where the patient dies during admission are excluded
from the calculation, as these are considered unlikely to be
avoidable. Disease prevalence and availability of  hospital
care  may  explain  some,  but  not  all,  variations  across
countries. Differences in coding practices and data coverage
of  the  national  hospital  sector  may  also  affect  the
comparability of data.
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Figure 6.10. Congestive heart failure hospital admission in adults, 2012 and 2017 (or nearest years)
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Figure 6.11. Diabetes hospital admission in adults, 2012 and 2017 (or nearest years)
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6. MORTALITY FOLLOWING ACUTE MYOCARDIAL INFARCTION (AMI)
Mortality  due  to  coronary  heart  diseases  has  declined
substantially over the past few decades (see indicator “Mortality
from circulatory diseases” in Chapter 3). Reductions in smoking
(see  indicator  “Smoking  among  adults”  in  Chapter  4)  and
improvements in treatment for heart diseases have contributed
to  these  declines.  Despite  this  progress,  acute  myocardial
infarction (AMI or heart attack) remains the leading cause of
cardiovascular  deaths  in  Europe,  highlighting  the  need  for
further reductions in risk factors and care quality improvements
(OECD/The King’s Fund, 2020).
A good indicator of acute care quality is the 30‑day mortality
rate  following  AMI  after  hospital  admission.  The  measure
reflects  the  processes  of  care,  such  as  timely  transport  of
patients  and  effective  medical  interventions.  However,  the
indicator is influenced not only by the quality of care provided in
hospitals, but also by differences in hospital transfers, average
length of stay and AMI severity.
Figure 6.12 shows mortality rates within 30 days of admission to
hospital for AMI using unlinked data – that is, only counting
deaths that  occurred in  the hospital  where the patient  was
initially admitted. Across EU countries, the lowest rates in 2017
were in Denmark, the Netherlands, and Sweden (less than 4%
of patients aged 45 and over), while the highest rate was in
Latvia (over 13%).
Figure  6.13  shows  the  same  30‑day  mortality  rate  but
calculated  based  on  linked  data  whereby  the  deaths  are
recorded regardless of where they occurred (i.e. either in the
hospital where the patient was initially admitted, after transfer to
another hospital or after being discharged). Based on these
linked data, the AMI mortality rates in 2017 ranged from 4% in
the Netherlands to over 14% in Latvia.
Thirty-day mortality rates for AMI have decreased substantially
between 2007 and 2017. Across EU countries for which data
are available, they fell by around 30% on average from 9.2% to
6.5% based on unlinked data and from 12.4% to 9.3% based on
linked  data.  Better  and  more  timely  access  to  acute  care
following an AMI, including timely transportation of patients and
admissions  in  specialised  health  facilities,  such  as
percutaneous  catheter  intervention-capable  centres,  have
contributed to the reduction in mortality rates (OECD, 2015).
Mortality rates for patients admitted with AMI vary significantly
not only across countries, but also across different hospitals in
each country. As shown in Figure 6.14, differences in 30‑day
mortality rates following AMI across hospitals in each country
are  often  much larger  than across  countries.  In  general,  a
greater volume and concentration of acute care for AMI patients
in  specialised  hospital  services  is  associated  with  lower
mortality rates (Lalloué et al., 2019).
Definition and comparability
The mortality  rate  measures  the  percentage of  people
aged  45  and  over  who  died  within  30  days  following
admission to hospital for AMI. National rates are age-sex
standardised to the 2010 OECD population aged 45 and over
admitted to hospital  for AMI (ICD‑10 codes I21‑I22).  The
rates are also adjusted for co-morbidity and previous AMI
(linked data only). The reference population for hospital rates
is constructed from data from participating countries (Padget
et al., 2019).
Besides differences in the coverage of deaths (numerator),
the denominator varies between the indicator using linked
and unlinked data.  The indicator calculated with unlinked
data uses a total number of admissions to hospital with a
primary diagnosis of AMI as the denominator. The indicator
using linked data uses a total number of patients admitted to
hospital with a primary diagnosis of AMI as the denominator.
If patients were admitted multiple times, the last admission is
counted in the denominator.
Figure 6.14 is a turnip plot that graphically represents the
relative dispersion of rates across hospitals in each country.
Hospitals with fewer than 50 AMI admissions were excluded
to improve data reliability.
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Figure 6.12. Thirty-day mortality after hospital admission for AMI based on unlinked data, 2007 and 2017 (or nearest years)
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Figure 6.13. Thirty-day mortality after hospital admission for AMI based on linked data, 2007 and 2017 (or nearest years)
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Figure 6.14. Variation across hospitals in 30-day mortality after admission for AMI, 2015-17
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6. MORTALITY FOLLOWING STROKE
Stroke is the second leading cause of death after heart disease
in  Europe  (see  the  indicator  “Mortality  from  circulatory
diseases” in Chapter 3). Across EU countries, stroke accounted
for 375 000 deaths in 2017, and the number is expected to rise
by one‑third by 2035 due to population ageing and increases in
some risk factors (OECD/The King’s Fund, 2020). Of the two
types of stroke, about 85% are ischaemic (caused by clotting)
and 15% are haemorrhagic (caused by bleeding).
Figure 6.15 shows mortality rates within 30 days of hospital
admission for ischaemic stroke where the death occurred in the
same  hospital  as  the  initial  admission  (unlinked  data).
Figure 6.16 shows mortality rates where deaths are recorded
regardless of where they occurred, including in another hospital
or outside the hospital (linked data).
Using  unlinked  data,  the  mortality  rates  within  30  days  of
hospital admission for ischaemic stroke were highest in Latvia,
Malta and Lithuania with rates over 15% in 2017. They were
lowest  in  Nordic  countries  (Denmark,  Iceland,  Norway  and
Sweden) and in the Netherlands with rates of less than 6%.
Generally,  countries  that  have  30‑day  mortality  rates  for
ischaemic stroke lower than the EU average also tend to have
lower  30‑day  mortality  rates  for  acute  myocardial
infarction  (AMI)  (see  indicator  “Mortality  following  acute
myocardial infarction”). This suggests that certain aspects of
acute care delivery influence outcomes for both stroke and AMI
patients.
Across the smaller group of countries that reported linked data,
the case-fatality rates were highest in Latvia and Lithuania, with
over 20% of patients dying within 30 days of being admitted to
hospital for stroke. They were lowest in the Netherlands and
Norway,  with rates below 9%. These rates are higher than
those based on unlinked data because they capture all deaths.
Treatment for ischaemic stroke has advanced greatly over the
last decades, with more effective systems and processes now
in  place  in  many  European  countries  including  specialised
stroke units involving multidisciplinary teams devoted to care
for stroke patients, and medical progress such as thrombolysis
and thrombectomy (OECD, 2015). Between 2007 and 2017,
30‑day case-fatality rates for ischaemic stroke decreased by
over 15% on average across EU countries, based either on
unlinked data (a reduction from 11.4% to 9.0%) or linked data (a
reduction from 14.2% to 12.0%).
Since the onset of the COVID‑19 pandemic, reduced or delayed
access to care for stroke patients and stretched resources for
stroke care delivery  have been reported in  some countries
(Aguiar  de Sousa et  al.,  2020;  Bersano et  al.,  2020).  This
highlights the importance of continuous monitoring of mortality
rates after hospital admissions for stroke to assess any impact
of COVID‑19 in the provision of timely and quality care to stroke
patients.
Mortality  rates  following  hospital  admissions  for  ischaemic
stroke vary not only across countries, but also across different
hospitals in each country. Figure 6.17 shows that differences in
30‑day mortality rates across hospitals within each country are
often larger than differences across countries. Reducing these
variations is key to providing more equitable care and reducing
overall mortality rates.
Strategies  to  reduce  mortality  rates  from  stroke  include
providing timely transportation of patients, timely delivery of
reperfusion therapy through pre-hospital triage via telephone or
in the ambulance, evidence-based medical interventions and
access to high-quality specialised facilities such as stroke units
(OECD, 2015).
Definition and comparability
National mortality rates are defined in indicator “Mortality
following  acute  myocardial  infarction”.  The  definition  of
ischaemic stroke only includes ICD‑10 codes I63‑I64 and
may differ from broader definitions used at the national level.
Figure 6.17 is a turnip plot that graphically represents the
relative dispersion of rates across hospitals in each country.
The  data  include  only  ICD‑10  I63  (cerebral  infarction).
Hospitals with fewer than 50 stroke admissions are excluded
to improve data reliability. Rates are adjusted for age, sex,
co-morbidity, stroke severity and previous stroke (linked data
only).
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Figure 6.15. Thirty-day mortality after admission to hospital for ischaemic stroke based on unlinked data, 2007 and 2017 (or
nearest years)
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Age-sex standardised rate per 100 admissions of adults aged 45 years and over
Note: The EU average is unweighted. 1. Three-year average.
Source: OECD Health Statistics 2020.
StatLink 2 https://stat.link/vmsknb
Figure 6.16. Thirty-day mortality after admission to hospital for ischaemic stroke based on linked data, 2007 and 2017 (or nearest
years)
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Age-sex standardised rate per 100 patients aged 45 years and over
Note: The EU average is unweighted. 1. Three-year average.
Source: OECD Health Statistics 2020.
StatLink 2 https://stat.link/462uwx
Figure 6.17. Variation across hospitals in 30-day mortality after admission for ischaemic stroke, 2015-17
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6. WAITING TIMES FOR HIP FRACTURE SURGERY
Hip  fractures  are  common  health  problems  and  causes  of
hospitalisation among older people, often related to falls and
the loss of skeletal strength from osteoporosis. With increasing
life expectancy, hip fractures will likely have an even greater
public health impact in the coming years.
In  nearly  all  instances  following  a  hip  fracture,  surgical
intervention is required to repair or replace the hip joint. There is
general  agreement that  early  surgical  intervention improves
patient outcomes and minimises the risk of complications, and
that surgery should normally occur within two days (48 hours) of
hospitalisation. The guidelines in some countries stipulate even
more rapid intervention. For example, in the United Kingdom,
the National Institute for Health and Care Excellence (NICE)
clinical  guidelines  recommend  that  hip  fracture  surgery  be
performed on the day of hospital admission or the next day
(NICE, 2017).
On average across EU countries, more than three quarters
(76%) of patients aged 65 and over admitted for a hip fracture
were operated within two days in 2017, with most of them being
treated either on the same day of admission or the next day
(Figure 6.18). In Denmark and the Netherlands, the proportion
of patients operated within two days reached more than 95%.
By contrast, less than half of patients aged 65 and over were
operated within two days following their admission for a hip
fracture in Latvia and Portugal.
Between 2012 and 2017, there has been a slight increase in the
share of patients operated within two days on average across
EU countries,  from 73% to  76% (Figure  6.19).  Substantial
progress has been achieved in Italy and Spain in meeting the
recommended clinical  guideline  of  operating  patients  within
two days, although both countries still remain far from achieving
their target. Over the same time period, Latvia, Lithuania and
Portugal moved away from this target, having registered a slight
decrease  in  the  share  of  hip-fractured  patients  undergoing
surgery within two days of admission.
In Italy, progress achieved in providing surgical treatment within
48 hours of admission to a larger share of hip-fractured patients
was  mainly  achieved  by  regularly  monitoring  and  reporting
waiting times at the hospital level and reducing waiting times in
those regions and hospitals that were lagging behind (OECD,
2015a).
In Portugal, the proportion of patients operated within two days
after a hip fracture has decreased from 47% in 2011 to 44% in
2017, despite greater efforts to monitor this performance target
at the hospital level and the provision of financial incentives to
achieve more timely hip fracture repairs (OECD, 2015b).
Waiting times for surgery in general are influenced by many
factors, including hospitals’ surgical theatre capacity and the
management  of  demand  for  different  surgical  procedures
(OECD, 2020).
Definition and comparability
The  indicator  of  waiting  times  for  surgery  following
admission for a hip fracture is defined as the proportion of
patients aged 65 years and over admitted to hospital with a
diagnosis of upper femur fracture who had surgery within two
calendar days of their admission. The capacity to capture
time of admission and surgery in hospital administrative data
varies across countries, resulting in the inability to precisely
record surgery within 48 hours in some countries.
While cases where the hip fractures occurred during the
admission to hospital should be excluded, not all countries
have a ‘present on admission’ flag in their datasets to enable
them to identify such cases accurately.
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Figure 6.18. Hip fracture surgery initiation after admission to the hospital, 2017 (or nearest year)
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Note: The EU average is unweighted. Sweden provided data within 12, 24 and 48 hours. 1. Three-year average.
Source: OECD Health Statistics 2020.
StatLink 2 https://stat.link/8ldikc
Figure 6.19. Hip fracture surgery initiation within two days after admission to the hospital, 2012 and 2017 (or nearest years)
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6. BREAST CANCER OUTCOMES
Breast cancer is the most frequent cancer among women in
Europe, and it is expected that more than 355 000 new cases
will  be diagnosed in the EU in 2020 (see indicator “Cancer
incidence and mortality” in Chapter 3). The main risk factors for
breast  cancer  are  age,  genetic  predisposition,  estrogen
replacement  therapy,  and lifestyle  factors  including obesity,
physical inactivity, nutrition habits and alcohol consumption.
Since  the  1980s,  most  European  countries  have  adopted
breast  cancer  screening  programmes  to  improve  early
detection  rates  (OECD,  2013).  The  increasing  number  of
countries that  have set  up population-based mammography
screening  programmes  have  contributed  to  increasing  the
share of women diagnosed at an early stage. Together with
technological advances in treatment of breast cancer, these
two  factors  have  contributed  to  a  significant  reduction  in
mortality from breast cancer over the last decades. During the
period 2010‑14, about half of women diagnosed with breast
cancer in EU countries were at an early stage, while 10% of
women were diagnosed at an advanced stage (Figure 6.20).
In all European countries, the five‑year net survival for women
with breast  cancer  has improved in  recent  years,  reflecting
earlier  detection  from  increased  screening  and  overall
improvement  in  the  quality  of  cancer  care  (Allemani  et  al.,
2018). For women diagnosed at an early or localised stage, the
cumulative  probability  of  surviving  their  cancer  for  at  least
five  years  after  diagnosis  is  on  average  96%  in  the  EU.
However, survival for women diagnosed at an advanced stage
is still low at 38% (Figure 6.21).
For all stages of breast cancer combined, Western European
countries have all attained a five‑year net survival of at least
80%, but net survival is still lower in several Central and Eastern
European countries, despite increases in recent years.
The  COVID‑19  pandemic  severely  disrupted  breast  cancer
screening programmes and treatments in the first half of 2020.
Many European countries reported delays in routine screening
programmes  because  some  mammography  units  were
temporarily shut down or because many women avoided to go
to their  mammogram appointment for fear of being infected
(EC, 2020). This may result in a greater proportion of women
diagnosed at a more advanced stage. The quality of cancer
care  was  also  adversely  affected  during  the  COVID‑19
pandemic by delays in access to treatment and postponement
of  follow-up  (EC,  2020).  This  emphasises  the  need  for
continuous monitoring of  survival  to draw lessons from any
adverse impact for the future.
In recent years, health care providers and patients in European
countries  have  increasingly  used  patient-reported  outcome
measures (PROMs) to help inform difficult clinical decisions on
breast  cancer  treatment  based  on  each  patient’s  own
assessment of quality of life during or after treatment (OECD,
2019).
The rate of mortality from breast cancer in the EU as a whole is
expected to be about 34 per 100 000 women in 2020, without
taking  into  account  any  possible  impact  of  COVID‑19
(Figure 6.22).
Definition and comparability
The stage at diagnosis for breast cancer is categorised
according to the Tumour, Nodes, Metastasis (TNM) staging
system  (7th  edition).  In  this  analysis,  “early  or  localised
stages” refers to tumours without lymph node involvement or
metastasis  (T1‑3,  N0,  M0),  “intermediate stage”  refers to
tumours  with  lymph node involvement  but  no metastasis
(T1‑3,  N1‑3,  M0),  and  “advanced  stage”  refers  to  large
tumours with ulceration or involvement of the chest wall, and
those that have metastasised to other organs (T4, any N, M0
or M1).
Five-year net  survival  is  the cumulative probability  that
cancer patients survive their cancer for at least five years
since diagnosis, after controlling for the risks of death from
other causes and taking into account that competing risks of
deaths are higher in the elderly. Cancer survival estimates
are age-standardised with the International Cancer Survival
Standard (ICSS) weights.
Cancer patient data were provided by national or regional
cancer  registries.  Quality  control,  analysis  of  stage
distribution and estimation of age-standardised five‑year net
survival were performed centrally as part of CONCORD, the
global programme for the surveillance of cancer survival, led
by the London School  of  Hygiene and Tropical  Medicine
(Allemani  et  al.,  2018).  International  comparisons  of  net
survival by stage are affected by coding practices and the
completeness of data on stage, which differ widely between
countries, so caution is needed in interpreting these data.
See  indicator  “Cancer  incidence  and  mortality”  in
Chapter 3 for the sources and method underlying cancer
mortality rates.
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6. INCIDENCE, SURVIVAL AND MORTALITY FOR LUNG CANCER
In  Europe,  lung  cancer  is  the  second  most  commonly
diagnosed form of cancer after prostate cancer among men,
and the third most common cancer after breast and colorectal
cancer  among  women.  In  2020,  about  320  000  people  in
EU countries are expected to be newly diagnosed with lung
cancer, and it is expected to continue to be the leading cause of
cancer death with over 257 000 deaths across the EU (JRC,
2020).  The  main  risk  factors  for  lung  cancer  are  tobacco
smoking and environmental factors, particularly air pollution.
Partly reflecting different historical trends in smoking between
men and women, the incidence of lung cancer is higher among
men  than  women  in  all  European  countries,  although  the
gender gap has narrowed as incidence rates decreased more
rapidly among men in most countries in recent decades (Fidler-
Benaoudia et al., 2020). In 2020, the incidence rate of lung
cancer among men in the EU as a whole is expected to be close
to 100 per  100 000 men,  more than twice the rate among
women (45  per  100 000 women).  The incidence rates  are
almost the same for men and women in Denmark and Sweden,
reflecting a narrower gender gap in smoking in recent decades
(Figure 6.23).
Compared  with  breast  and  colorectal  cancers,  lung  cancer
continues to be associated with relatively  low survival  after
diagnosis.  For  patients  diagnosed  with  lung  cancer  during
2010‑14, the cumulative probability of surviving their cancer for
at least five years (after correction for other causes of death)
was 15% on average across EU countries. These probabilities
range from 10% or less in Croatia, Lithuania and Bulgaria to
20% in Austria, Sweden, Iceland and Switzerland (Figure 6.24).
This suggests significant differences in timely diagnosis and
access  to  pharmaceuticals  and  other  treatments.  Various
pharmaceuticals have been approved and covered by public
payers for lung cancer treatment in Europe, but the availability
of new drugs for the treatment of some types of lung cancer
(e.g. non-small  cell)  varies greatly across countries (OECD,
2020).
Between 2000‑04 and 2010‑14, five‑year net survival following
diagnosis  of  lung  cancer  increased  from  11%  to  15%  on
average across EU countries. All EU countries have achieved
progress except Croatia.
The overall mortality rate from lung cancer in 2020 is expected
to be 54 per 100 000 population in the EU as a whole. Cross-
country variations in mortality rate are more than three‑fold for
men and more than four‑fold for women (Figure 6.25). Hungary
is expected to have the highest mortality rate from lung cancer
in 2020 for both men and women. Reflecting differences in
incidence rates, the gender gap in mortality rates is small in
Nordic countries such as Sweden and Denmark, and large in
some Southern and Eastern European countries (e.g. Greece
and Estonia).
In  general,  trends  in  mortality  rates  for  lung  cancer  have
followed trends in incidence rates with a time lag as survival
probabilities have remained relatively low in all countries. This
is  partly  due  to  the  absence  of  any  large-scale  screening
programme for  lung cancer in EU countries,  particularly  for
high-risk populations, impeding the detection and treatment of
lung cancer at an early stage. Effective treatment of lung cancer
also remains difficult. The most promising approach to reducing
lung cancer mortality is therefore to strengthen prevention to
further  reduce  incidence,  notably  through  tobacco  control
policies and policies to reduce air pollution (see Chapter 2 on air
pollution).
Definition and comparability
The 2020 cancer incidence and mortality estimates have
been  computed  using  the  European  Cancer  Information
System (ECIS) which is used for reporting the cancer burden
in Europe. See the indicator “Cancer incidence and mortality”
in  Chapter  3  for  additional  information  on  the  method
underlying these estimations.
Five-year net  survival  is  the cumulative probability  that
cancer patients survive their cancer for at least five years
since diagnosis, after controlling for the risks of death from
other causes and taking into account that competing risks of
deaths are higher in the elderly. Cancer survival estimates
are age-standardised with the International Cancer Survival
Standard (ICSS) weights.
Cancer patient data were provided by national or regional
cancer  registries.  Quality  control,  analysis  of  stage
distribution and estimation of age-standardised five‑year net
survival were performed centrally as part of CONCORD, the
global programme for the surveillance of cancer survival, led
by the London School  of  Hygiene and Tropical  Medicine
(Allemani et al., 2018).
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Figure 6.24. Lung cancer five-year net survival (%), patients diagnosed during 2000-04 and 2010-14
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6. SCREENING AND SURVIVAL FOR COLORECTAL CANCER
Colorectal cancer is the third most common cause of cancer
death after prostate and lung cancers among men, and the
second  most  common  cause  after  breast  cancer  among
women. It is estimated that about 190 000 men and 150 000
women will be diagnosed with colorectal cancer in the EU in
2020,  and  156  000  people  will  die  from  it  (see  indicator
“Mortality from cancer” in Chapter 3; JRC, 2020). The main risk
factors for colorectal cancer include age; ulcerative colitis; a
personal or family history of colorectal cancer or polyps; lifestyle
factors, such as a diet high in fat and low in fibre, physical
inactivity, obesity, tobacco and alcohol consumption.
After  having  introduced  population-based  screening
programmes for breast and cervical cancer, a growing number
of European countries have also introduced free, large scale
screening  programmes  for  colorectal  cancer.  These
programmes provide faecal occult blood tests either annually or
every other year, mostly to people in their 50s and 60s (EC,
2017;  IARC,  2017).  Participation  rates  in  colorectal  cancer
screening varies from a high of over 70% in the Netherlands to a
low of less than 20% in Hungary (in 2014) and Latvia (in 2018).
Hungary  has  introduced a  new population-based screening
programme for colorectal cancer in 2020 to increase screening
rates. In most countries, screening rates are at least slightly
higher among women than men (Figure 6.26).
Cross-country variations in survival  following a diagnosis of
colon cancer are wider than for many other types of cancer,
such as breast and lung cancer (see indicators “Breast cancer
outcomes”  and  “Incidence,  survival  and  mortality  for  lung
cancer”).  This  suggests large differences in  the capacity  to
ensure timely diagnosis and access to pharmaceuticals and
other  treatments  for  colon  cancer.  On  average  across
EU countries, the five‑year net survival for colon cancer was
about 60% for people diagnosed during 2010‑14, ranging from
65% or more in Belgium, Finland, Sweden and Germany to less
than 55% in many Central and Eastern European countries
including  Latvia,  Croatia,  the  Slovak  Republic,  Romania,
Bulgaria and Poland (Figure 6.27). These countries also have
low five‑year  net  survival  for  rectal  cancer  (Allemani  et  al.,
2018).  Various drugs have been approved and covered by
public payers for colorectal cancer treatment in Europe, but the
availability of new drugs varies across countries (OECD, 2020).
Advances  in  diagnosis  and  treatment  of  colorectal  cancer,
including improved surgical techniques, radiation therapy and
combined  chemotherapy,  have  contributed  to  increasing
survival  rates  between 2000‑04 and 2010‑14.  The average
five‑year  net  survival  rate for  colon cancer  in  EU countries
increased from 54% to 59% between 2000‑04 and 2010‑14,
and from 51% to  58% for  rectal  cancer.  Survival  for  colon
cancer  increased  particularly  rapidly  in  many  Central  and
Eastern  European countries  (Bulgaria,  the Czech Republic,
Denmark, Estonia, Latvia, Lithuania and Slovenia).
In all EU countries, mortality rates from colorectal cancer are
substantially  higher  among  men  than  among  women
(Figure 6.28). Together with the promotion of healthy lifestyles,
efforts  to  increase  colorectal  cancer  screening  rates,
particularly among men, may reduce this gender gap to some
extent.
Definition and comparability
Colorectal  cancer  screening  rates  are  based  on
programme  or  survey  data.  Differences  in  the  target
population and screening frequency in national screening
programmes  may  limit  the  comparability  of  programme-
based data. Survey data may be affected by recall bias.
Five-year net  survival  is  the cumulative probability  that
cancer patients survive their cancer for at least 5 years since
diagnosis, after controlling for the risks of death from other
causes  and  taking  into  account  that  competing  risks  of
deaths are higher in the elderly. Cancer survival estimates
are age-standardised with the International Cancer Survival
Standard (ICSS) weights.
Cancer patient data were provided by national or regional
cancer  registries.  Quality  control,  analysis  of  stage
distribution and estimation of age-standardised five‑year net
survival were performed centrally as part of CONCORD, the
global programme for the surveillance of cancer survival, led
by the London School  of  Hygiene and Tropical  Medicine
(Allemani et al., 2018).
The 2020 cancer mortality estimates have been computed
using  the  European  Cancer  Information  System  (ECIS)
which is used for reporting the cancer burden in Europe. See
the indicator “Cancer incidence and mortality” in Chapter 3
for additional information on the method underlying these
estimations.
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Figure 6.27. Colon cancer five-year net survival (%), patients diagnosed during 2000-04 and 2010-14
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Note: The EU average is unweighted. 1. Coverage is less than 100% of the national population. 2. Survival estimates are considered less reliable. 3. Data for 2000‑04
refer to 2005‑09.
Source: CONCORD programme, London School of Hygiene and Tropical Medicine.
StatLink 2 https://stat.link/kmf50a
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6. HEALTH CARE-ASSOCIATED INFECTIONS
The  ECDC estimates  that  3.1‑4.6  million  people  acquire  a
health care-associated infection (HAI) each year in acute care
hospitals  in  EU  countries,  Iceland,  Norway  and  the
United  Kingdom  (Suetens  et  al.,  2018).  HAIs  can  lead  to
significant increases in patient morbidity, mortality and cost for
the health system. More than 90 000 people die each year in
EU countries, Iceland, Norway and the United Kingdom due to
the six most common infections in health care settings (Cassini,
2016).  HAIs are the single most deadly and costly adverse
event,  representing  up  to  6%  of  public  hospital  budgets
(Slawomirski et al, 2018).
Prevention of HAIs is even more critical in the long-term care
(LTC) sector, as residents of LTC facilities are more frail and
have additional  risk factors for developing HAIs. During the
COVID‑19  pandemic,  LTC  facilities  have  been  particularly
vulnerable  places  for  the  spread of  infections,  with  several
countries reporting large outbreaks that led to high death rates.
The high prevalence of conditions such as dementia and other
neurological  disorders  among  LTC residents  made  it  more
difficult to diagnose people with COVID‑19 at an early stage,
and many cases were identified too late (ECDC, 2020; see also
Chapter 1 on resilience to COVID‑19).
Most  HAIs  are  considered  to  be  avoidable  through  better
infection  prevention  and  control.  At  the  hospital  level,  key
components  of  effective  infection  prevention  and  control
strategies include the creation of a local infection control team,
staff  training,  use  of  evidence-based  guidelines,  infection
surveillance  and  feedback  and  rigorous  maintenance  of
environmental hygiene (WHO, 2016).
On average across EU countries, 5.7% of patients acquired an
infection during their hospital stay in 2016‑17 (Figure 6.29).
Cross-country differences in the prevalence of HAIs need to be
interpreted with caution, because the data are affected by sites
selected for data collection, differences in reporting practices
and varied risks of developing HAIs among patients (see more
details in “Definition and comparability”).
Compounding  the  impact  of  HAIs  are  infections  due  to
antimicrobial-resistant  (AMR)  bacteria,  which  can  lead  to
complications,  longer  hospital  stays,  or  death.  A  single
antibiotic-resistant  infection  has  been  estimated  to  cost
between EUR 8 500 and 34 000 more than a non-resistant
infection,  due  to  additional  hospital  days  and  additional
treatment  costs  (OECD,  2017).  The  inappropriate  and
excessive  use  of  antibiotics  contribute  to  the  increasing
incidence of HAIs caused by AMR bacteria in hospitals and in
the community, making these HAIs difficult or even impossible
to treat. The share of antibiotic-resistant infections ranged from
about 5% in Finland to over 60% of all HAI cases in Romania
and Cyprus, although these rates should also be interpreted
with  caution  due  to  small  sample  sizes  in  some  cases
(Figure 6.29).
In LTC facilities, the prevalence of HAIs among LTC residents
was  3.6%  on  average  across  EU  countries  in  2016‑17
(Figure  6.30).  Cross-country  differences  also  need  to  be
interpreted with  caution because of  differences in  reporting
practices and in patient mix. The impact of HAIs in LTC facilities
is also increased by the rise of  AMR bacteria.  On average
across countries, about one‑third of HAIs in LTC facilities were
resistant  to  antibiotics,  about  the  same  proportion  as  in
hospitals.
Definition and comparability
The data are based on a point prevalence survey (PPS) of
health care-associated infections conducted in 2016‑17 in
acute care hospitals and LTC facilities in Europe, initiated
and coordinated by ECDC. Validation studies of  national
PPS data were carried out in a subgroup of hospitals and
generally found an underestimation of the true prevalence,
which  allowed  to  make  a  more  robust  estimation  of  the
burden of health care-associated infections.
PPSs  currently  represent  the  best  tool  for  collecting
internationally comparable HAI data, but they are subject to
possible biases due to facility selection, reporting practices or
observer training. Many factors – including increased patient
age, limited mobility and use of invasive medical devices –
may  increase  the  risk  of  developing  an  HAI  and  may
influence the variability of rates between countries.
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Figure 6.29. Percentage of hospitalised patients with at least one health care-associated infection and the proportion of these



















Prevalence of HAI % resistant
% HAI % resistant
Note: The EU average is unweighted. Country representativeness of data is limited in Bulgaria and the Netherlands. Data from Norway include partial imputation for
missing types of infections. 1. Under 5% of patients were included from intensive care units (ICU). 2. Over 5% of patients were included from ICU. 3. Unweighted average
for England, Northern Ireland and Wales.
Source: Suetens, C. et al. (2018), ECDC 2016‑17 Point prevalence survey.
StatLink 2 https://stat.link/1sc4xo
Figure 6.30. Percentage of long-term care facility residents with at least one health care-associated infection and the proportion





















Prevalence of HAI % resistant
% HAI % resistant
Note: The EU average is unweighted. Based on composite antibiotic resistance indicator developed by ECDC. Only countries with over 15 bacteria isolated included.
1. Under 45% of residents sampled were wheelchair bound or bedridden. 2. Over 45% of residents sampled were wheelchair bound or bedridden, suggesting higher risks
of HAIs. 3. No data was available on the proportion of wheelchair bound or bedridden residents.
Source: ECDC.
StatLink 2 https://stat.link/98bogr
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6. SAFE PRESCRIBING
The  safety  and  adequacy  of  prescribing  guidelines  and
practices can be analysed to develop indicators of health care
quality,  supplementing  consumption  and  expenditure
information  (see  indicator  “Pharmaceutical  expenditure”  in
Chapter 5). The overuse, underuse or misuse of prescription
medicines can cause significant hazards to health and lead to
wasteful expenditure (OECD, 2017). These risks apply notably
to the use of antibiotics, opioids and benzodiazepines.
Antibiotics should be prescribed only where there is a need that
is clearly supported by evidence to reduce the risk of resistant
strains of bacteria. Furthermore, second-line antibiotics such as
quinolones and cephalosporins should generally be used only
when first-line antibiotics have proven ineffective. Antimicrobial
resistance (AMR) is a growing threat to people’s health and to
economies (OECD, 2018).
Total volumes of all antibiotics prescribed in primary care varied
over three‑fold across European countries in 2017, with Estonia
and Sweden reporting the lowest volumes (at 10 DDD per 1 000
population per day), and Greece and Italy reporting the highest
(at about 30 DDD or more). Volumes of second-line antibiotics
varied  over  20‑fold  across  countries:  Denmark,  Norway,
Sweden and the United Kingdom reported the lowest volumes
of  second-line  antibiotics,  whereas  Greece,  Italy  and  the
Slovak Republic reported the highest (Figure 6.31). Besides
cross-country  differences  in  the  prevalence  of  antibiotic-
resistant  bacteria,  variation  in  the  volumes  of  antibiotics
prescribed  is  likely  to  be  explained  by  differences  in  the
guidelines  and  incentives  that  influence  primary  care
prescribers  and  attitudes  and  expectations  of  patients
regarding the treatment of infectious diseases.
Opioids are often used to treat acute pain and pain associated
with  cancer.  Over  the  last  decade,  they  have  been  used
increasingly  to  treat  chronic  pain,  despite  the  risk  of
dependence, dose increase, shortness of  breath and death
(OECD, 2019). Across EU countries, the average volume of
opioids  prescribed  in  primary  care  in  2017  was  almost  15
defined daily  doses (DDDs)  per  1  000 population  per  day.
Iceland reports volumes more than twice the EU average, while
Italy and Estonia report the lowest volumes (Figure 6.32). While
these numbers reflect  prescription patterns in primary care,
they are also influenced by differences in the availability of
these products, as the availability of opioids is also low in these
countries (OECD, 2019). Cross-country variations can also be
explained  in  part  by  differences  in  clinical  practice  in  pain
management,  as  well  as  differences  in  regulation,  legal
frameworks  for  opioids,  prescribing  policies  and  treatment
guidelines.
Despite  the  risk  of  adverse  side  effects  such  as  fatigue,
dizziness and confusion, benzodiazepines are often prescribed
for older adults for anxiety and sleep disorders. Long-term use
of  benzodiazepines can lead to  adverse events  (falls,  road
accidents and overdoses), tolerance, dependence and dose
escalation. As well as the period of use, there is concern about
the type of benzodiazepine prescribed, with long-acting types
not recommended for older adults because they take longer for
the body to eliminate (OECD, 2017).
Italy  reports  the lowest  use of  long-acting benzodiazepines
among people aged 65 and over (close to 0) while Estonia,
Slovenia  and  Spain  report  the  highest  use  among  the
12 EU countries providing these data. Their chronic use is also
lowest  in  Italy  but  highest  in  Ireland,  Portugal  and  Spain
(Figure 6.33). The large variation can be explained in part by
different  reimbursement  and  prescribing  policies  for
benzodiazepines, as well as possible differences in disease
prevalence and treatment guidelines.
Definition and comparability
Defined  daily  dose  (DDD)  is  the  assumed  average
maintenance  dose  per  day  for  a  drug  used  for  its  main
indication in adults. For instance, the DDD for oral aspirin
equals 3 grammes, the assumed maintenance daily dose to
treat  pain  in  adults.  DDDs do not  necessarily  reflect  the
average daily dose actually used in a given country. For more
detail, see http://www.whocc.no/atcddd.
Data coverage varies across countries.  Austria,  Latvia,
Estonia,  Portugal,  Spain  and  Sweden  include  data  for
primary care physicians only, while others include data from
other providers. Data relate to reimbursed prescriptions, with
the  exception  of  Iceland,  the  Netherlands  (for
benzodiazepines  only)  and  Slovenia,  which  include  non-
reimbursed  medicines.  Data  for  Germany  are  based  on
prescription data of statutory health insurance for outpatient
care.  Further  information  on  sources  and  methods  is
available  at  the  following  OECD  website:  https://
qdd.oecd.org/subject.aspx?Subject=hcqo_meta.
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All - 2017 2nd line
DDDs per 1000 population, per day
Note: The EU average is unweighted. All antimicrobial products defined with ATC code J01, and second-line with ATC codes J01D and J01M. 1. Three-year average.
2. Data from European Centre for Disease Prevention and Control as OECD Health Statistics data are not available.
Source: OECD Health Statistics 2020 and ECDC.
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DDDs per 1 000 population aged 18 and over, per day
Note: The EU average is unweighted. Exclusion of products used in the treatment of addiction. 1. Three-year average.
Source: OECD Health Statistics 2020.
StatLink 2 https://stat.link/wvsztx































Long-acting benzodiazepines Chronic use of benzodiazepines
DDDs per 1 000 population aged 65 years and over, per day
Note: The EU average is unweighted. 1. Three-year average.
Source: OECD Health Statistics 2020.
StatLink 2 https://stat.link/wb72qj
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and use of services
Most  EU countries  have  achieved universal  coverage for  a  core  set  of  health
services, although the range of services covered and the degree of cost-sharing
vary.  Effective  access to  care  can be restricted for  financial  reasons,  but  also
because of health workforce shortages, long waiting times or long distance to travel
to the closest health care facility. In most EU countries, only a small share of the
population reported unmet needs for health care in 2018, but this proportion was
higher among low-income households, mainly for financial reasons. On average
across EU countries, around a fifth of all health spending is paid out-of-pocket by
households, but with wide variations across countries. In general, countries that have
a higher  share of  out-of-pocket  spending also have a  higher  proportion  of  the
population  facing  catastrophic  out-of-pocket  payments  for  health  services,
particularly among low-income groups. Although the number of doctors and nurses
per  population has increased over  the past  decade in  nearly  all  EU countries,
shortages persist in many countries and were brought to light during the COVID‑19
pandemic. Long waiting time for some health services such as elective surgery is an
important policy issue in many EU countries, as it restricts timely access to care and
generates patient  dissatisfaction.  Even before the COVID‑19 pandemic,  waiting
times for elective surgery were on the rise in many countries as the demand for
surgery was increasing more rapidly than the supply.
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Accessibility  to  health  care can be limited for  a  number  of
reasons, including cost, distance to the closest health facility
and waiting times.  Unmet  care needs may result  in  poorer
health  for  people  forgoing  care  and  may  increase  health
inequalities if such unmet needs are concentrated among poor
people. There are many ways to seek information from the
population about  unmet health  care needs that  will  provide
different results. The data presented here are based on the EU
Statistics on Income and Living Conditions survey (EU-SILC)
as  they  are  the  most  timely  and  comparable  source  of
information available across all EU countries.
In  all  European  countries,  most  of  the  population  in  2018
reported  that  they  had  no  unmet  care  needs  for  financial
reasons, geographic reasons or waiting times, based on EU-
SILC (Figure 7.1). However, in Estonia and Greece, at least 8%
of the population reported some unmet needs for health care,
with  the  burden  falling  mostly  on  people  from  low-income
households, particularly in Greece. Nearly one in five Greek
people in the lowest income quintile reported going without
some medical care when they needed it – these unmet needs
were mainly for financial reasons. In Estonia, long waiting times
are the main reason for people to report unmet care needs,
which  are  partly  explained  by  the  limited  volume  of  some
services (such as specialist consultations) fully reimbursed by
public health insurance. The Estonian Health Insurance Fund
provided additional funding in 2018 to improve the availability of
specialist  services  and  treatments,  which  resulted  in  a
reduction in waiting times for at least some services (OECD,
2020a).
In most countries, a larger proportion of the population indicates
some  unmet  needs  for  dental  care  than  for  medical  care
(Figure 7.2). This is mainly because dental care is only partially
included (or not included at all)  in public schemes in many
countries and so must either be paid out-of-pocket or covered
through  purchasing  private  health  insurance  (see  indicator
“Extent of health care coverage”). More than 1 in 12 people
(8%) in Portugal, Latvia and Greece reported unmet needs for
dental care in 2018, mainly for financial reasons. According to
EU-SILC, only a very small proportion of people in Malta, the
Netherlands,  Luxembourg,  Germany  and  Austria  reported
unmet  dental  care  needs  in  2018,  but  in  the  latter  three
countries at least, this proportion was much greater based on
the results from the European Health Interview Survey in 2014
only including those who said that they actually had dental care
needs (OECD, 2020b).
Unmet needs for medical care and dental care have generally
decreased on average across EU countries since reaching a
peak  around  2013,  although  unmet  medical  care  needs
increased in 2018 in some countries like Estonia, Finland and
Poland (Figure 7.3 and Figure 7.4). The gap in unmet medical
and dental care needs between poor people and rich people
remains large: on average across EU countries, people in the
lowest income quintile are still four times more likely to report
unmet medical care needs than those in the highest quintile,
and six times more likely to report unmet dental care needs.
Indicators  of  self-reported  unmet  care  needs  should  be
assessed  together  with  other  indicators  of  affordability  and
accessibility to care, such as the extent of health care coverage,
the amount of out-of-pocket payments, and the actual use of
health services. Strategies to improve access to care for poor
people  and  disadvantaged  groups  need  to  tackle  not  only
affordability issues, but also effective access to services by
promoting  an  adequate  supply  and  distribution  of  health
workers and services throughout the country.
Definition and comparability
Questions on unmet health care needs are included in the
European Union Statistics on Income and Living Conditions
survey (EU-SILC). People are asked whether there was a
time in the previous 12 months when they felt they needed
medical care or dental care but did not receive it, followed by
a question as to why the need for care was unmet. The data
presented here focus on three reasons: the care was too
expensive, the distance to travel too far or waiting times too
long.
Cultural factors may affect responses to questions about
unmet care needs. There are also some variations in the
survey question across countries: while most countries refer
to  both  a  medical  examination  or  treatment,  in  some
countries  (e.g.  Czech Republic,  Slovenia  and Spain)  the
question only refers to a medical examination or a doctor
consultation, resulting in lower rates of unmet needs. The
question in  Germany refers  to  unmet  needs for  “severe”
illnesses, also resulting in some under-estimation compared
with other countries. Some changes in the survey question in
some countries in 2015 and 2016 have also led to substantial
reductions.  Caution  is  therefore  required  in  comparing
variations across countries and over time.
Income quintile groups are computed on the basis of the
total  equivalised  disposable  income  attributed  to  each
member of the household. The first quintile group represents
the 20% of the population with the lowest income, and the
fifth quintile group the 20% of the population with the highest
income.
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Figure 7.1. Unmet need for medical examination due to
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Figure 7.3. Evolution in unmet medical care need due to
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Figure 7.2. Unmet need for dental examination due to financial,
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Figure 7.4. Evolution in unmet dental care need due to
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7. FINANCIAL HARDSHIP AND OUT-OF-POCKET EXPENDITURE
Where  health  systems  fail  to  provide  adequate  financial
protection,  people may not  have enough money to  pay for
health care or meet other basic needs. As a result,  lack of
financial  protection  can  reduce  access  to  health  care,
undermine  health  status,  deepen  poverty  and  exacerbate
health and socio-economic inequalities. On average across EU
member states, around a fifth of all spending on health care
comes  directly  from  patients  through  out-of-pocket  (OOP)
payments (see indicator “Financing of health expenditure” in
Chapter  5).  People  experience financial  hardship  when the
burden of such OOP payments is large in relation to their ability
to pay. Poor households and those who have to pay for long-
term  treatment  such  as  medicines  for  chronic  illness  are
particularly vulnerable.
The share of  household consumption spent  on health  care
provides an aggregate assessment of the financial burden of
OOP expenditure. Across EU member states, about 3% of total
household spending was on health care goods and services,
ranging from 2% or  less in  France,  Luxembourg,  Slovenia,
Romania and Croatia to more than 7% in Malta (Figure 7.5).
The share is also relatively high in Switzerland (6%).
Health systems in EU countries differ in the degree of coverage
for different health goods and services (see indicator “Extent of
health  care  coverage”).  Household  spending  on
pharmaceuticals and other medical goods was the main health
care expense for people, followed by spending on outpatient
care (Figure 7.6). These two components typically account for
almost  two‑thirds  of  household  spending  on  health  care.
Household spending on dental care and long-term health care
can also be high, averaging 13% and 11% of OOP spending on
health  respectively,  followed by  spending  on  inpatient  care
(10%).
The indicator most widely used to measure financial hardship
associated with OOP payments for households is the incidence
of catastrophic spending on health (Cylus et al., 2018). This
varies  considerably  across  European  countries,  from fewer
than  2%  of  households  experiencing  catastrophic  health
spending in France, Sweden, the United Kingdom, Ireland, the
Czech Republic and Slovenia, to over 8% of households in
Portugal, Poland, Greece and Hungary. In Latvia, Lithuania and
Bulgaria, the proportion is even higher, reaching 15% or more
(Figure 7.7). Across all countries, poorer households (i.e. those
in  the  bottom  consumption  quintile)  are  most  likely  to
experience catastrophic health spending, despite the fact that
many countries have put in place policies to safeguard financial
protection.
Countries with comparatively high levels of public spending on
health and low levels of OOP payments typically have a lower
incidence of catastrophic spending. However, policy choices
are also important, particularly around coverage policy (WHO
Regional Office for Europe, 2019). Population entitlement to
publicly  financed  health  care  is  a  prerequisite  for  financial
protection,  but  not  a  guarantee  of  it.  Countries  with  a  low
incidence of catastrophic spending on health are also more
likely to exempt poor people and frequent users of care from co-
payments; use low fixed co-payments instead of percentage
co-payments, particularly for outpatient medicines; and cap the
co-payments a household has to pay over a given time period
(e.g.  Austria,  Czech  Republic,  Ireland  and  the
United Kingdom).
Definition and comparability
Out-of-pocket  (OOP) payments are expenditures borne
directly  by  a  patient  where  neither  public  nor  private
insurance cover the full cost of the health good or service.
They include cost-sharing and other expenditure paid directly
by  private  households  and  should  also  ideally  include
estimations of informal payments to health providers.
Catastrophic health spending is an indicator of financial
protection used to monitor progress towards universal health
coverage (UHC). It is defined as OOP payments that exceed
a predefined  percentage  of  the  resources  available  to  a
household  to  pay  for  health  care.  Household  resources
available to pay for care can be defined in different ways,
leading to measurement differences. In the data presented
here,  these  resources  are  defined  as  household
consumption minus a standard amount representing basic
spending on food, rent and utilities (water, electricity, gas and
other fuels). The threshold used to define households with
catastrophic  spending  is  40%.  Microdata  from  national
household  budget  surveys  are  used  to  calculate  this
indicator.
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Figure 7.5. Out-of-pocket spending on health as share of final household consumption, 2018 (or nearest year)
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Note: The EU average is unweighted.
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7. POPULATION COVERAGE FOR HEALTH CARE
The share of  the population covered by a public  or  private
scheme provides some indication of  the financial  protection
against the costs associated with health care, but this is not a
complete  indicator  of  affordability  as  the  range  of  services
covered  and  the  degree  of  cost-sharing  applied  to  those
services also matter. These three dimensions – the ‘breadth’,
‘depth’ and ‘height’ of coverage – define how comprehensive
health care coverage is in a country. The indicator presented
here on population coverage looks at the first dimension only,
whereas  the  next  indicator  on  the  extent  of  health  care
coverage  takes  a  broader  look  at  these  three  dimensions
together.
Most European countries have achieved universal (or near-
universal)  coverage  of  health  care  costs  for  a  core  set  of
services, usually including consultations with doctors, tests and
examinations,  and  hospital  care  (Figure  7.8).  Yet,  in  some
countries coverage of these core services may not be universal.
In Ireland, for example, only Medical Card and GP Card holders
(less than 50% of the population) were covered for the costs of
GP visits in 2019, although recent reform proposals suggest a
gradual  roll  out  of  primary  care  coverage  to  the  entire
population (OECD/European Observatory on Health Systems
and Policies, 2019a).
Three EU countries (Bulgaria, Romania and Cyprus) still had at
least 10% of their population not covered for health care costs
in recent years. In Bulgaria, at least one person in ten did not
have  health  insurance  in  2017,  although  other  estimates
suggest that this proportion may be closer to one in seven. This
mainly  concerns  people  in  informal  employment,  long-term
unemployed people and the Roma population who do not pay
health insurance premiums either because they cannot afford it
or for other reasons (OECD/European Observatory on Health
Systems  and  Policies,  2019b).  In  general,  people  without
insurance have free access to some services, like emergency
care or care during pregnancy, but they need to cover all other
costs out of pocket.
In Romania, the number of people without coverage is difficult
to quantify because of the significant number of Romanians
working abroad who are still counted as residents (around 3 to
4 million people) and thus appear in the statistics as having no
insurance. The uninsured population living in Romania include
mainly  people  working  in  the  agricultural  sector,  the  self-
employed,  unemployed  people  who  are  not  registered  for
unemployment or social security benefits, and Roma people
who do not have identity cards (precluding them from enrolling
into the social security system). As in Bulgaria, the uninsured
can  only  access  a  minimum  benefits  package,  covering
emergency  care,  treatment  of  communicable  diseases  and
care  during  pregnancy  (OECD/European  Observatory  on
Health Systems and Policies, 2019c).
In 2019, Cyprus started to implement a major reform to move
towards universal health coverage through the implementation
of a National Health Insurance System (NHIS), although not all
the population had registered to be beneficiaries of the new
system as of early 2020. Beyond addressing coverage gaps,
the new NHIS also aims to address the current fragmentation
between  the  public  and  private  systems  (European
Commission, 2020).
Although basic  primary  health  coverage generally  covers  a
defined set  of  benefits,  in many countries accessing health
services entails some degree of cost sharing for the majority of
users. In most countries, additional health coverage can be
purchased through private insurance to cover any cost-sharing
left  after  basic  coverage  (complementary  insurance),  add
additional services (supplementary insurance) or provide faster
access or larger choice of providers (duplicate insurance). In
most EU countries, only a small proportion of the population has
an additional private health insurance, with the exception of
France, Slovenia, Belgium, the Netherlands, Luxembourg and
Croatia,  where  half  or  more  of  the  population  has  private
coverage (Figure 7.9).
Definition and comparability
Population coverage for health care is defined as the share
of the population covered for a set of health care goods and
services  under  public  programmes  and  through  private
health insurance. Public coverage refers both to government
programmes,  generally  financed  by  taxation,  and  social
health insurance, generally financed by payroll taxes. The
take-up  of  private  health  insurance  is  often  voluntary,
although it  may be  mandatory  by  law or  compulsory  for
employees as part of their working conditions.
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7. EXTENT OF HEALTH CARE COVERAGE
In addition to the share of the population entitled to core health
services, the extent of health care coverage is defined by the
range of services included in a publicly defined benefit package
and the proportion of costs covered. Figure 7.10 assesses the
extent of coverage for selected health care goods and services,
by  calculating  the  share  of  expenditure  covered  under
government  schemes  or  compulsory  health  insurance.
Differences across countries in the extent of coverage can be
due to specific goods and services being included or excluded
in the publicly defined benefit package (e.g. a particular drug or
medical  treatment);  different  cost-sharing  arrangements;  or
some  services  only  being  covered  for  specific  population
groups in a country (e.g. dental treatment).
On average, across EU member states, almost three‑quarters
of  all  health  care  costs  were  covered  by  government  or
compulsory  health  insurance  schemes  (see  indicator
“Financing  of  health  expenditure”  in  Chapter  5),  but  in  all
countries this proportion varies across the types of care service.
Inpatient  services  in  hospitals  are  more  comprehensively
covered than any other type of care. Across the EU, 88% of all
inpatient  costs  are  borne  by  government  or  compulsory
insurance schemes. In many countries, patients have access to
free acute inpatient care, or only have to make a small co-
payment. As a result, coverage rates are near 100% in Estonia,
Romania, Sweden, Norway and Iceland. Only in Cyprus and
Greece is the financial coverage for the cost of inpatient care
70% or lower. In these countries, some patients may choose
treatment  in  private  facilities,  where  coverage  is  not  (fully)
included in the public benefit package.
Around three‑quarters of spending on outpatient medical care
in EU member states are borne by government and compulsory
insurance  schemes.  Coverage  ranged  from  under  40%  in
Cyprus and below 60% in Bulgaria, Greece, Italy, Malta and
Portugal  to 90% or more in the Czech Republic,  Denmark,
Germany, the Slovak Republic and Sweden. Outpatient primary
and specialist care are frequently free at the point of service, but
user charges may still  apply for  specific  services or if  non-
contracted  private  providers  are  consulted.  For  example  in
Denmark, where 92% of total costs are covered, user charges
exist for visits to psychologists and physiotherapists.
Public coverage for dental care costs is far more limited across
the EU due to restricted service packages (frequently limited to
children) and higher levels of cost-sharing. On average, only
around 30% of costs are borne by government schemes or
compulsory  insurance.  Only  three  EU  countries  (Croatia,
Germany and the Slovak Republic) publicly cover more than
half of total spending for dental care. In Greece and Spain,
dental care costs for adults without any specific entitlement are
not covered. Voluntary health insurance may play an important
role in providing financial protection when dental care is not
comprehensively covered in the benefit package (e.g. in the
Netherlands).
Coverage  for  pharmaceuticals  is  also  typically  less
comprehensive than for inpatient and outpatient care. Across
the  EU,  56%  of  pharmaceutical  costs  are  covered  by
government or compulsory insurance schemes. This share is
less  than  40%  in  Bulgaria,  Cyprus,  Latvia,  Lithuania  and
Poland. Coverage is most generous in Germany (82%) and
France (81%). Over-the-counter medications – which by their
nature are not usually covered by public schemes – play an
important role in some countries (see indicator “Pharmaceutical
Expenditure” in Chapter 5).
Therapeutic  appliances  such  as  glasses  and  other  eye
products, hearing aids and other medical devices are typically
covered to a lesser extent than other health care goods and
services, with the exception of dental care. Government and
compulsory insurance schemes cover more than 50% of these
expenses in only four EU countries. In the case of corrective
eye products, compulsory coverage is often limited to paying
partially for the cost of glasses, while private households are left
to bear the full cost of the frames if they are not covered by
complementary insurance.
Definition and comparability
Health  care  coverage  is  defined  by  the  share  of  the
population entitled to services (“breadth of coverage”), the
range of services included in a benefit package (“depth of
coverage”) and the proportion of costs covered (“height of
coverage”)  by  government  schemes  and  compulsory
insurance schemes. Coverage provided by voluntary health
insurance and other voluntary schemes such as charities or
employers is not considered. The core functions analysed
here are defined based on definitions in the System of Health
Accounts 2011. Hospital care refers to inpatient curative and
rehabilitative care in hospitals, outpatient medical care to all
outpatient curative and rehabilitative care excluding dental
care,  pharmaceuticals  to prescribed and over-the-counter
medicines  including  medical  non-durables.  Therapeutic
appliances are glasses and other eye products, hearing aids
and other medical devices.
Comparing the shares of the costs covered for different
types of services is a simplification in assessing the full extent
of health care coverage in a country. For example, a country
with more restricted population coverage but a very generous
benefit basket may display a lower share of coverage than a
country where the entire population is entitled to services but
with a more limited benefit basket. Yet, this method is still
useful to highlight any gaps in coverage.
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Figure 7.10. Health care coverage for selected goods and services, 2018 (or nearest year)








































































































































































































Note: Outpatient medical services mainly refer to services provided by generalists and specialists in the outpatient sector. Pharmaceuticals include prescribed and over-
the-counter medicines as well as medical non-durables. Therapeutic appliances refer to vision products, hearing aids, wheelchairs and other medical devices. N/A means
data not available. The EU average is unweighted.
Source: OECD Health Statistics 2020.
StatLink 2 https://stat.link/gq439x
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7. AVAILABILITY OF DOCTORS
Doctors and other health workers are crucial for addressing the
health needs of the population in normal circumstances and
even more so during exceptional circumstances such as the
COVID‑19 pandemic. Proper access to medical care requires a
sufficient number of doctors, with a proper mix of generalists
and specialists and a proper geographic distribution to serve
the population in the whole country.
In 2018, Greece had the highest number of doctors with 6.1 per
1 000 population, but this number is an over-estimation as it
includes  all  doctors  licensed  to  practice  (including  retired
physicians  and  those  who  might  have  emigrated  to  other
countries).  Austria and Portugal also had a high number of
doctors per population, but the number in Portugal is also over-
estimated for the same reason as in Greece (the number of
practising doctors in Portugal is likely slightly below the EU
average). On the other side of the spectrum, the number of
doctors  per  capita  was  lowest  in  Poland,  Luxembourg,
Romania and Belgium (Figure 7.11).
Between 2008 and 2018, the number of  doctors per capita
increased  in  all  EU countries,  although the  rise  in  France,
Latvia,  Estonia  and  the  Slovak  Republic  has  been  very
marginal.  On  average  across  EU  countries,  the  number
increased from 3.3 doctors per 1 000 population in 2008 to 3.8
in 2018, a growth of 15% taking into account the population
increase.
There were a lot of concerns in the late 2000s about projected
shortages of doctors arising from population ageing and the
ageing  of  the  medical  workforce  (OECD,  2008).  These
concerns  prompted  many  EU  countries  to  take  actions  to
anticipate the retirement of a large number of doctors, notably
by increasing the number of medical students, to replace those
retiring (OECD, 2016). Several countries also took actions to
postpone the retirement of current doctors and recruited more
doctors from abroad (OECD, 2019a).
In many countries, the main concern has been about growing
shortages  of  general  practitioners,  particularly  in  rural  and
remote regions. Whereas the overall  number of doctors per
capita has increased in nearly all countries, the share of general
practitioners  (GPs)  has  come  down  in  most  countries.  On
average across EU countries, only about one in five doctors
were GPs in 2018 (Figure 7.12). Greece and Poland have the
lowest share of GPs, while Portugal, Finland and Belgium have
been  able  to  maintain  a  better  balance  between  GPs  and
specialists. Several countries have taken steps over the past
decade to increase the number of postgraduate training places
in general medicine. For example, in France, about 40% of all
new  postgraduate  training  places  have  been  allocated  to
general medicine since 2017, a greater proportion than in most
other EU countries. However, in France as in other countries, it
remains a challenge to attract a sufficient number of medical
students to fill  the available training places, given the lower
remuneration  and  perceived  prestige  of  general  practice
(OECD/European Observatory of Health Systems and Policies,
2019).
The uneven geographic distribution of doctors and difficulties in
recruiting  and  retaining  doctors  in  remote  and  sparsely
populated  areas  is  another  persisting  challenge  in  many
European countries. In all countries, the density of physicians is
generally greater in urban regions, reflecting the concentration
of specialised services such as surgery in urban centres as well
as  physicians’  preferences  to  live  and  practice  in  cities.
Differences in the density of doctors between urban and rural
regions are highest in the Slovak Republic, the Czech Republic
and Greece (OECD, 2019b).
Many countries provide different types of financial and other
incentives to attract and retain doctors in underserved areas,
including one‑time subsidies to help them set up their practice
as well as recurrent payments such as income guarantees and
bonus payments. A number of countries have also introduced
measures to encourage students from underserved regions to
enrol in medical schools (OECD, 2016).
Definition and comparability
Practising  physicians  are  defined  as  doctors  who  are
providing care for patients. In some countries, the numbers
also include doctors working in administration, management,
academic  and  research  positions  (“professionally  active”
physicians), adding another 5‑10% of doctors. Greece and
Portugal report all physicians entitled to practice, resulting in
an  even  greater  overestimation.  In  Belgium,  a  minimum
threshold of activities (500 consultations per year) is set for
general  practitioners  to  be  considered  to  be  practising,
resulting  in  an  under-estimation  compared  with  other
countries that do not set such a threshold.
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Figure 7.12. Share of different categories of doctors, 2018 (or nearest year)
46
37 37
30 28 26 26 24 22 21 21 21 20 20 19 19 18 18 16 16 15 15 14 13 9 6













General practitioners Other generalists¹ Specialists Other doctors (not further defined)
Note: The EU average is unweighted. 1. Other generalists include non-specialist doctors working in hospital and recent medical graduates who have not started yet their
post-graduate specialty training. 2. In Portugal, only about 30% of doctors employed by the public sector (NHS) are working as GPs in primary care, with the other 70%
working in hospital.
Source: OECD Health Statistics 2020; Eurostat Database.
StatLink 2 https://stat.link/52bsc4
HEALTH AT A GLANCE: EUROPE 2020 © OECD/European Union 2020 213
7. CONSULTATIONS WITH DOCTORS
Consultations  with  doctors  are,  for  most  people,  the  most
frequent contacts with health services and often provide an
entry point for subsequent medical  treatment.  Consultations
can take place in different settings, including doctors’ offices,
hospital  outpatient  departments  or  patients’  own  homes.
Increasingly,  consultations  can  also  take  place  online  and
through  video  calls,  through  the  development  of
teleconsultations  (Oliveira  Hashiguchi,  2020).  The  use  of
teleconsultations  increased  greatly  during  the  COVID‑19
pandemic as a way to protect both patients and doctors and
avoid spreading the virus. For example, in France, the number
of teleconsultations reached close to 1 million per week in April
2020 compared to around 10 000 per week before March. In
Norway,  the  share  of  teleconsultations  with  a  general
practitioner rose from 5% before the pandemic to almost 60%
during the pandemic.
In 2018, on average across EU countries, people had between
six  and  seven  physical  (face-to-face)  consultations  with  a
doctor in that year. The number of consultations with doctors
was  highest  in  the  Slovak  Republic,  Hungary,  Germany,
Lithuania and the Netherlands, with nine consultations or more
per  year.  It  was  lowest  in  Sweden,  Greece,  Denmark  and
Finland (Figure 7.13).
Differences in health service delivery and payment methods
can explain some of the variations across countries. In Sweden,
Finland and Ireland, the low number of doctor consultations can
be explained partly by the fact that nurses and other health
professionals play an important role in primary care centres,
lessening  the  need  to  consult  doctors.  In  these  countries,
nurses can play a greater role in the management of patients
with chronical diseases and in dealing with patients with minor
health issues (OECD, 2020). Some countries, which pay their
doctors mainly by fee-for-service (e.g. the Slovak Republic, the
Czech Republic or Germany), tend to have higher consultation
rates than other countries where doctors are mainly paid by
salaries or capitation (Finland, Denmark, Sweden). The level of
co-payment may also explain some of the variations across
countries. In Switzerland and Ireland, for example, patient co-
payments are high for  a large proportion of  the population,
which may result in fewer consultations.
The estimated number of consultations per doctor is highest in
Poland,  Hungary  and  the  Slovak  Republic,  with  more  than
3 000 consultations per doctor per year. It is lowest in Sweden,
Denmark, Austria, Finland and Bulgaria with less than 1 500
consultations per doctor (Figure 7.14). This indicator should not
be  taken  as  a  measure  of  doctors’  productivity,  since
consultations can vary in length and effectiveness, and also
because it  excludes other services delivered by doctors for
hospital inpatients, time spent on research, administration or
care co-ordination,  as well  as new ways of  interacting with
patients.
Looking  at  trends  over  time  in  the  estimated  number  of
consultations per doctor per year, the number has decreased
slightly since 2000 in Austria, Denmark, France, Germany and
Sweden, as the number of doctors has increased more rapidly
than the number of traditional consultations, whereas it  has
increased in Poland (Figure 7.15).
As  already  noted,  alternatives  to  traditional  face-to-face
consultations are growing rapidly in many countries through the
use  of  digital  technologies,  providing  new  opportunities  to
facilitate patient  and doctor  interactions in  various ways.  In
2019,  primary  care  physicians  in  Sweden  and  the
United Kingdom were more likely to report  offering patients
web-based communication options such as prescription refill,
test results or visit summary viewing capabilities than those in
France, Switzerland, Norway and the Netherlands (Michelle
et al., 2019).
Definition and comparability
Consultations with doctors refer to the number of face-to-
face contacts with physicians, including both generalists and
specialists.  There  are  variations  across  countries  in  the
coverage  of  different  types  of  consultations,  notably  in
outpatient departments of hospitals. The data come mainly
from  administrative  sources,  although  in  some  countries
(Ireland, the Netherlands, Spain and Switzerland) the data
come  from  health  interview  surveys.  Data  from
administrative sources tend to be higher than those from
surveys because of problems with recall and non-response
rates, leading to an under-estimation.
The data for the Netherlands exclude contacts for maternal
and child care. In Austria and Germany, the data include only
the number of cases of physicians’ treatment according to
reimbursement  regulations  under  the  Social  Health
Insurance Scheme (a case only counts the first contact over
a three‑month period, even if the patient consults a doctor
more  often,  leading  to  an  under-estimation).  Telephone
contacts are included in a few countries (e.g. Ireland, Spain).
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Figure 7.14. Estimated number of consultations per doctor, 2018 (or nearest year)
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7. AVAILABILITY OF DENTISTS AND CONSULTATIONS WITH DENTISTS
Oral health is an important, although often neglected public
health  issue.  The  economic  burden  of  oral  diseases  is
substantial. Oral diseases account for more than 5% of total
health  spending  on  average  across  EU  countries,  and
productivity losses due to oral diseases have been estimated at
around EUR 57 billion a year (Platform for Better Oral Health in
Europe, 2019). Dentists play a key role in both preventing and
treating oral health problems.
In 2018, there were between 0.4 and 1.2 practising dentists per
1 000 population across EU countries (Figure 7.16). Greece,
Cyprus, Portugal, Bulgaria, Lithuania, Estonia and Luxembourg
had the highest number of dentists per capita, with at least one
dentist per 1 000 population, although the numbers in Greece
and Portugal are over-estimated as they include all dentists
licensed to practice. The number of dentists per capita was
lowest in Poland, Malta and the Slovak Republic.
Between 2008 and 2018, the number of dentists per capita
increased or remained stable in most EU countries, except in
Greece  and  Denmark  where  it  decreased.  The  number  of
dentists per capita rose particularly strongly in Portugal, Spain,
Romania, Lithuania and Hungary, with an increase of 40% or
more since 2008 (Figure 7.16). In most of these countries, this
rise in the number of dentists was driven by a large increase in
the number of students admitted and graduating from dentistry
programmes.
While there is no general consensus about how often people
should visit a dentist, the recommendation in several countries
is that  children should have a visit  at  least  once a year to
prevent  and treat  quickly  any problem, while adults  without
problems may wait as long as two years. On average across
EU countries,  people had just  over one consultation with a
dentist in 2018. The number of consultations with a dentist was
highest in the Netherlands, the Czech Republic and Lithuania,
whereas it was lowest in Romania and Ireland (Figure 7.17).
A higher number of dentists per capita generally tends to be
associated  with  a  higher  number  of  dentist  consultations.
However, for a given number of dentists per capita, there can
be  wide  differences  in  the  average  number  of  dentist
consultations. For instance, while the Netherlands has slightly
fewer dentists per capita than Austria and France, the average
number of dentist consultations is almost two times greater.
The higher number of consultations in the Netherlands can be
explained by the strong preference of people for regular dental
check-ups  arising  from  well-established  programmes  to
promote prevention of oral health issues at a young age. The
National  Dutch  programme  “Keep  your  Mouth  Healthy”
provides oral health education to children and is considered one
of  the  best  practices  in  Europe.  Several  other  European
countries have similar programmes of oral health promotion
and prevention among children and adolescents (Platform for
Better Oral Health in Europe, 2015).
The extent of public coverage for dental care costs can also
partly  explain  some  of  the  cross-country  variations  in  the
number of dentist consultations (see indicator “Extent of health
care coverage”). In Romania for example, only 6% of dental
care spending is  publicly  funded.  By contrast,  in  Germany,
more than 60% of dental spending is publicly covered. In the
Netherlands, while dental care is not comprehensively covered
in the benefit  package, voluntary health insurance plays an
important role in providing financial protection for dental care.
Definition and comparability
The number of dentists includes both salaried and self-
employed dentists. In most countries, the data only include
dentists providing direct services to clients/patients. This is
not  the  case  however  in  Ireland,  Greece,  Montenegro,
Portugal  and  Spain,  where  the  data  refer  to  all  dentists
licensed to practice (including those who may not be actively
practising), resulting in an over-estimation of the number of
practising dentists.
The average number of consultations with a dentist per
year  includes  visits  at  the  dentist’s  office  as  well  as  in
outpatient departments in hospital, although the coverage of
these settings may differ across countries. The data come
mainly  from  administrative  sources,  although  in  some
countries (Ireland, the Netherlands, Spain and Switzerland)
the  data  come from health  interview surveys.  Data  from
administrative sources tend to be higher than those from
surveys because of problems with recall and non-response
rates and also because some surveys only cover adults,
resulting in an under-estimation if the number of visits among
children is greater. Austria, Cyprus, Hungary, Serbia and the
United  Kingdom  do  not  cover  consultations  privately
financed or provided in the private sector, also resulting in an
under-estimation.
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7. AVAILABILITY OF NURSES
Nurses play a critical role in providing care in hospitals and
long-term care institutions under normal circumstances, and
their  role  was  even  more  critical  during  the  COVID‑19
pandemic. Pre-existing shortages of nurses were exacerbated
during the peak of the epidemic, also because many nurses
themselves became infected by the virus (see Chapter 1 on
resilience to COVID‑19).
The demand for nurses is expected to continue to rise in the
years ahead because of population ageing while many nurses
are  approaching  retirement  age.  Concerns  about  growing
shortages have prompted actions in many countries to increase
the  training  of  new  nurses.  Some  countries  have  also
addressed current shortages by recruiting nurses from abroad
(OECD, 2019). Increasing the retention rate of nurses in the
profession  remains  a  key  issue  in  most  countries  to  avoid
current and future shortages.
On average across EU countries, there were 8.2 nurses per
1 000 population in 2018, a rise from 7.4 in 2008 (Figure 7.18).
Among EU countries, the number of nurses per capita was
highest in 2018 in Finland, Germany and Ireland. The number
was  greater  in  Norway,  Switzerland  and  Iceland,  although
about one‑third of nurses in these latter two countries and in
Finland are trained at a lower level than general nurses and
perform  lower  tasks.  In  some  other  countries  that  have
relatively low numbers of nurses such as Italy and Spain, a
large number of health care assistants (or nursing aids) provide
assistance to nurses. Greece has the lowest number of nurses
per  capita  among  EU countries,  but  the  data  only  include
nurses working in hospital.
Between 2008 and 2018, the number of nurses per capita has
increased  in  most  EU  countries,  except  in  Latvia,  the
Slovak Republic and Ireland where it has decreased at least
slightly. Looking at other European countries, the number of
nurses per capita has increased substantially in Norway and
Switzerland. In Switzerland, this has been driven mainly by a
strong rise in the number of lower-level nurses. In Norway, the
government has adopted a series of measures in recent years
to recruit more students to nursing education programmes and
improve the working conditions of nurses to increase retention
rates.  A  multi-year  Competence  Lift  2020  action  plan  was
adopted in 2016 to increase the number and competencies of
nurses and other health workers to avoid future shortages. This
action plan will be extended over the next five years under the
Competence Lift 2025.
The  number  of  nurses  per  capita  has  come  down  in  the
United Kingdom over the past decade, driven at least partly by a
reduction in the number of domestic graduates until 2017 as
well as a sharp reduction in the inflow of foreign-trained nurses
in 2017,  although the numbers have picked up since then.
Important changes in the mix of nurses and other clinical staff
(including health care assistants and nursing assistants) have
also  occurred  over  the  last  decade.  While  in  2009/10  the
number of nurses and support  staff  were roughly equal,  by
2018/19, there were about 10% more support staff than nurses
in full-time equivalent employment (Buchan et al., 2019).
Nurses greatly outnumber physicians in most EU countries. In
2018, there were more than two nurses per doctor on average
across EU countries, with the nurse-to-doctor ratio reaching
about  four  or  more  in  Finland,  Luxembourg,  Ireland,
Switzerland, Iceland and Norway (Figure 7.19). The ratio was
much  lower  in  Southern  European  countries  as  well  as  in
Latvia.
In response to shortages of doctors, several countries have
started to implement more advanced roles for nurses in hospital
and  primary  care,  including  “nurse  practitioner”
roles.  Evaluations  of  nurse  practitioners  in  primary  care  in
countries like Finland, the United Kingdom and Ireland show
that advanced practice nurses can improve access to services
and reduce waiting times, while delivering the same quality of
care as doctors for a range of patients, including those with
minor illnesses and those needing routine follow-ups. These
evaluations find a high patient satisfaction rate, while the impact
on cost is either cost-reducing or cost-neutral  (Maier et  al.,
2017).
Definition and comparability
The number of nurses includes those providing services
for patients (“practising”), but in some countries also those
working  as  managers,  educators  or  researchers
(“professionally  active”).  In  countries  where  there  are
different levels of nurses, the data include both “professional”
nurses  (including  general  and  specialist  nurses)  and
“associate professional” nurses who have a lower level of
qualifications but are nonetheless recognised and registered
as nurses in their country. Health care assistants (or nursing
aids) who are not recognised as nurses are excluded. Austria
and Greece report only nurses working in hospitals (resulting
in an underestimation).
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7. USE OF DIAGNOSTIC TECHNOLOGIES
Technology plays an important role in health systems, allowing
physicians to better diagnose and treat patients. However, new
technologies can also drive up costs, particularly if they are
overused or misused.
This section focusses on the use of three diagnostic imaging
technologies that can help diagnose different health problems:
computed  tomography  (CT),  magnetic  resonance  imaging
(MRI) and positron emission tomography (PET) exams. CT and
MRI exams both show images of internal organs and tissues,
while PET scans show other information and problems at the
cellular  level.  Unlike  more  traditional  radiography  and  CT
scanning,  MRI  and  PET exams do  not  expose  patients  to
ionising radiation, which can increase the risk of cancer if the
exposition of radiation is not properly managed. CT exams were
first introduced in the 1970s, MRI exams in the 1970s and the
1980s, while PET exams were introduced later on, around the
year 2000.
The most recent data from 2018 show that the use of these
three diagnostic exams taken together was highest in Austria,
France, Luxembourg, Belgium and Germany, with utilisation
rates 50% higher than the average across EU countries. The
utilisation rate was lowest in Romania and Bulgaria with rates
more than 50% lower than the EU average (Figure 7.20).
Figure 7.21 highlights the large variation in the use of MRI
exams between Western European countries and Central and
Eastern European countries. While the use of MRI exams has
increased over the past two decades in all  countries,  there
remain in 2018 a ten‑fold difference in their use between the
three countries that use them the most (Germany, Austria and
France)  and  the  three  countries  that  use  them  the  least
(Cyprus, Romania and Bulgaria).
In most countries, CT exams continue to be the most frequently
used of the three diagnostic technologies considered here. This
is  notably  the case in  countries  like  Belgium,  Luxembourg,
Greece, Portugal, Cyprus, Romania and Bulgaria where the
use of CT exams is still more than two‑times greater than MRI
exams (Figure 7.20). This is because the use of CT exams has
continued to increase during the past two decades, although in
most  cases  at  a  slower  rate  than  that  of  MRI  exams.  In
Germany, both CT exams and MRI exams have continued to
increase over the past 15 years, but the use of MRI exams has
increased more rapidly so that it is now almost equal to that of
CT exams. The use of PET scans has also increased over the
past two decades, but remain much more limited than that of CT
exams and MRI exams.
Clinical guidelines have been developed in many countries to
help physicians determine when they should use these different
diagnostic technologies and to avoid overuse, although these
guidelines are not always implemented in practice. Through the
Choosing Wisely® campaign, which began in the United States
in 2012 and emulated in other countries since then, medical
societies have identified a number of cases when MRI or other
imaging tests are frequently used but are unlikely to provide any
benefit  to  patients.  One example  is  to  use  MRI  to  seek  a
diagnosis for low back pain or for migraine. The Royal College
of Physicians in the United Kingdom has recommended, based
on evidence from the National Institute for Health and Clinical
Excellence (NICE),  that patients with low back pain or with
suspected  migraine  do  not  routinely  need  an  imaging  test
(Choosing Wisely UK, 2018).
Definition and comparability
While the data in most countries cover CT, MRI and PET
exams in hospitals as well as in the ambulatory sector, the
data coverage is more limited in some countries. Any CT,
MRI and PET exams performed outside hospitals are not
included in Portugal, Switzerland and the United Kingdom.
Exams  in  Cyprus  only  cover  public  hospitals.  The
Netherlands only report data on publicly financed exams.
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Figure 7.20. CT, MRI and PET exams per 1 000 population, 2018 (or nearest year)
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7. HOSPITAL BEDS AND DISCHARGES
The number  of  hospital  beds  provides  an  indication  of  the
resources  available  for  delivering  services  to  inpatients  in
hospitals for different types of care. The COVID‑19 pandemic
highlighted the need to have a sufficient number of hospital
beds and flexibility  in  their  use to address any unexpected
increase in demand for intensive care, together with a sufficient
number of doctors and nurses with the right skills to provide the
required services (see Chapter 1 on resilience to COVID‑19).
Germany,  Bulgaria  and  Austria  had  the  highest  number  of
hospital beds per capita before the COVID‑19 pandemic, with
more than seven beds per 1 000 population in 2018. This was
well above the EU average of five beds, and about three times
greater  than  the  number  in  Sweden,  Denmark  and  the
United Kingdom (Figure 7.22).
Since  2000,  the  number  of  hospital  beds  per  capita  has
decreased  in  all  EU  countries  due  at  least  partly  to  the
development of day care options and reductions in the average
length of stay for hospitalised patients (see indicator “Average
length of stay in hospital”). On average, the number of hospital
beds per capita fell by slightly more than 20% between 2000
and  2018.  This  reduction  was  particularly  pronounced  in
Finland,  Denmark,  Sweden,  Latvia,  the  Netherlands  and
Estonia, with a reduction of more than one‑third.
Hospital discharges in 2018 were highest in the three countries
that  had  the  highest  number  of  hospital  beds  –  Bulgaria,
Germany and Austria. Discharge rates in these three countries
were more than 40% higher than the EU average (Figure 7.23).
The strong increase in hospital admission and discharge rates
in Bulgaria over the past two decades has been driven by the
rapid expansion of private hospitals in terms of bed capacity
and activities, while the size of the public hospital sector was
diminishing (OECD/European Observatory on Health Systems
and Policies, 2019).
Hospital  discharge  rates  in  2018  were  lowest  in  the
Netherlands, Portugal,  Italy and Spain, with discharge rates
more  than  one‑third  lower  than  the  EU  average.  These
variations in admission and discharge rates reflect to a large
extent differences in the supply of beds, clinical practices, and
payment systems that might provide incentives for hospitals to
admit patients.
High occupancy rates of curative (acute) care beds can be
symptomatic of a hospital sector under pressure, and may lead
to bed shortages when there is an unexpected surge in demand
as was the case under the COVID‑19 pandemic. On the other
hand, low occupancy rates reflect some underuse of resources.
Although there is no general consensus about the “optimal”
occupancy  rate,  an  occupancy  rate  of  about  85% is  often
considered as a maximum to reduce the risk of bed shortages
when there is a sudden increase in need for admissions and to
reduce the risk of infections and other patient safety issues
(NICE,  2018).  In  2018,  the bed occupancy rate  in  curative
(acute) care units was higher than 85% in one country only,
Ireland (Figure 7.24). The bed occupancy rate in Ireland has
increased over the past two decades to reach more than 90% in
2018. A 2018 government report concluded that the hospital
infrastructure in Ireland was simply not adequate to meet the
current demand and to cope with the projected increases due to
population ageing (Department of Health, 2018).
Definition and comparability
Hospital  beds  include  all  beds  that  are  regularly
maintained and staffed and are immediately available for
use. They include beds in general hospitals, mental health
and  substance  abuse  hospitals,  and  other  specialty
hospitals. Beds in nursing and residential care facilities are
excluded. Data for some countries do not cover all hospitals.
In the United Kingdom, data are restricted to public hospitals.
In Ireland, data refer to acute hospitals only. Data for Sweden
exclude private beds that are privately financed. Beds for
same-day  care  may  be  included  in  some  countries
(e.g. Austria, Luxembourg, the Netherlands).
Discharge is defined as the release of a patient who has
stayed at least one night in hospital. Same-day separations
are excluded. Healthy babies born in hospitals are excluded
completely (or almost completely) from hospital discharge
rates  in  several  countries  (e.g.  Austria,  Estonia,  Finland,
Greece,  Ireland,  Lithuania,  Luxembourg,  Montenegro,
Norway, Serbia and Spain). These comprise between 3%
and 10% of all discharges. Data for some countries do not
cover all hospitals. In Ireland and the United Kingdom, data
are restricted to public or publicly funded hospitals only. Data
for the Netherlands and North Macedonia include only acute
care, resulting in some under-estimation.
The  occupancy  rate  for  curative  (acute)  care  beds  is
calculated as the number of  hospital  bed-days related to
curative care divided by the number of available curative care
beds (multiplied by 365).
References
Department of Health (2018), Health Service Capacity Review 2018
Executive  Report:  Review  of  Health  Demand  and  Capacity
Requirements in Ireland to 2031‑ Findings and Recommendations,
Dublin.
OECD/European Observatory on Health Systems and Policies (2019),
Bulgaria: Country Health Profile 2019, State of Health in the EU,
OECD Publishing, Paris/European Observatory on Health Systems
and Policies, Brussels, https://doi.org/10.1787/34781ac1-en.
NICE (2018), Emergency and acute medical care in over 16s: service
delivery  and  organisation,  Chapter  39  Bed  Occupancy,  NICE
guideline 94, March 2018, https://www.nice.org.uk/guidance/ng94/.
222 HEALTH AT A GLANCE: EUROPE 2020 © OECD/European Union 2020
7. HOSPITAL BEDS AND DISCHARGES
Figure 7.22. Hospital beds per 1 000 population, 2000 and 2018 (or nearest year)
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7. AVERAGE LENGTH OF STAY IN HOSPITAL
The average length of stay in hospital is often regarded as an
indicator of efficiency in health service delivery. All else being
equal, a shorter stay will reduce the cost per discharge and shift
care from inpatient to less expensive settings. Longer stays can
be a sign of poor care coordination, resulting in some patients
waiting unnecessarily in hospital until rehabilitation or long-term
care can be arranged. At the same time, some patients may be
discharged too early,  when staying in hospital  longer could
have improved their health outcomes or reduce chances of re-
admissions.
In 2018, the average length of stay in hospitals for all causes of
hospitalisation was 7.5 days across EU countries (Figure 7.25).
The average length of stay was shortest in Bulgaria, Denmark,
Sweden and Cyprus, with patients staying in hospitals for less
than 6 days on average. The Netherlands had also one of the
shortest  stays,  but  the  length  of  stay  is  under-estimated
because it only includes stays for curative (acute) care that are
typically shorter. The average length of stay was highest in
Hungary, the Czech Republic, Luxembourg and Portugal, with
patients staying in hospitals for more than 9 days on average. In
Hungary and the Czech Republic, many hospitals have long-
term care units, explaining at least partly relatively long average
length of stay. In Germany, long average length of stay partly
relates to extensive capacities to provide rehabilitation care in
hospitals.
The average length of stay in hospital has decreased since
2000 in nearly all EU countries, falling from almost 10 days in
2000 to 7.5 days in 2018 on average. It fell particularly quickly in
some  countries  that  had  relatively  long  stays  in  2000
(e.g.  Bulgaria,  Finland,  the  United  Kingdom,  Switzerland,
Croatia, Latvia and Lithuania). This reduction in average length
of stay has generally been accompanied by a reduction in the
number of  hospital  beds.  For  example,  in  Finland the 36%
reduction  in  average  length  of  stay  since  2000  has  been
accompanied by a 50% reduction in the number of hospital
beds  per  capita  (see  indicator  on  hospital  beds  and
discharges). Hungary and Italy are the only two countries where
there has been a slight increase in average length of stay in
hospital. In Hungary, this is mainly due to a growing use of
hospital beds for rehabilitation and long-term care. The average
length  of  stay  for  curative  (acute)  care  has  decreased  in
Hungary as in other countries over the past decade.
Focusing on average length of stay for specific diseases or
conditions can remove some of the effect of different case mix
and severity of patients admitted to hospital. Figure 7.26 shows
that the average length of stay for a normal delivery is generally
greater  in  Central  and  Eastern  European countries  than  in
Western  Europe.  It  ranges  from less  than two days  in  the
Netherlands,  Iceland  and  the  United  Kingdom,  to  almost
five days in Hungary, Cyprus and the Slovak Republic. The
length of  stay for  a normal  delivery has become shorter  in
nearly all countries, dropping from more than four days in 2000
to  about  three  and  half  days  in  2018  on  average  in
EU countries.
Beyond  differences  in  clinical  needs,  several  factors  can
explain these cross-country variations in lengths of stay. The
combination  of  an  abundant  supply  of  beds  together  with
hospital payment methods may provide incentives for hospitals
to  keep  patients  longer.  A  growing  number  of  countries
(e.g.  France,  Germany,  Poland,  Austria  and Sweden)  have
moved  to  prospective  payment  methods  often  based  on
diagnosis-related groups (DRGs) to set payments based on the
estimated cost of hospital care for different patient groups in
advance of service provision. These payment methods have
the advantage of encouraging providers to reduce the cost of
each hospitalisation. Strengthening access to primary care and
community  care  can  also  help  reduce  hospital  stays.  An
important  constraint  in  many  countries  is  the  shortage  of
capacity  and  resources  in  intermediate  or  long-term  care
facilities,  or  in  providing  home-based  care.  Many  countries
(e.g. the Netherlands, France and Norway) have taken steps in
recent  years  to  increase  the  capacity  of  intermediate  care
facilities and home-based care that can serve as alternatives to
hospitals (OECD, 2020). Such initiatives can provide effective
responses to the needs of ageing populations and the growing
burden of chronic conditions.
Definition and comparability
Average length of stay refers to the average number of
days that patients spend in hospital. It is generally measured
by dividing the total number of days stayed by all inpatients
during a year by the number of admissions or discharges.
Day cases are excluded.
The  data  cover  all  inpatient  cases  (including  not  only
curative/acute  care  cases),  with  the  exception  of  the
Netherlands and North Macedonia where the data refer to
curative/acute care only (resulting in a substantial  under-
estimation).
Average length of stay of healthy babies born in hospitals
are  excluded  in  several  countries  (e.g.  Austria,  Estonia,
Finland,  Greece,  Ireland,  Lithuania,  Luxembourg,
Montenegro, Norway, Serbia and Spain), resulting in a slight
over-estimation of  average length  of  stay  compared with
other countries. In Cyprus, Ireland and the United Kingdom,
data are restricted to public or publicly funded hospitals only.
Data for normal delivery refer to ICD‑10 code O80.
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Figure 7.25. Average length of stay in hospital, 2000 and 2018 (or nearest year)
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Note: The EU average is unweighted. 1. Data refer to average length of stay for curative (acute) care (resulting in an under-estimation).
Source: OECD Health Statistics 2020; Eurostat Database.
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7. WAITING TIMES FOR ELECTIVE SURGERY
Long waiting times for elective (non-urgent) surgery have been
a  longstanding  issue  in  many  European  countries  as  they
generate  dissatisfaction  for  patients  because  the  expected
benefits of treatments are postponed. The COVID‑19 pandemic
will likely increase waiting times for many elective surgery, at
least temporarily, as non-urgent interventions have often been
postponed during the peak of the epidemic.
The data presented in this section focus on three high-volume
surgical  procedures:  cataract  surgery,  hip  replacement  and
knee replacement. They review the experience of patients who
have been treated after waiting for a certain period of time and
those who were still on the waiting list.
The median waiting times for people who received a cataract
surgery in 2019 (or 2018) varied from about 30 days in Italy,
Hungary  and  Denmark,  to  about  150  days  in  Estonia  and
250 days in Poland (Figure 7.27, left panel). The proportion of
patients remaining on the waiting list for a period of more than
three months during that same year varied from 7% in Hungary
to over 85% in Estonia, Poland and Slovenia (Figure 7.27, right
panel).
For hip replacement, the median waiting times ranged from 35
to 50 days in  Denmark,  Hungary and Italy,  to  180 days in
Poland and 250 days in Estonia (Figure 7.28, left panel). The
proportion of patients remaining on the waiting list for more than
three months ranged from 25% of all patients in Sweden to 90%
or more in Estonia and Slovenia (Figure 7.28, right panel).
The  pattern  is  generally  the  same  for  knee  replacement,
although in most countries the waiting times are slightly longer
than for hip replacement (Figure 7.29).
Among the group of countries with relatively short waiting times,
Italy has managed to keep waiting times for elective surgery
relatively  short  in  recent  years  despite  tight  budgetary
constraints,  and  Denmark  and  Hungary  have  managed  to
reduce waiting times through an effective policy mix. Denmark
has managed to reduce waiting times over the past decade
mainly through the implementation of a waiting time guarantee
for patients, initially set at two months from a GP or specialist
referral to treatment in 2002, but then reduced to one month in
2007 (OECD, 2020).
Hungary has achieved substantial progress in reducing waiting
times  for  elective  surgery  in  recent  years  through  the
implementation of a mix of supply-side measures and better
management  of  demand.  One  of  the  main  goals  of  the
Hungarian 2014‑20 health sector strategy has been to reduce
waiting  times  to  less  than  60  days  for  minor  surgery  (like
cataract surgery) and less than 180 days for major surgery (like
hip and knee replacement) for all patients across the country.
To achieve this goal, the government has adopted new laws
and  regulations  on  the  management  of  waiting  lists  and
supported the development of an online waiting list system to
monitor the situation in real-time across the country. It  also
provided  additional  payments  to  reduce  waiting  times  in
selected  clinical  areas  and  hospitals,  and  encouraged  a
reallocation of patients from providers with longer waiting times
to those with shorter waiting times (OECD, 2020).
Among the  group  of  countries  with  long  waiting  times,  the
median  waiting  times  to  get  a  cataract  surgery  in  Estonia
decreased sharply between 2009 and 2014, but then increased
again between 2014 and 2019 although it didn’t go back to the
very high level of a decade earlier. Recent trends in waiting
times for hip and knee replacement are worse, with waiting
times increasing to levels exceeding those of ten years ago. In
2018,  the  Estonian  Health  Insurance  Fund  provided  an
additional EUR 34 million to finance about 140 000 additional
treatments with the goal of reducing waiting times for cataract
surgery and hip and knee replacement. The increase in surgical
activities in 2018 and 2019 led to a reduction in waiting times for
cataract  surgery  and  hip  replacement,  but  not  for  knee
replacement (OECD, 2020).
In  Poland,  waiting  times  for  all  three  surgical  interventions
decreased substantially between 2014 and 2018 (latest year
available), following the adoption of measures to increase the
supply of elective surgery. Until 2018, if the demand for services
exceeded what had been budgeted for, elective procedures
were  rationed  through  waiting  lists  and  treatments  were
postponed to the next year. Since 2018, additional funding is
provided for additional treatments. Information on waiting times
for different treatments in public hospitals are now also more
easily accessible to patients through a dedicated website. A
growing number of Polish people also purchase a private health
insurance to get quicker access to services in private hospitals
(OECD, 2020).
Definition and comparability
Two different measures of waiting times are presented in
this section: 1) from the time that a specialist adds a patient to
the waiting list for an operation to the time that the patient
receives the operation; and 2) the waiting times for patients
who are still  on the waiting lists at a given point in time.
Waiting times for the first measure are reported in the median
number of days. The median is the value which separates a
distribution in two equal parts (meaning that half the patients
have longer waiting times and the other half shorter waiting
times). Compared with the average, the median minimises
the  influence  of  outliers  (patients  with  very  long  waiting
times).
The  data  come  from  administrative  databases.  The
management  of  administrative  data  can  vary  across
countries. In some countries, patients who refuse on several
occasions to receive the procedure are removed from the list,
while they continue to be kept on the list in other countries
(e.g. Estonia).
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Table A A.1. Total population, mid-year, thousands, 1960 to 2019
 1960 1970 1980 1990 2000 2010 2015 2016 2017 2018 2019
Austria 7 048 7 467 7 549 7 678 8 012 8 363 8 643 8 737 8 798 8 841 8 880
Belgium 9 153 9 656 9 859 9 967 10 251 10 896 11 274 11 331 11 375 11 427 11 503
Bulgaria 7 867 8 490 8 862 8 718 8 170 7 396 7 178 7 128 7 076 7 025 6 976
Croatia 4 140 4 412 4 600 4 777 4 468 4 296 4 208 4 172 4 130 4 091 4 067
Cyprus 573 614 509 580 694 829 848 852 860 870 882
Czech Republic 9 602 9 858 10 304 10 333 10 255 10 474 10 546 10 566 10 594 10 630 10 672
Denmark 4 580 4 929 5 123 5 141 5 340 5 548 5 683 5 728 5 765 5 794 5 814
Estonia 1 212 1 360 1 477 1 569 1 397 1 331 1 315 1 316 1 317 1 322 1 327
Finland 4 430 4 606 4 780 4 986 5 176 5 363 5 480 5 495 5 508 5 516 5 522
France 45 684 50 772 53 880 58 171 60 762 64 819 66 548 66 724 66 864 66 966 67 056
Germany1 55 608 61 098 61 549 63 202 82 212 81 777 81 687 82 349 82 657 82 906 83 093
Greece 8 332 8 793 9 643 10 197 10 806 11 121 10 821 10 776 10 755 10 733 10 717
Hungary 9 984 10 338 10 711 10 374 10 211 10 000 9 843 9 814 9 788 9 776 9 771
Ireland 2 829 2 957 3 413 3 514 3 805 4 560 4 702 4 755 4 807 4 867 4 934
Italy 50 200 53 822 56 434 56 719 56 942 59 277 60 731 60 627 60 537 60 422 60 302
Latvia 2 121 2 359 2 512 2 663 2 368 2 098 1 978 1 960 1 942 1 927 1 914
Lithuania 2 779 3 140 3 413 3 698 3 500 3 097 2 905 2 868 2 828 2 802 2 794
Luxembourg 314 339 364 382 436 507 570 582 596 608 620
Malta 327 303 317 354 390 415 445 455 468 485 504
Netherlands 11 487 13 039 14 150 14 952 15 926 16 615 16 940 17 030 17 131 17 232 17 345
Poland 29 637 32 664 35 574 38 111 38 259 38 043 37 986 37 970 37 975 37 975 37 965
Portugal 8 858 8 680 9 766 9 983 10 290 10 573 10 358 10 325 10 300 10 284 10 286
Romania 18 407 20 250 22 207 23 202 22 443 20 247 19 816 19 702 19 587 19 473 19 366
Slovak Republic 4 068 4 538 4 980 5 299 5 389 5 391 5 424 5 431 5 439 5 447 5 454
Slovenia 1 585 1 725 1 901 1 998 1 989 2 049 2 064 2 065 2 066 2 074 2 088
Spain 30 455 33 814 37 491 38 867 40 568 46 577 46 445 46 484 46 593 46 798 47 134
Sweden 7 485 8 043 8 311 8 559 8 872 9 378 9 799 9 923 10 058 10 175 10 279
EU27 (total) 355 968 385 138 406 418 418 764 428 929 441 041 444 235 445 167 445 816 446 461 447 265
Albania 1 609 2 135 2 672 3 267 3 060 2 913 2 881 2 876 2 873 2 866 2 854
Iceland 176 204 228 255 281 318 331 335 343 353 361
Montenegro .. .. .. .. 605 619 622 622 622 622 622
North Macedonia 1 392 1 629 1 891 1 882 2 026 2 055 2 070 2 072 2 075 2 076 2 077
Norway 3 581 3 876 4 086 4 241 4 491 4 889 5 189 5 235 5 277 5 312 5 348
Serbia .. .. .. .. 7 516 7 291 7 095 7 058 7 021 6 983 6 945
Switzerland 5 328 6 181 6 319 6 716 7 184 7 825 8 282 8 373 8 452 8 514 8 575
Turkey 27 438 35 294 44 522 56 104 65 809 73 142 78 218 79 278 80 313 81 407 82 579
United Kingdom 52 400 55 663 56 314 57 248 58 893 62 766 65 116 65 612 66 059 66 460 66 836
Note: Data for 2019 are provisional and subject to revisions.
1. Population figures for Germany prior to 1991 refer to West Germany.
Source: Eurostat Database (data extracted in September 2020).
StatLink 2 https://stat.link/z4jwx1
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Table A A.2. Share of the population aged 65 and over, 1 January, 1960 to 2019
 1960 1970 1980 1990 2000 2010 2015 2016 2017 2018 2019
Austria 12.1 14.0 15.5 14.9 15.4 17.6 18.5 18.4 18.5 18.7 18.8
Belgium 12.0 13.3 14.3 14.8 16.8 17.2 18.1 18.2 18.5 18.7 18.9
Bulgaria 7.4 9.4 11.8 13.0 16.2 18.2 20.0 20.4 20.7 21.0 21.3
Croatia .. .. .. .. .. 17.8 18.8 19.2 19.6 20.1 20.6
Cyprus .. .. .. 10.8 11.2 12.5 14.6 15.1 15.6 15.9 16.1
Czech Republic 9.5 11.9 13.6 12.5 13.8 15.3 17.8 18.3 18.8 19.2 19.6
Denmark 10.5 12.2 14.3 15.6 14.8 16.3 18.6 18.8 19.1 19.3 19.6
Estonia 10.5 11.7 12.5 11.6 14.9 17.4 18.8 19.0 19.3 19.6 19.8
Finland 7.2 9.0 11.9 13.3 14.8 17.0 19.9 20.5 20.9 21.4 21.8
France 11.6 12.8 14.0 13.9 15.8 16.6 18.4 18.9 19.3 19.7 20.1
Germany1 10.8 13.0 15.6 15.3 16.2 20.7 21.0 21.1 21.2 21.4 21.5
Greece 9.4 11.1 13.1 13.7 17.3 19.0 20.9 21.3 21.5 21.8 22.0
Hungary 8.9 11.5 13.5 13.2 15.0 16.6 17.9 18.3 18.7 18.9 19.3
Ireland 11.1 11.1 10.7 11.4 11.2 11.2 12.9 13.2 13.5 13.8 14.1
Italy 9.3 10.8 13.1 14.7 18.1 20.4 21.7 22.0 22.3 22.6 22.8
Latvia .. 11.9 13.0 11.8 14.8 18.1 19.4 19.6 19.9 20.1 20.3
Lithuania .. 10.0 11.3 10.8 13.7 17.3 18.7 19.0 19.3 19.6 19.8
Luxembourg 10.8 12.5 13.7 13.4 14.3 14.0 14.2 14.2 14.2 14.3 14.4
Malta .. .. 8.4 10.4 11.8 14.9 18.2 18.5 18.8 18.8 18.7
Netherlands 8.9 10.1 11.5 12.8 13.6 15.3 17.8 18.2 18.5 18.9 19.2
Poland 5.8 8.2 10.2 10.0 12.1 13.6 15.4 16.0 16.5 17.1 17.7
Portugal 7.8 9.2 11.2 13.2 16.0 18.3 20.3 20.7 21.1 21.5 21.8
Romania .. 8.5 10.3 10.3 13.2 16.1 17.0 17.4 17.8 18.2 18.5
Slovak Republic 6.8 9.1 10.6 10.3 11.4 12.4 14.0 14.4 15.0 15.5 16.0
Slovenia .. .. .. 10.6 13.9 16.5 17.9 18.4 18.9 19.4 19.8
Spain 8.2 9.5 11.1 13.4 16.5 16.8 18.5 18.7 19.0 19.2 19.4
Sweden 11.7 13.6 16.2 17.8 17.3 18.1 19.6 19.8 19.8 19.8 19.9
EU27 (total) .. .. .. 13.7 15.6 17.6 19.0 19.3 19.7 20.0 20.3
Albania .. .. .. .. .. 10.7 12.4 12.8 13.1 13.6 14.1
Iceland 8.0 8.8 9.8 10.6 11.6 12.0 13.5 13.9 14.0 14.1 14.2
Montenegro .. .. .. .. 12.2 12.9 13.7 14.1 14.4 14.8 15.2
North Macedonia .. .. .. .. 9.8 11.6 12.7 13.0 13.3 13.6 14.1
Norway 10.9 12.8 14.7 16.3 15.3 14.9 16.1 16.4 16.6 16.9 17.2
Serbia .. .. .. .. 16.0 17.0 18.5 19.0 19.4 19.9 20.4
Switzerland 10.2 11.2 13.8 14.6 15.3 16.8 17.8 18.0 18.1 18.3 18.5
Turkey 3.5 4.4 4.7 4.3 5.4 7.0 8.0 8.2 8.3 8.5 8.8
United Kingdom 11.7 12.9 14.9 15.7 15.8 16.3 17.7 17.9 18.1 18.2 18.4
Note: Data for 2019 are provisional and subject to revisions.
1. Population figures for Germany prior to 1991 refer to West Germany.
Source: Eurostat Database (data extracted in September 2020).
StatLink 2 https://stat.link/iy7j29
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Table A A.3. Crude birth rate, per 1 000 population, 1960 to 2019
 1960 1970 1980 1990 2000 2010 2015 2016 2017 2018 2019
Austria 17.9 15.0 12.0 11.8 9.8 9.4 9.8 10.0 10.0 9.7 9.6
Belgium 16.8 14.7 12.6 12.4 11.4 11.9 10.8 10.8 10.5 10.4 10.1
Bulgaria 17.8 16.3 14.5 12.1 9.0 10.2 9.2 9.1 9.0 8.9 8.8
Croatia 18.4 13.8 14.8 11.6 9.8 10.1 8.9 9.0 8.9 9.0 8.9
Cyprus 26.2 19.2 20.4 18.3 12.2 11.8 10.8 11.1 10.7 10.7 10.9
Czech Republic 13.4 15.0 14.9 12.6 8.9 11.2 10.5 10.7 10.8 10.7 10.5
Denmark 16.6 14.4 11.2 12.3 12.6 11.4 10.2 10.8 10.6 10.6 10.5
Estonia 16.7 15.8 15.0 14.2 9.4 11.9 10.6 10.7 10.5 10.9 10.6
Finland 18.5 14.0 13.2 13.1 11.0 11.4 10.1 9.6 9.1 8.6 8.3
France 17.9 16.7 14.9 13.4 13.1 12.8 12.0 11.8 11.5 11.3 11.2
Germany1 17.4 13.3 10.1 11.5 9.3 8.3 9.0 9.6 9.5 9.5 9.4
Greece 18.9 16.5 15.4 10.0 9.6 10.3 8.5 8.6 8.2 8.1 7.8
Hungary 14.7 14.7 13.9 12.1 9.6 9.0 9.4 9.7 9.7 9.6 9.5
Ireland 21.5 21.8 21.7 15.1 14.4 16.5 13.9 13.4 12.9 12.5 12.1
Italy 18.1 16.7 11.3 10.0 9.5 9.5 8.0 7.8 7.6 7.3 7.0
Latvia 16.7 14.6 14.1 14.2 8.6 9.4 11.1 11.2 10.7 10.0 9.8
Lithuania 22.5 17.7 15.2 15.4 9.8 9.9 10.8 10.7 10.1 10.0 9.8
Luxembourg 16.0 13.0 11.4 12.9 13.1 11.6 10.7 10.4 10.4 10.3 10.0
Malta 26.2 17.6 17.7 15.2 11.3 9.4 9.7 9.8 9.2 9.2 8.6
Netherlands 20.8 18.3 12.8 13.2 13.0 11.1 10.1 10.1 9.9 9.8 9.7
Poland 22.6 16.8 19.6 14.4 9.9 10.9 9.7 10.1 10.6 10.2 9.9
Portugal 24.1 20.8 16.2 11.7 11.7 9.6 8.3 8.4 8.4 8.5 8.4
Romania 19.1 21.1 18.0 13.6 10.4 10.5 10.2 10.4 10.3 10.4 9.6
Slovak Republic 21.7 17.8 19.1 15.1 10.2 11.2 10.3 10.6 10.7 10.6 10.5
Slovenia 17.6 15.9 15.7 11.2 9.1 10.9 10.0 9.9 9.8 9.4 9.3
Spain 21.7 19.5 15.2 10.3 9.8 10.4 9.0 8.8 8.4 7.9 7.6
Sweden 13.7 13.7 11.7 14.5 10.2 12.3 11.7 11.8 11.5 11.4 11.1
EU27 (total) 18.5 16.4 14.1 12.2 10.5 10.4 9.7 9.8 9.7 9.5 9.3
Albania 43.3 32.5 26.5 25.1 16.7 11.7 11.4 11.0 10.7 10.1 10.0
Iceland 28.0 19.7 19.8 18.7 15.3 15.4 12.5 12.0 11.9 12.0 12.3
Montenegro .. .. .. .. 15.2 12.0 11.9 12.2 11.9 11.7 11.6
North Macedonia 31.7 23.2 21.0 18.8 14.5 11.8 11.1 11.1 10.5 10.3 9.6
Norway 17.3 16.7 12.5 14.4 13.2 12.6 11.3 11.3 10.7 10.4 10.2
Serbia .. .. .. .. 9.8 9.4 9.3 9.2 9.2 9.2 9.3
Switzerland 17.7 16.1 11.7 12.5 10.9 10.3 10.5 10.5 10.3 10.3 10.0
Turkey .. .. .. .. 21.1 16.9 16.9 16.5 16.1 15.3 14.3
United Kingdom 17.5 16.2 13.4 13.9 11.5 12.9 11.9 11.8 11.4 11.0 10.7
Note: Crude birth rate is defined as the number of live births per 1 000 population.
1. Population figures for Germany prior to 1991 refer to West Germany.
Source: Eurostat Database (data extracted in September 2020).
StatLink 2 https://stat.link/kev3i7
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Table A A.4. Total fertility rate, number of children per women aged 15-49, 1960 to 2018, or nearest year
 1960 1970 1980 1990 2000 2010 2015 2016 2017 2018
Austria 2.69 2.29 1.65 1.46 1.36 1.44 1.49 1.53 1.52 1.47
Belgium 2.54 2.25 1.68 1.62 1.67 1.86 1.70 1.68 1.65 1.62
Bulgaria 2.31 2.17 2.05 1.82 1.26 1.57 1.53 1.54 1.56 1.56
Croatia .. .. .. .. 1.46 1.55 1.40 1.42 1.42 1.47
Cyprus .. .. 2.48 2.41 1.64 1.44 1.32 1.37 1.32 1.32
Czech Republic 2.09 1.92 2.08 1.90 1.15 1.51 1.57 1.63 1.69 1.71
Denmark 2.57 1.95 1.55 1.67 1.77 1.87 1.71 1.79 1.75 1.73
Estonia 1.98 2.17 2.02 2.05 1.36 1.72 1.58 1.60 1.59 1.67
Finland 2.72 1.83 1.63 1.78 1.73 1.87 1.65 1.57 1.49 1.41
France 2.73 2.47 1.95 1.78 1.89 2.03 1.96 1.92 1.90 1.88
Germany .. .. .. .. 1.38 1.39 1.50 1.60 1.57 1.57
Greece 2.23 2.40 2.23 1.39 1.25 1.48 1.33 1.38 1.35 1.35
Hungary 2.02 1.98 1.91 1.87 1.32 1.25 1.45 1.53 1.54 1.55
Ireland 3.78 3.85 3.21 2.11 1.89 2.05 1.85 1.81 1.77 1.75
Italy 2.40 2.38 1.64 1.33 1.26 1.46 1.35 1.34 1.32 1.29
Latvia .. .. .. .. 1.25 1.36 1.70 1.74 1.69 1.60
Lithuania .. 2.40 1.99 2.03 1.39 1.50 1.70 1.69 1.63 1.63
Luxembourg 2.29 1.97 1.50 1.60 1.76 1.63 1.47 1.41 1.39 1.38
Malta .. .. 1.99 2.02 1.68 1.36 1.37 1.37 1.26 1.23
Netherlands 3.12 2.57 1.60 1.62 1.72 1.79 1.66 1.66 1.62 1.59
Poland .. .. .. 2.06 1.37 1.41 1.32 1.39 1.48 1.46
Portugal 3.16 3.01 2.25 1.56 1.55 1.39 1.31 1.36 1.38 1.42
Romania .. 2.59 2.43 1.83 1.31 1.59 1.62 1.69 1.71 1.76
Slovak Republic 3.04 2.41 2.32 2.09 1.30 1.43 1.40 1.48 1.52 1.54
Slovenia .. .. 1.93 1.46 1.26 1.57 1.57 1.58 1.62 1.60
Spain .. 2.90 2.22 1.36 1.22 1.37 1.33 1.34 1.31 1.26
Sweden 2.07 1.92 1.68 2.13 1.54 1.98 1.85 1.85 1.78 1.76
EU27 (total) .. .. .. .. 1.43 1.57 1.54 1.57 1.56 1.55
Albania .. .. .. .. 1.90 1.63 1.59 1.54 1.48 1.37
Iceland 3.99 2.81 2.48 2.30 2.08 2.20 1.80 1.74 1.71 1.71
Montenegro .. .. .. .. 1.69 1.70 1.74 1.79 1.78 1.76
North Macedonia .. .. .. 2.23 1.88 1.56 1.50 1.50 1.43 1.42
Norway 2.94 2.50 1.72 1.93 1.85 1.95 1.72 1.71 1.62 1.56
Serbia .. .. .. .. 1.48 1.40 1.46 1.46 1.49 1.49
Switzerland 2.44 2.10 1.55 1.58 1.50 1.52 1.54 1.54 1.52 1.52
Turkey .. .. .. .. .. 2.04 2.14 2.11 2.07 1.99
United Kingdom .. 2.04 1.90 1.83 1.64 1.92 1.80 1.79 1.74 1.68
Source: Eurostat Database (data extracted in September 2020).
StatLink 2 https://stat.link/d4im6h
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